Biomarker pairs for predicting preterm birth

This application incorporates by reference a Sequence Listing submitted as an ASCII text file entitled 13271-056-999_SL.TXT created on Feb. 22, 2021, and having a size of 44,495 bytes.

The invention relates generally to the field of precision medicine and, more specifically to compositions and methods for determining the probability for preterm birth in a pregnant female.

BACKGROUND

According to the World Health Organization, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) every year. In almost all countries with reliable data, preterm birth rates are increasing. See, World Health Organization; March of Dimes; The Partnership for Maternal, Newborn & Child Health; Save the Children, Born too soon: the global action report on preterm birth, ISBN 9789241503433(2012). An estimated 1 million babies die annually from preterm birth complications. Globally, preterm birth is the leading cause of newborn deaths (babies in the first four weeks of life) and the second leading cause of death after pneumonia in children under five years. Many survivors face a lifetime of disability, including learning disabilities and visual and hearing problems.

Across 184 countries with reliable data, the rate of preterm birth ranges from 5% to 18% of babies born. Blencowe et al., “National, regional and worldwide estimates of preterm birth.” The Lancet, 9; 379(9832):2162-72 (2012). While over 60% of preterm births occur in Africa and south Asia, preterm birth is nevertheless a global problem. Countries with the highest numbers include Brazil, India, Nigeria and the United States of America. Of the 11 countries with preterm birth rates over 15%, all but two are in sub-Saharan Africa. In the poorest countries, on average, 12% of babies are born too soon compared with 9% in higher-income countries. Within countries, poorer families are at higher risk. More than three-quarters of premature babies can be saved with feasible, cost-effective care, for example, antenatal steroid injections given to pregnant women at risk of preterm labor to strengthen the babies' lungs.

Infants born preterm are at greater risk than infants born at term for mortality and a variety of health and developmental problems. Complications include acute respiratory, gastrointestinal, immunologic, central nervous system, hearing, and vision problems, as well as longer-term motor, cognitive, visual, hearing, behavioral, social-emotional, health, and growth problems. The birth of a preterm infant can also bring considerable emotional and economic costs to families and have implications for public-sector services, such as health insurance, educational, and other social support systems. The greatest risk of mortality and morbidity is for those infants born at the earliest gestational ages. However, those infants born nearer to term represent the greatest number of infants born preterm and also experience more complications than infants born at term.

To prevent preterm birth in women who are less than 24 weeks pregnant with an ultrasound showing cervical opening, a surgical procedure known as cervical cerclage can be employed in which the cervix is stitched closed with strong sutures. For women less than 34 weeks pregnant and in active preterm labor, hospitalization may be necessary as well as the administration of medications to temporarily halt preterm labor and/or promote the fetal lung development. If a pregnant women is determined to be at risk for preterm birth, health care providers can implement various clinical strategies that may include preventive medications, for example, 17-α hydroxyprogesterone caproate (Makena) injections and/or vaginal progesterone gel, cervical pessaries, restrictions on sexual activity and/or other physical activities, and alterations of treatments for chronic conditions, such as diabetes and high blood pressure, that increase the risk of preterm labor.

There is a great need to identify and provide women at risk for preterm birth with proper antenatal care. Women identified as high-risk can be scheduled for more intensive antenatal surveillance and prophylactic interventions. Current strategies for risk assessment are based on the obstetric and medical history and clinical examination, but these strategies are only able to identify a small percentage of women who are at risk for preterm delivery. Prior history of spontaneous PTB (sPTB) is currently the single strongest predictor of subsequent PTB. After one prior sPTB the probability of a second PTB is 30-50%. Other maternal risk factors include: black race, low maternal body-mass index, and short cervical length. Amniotic fluid, cervicovaginal fluid, and serum biomarker studies to predict sPTB suggest that multiple molecular pathways are aberrant in women who ultimately deliver preterm. Reliable early identification of risk for preterm birth would enable planning appropriate monitoring and clinical management to prevent preterm delivery. Such monitoring and management might include: more frequent prenatal care visits, serial cervical length measurements, enhanced education regarding signs and symptoms of early preterm labor, lifestyle interventions for modifiable risk behaviors such as smoking cessation, cervical pessaries and progesterone treatment. Finally, reliable antenatal identification of risk for preterm birth also is crucial to cost-effective allocation of monitoring resources.

Despite intense research to identify at-risk women, PTB prediction algorithms based solely on clinical and demographic factors or using measured serum or vaginal biomarkers have not resulted in clinically useful tests. More accurate methods to identify women at risk during their first pregnancy and sufficiently early in gestation are needed to allow for clinical intervention. The present invention addresses this need by providing compositions and methods for determining whether a pregnant woman is at risk for preterm birth. Related advantages are provided as well.

SUMMARY

The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female.

The invention provides surrogate peptides of the isolated biomarkers selected from the group set forth in Table 26. In some embodiments, the surrogate peptides of the isolated biomarkers are selected from the group of surrogate peptides set forth in Table 26. The biomarkers of the invention and their surrogate peptides can be used in methods to predict risk for pre-term birth in a pregnant female. In some embodiments, the surrogate peptides correspond to isolated biomarkers selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.

The invention provides stable isotope labeled standard peptides (SIS peptides) corresponding to the surrogate peptides selected from the group set forth in Table 26. The biomarkers of the invention, their surrogate peptides and the SIS peptides can be used in methods to predict risk for pre-term birth in a pregnant female. In some embodiments, the SIS peptides correspond to surrogate peptides of the isolated biomarkers selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.

The invention provides a pair of isolated biomarkers selected from the group consisting of the isolated biomarkers listed in Table 26, wherein the pair of biomarkers exhibits a change in ratio value between pregnant females at risk for pre-term birth and term controls.

The invention provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in ratio value between pregnant females at risk for pre-term birth and term controls.

The invention provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in ratio value between pregnant females at risk for pre-term birth and term controls.

In one embodiment, the invention provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.

In one embodiment, the invention provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.

In one embodiment, the invention provides a composition comprising a pair of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In one embodiment, the invention provides a composition comprising a pair of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In a particular embodiment, the invention provides a pair of isolated biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth compared to term controls. In a further embodiment, the invention provides a pair of isolated biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a higher ratio in pregnant females at risk for pre-term birth compared to term controls.

In one embodiment, the invention provides a composition comprising a pair of surrogate peptides corresponding to a pair of biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a higher ratio in pregnant females at risk for pre-term birth compared to term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In a further embodiment, the invention provides a panel of at least two pairs of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the panel comprises stable isotope labeled standard peptides (SIS peptides) for surrogate peptides derived from each of said biomarkers.

In a further embodiment, the invention provides a panel of at least two pairs of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the panel comprises stable isotope labeled standard peptides (SIS peptides) for surrogate peptides derived from each of said biomarkers.

In an additional embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the panel comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In an additional embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the panel comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In a further embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein at least one of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In a further embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein at least one of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In an additional embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein a calculated score, derived from the panel of at least two pairs of biomarkers exhibits a change in value between pregnant females and term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In an additional embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein a calculated score, derived from the panel of at least two pairs of biomarkers exhibits a change in value between pregnant females and term controls. In one embodiment, the composition comprises stable isotope labeled standard peptides (SIS peptides) for each of the surrogate peptides.

In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a ratio for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female. In some embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

In some embodiments, determining the probability for preterm birth in a pregnant female encompasses an initial step that includes formation of a probability/risk index by measuring the ratio of isolated biomarkers selected from the group in a cohort of preterm pregnancies and term pregnancies with known gestational age at birth. In further embodiments, the preterm risk index is formed by measuring the ratio of IBP4/SHBG in a cohort of preterm and term pregnancies where the gestational age at birth is recorded. In some embodiments, determining the probability for preterm birth in a pregnant female comprises measuring the ratio of IBP4/SHBG and comparing the value to the index to derive the preterm risk using the same isolation and measurement technologies to derive IBP4/SHBG as in the index group.

In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS to determine the probability for preterm birth in the pregnant female. In some embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female. In some embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

In another embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a change in reversal value for a panel of at least two pairs of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS to determine the probability for preterm birth in the pregnant female. In another embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a change in reversal value for a panel of at least two pairs of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female. In some embodiments, the reversal value reveals the existence of a change in the relative intensities of the individual biomarkers between the pregnant female and a term control and indicates the probability for preterm birth in the pregnant female. In additional embodiments, the measuring step comprises measuring surrogate peptides of the biomarkers in the biological sample obtained from the pregnant female. In some embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for a pair of biomarkers consisting of IBP4 and SHBG to determine the probability for preterm birth in the pregnant female. In some embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for a pair of biomarkers consisting of a ratio of IBP4 over SHBG (IBP4/SHBG) to determine the probability for preterm birth in the pregnant female, wherein a higher ratio in pregnant female compared to term controls indicates an increased risk for pre-term birth. In further embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for a pair of biomarkers IBP4 and SHBG to determine the probability for preterm birth in the pregnant female. In some embodiments, the pregnant female has a body mass index (BMI) of greater than 22 and less or equal to 37 kg/m². In some embodiments, the method comprises an initial step of obtaining a biological sample. In some embodiments, the method comprises detecting, measuring or quantifying an SIS surrogate peptide of each of the biomarkers.

The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent.

In one embodiment the invention provides a method of detecting IBP4 and SHBG in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether IBP4 and SHBG are present in the biological sample by contacting the biological sample with a capture agent that specifically binds IBP4 and a capture agent that specifically binds SHBG; and c. detecting binding between IBP4 and the capture agent and between SHBG and the capture agent. In one embodiment, the method comprises measuring a reversal value for the pair of biomarkers. In a further embodiment, the existence of a change in reversal value between the pregnant female and a term control indicates the probability for preterm birth in the pregnant female. In one embodiment, the sample is obtained between 19 and 21 weeks of gestational age. In a further embodiment, the capture agent is selected from the group consisting of and antibody, antibody fragment, nucleic acid-based protein binding reagent, small molecule or variant thereof. In an additional embodiment, the method is performed by an assay selected from the group consisting of enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (MA).

The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; and b. detecting whether the pair of isolated biomarkers is present in the biological sample comprising subjecting the sample to a proteomics work-flow comprised of mass spectrometry quantification.

In one embodiment the invention provides a method of detecting IBP4 and SHBG in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; and b. detecting whether the pair of isolated biomarkers is present in the biological sample comprising subjecting the sample to a proteomics work-flow comprised of mass spectrometry quantification.

In some embodiments, the reversal value reveals the existence of a change in the relative intensities of the individual biomarkers between the pregnant female and a term control and indicates the probability for preterm birth in the pregnant female. In additional embodiments, the measuring step comprises measuring surrogate peptides of the biomarkers in the biological sample obtained from the pregnant female. In one embodiment a preterm risk index is formed by measuring the ratio of IBP4/SHBG in a cohort of preterm and term pregnancies where the gestational age at birth is recorded. Then, in clinical practice the measured ratio of IBP4/SHBG in an individual pregnancy is compared in the index to derive the preterm risk using the same isolation and measurement technologies to derive IBP4/SHBG as in the index group.

Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1. Blood draw windows. Individual reversal performance is shown across blood draw windows. Reversals shown: IBP4/SHBG; VTNC/VTDB; IBP4/SHBG; VTNC/SHBG; IBP4/SHBG; CATD/SHBG; PSG2/ITIH4; CHL1/ITIH4; PSG2/C1QB; PSG2/FBLN3; HEMO/IBP6; HEMO/PTGDS.

FIG. 2. Discovery case, verification case and validation case for GABD.

FIGS. 3A-3C. Protein expression during pregnancy. Various proteins can be analyzed based on known protein behavior and knowing proteins/pathways that are not affected by preterm birth. FIGS. 3A-3C show expression of pregnancy-related proteins during gestation. These proteins and their networks are unaffected by preterm pathology in the gestational age shown.

FIG. 4. Protein expression during pregnancy. FIG. 4 shows an enlarged version of the graph shown in FIG. 3 relating to placenta-specific growth hormone.

FIGS. 5A-5B. Protein pathology during pregnancy. Insulin-like growth factor binding protein 4 (IBP4) was over-expressed by at least 10% in blood draw window 19-21 weeks. Sex hormone binding globulin (SHBG) was under-expressed by at least 10% in blood draw window 19-21 weeks.

FIG. 6. Verification selection criteria. FIG. 6 describes criteria for performing a clinically and analytically robust preterm test of high performance.

FIG. 7. Monte Carlo Cross Validation (MCVV). MCCV is a conservative method that estimates how well a classifier will perform on an independent set of samples drawn from the same population (e.g. PAPR).

FIG. 8. Analysis of [IBP4]/[SHBG CHL1 CLUS]. CHL1 and CLUS increased performance by 0.03 relative to IBP4/SHBG only.

FIG. 9. Power and sample size analysis. Power and sample size analysis predicts the likelihood that a study is powered sufficiently to reject the null hypothesis (AUC=0.5) at thresholds of sample number and performance estimates.

FIG. 10. Pregnancy clock and time to birth. Multiple analytes that increase in pregnancy but are not different in PTB cases and controls can be used to date pregnancy biochemically. Biochemical dating could be useful for confirmation of dating by date of last menstrual period or ultrasound dating, or prior to subsequent determinations of sPTB risk, TTB or GAB prediction.

FIG. 11. Classifier development. FIG. 11 shows criteria for developing classifiers.

FIG. 12. Pathway coverage in discovery assay. FIG. 12 shows the distribution of proteins by pathway.

FIG. 13. PCA of discovery data detects changes across the blood draw windows and therefore indicates that the highly multiplexed assay is sensitive to gestational age.

FIG. 14. Hierarchical clustering of proteins measured in discovery samples.

FIG. 15. Placenta specific protein branch within larger cluster. The right panel lists a module of genes that is expressed during pregnancy identified by Thompson and the left panel demonstrates that the discovery serum-proteomics assay reproduces the correlated expression of this module. (Thompson et al., Genome Res. 12(10):1517-1522 (2002).

FIG. 16. Dysregulated proteins PreTRM™ samples.

FIG. 17. Highlighted Sex hormone binding globulin (SHGB) biology. SHBG is expressed in placental cells (right). SHBG may be responsible for controlling the levels of free testosterone and estrogen levels in the placental fetal compartment (left).

FIG. 18. Interactions of IBP4, IGF2, PAPP-A and PRG2. IBP4 is a negative regulator of IGF2. IBP4 is freed from IGF2 by PAPPA mediated proteolysis. Low levels of PAPPA have been implicated in IUGR and PE. Elevated levels of IBP4 are indicative of suppressed activity of IGF2. PTB cases have suppressed levels of PAPPA, PRG2 and elevated levels of IBP4.

FIG. 19. Insulin-like growth factor binding protein 4 (IBP4). IBP4 is up-regulated in PTB cases. IGF2 stimulates proliferation, differentiation and invasion of EVT in early pregnancy. IGF activity is essential for normal placentation and fetal growth. IBP4 mediates autocrine and paracrine control of IGF2 activity at the maternal-fetal interface. Activity of IGF2 expressed by cytotrophoblasts is balanced by IBP produced by decidual cells. Elevated IBP4 and reduced IGF2 in 1st trimester correlated with placental dysfunction (e.g. IUGR/SGA).

FIGS. 20A-20C. MS vs ELISA correlation for IBP4, SHBG and CHL1. Mass spectrometry and ELISA are in good agreement for key analytes. Agreement in two orthogonal platforms asserts analyte measurement reliability.

FIG. 21. PTB classification by IBP4/SHBG in discovery samples from 19-21 weeks GABD. Discovery samples for weeks 19-21 of gestation were divided by high and low BMI. IBP4/SHBG reversal values are higher in the high BMI category due to lower SHBG values. Separation of cases and controls is greater at lower BMI.

FIG. 22. Suppressed SHBG levels in PTB cases at low BMI. Linear fits of SHBG serum levels in PAPR subjects across GABD. SHBG levels are suppressed by high BMI. SHBG levels increase across gestation. PTB cases at low BMI have reduced SHBG levels that increase across gestation at an accelerated rate. Figure discloses SEQ ID NO:18.

FIG. 23 summarizes the distribution of study subjects in PAPR.

FIG. 24 shows the ROC curve and corresponding AUC value using the IBP4/SHBG predictor to classify the BMI stratified validation sample set.

FIG. 25 shows prevalence adjusted positive predictive value (PPV), a measure of clinical risk, as a function of predictor score. The calculated association of predictor score and PPV, allows the determination of probability of sPTB risk for any unknown subject. Top (purple) line underneath risk curve graph corresponds to GAB<35 0/7 weeks; second line (red) from top corresponds to GAB between 35 0/7 and 37 0/7/weeks; third line (green) from corresponds to GAB between 37 0/7 and 39 0/7/weeks; fourth line (blue) from top corresponds to GAB 39 0/7 weeks≤GAB.

FIG. 26 displays rate of births for the high and low risk groups as events in a Kaplan Meier analysis. High and low risk was defined as above or below a relative risk of 2× the average population risk of sPTB (=14.6%) from data in FIG. 25.

FIG. 27 shows an ROC curve corresponding to the predictor performance using a combination of subjects from the blinded verification and validation analyses within the optimal BMI and GA interval. The ROC curve for the combined sample corresponds to an AUROC of 0.72 (p=0.013)

FIG. 28 shows 44 proteins were either up- or down-regulated in overlapping 3-week GA intervals and passed analytic filters.

FIG. 29 shows the top performing reversal overall, IBP4/SHBG, had an AUROC=0.74 in the interval from 19 0/7 through 21 6/7.

FIG. 30 shows the mean AUROC of 0.76 obtained from 2,000 bootstrap iterations. The blinded IBP4/SHBG AUROC performance on verification samples was 0.77 and 0.79 for all subjects and BMI stratified subjects, respectively, in good agreement with performance obtained in discovery. Following blinded verification, discovery and verification samples were combined for the bootstrap performance determination.

FIGS. 31A-31B show sPTB Case vs Control Separation Derived by MS vs ELISA Score Values

FIGS. 32A-32B show Immunoassay versus MS ROC Analyses without BMI restriction.

FIGS. 33A-33B show Immunoassay versus MS ROC Analyses for BMI higher than 22 and less or equal to 37.

FIGS. 34A-34B show the correlation between MS and ELISA derived IBP4/SHBG score values within GABD 133-146, for BMI stratified subjects (left panel) and all subjects (right panel).

FIGS. 35A-35B show ELISA and MS Separation of Controls and Cases (BMI stratified)

FIGS. 36A-36B show Elisa and MS Separation of Controls and Cases (All BMI)

FIG. 37 shows comparison of SHBG measurements by Abbott Architect CMIA, semi-automated immunoassay instruments and Sera Prognostics' proteomic analysis method involving immuno-depletion of samples, enzymatic digestion and analysis on an Agilent 6490 Mass Spectrometer.

FIG. 38 shows comparison of SHBG measurements by Roche cobas e602 analyzer, semi-automated immunoassay instruments and Sera Prognostics' proteomic analysis method involving immuno-depletion of samples, enzymatic digestion and analysis on an Agilent 6490 Mass Spectrometer.

FIG. 39 shows comparison of SHBG measurements by Abbott Architect CMIA and Roche cobas e602 analyzer, both semi-automated immunoassay instruments.

FIG. 40 shows the domain and structural characteristics of the longest isoform of the IBP4 protein (Uniprot: P22692). The IBP4 QCHPALDGQR (aa, 214-223) peptide (SEQ ID NO: 2) is located within the Thyroglobulin type 1 domain. IBP4 has a single N-linked glycosylation site at residue 125.

FIG. 41 highlights the position of the QCHPALDGQR peptide (SEQ ID NO: 2) in the two IBP4 isoforms (SEQ ID NOS 158 and 159, respectively, in order of appearance).

FIG. 42 shows the domain and structural characteristics of the longest isoform of the SHBG protein (Uniprot: P04278). The SHBG IALGGLLFPASNLR (aa, 170-183) peptide (SEQ ID NO: 18) is located in the first Lamin G-like domain. SHBG has three glycosylation sites; two N-linked sites at residue 380 and 396; one O-linked site at residue 36.

FIG. 43 highlights the position of the IALGGLLFPASNLR peptide (SEQ ID NO: 18) in exon 4 within the seven isoforms of SHBG (SEQ ID NOS 160, 160, 160, 160, 160, 160, and 161, respectively, in order of appearance).

FIG. 44 shows the average response ratio for IBP4 levels separately for sPTB cases and term controls across gestational age at blood draw (GABD). Cross sectional discovery data was analyzed by smoothing using a sliding 10 day window. Case versus control signal corresponds to an approximate maximal 10% difference.

FIG. 45 shows the average response ratio for SHBG levels separately for sPTB cases and term controls across gestational age at blood draw (GABD). Cross sectional discovery data was analyzed by smoothing using a sliding 10 day window. Case versus control signal corresponds to an approximate maximal 10% difference.

FIG. 46 shows the IBP4/SHBG predictor score separately for sPTB cases and term controls across gestational age at blood draw (GABD). Cross sectional discovery data was analyzed by smoothing using a sliding 10 day window. The maximal difference between the two curves corresponds to approximately a 20% difference, compared with the approximate 10% difference in signal for the individual analytes (FIGS. 45 and 46). These data demonstrate the amplification of diagnostic signal obtained by employing the IBP4/SHBG reversal strategy.

FIGS. 47A-47B show the amplification of diagnostic signal as a result of the formation of many different reversals. To investigate whether formation of reversals in general amplifies diagnostic signal we examined the diagnostic performance of reversals formed by many different proteins by ROC analysis. Shown in the top panel (FIG. 47A) is the range of AUC values (sPTB case vs term control) using datasets from samples collected between 19/0 weeks and 21/6 weeks gestation. The adjacent box plots show the range in ROC performance for the individual up-regulated and down-regulated proteins used to form the associated reversals. Similarly, the lower panel (FIG. 47B) shows the p-values derived from a Wilcoxon test (sPTB case vs. term controls) for reversals are more significant than those for the corresponding individual proteins.

FIG. 48 shows the analytical coefficient of variation (CV) for the measure of individual IBP4 and SHBG response ratios and for the calculated corresponding reversal score. Pooled control serum samples from pregnant donors (pHGS) free of biological variability, were analyzed in multiple batches and across several days. Reversal variability is less than the variability associated with the individual proteins. These data indicate that formation of the reversal controls for analytical variability that occurs during the laboratory processing of samples. Analytical variability is not a biological phenomenon.

FIG. 49 shows the analytical CVs for many reversals and their individual up- and down-regulated proteins. To investigate whether formation of reversals in general amplifies diagnostic signal we examined ROC performance (AUC) of high performing reversals (AUC>0.6) formed by the ratio of many proteins. Shown in the top panel is the range of AUC values (sPTB case vs term control) using datasets from samples collected between 19/0 weeks and 21/6 weeks gestation. The adjacent box plots show the range in ROC performance for the individual up-regulated and down-regulated proteins used to form the associated reversals. Similarly, p values derived from a Wilcoxon test (sPTB case vs. term controls) for reversals are more significant than those for the corresponding individual proteins.

FIG. 50 shows PreTRM™ score comparison for subjects annotated as medically indicated for preeclampsia versus other indications.

FIG. 51 shows a table of metrics of IBP4/SHBG predictor performance in the validation sample set (BMI>22<=37). Using different boundaries to define cases (below the cut-off) from controls (above the cut-off) the predictor sensitivity, specificity, area under the ROC curve (AUC) and odds ratio were determined.

FIG. 52 shows a reversal intensity heatmap with diabetes annotation. The red arrows show diabetes cases. The samples are listed on the bottom with PTB cases on the right and term births on the left side of the screen. The diabetes patients are clustered on the right, showing that it is possible to build a diagnostic test from the biomarkers to predict gestational diabetes.

FIG. 53 shows hierarchical clustering of analyte response ratios.

FIGS. 54A-54D show differentially expressed proteins that function in extracellular matrix interactions.

FIGS. 55A-55D show kinetic plots of differentially expressed proteins with functions in the IGF-2 pathway that show maximum separation at 18 weeks.

FIG. 56A shows a schematic of interactions between IGF-2, IBP4, PAPP1 and PRG2 proteins affecting bioavailability of these proteins in sPTB; FIG. 56B shows a schematic of intracellular signals preferentially activated by insulin binding to the IR-B and by insulin and IGFs binding to either IR-A or IGF1R.

FIGS. 57A-57C show kinetic plots of differentially expressed proteins with functions in metabolic hormone balance.

FIGS. 58A-58F show kinetic plots of differentially expressed proteins with functions in angiogenesis.

FIGS. 59A-59D show kinetic plots of differentially expressed proteins with functions in innate immunity.

FIGS. 60A-60D show kinetic plots of differentially expressed proteins with functions in coagulation.

FIGS. 61A-61D show kinetic plots of differentially expressed serum/secreted proteins.

FIGS. 62A-62D show kinetic plots of differentially expressed PSGs/IBPs.

FIGS. 63A-63D show kinetic plots of differentially expressed ECM/cell surface proteins.

FIGS. 64A-64D show kinetic plots of differentially expressed complement/acute phase proteins-1.

FIGS. 65A-65D show kinetic plots of differentially expressed shows kinetic plots of differentially expressed complement/acute phase proteins-2.

FIGS. 66A-66D show kinetic plots of differentially expressed complement/acute phase proteins-3.

FIGS. 67A-67E show kinetic plots of differentially expressed complement/acute phase proteins-4.

FIGS. 68A-68I show kinetic plots for analytes specified in FIGS. 68A through 68I with data from gestational age at blood draw (GABD) of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:162, 163, 164, 165, 34, 166, 167, 151, and 152, respectively, in order of appearance.

FIGS. 69A-69I show kinetic plots for analytes specified in FIGS. 69A through 69I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:168, 169, 37, 38, 40, 170, 42, 171 and 172, respectively, in order of appearance.

FIGS. 70A-70I show kinetic plots for analytes specified in FIGS. 70A through 70I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:173, 47, 174, 175, 48, 50, 51, 52 and 54, respectively, in order of appearance.

FIGS. 71A-71I show kinetic plots for analytes specified in FIGS. 71A through 71I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:55, 176, 177, 178, 179, 56, 57, 58 and 180, respectively, in order of appearance.

FIGS. 72A-72I show kinetic plots for analytes specified in FIGS. 72A through 72I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:67, 68, 181, 70, 71, 72, 74, 76 and 182, respectively, in order of appearance.

FIGS. 73A-73I show kinetic plots for analytes specified in FIGS. 73A through 73I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:183, 78, 79, 184, 80, 81, 185, 83 and 186, respectively, in order of appearance.

FIGS. 74A-74I show kinetic plots for analytes specified in FIGS. 74A through 74I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:187, 188, 84, 189, 190, 86, 87, 191 and 192, respectively, in order of appearance.

FIGS. 75A-75I show kinetic plots for analytes specified in FIGS. 75A through 75I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:88, 89, 193, 194, 195, 196, 197, 198 and 199, respectively, in order of appearance.

FIGS. 76A-76I shows kinetic plots for analytes specified in FIGS. 76A through 76I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:200, 92, 93, 201, 202, 203, 95, 204 and 97, respectively, in order of appearance.

FIGS. 77A-77I show kinetic plots for analytes specified in FIGS. 77A through 77I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:98, 99, 100, 1, 2, 101, 102, 205 and 206, respectively, in order of appearance.

FIGS. 78A-78I shows kinetic plots for analytes specified in FIGS. 78A through 78I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:103, 107, 207, 208, 111, 209, 112, 113 and 210, respectively, in order of appearance.

FIGS. 79A-79I show kinetic plots for analytes specified in FIGS. 79A through 79I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:116, 117, 118, 119, 211, 212, 120, 213 and 121, respectively, in order of appearance.

FIGS. 80A-80I show kinetic plots for analytes specified in FIGS. 80A through 80I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:153, 122, 124, 125, 214, 126, 215, 216 and 128, respectively, in order of appearance.

FIGS. 81A-81I show kinetic plots for analytes specified in FIGS. 81A through 81I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:129, 131, 132, 133, 134, 217, 154, 218 and 136, respectively, in order of appearance.

FIGS. 82A-82I show kinetic plots for analytes specified in FIGS. 82A through 82I with data from 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:219, 137, 220, 221, 222, 223, 18, 138 and 139, respectively, in order of appearance.

FIGS. 83A-83I show kinetic plots for analytes specified in FIGS. 83A through 83I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:224, 140, 141, 142, 225, 143, 226, 227 and 228, respectively, in order of appearance.

FIGS. 84A-84I show kinetic plots for analytes specified in FIGS. 84A through 84I with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:229, 230, 231, 232, 233, 234, 235, 156 and 155, respectively, in order of appearance.

FIGS. 85A-85G shows kinetic plots for peptide transitions specified in FIGS. 85A through 85G with data from GABD of 17 weeks 0 days, through 28 weeks, 6 days. Figures disclose SEQ ID NOS:147, 149, 150, 236, 237, 238 and 239, respectively, in order of appearance.

FIGS. 86A-86I show kinetic plots for peptide transitions specified in FIGS. 86A through 86I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:37, 38, 40, 42, 47, 48, 50, 51 and 52, respectively, in order of appearance.

FIGS. 87A-87I show kinetic plots for peptide transitions specified in FIGS. 87A through 87I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:54, 55, 56, 57, 58, 59, 60, 61 and 62, respectively, in order of appearance.

FIGS. 88A-88I show kinetic plots for peptide transitions specified in FIGS. 88A through 88I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:64, 66, 67, 68, 70, 71, 72, 74 and 76, respectively, in order of appearance.

FIGS. 89A-89I show kinetic plots for peptide transitions specified in FIGS. 89A through 89I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:78, 79, 80, 81, 82, 83, 84, 86 and 87, respectively, in order of appearance.

FIGS. 90A-90I show kinetic plots for peptide transitions specified in FIGS. 90A through 90I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:88, 89, 92, 93, 95, 97, 98, 99 and 100, respectively, in order of appearance.

FIGS. 91A-91I show kinetic plots for peptide transitions specified in FIGS. 91A through 91I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:2, 101, 102, 103, 107, 111, 112, 113 and 114, respectively, in order of appearance.

FIGS. 92A-92I show kinetic plots for peptide transitions specified in FIGS. 92A through 92I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:116, 117, 118, 119, 120, 121, 122, 124 and 125, respectively, in order of appearance.

FIGS. 93A-93I show kinetic plots for peptide transitions specified in FIGS. 93A through 93I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:126, 128, 129, 131, 132, 133, 134, 135 and 136, respectively, in order of appearance.

FIGS. 94A-94I show kinetic plots for peptide transitions specified in FIGS. 94A through 94I using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:137, 18, 138, 139, 140, 141, 142, 143 and 144, respectively, in order of appearance.

FIGS. 95A-95C show kinetic plots for peptide transitions specified in FIGS. 95A through 95C using gestational age at birth cutoff of <37 0/7 versus >=37 0/7 weeks. Figures disclose SEQ ID NOS:147, 149 and 150, respectively, in order of appearance.

FIGS. 96A-96I show kinetic plots for peptide transitions specified in FIGS. 96A through 96I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:37, 38, 40, 42, 47, 48, 50, 51 and 52, respectively, in order of appearance.

FIGS. 97A-97I show kinetic plots for peptide transitions specified in FIGS. 97A through 97I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:54, 55, 56, 57, 58, 59, 60, 61 and 62, respectively, in order of appearance.

FIGS. 98A-98I show kinetic plots for peptide transitions specified in FIGS. 98A through 98I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:64, 66, 67, 68, 70, 71, 72, 74 and 76, respectively, in order of appearance.

FIGS. 99A-99I show kinetic plots for peptide transitions specified in FIGS. 99A through 99I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:78, 79, 80, 81, 82, 83, 84, 86 and 87, respectively, in order of appearance.

FIGS. 100A-100I show kinetic plots for peptide transitions specified in FIGS. 100A through 100I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:88, 89, 92, 93, 95, 97, 98, 99 and 100, respectively, in order of appearance.

FIGS. 101A-101I show kinetic plots for peptide transitions specified in FIGS. 101A through 101I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:2, 101, 102, 103, 107, 111, 112, 113 and 114, respectively, in order of appearance.

FIGS. 102A-102I show kinetic plots for peptide transitions specified in FIGS. 102A through 102I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:116, 117, 118, 119, 120, 121, 122, 124 and 125, respectively, in order of appearance.

FIGS. 103A-103I show kinetic plots for peptide transitions specified in FIGS. 103A through 103I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:126, 128, 129, 131, 132, 133, 134, 135 and 136, respectively, in order of appearance.

FIGS. 104A-104I show kinetic plots for peptide transitions specified in FIGS. 104A through 104I using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:137, 18, 138, 139, 140, 141, 142, 143 and 144, respectively, in order of appearance.

FIGS. 105A-105C show kinetic plots for peptide transitions specified in FIGS. 105A through 105C using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Figures disclose SEQ ID NOS:147, 149 and 150, respectively, in order of appearance.

FIGS. 106A-106C show IBP4 and SHBG levels and IBP4/SHBG reversal values in sPTB cases and controls separately.

FIGS. 107A-107D show the correlation of MSD results with commercial ELISA kits and MS-MRM.

FIGS. 108A-108B provide box plots showing examples of reversals with good performance in weeks 19-20 in preterm labor in the absence of PPROM (PTL). Figures disclose SEQ ID NOS:2, 134, 2 and 103, respectively, in order of appearance.

FIGS. 109A-109D provide box plots showing examples of reversals with good performance in weeks 19-20 in preterm premature rupture of membranes (PPROM). Figures disclose SEQ ID NOS:2, 120, 47, 120, 107, 18, 124 and 142, respectively, in order of appearance.

FIG. 110 is a risk curve showing relationships between the Predictor Score (ln IBP4/SHBG) and the prevalence adjusted relative risk of sPTB (Positive Predictive Value), using a cut-off of <37 0/7 weeks vs >=37 0/7 weeks gestation. Top (purple) line underneath risk curve graph corresponds to sPTB (GAB<35 weeks); second line (red) from top corresponds to sPTB (35≤GAB<37 weeks); third line (green) from corresponds to TERM (37≤GAB<39 weeks); fourth line (blue) from top corresponds to TERM (39 weeks≤GAB).

FIG. 111 is a risk curve showing relationships between the Predictor Score (ln IBP4/SHBG) and the prevalence adjusted relative risk of sPTB (Positive Predictive Value), using a cut-off of <35 0/7 weeks vs >=35 0/7 weeks gestation. Top (purple) line underneath risk curve graph corresponds to sPTB (GAB<35 weeks); second line (red) from top corresponds to sPTB (35≤GAB<37 weeks); third line (green) from corresponds to TERM (37≤GAB<39 weeks); fourth line (blue) from top corresponds to TERM (39 weeks≤GAB).

DETAILED DESCRIPTION

The present disclosure is based, generally, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of preterm birth relative to controls. The present disclosure is further specifically based, in part, on the unexpected discovery that reversal values of pairs of biomarkers disclosed herein can be utilized in methods of determining the probability for preterm birth in a pregnant female with high sensitivity and specificity. The proteins and peptides disclosed herein as components of ratios and/or reversal pairs serve as biomarkers for classifying test samples, predicting probability of preterm birth, predicting probability of term birth, predicting gestational age at birth (GAB), predicting time to birth (TTB) and/or monitoring of progress of preventative therapy in a pregnant female at risk for PTB, either individually, in ratios, reversal pairs or in panels of biomarkers/reversal pairs. A reversal value is the ratio of the relative peak area of an up regulated biomarker over the relative peak area of a down regulated biomarker and serves to both normalize variability and amplify diagnostic signal. The invention lies, in part, in the selection of particular biomarkers that, when paired together, can predict the probability of pre-term birth based on reversal values. Accordingly, it is human ingenuity in selecting the specific biomarkers that are informative upon being paired in novel reversals that underlies the present invention.

The term “reversal value” refers to the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal. Out of all the possible reversals within a narrow window, a subset can selected based on individual univariate performance. As disclosed herein, the ratio of the relative peak area of an up regulated biomarker over the relative peak area of a down regulated biomarker, referred herein as a reversal value, can be used to identify robust and accurate classifiers and predict probability of preterm birth, predicting probability of term birth, predicting gestational age at birth (GAB), predicting time to birth and/or monitoring of progress of preventative therapy in a pregnant female. The present invention is thus based, in part, on the identification of biomarker pairs where the relative expression of a biomarker pair is reversed that exhibit a change in reversal value between PTB and non-PTB. Use of a ratio of biomarkers in the methods disclosed herein corrects for variability that is the result of human manipulation after the removal of the biological sample from the pregnant female. Such variability can be introduced, for example, during sample collection, processing, depletion, digestion or any other step of the methods used to measure the biomarkers present in a sample and is independent of how the biomarkers behave in nature. Accordingly, the invention generally encompasses the use of a reversal pair in a method of diagnosis or prognosis to reduce variability and/or amplify, normalize or clarify diagnostic signal.

While the term reversal value refers to the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal, it is also contemplated that a pair of biomarkers of the invention could be measured by any other means, for example, by substraction, addition or multiplication of relative peak areas. The methods disclosed herein encompass the measurement of biomarker pairs by such other means.

This method is advantageous because it provides the simplest possible classifier that is independent of data normalization, helps to avoid overfitting, and results in a very simple experimental test that is easy to implement in the clinic. The use of marker pairs based on changes in reversal values that are independent of data normalization enabled the development of the clinically relevant biomarkers disclosed herein. Because quantification of any single protein is subject to uncertainties caused by measurement variability, normal fluctuations, and individual related variation in baseline expression, identification of pairs of markers that may be under coordinated, systematic regulation enables robust methods for individualized diagnosis and prognosis.

The disclosure provides biomarker reversal pairs and associated panels of reversal pairs, methods and kits for determining the probability for preterm birth in a pregnant female. One major advantage of the present disclosure is that risk of developing preterm birth can be assessed early during pregnancy so that appropriate monitoring and clinical management to prevent preterm delivery can be initiated in a timely fashion. The present invention is of particular benefit to females lacking any risk factors for preterm birth and who would not otherwise be identified and treated.

By way of example, the present disclosure includes methods for generating a result useful in determining probability for preterm birth in a pregnant female by obtaining a dataset associated with a sample, where the dataset at least includes quantitative data about the relative expression of biomarker pairs that have been identified as exhibiting changes in reversal value predictive of preterm birth, and inputting the dataset into an analytic process that uses the dataset to generate a result useful in determining probability for preterm birth in a pregnant female. As described further below, quantitative data can include amino acids, peptides, polypeptides, proteins, nucleotides, nucleic acids, nucleosides, sugars, fatty acids, steroids, metabolites, carbohydrates, lipids, hormones, antibodies, regions of interest that serve as surrogates for biological macromolecules and combinations thereof.

In addition to the specific biomarkers identified in this disclosure, for example, by accession number in a public database, sequence, or reference, the invention also contemplates use of biomarker variants that are at least 90% or at least 95% or at least 97% identical to the exemplified sequences and that are now known or later discovered and that have utility for the methods of the invention. These variants may represent polymorphisms, splice variants, mutations, and the like. In this regard, the instant specification discloses multiple art-known proteins in the context of the invention and provides exemplary accession numbers associated with one or more public databases as well as exemplary references to published journal articles relating to these art-known proteins. However, those skilled in the art appreciate that additional accession numbers and journal articles can easily be identified that can provide additional characteristics of the disclosed biomarkers and that the exemplified references are in no way limiting with regard to the disclosed biomarkers. As described herein, various techniques and reagents find use in the methods of the present invention. Suitable samples in the context of the present invention include, for example, blood, plasma, serum, amniotic fluid, vaginal secretions, saliva, and urine. In some embodiments, the biological sample is selected from the group consisting of whole blood, plasma, and serum. In a particular embodiment, the biological sample is serum. As described herein, biomarkers can be detected through a variety of assays and techniques known in the art. As further described herein, such assays include, without limitation, mass spectrometry (MS)-based assays, antibody-based assays as well as assays that combine aspects of the two.

Protein biomarkers that are components of reversal pairs described herein include, for example, Insulin-Like Growth Factor Binding Protein 4 (IBP4), Sex Hormone Binding Globulin (SHBG), Vitronectin (VTNC), Group-Specific Component (Vitamin D Binding Protein) (VTDB), cathepsin D (lysosomal aspartyl protease) (CATD), pregnancy specific beta-1-glycoprotein 2 (PSG2), Inter-Alpha-Trypsin Inhibitor Heavy Chain Family, Member 4 (ITIH4), cell adhesion molecule L1-like (CHL1), Complement Component 1, Q Subcomponent, B Chain (C1QB), Fibulin 3 (FBLN3), Hemopexin (HEMO or HPX), Insulin-Like Growth Factor Binding Protein 6 (IBP6), prostaglandin D2 synthase 21 kDa (PTGDS)

The invention provides isolated biomarkers selected from the group set forth in Table 26. The biomarkers of the invention can predict risk for pre-term birth in a pregnant female. In some embodiments, the isolated biomarkers are selected from the group consisting of IBP4, SHBG, VTNC, VTDB, CATD, PSG2, ITIH4, CHL1, C1QB, FBLN3, HPX, and PTGDS. In some embodiments, the isolated biomarkers are selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.

The invention provides surrogate peptides of the isolated biomarkers selected from the group set forth in Table 26. In some embodiments, the surrogate peptides of the isolated biomarkers are selected from the group of surrogate peptides set forth in Table 26. The biomarkers of the invention and their surrogate peptides can be used in methods to predict risk for pre-term birth in a pregnant female. In some embodiments, the surrogate peptides correspond to isolated biomarkers selected from the group consisting of IBP4, SHBG, VTNC, VTDB, CATD, PSG2, ITIH4, CHL1, C1QB, FBLN3, HPX, and PTGDS. In some embodiments, the surrogate peptides correspond to isolated biomarkers selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.

The invention provides stable isotope labeled standard peptides (SIS peptides) corresponding to the surrogate peptides selected from the group set forth in Table 26. The biomarkers of the invention, their surrogate peptides and the SIS peptides can be used in methods to predict risk for pre-term birth in a pregnant female. In some embodiments, the SIS peptides correspond to surrogate peptides of the isolated biomarkers selected from the group consisting of IBP4, SHBG, VTNC, VTDB, CATD, PSG2, ITIH4, CHL1, C1QB, FBLN3, HPX, and PTGDS. In some embodiments, the SIS peptides correspond to surrogate peptides of the isolated biomarkers selected from the group consisting of IBP4, SHBG, PSG3, LYAM1, IGF2, CLUS, IBP3, INHBC, PSG2, PEDF, CD14, and APOC3.

In some embodiments, the invention provides a pair of isolated biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth compared to term controls. In a further embodiment, the invention provides a pair of isolated biomarkers IBP4/SHBG, wherein the pair of biomarkers exhibits a higher ratio in pregnant females at risk for pre-term birth compared to term controls.

In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for IBP4/SHBG to determine the probability for preterm birth in said pregnant female. In additional embodiments the sample is obtained between 19 and 21 weeks of GABD. In further embodiments the sample is obtained between 19 and 22 weeks of GABD.

Included within the embodiments of the invention, are iterative methods of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, HPX/PTGDS and any other pair of biomarkers selected from the proteins described and/or exemplified herein to determine the probability for preterm birth in said pregnant female, wherein the existence of a change in reversal value between the pregnant female and a term control determines the probability for preterm birth in the pregnant female. Iterative performance of the methods described herein includes subsequent measurements obtained from a single sample as well as obtaining subsequent samples for measurement. For example, if it is determined that the probability for preterm birth in a pregnant female, which can be expressed as a risk score, is above a specified value, the method can be repeated using a distinct reversal pair from the same sample or the same or a distinct reversal pair from a subsequent sample to further stratify the risk for sPTB.

In addition to the specific biomarkers, the disclosure further includes biomarker variants that are about 90%, about 95%, or about 97% identical to the exemplified sequences. Variants, as used herein, include polymorphisms, splice variants, mutations, and the like. Although described with reference to protein biomarkers, changes in reversal value can be identified in protein or gene expression levels for pairs of biomarkers.

Additional markers can be selected from one or more risk indicia, including but not limited to, maternal characteristics, medical history, past pregnancy history, and obstetrical history. Such additional markers can include, for example, previous low birth weight or preterm delivery, multiple 2nd trimester spontaneous abortions, prior first trimester induced abortion, familial and intergenerational factors, history of infertility, nulliparity, placental abnormalities, cervical and uterine anomalies, short cervical length measurements, gestational bleeding, intrauterine growth restriction, in utero diethylstilbestrol exposure, multiple gestations, infant sex, short stature, low prepregnancy weight, low or high body mass index, diabetes, hypertension, urogenital infections (i.e. urinary tract infection), asthma, anxiety and depression, asthma, hypertension, hypothyroidism. Demographic risk indicia for preterm birth can include, for example, maternal age, race/ethnicity, single marital status, low socioeconomic status, maternal age, employment-related physical activity, occupational exposures and environment exposures and stress. Further risk indicia can include, inadequate prenatal care, cigarette smoking, use of marijuana and other illicit drugs, cocaine use, alcohol consumption, caffeine intake, maternal weight gain, dietary intake, sexual activity during late pregnancy and leisure-time physical activities. (Preterm Birth: Causes, Consequences, and Prevention, Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman R E, Butler A S, editors. Washington (DC): National Academies Press (US); 2007). Additional risk indicia useful for as markers can be identified using learning algorithms known in the art, such as linear discriminant analysis, support vector machine classification, recursive feature elimination, prediction analysis of microarray, logistic regression, CART, FlexTree, LART, random forest, MART, and/or survival analysis regression, which are known to those of skill in the art and are further described herein.

It must be noted that, as used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a biomarker” includes a mixture of two or more biomarkers, and the like.

The term “about,” particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.

As used in this application, including the appended claims, the singular forms “a,” “an,” and “the” include plural references, unless the content clearly dictates otherwise, and are used interchangeably with “at least one” and “one or more.”

As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “contains,” “containing,” and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, product-by-process, or composition of matter that comprises, includes, or contains an element or list of elements does not include only those elements but can include other elements not expressly listed or inherent to such process, method, product-by-process, or composition of matter.

As used herein, the term “panel” refers to a composition, such as an array or a collection, comprising one or more biomarkers. The term can also refer to a profile or index of expression patterns of one or more biomarkers described herein. The number of biomarkers useful for a biomarker panel is based on the sensitivity and specificity value for the particular combination of biomarker values.

As used herein, and unless otherwise specified, the terms “isolated” and “purified” generally describes a composition of matter that has been removed from its native environment (e.g., the natural environment if it is naturally occurring), and thus is altered by the hand of man from its natural state so as to possess markedly different characteristics with regard to at least one of structure, function and properties. An isolated protein or nucleic acid is distinct from the way it exists in nature and includes synthetic peptides and proteins.

The term “biomarker” refers to a biological molecule, or a fragment of a biological molecule, the change and/or the detection of which can be correlated with a particular physical condition or state. The terms “marker” and “biomarker” are used interchangeably throughout the disclosure. For example, the biomarkers of the present invention are correlated with an increased likelihood of preterm birth. Such biomarkers include any suitable analyte, but are not limited to, biological molecules comprising nucleotides, nucleic acids, nucleosides, amino acids, sugars, fatty acids, steroids, metabolites, peptides, polypeptides, proteins, carbohydrates, lipids, hormones, antibodies, regions of interest that serve as surrogates for biological macromolecules and combinations thereof (e.g., glycoproteins, ribonucleoproteins, lipoproteins). The term also encompasses portions or fragments of a biological molecule, for example, peptide fragment of a protein or polypeptide that comprises at least 5 consecutive amino acid residues, at least 6 consecutive amino acid residues, at least 7 consecutive amino acid residues, at least 8 consecutive amino acid residues, at least 9 consecutive amino acid residues, at least 10 consecutive amino acid residues, at least 11 consecutive amino acid residues, at least 12 consecutive amino acid residues, at least 13 consecutive amino acid residues, at least 14 consecutive amino acid residues, at least 15 consecutive amino acid residues, at least 5 consecutive amino acid residues, at least 16 consecutive amino acid residues, at least 17 consecutive amino acid residues, at least 18 consecutive amino acid residues, at least 19 consecutive amino acid residues, at least 20 consecutive amino acid residues, at least 21 consecutive amino acid residues, at least 22 consecutive amino acid residues, at least 23 consecutive amino acid residues, at least 24 consecutive amino acid residues, at least 25 consecutive amino acid residues, or more consecutive amino acid residues.

As used herein, the term “surrogate peptide” refers to a peptide that is selected to serve as a surrogate for quantification of a biomarker of interest in an MRM assay configuration. Quantification of surrogate peptides is best achieved using stable isotope labeled standard surrogate peptides (“SIS surrogate peptides” or “SIS peptides”) in conjunction with the MRM detection technique. A surrogate peptide can be synthetic. An SIS surrogate peptide can be synthesized with heavy labeled for example, with an Arginine or Lysine, or any other amino acid at the C-terminus of the peptide to serve as an internal standard in the MRM assay. An SIS surrogate peptide is not a naturally occurring peptide and has markedly different structure and properties compared to its naturally occurring counterpart.

In some embodiments, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a ratio for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, HPX/PTGDS to determine the probability for preterm birth in said pregnant female, wherein the existence of a change in the ratio between the pregnant female and a term control determines the probability for preterm birth in the pregnant female. In some embodiments, the ratio may include an up-regulated protein in the numerator, a down-regulated protein in the denominator or both. For example, as exemplified herein, IBP4/SHBG is a ratio of an up-regulated protein in the numerator and a down-regulated protein in the denominator, which is defined herein as a “reversal”. In the instances where the ratio includes an up-regulated protein in the numerator, or a down-regulated protein in the denominator, the un-regulated protein would serve to normalize (e.g. decrease pre-analytical or analytical variability). In the particular case of a ratio that is a “reversal” both amplification and normalization are possible. It is understood, that the methods of the invention are not limited to the subset of reversals, but also encompass ratios of biomarkers.

As used herein, the term “reversal” refers to the ratio of the measured value of an upregulated analyte over that of a down-regulated analyte. In some embodiments, the analyte value is itself a ratio of the peak area of the endogenous analyte over that of the peak area of the corresponding stable isotopic standard analyte, referred to herein as: response ratio or relative ratio.

As used herein, the term “reversal pair” refers to biomarkers in pairs that exhibit a change in value between the classes being compared. The detection of reversals in protein concentrations or gene expression levels eliminates the need for data normalization or the establishment of population-wide thresholds. In some embodiments, the reversal pair is a pair of isolated biomarkers IBP4/SHBG, wherein the reversal pair exhibits a change in reversal value between pregnant females at risk for pre-term birth compared to term controls. In a further embodiment, the reversal pair IBP4/SHBG exhibits a higher ratio in pregnant females at risk for pre-term birth compared to term controls. Encompassed within the definition of any reversal pair is the corresponding reversal pair wherein individual biomarkers are switched between the numerator and denominator. One skilled in the art will appreciate that such a corresponding reversal pair is equally informative with regard to its predictive power.

This reversal method is advantageous because it provides the simplest possible classifier that is independent of data normalization, helps to avoid overfitting, and results in a very simple experimental test that is easy to implement in the clinic. The use of biomarker pairs based on reversals that are independent of data normalization as described herein has tremendous power as a method for the identification of clinically relevant PTB biomarkers. Because quantification of any single protein is subject to uncertainties caused by measurement variability, normal fluctuations, and individual related variation in baseline expression, identification of pairs of markers that can be under coordinated, systematic regulation should prove to be more robust for individualized diagnosis and prognosis.

The invention provides a composition comprising a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. In one embodiment, the compositions comprises stable isotope labeled standard peptides (SIS peptides) for surrogate peptides derived from each of said biomarkers.

In particular embodiments, the invention provides a pair of isolated biomarkers consisting of IBP4 and SHBG, wherein the pair exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.

IBP4 is a member of a family of insulin-like growth factor binding proteins (IBP) that negatively regulate the insulin-like growth factors IGF1 and IGF2. (Forbes et al. Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. Am J Physiol, Cell Physiol. 2008; 294(6):C1313-22). IBP4 is expressed by syncytiotrophoblasts (Crosley et al., IGFBP-4 and -5 are expressed in first-trimester villi and differentially regulate the migration of HTR-8/SVneo cells. Reprod Biol Endocrinol. 2014; 12(1):123) and is the dominant IBP expressed by extravillous trophoblasts (Qiu et al. Significance of IGFBP-4 in the development of fetal growth restriction. J Clin Endocrinol Metab. 2012; 97(8):E1429-39). Compared to term pregnancies, maternal IBP4 levels in early pregnancy are higher in pregnancies complicated by fetal growth restriction and preeclampsia. (Qiu et al., supra, 2012)

SHBG regulates the availability of biologically active unbound steroid hormones. Hammond G L. Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod. 2011; 85(3):431-41. Plasma SHBG levels increase 5-10 fold during pregnancy (Anderson D C. Sex-hormone-binding globulin. Clin Endocrinol (Oxf). 1974; 3(1):69-96) and evidence exists for extra-hepatic expression, including placental trophoblastic cells. (Larrea et al. Evidence that human placenta is a site of sex hormone-binding globulin gene expression. J Steroid Biochem Mol Biol. 1993; 46(4):497-505) Physiologically, SHBG levels negatively correlate with triglycerides, insulin levels and BMI. (Simó et al. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015; 26(7):376-83) BMI's effect on SHBG levels may explain, in part, the improved predictive performance with BMI stratification.

Intra-amniotic infection and inflammation have been associated with PTB, as has increased levels of proinflammatory cytokines including TNF-α and IL1-β (Mendelson C R. Minireview: fetal-maternal hormonal signaling in pregnancy and labor. Mol Endocrinol. 2009; 23(7):947-54; Gomez-Lopez et al. Immune cells in term and preterm labor. Cell Mol Immunol. 2014; 11(6):571-81). SHBG transcription in liver is suppressed by IL1-β and NF-kB mediated TNF-α signaling (Simó et al. Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab. 2015; 26(7):376-83), a pathway implicated in initiation of normal and abnormal labor (Lindstrom T M, Bennett P R. The role of nuclear factor kappa B in human labour. Reproduction. 2005; 130(5):569-81). Lower levels of SHBG in women destined for sPTB may be a result of infection and/or inflammation. Hence, SHBG may be critical for control of androgen and estrogen action in the placental-fetal unit in response to upstream inflammatory signals.

In one embodiment, the invention provides a composition comprising a pair of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.

In an additional embodiment, the invention provides a panel of at least two pairs of surrogate peptides, each pair of the of surrogate peptides corresponding to a pair of biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS, wherein each of the pairs exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls.

In an additional embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of the biomarker pairs specified in Tables 27 through 59, 61 through 72, 76 and 77 in a pregnant female to determine the probability for preterm birth in the pregnant female.

In an further embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of the biomarkers listed in Table 26 in a pregnant female to determine the probability for preterm birth in the pregnant female.

For methods directed to predicating time to birth, it is understood that “birth” means birth following spontaneous onset of labor, with or without rupture of membranes.

Although described and exemplified with reference to methods of determining probability for preterm birth in a pregnant female, the present disclosure is similarly applicable to methods of predicting gestational age at birth (GAB), methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth (TTB) in a pregnant female. It will be apparent to one skilled in the art that each of the aforementioned methods has specific and substantial utilities and benefits with regard maternal-fetal health considerations.

Furthermore, although described and exemplified with reference to methods of determining probability for preterm birth in a pregnant female, the present disclosure is similarly applicable to methods of predicting an abnormal glucola test, gestational diabetes, hypertension, preeclampsia, intrauterine growth restriction, stillbirth, fetal growth restriction, HELLP syndrome, oligohyramnios, chorioamnionitis, chorioamnionitis, placental previa, placental acreta, abruption, abruptio placenta, placental hemorrhage, preterm premature rupture of membranes, preterm labor, unfavorable cervix, postterm pregnancy, cholelithiasis, uterine over distention, stress. As described in more detail below, the classifier described herein is sensitive to a component of medically indicated PTB based on conditions such as, for example, preeclampsia or gestational diabetes.

In some embodiments, the present disclosure provides biomarkers, biomarker pairs and/or reversals, exemplified here by using ITIH4/CSH, that are strong predictors of time to birth (TTB) (FIG. 10). TTB is defined as the difference between the GABD and the gestational age at birth (GAB). This discovery enables prediction, either individually or in mathematical combination of such analytes of TTB or GAB. Analytes that lack a case versus control difference, but demonstrate changes in analyte intensity across pregnancy, are useful in a pregnancy clock according to the methods of the invention. Calibration of multiple analytes that may not be diagnostic of preterm birth of other disorders, could be used to date pregnancy. Such a pregnancy clock is of value to confirm dating by another measure (e.g. date of last menstrual period and/or ultrasound dating), or useful alone to subsequently and more accurately predict sPTB, GAB or TTB, for example. These analytes, also referred to herein as “clock proteins”, can be used to date a pregnancy in the absence of or in conjunction with other dating methods. Table 60 provides a list of clock proteins useful in a pregnancy clock of the invention to predict TTB and GAB.

In additional embodiments, the methods of determining probability for preterm birth in a pregnant female further encompass detecting a measurable feature for one or more risk indicia associated with preterm birth. In additional embodiments the risk indicia are selected form the group consisting of previous low birth weight or preterm delivery, multiple 2nd trimester spontaneous abortions, prior first trimester induced abortion, familial and intergenerational factors, history of infertility, nulliparity, gravidity, primigravida, multigravida, placental abnormalities, cervical and uterine anomalies, gestational bleeding, intrauterine growth restriction, in utero diethylstilbestrol exposure, multiple gestations, infant sex, short stature, low prepregnancy weight, low or high body mass index, diabetes, hypertension, and urogenital infections.

A “measurable feature” is any property, characteristic or aspect that can be determined and correlated with the probability for preterm birth in a subject. The term further encompasses any property, characteristic or aspect that can be determined and correlated in connection with a prediction of GAB, a prediction of term birth, or a prediction of time to birth in a pregnant female. For a biomarker, such a measurable feature can include, for example, the presence, absence, or concentration of the biomarker, or a fragment thereof, in the biological sample, an altered structure, such as, for example, the presence or amount of a post-translational modification, such as oxidation at one or more positions on the amino acid sequence of the biomarker or, for example, the presence of an altered conformation in comparison to the conformation of the biomarker in term control subjects, and/or the presence, amount, or altered structure of the biomarker as a part of a profile of more than one biomarker.

In addition to biomarkers, measurable features can further include risk indicia including, for example, maternal characteristics, age, race, ethnicity, medical history, past pregnancy history, obstetrical history. For a risk indicium, a measurable feature can include, for example, previous low birth weight or preterm delivery, multiple 2nd trimester spontaneous abortions, prior first trimester induced abortion, familial and intergenerational factors, history of infertility, nulliparity, placental abnormalities, cervical and uterine anomalies, short cervical length measurements, gestational bleeding, intrauterine growth restriction, in utero diethylstilbestrol exposure, multiple gestations, infant sex, short stature, low prepregnancy weight/low body mass index, diabetes, hypertension, urogenital infections, hypothyroidism, asthma, low educational attainment, cigarette smoking, drug use and alcohol consumption.

In some embodiments, the methods of the invention comprise calculation of body mass index (BMI).

In some embodiments, the disclosed methods for determining the probability of preterm birth encompass detecting and/or quantifying one or more biomarkers using mass spectrometry, a capture agent or a combination thereof.

In additional embodiments, the disclosed methods of determining probability for preterm birth in a pregnant female encompass an initial step of providing a biological sample from the pregnant female.

In some embodiments, the disclosed methods of determining probability for preterm birth in a pregnant female encompass communicating the probability to a health care provider. The disclosed of predicting GAB, the methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth in a pregnant female similarly encompass communicating the probability to a health care provider. As stated above, although described and exemplified with reference to determining probability for preterm birth in a pregnant female, all embodiments described throughout this disclosure are similarly applicable to the methods of predicting GAB, the methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth in a pregnant female. Specifically, the biomarkers and panels recited throughout this application with express reference to methods for preterm birth can also be used in methods for predicting GAB, the methods for predicting term birth, methods for determining the probability of term birth in a pregnant female as well methods of predicating time to birth in a pregnant female. It will be apparent to one skilled in the art that each of the aforementioned methods has specific and substantial utilities and benefits with regard maternal-fetal health considerations.

In additional embodiments, the communication informs a subsequent treatment decision for the pregnant female. In some embodiments, the method of determining probability for preterm birth in a pregnant female encompasses the additional feature of expressing the probability as a risk score.

In the methods disclosed herein, determining the probability for preterm birth in a pregnant female encompasses an initial step that includes formation of a probability/risk index by measuring the ratio of isolated biomarkers selected from the group in a cohort of preterm pregnancies and term pregnancies with known gestational age at birth. For an individual pregnancy, determining the probability of for preterm birth in a pregnant female encompasses measuring the ratio of the isolated biomarker using the same measurement method as used in the initial step of creating the probability/risk index, and comparing the measured ratio to the risk index to derive the personalized risk for the individual pregnancy. In one embodiment, a preterm risk index is formed by measuring the ratio of IBP4/SHBG in a cohort of preterm and term pregnancies where the gestational age at birth is recorded. Then, in clinical practice the measured ratio of IBP4/SHBG in an individual pregnancy is compared in the index to derive the preterm risk using the same isolation and measurement technologies to derive IBP4/SHBG as in the index group.

As used herein, the term “risk score” refers to a score that can be assigned based on comparing the amount of one or more biomarkers or reversal values in a biological sample obtained from a pregnant female to a standard or reference score that represents an average amount of the one or more biomarkers calculated from biological samples obtained from a random pool of pregnant females. In some embodiments, the risk score is expressed as the log of the reversal value, i.e. the ratio of the relative intensities of the individual biomarkers. One skilled in the art will appreciate that a risk score can be expressed based on a various data transformations as well as being expressed as the ratio itself. Furthermore, with particular regard to reversal pairs, one skilled in the art will appreciate the any ratio is equally informative if the biomarkers in the numerator and denominator are switched or that related data transformations (e.g. subtraction) are applied. Because the level of a biomarker may not be static throughout pregnancy, a standard or reference score has to have been obtained for the gestational time point that corresponds to that of the pregnant female at the time the sample was taken. The standard or reference score can be predetermined and built into a predictor model such that the comparison is indirect rather than actually performed every time the probability is determined for a subject. A risk score can be a standard (e.g., a number) or a threshold (e.g., a line on a graph). The value of the risk score correlates to the deviation, upwards or downwards, from the average amount of the one or more biomarkers calculated from biological samples obtained from a random pool of pregnant females. In certain embodiments, if a risk score is greater than a standard or reference risk score, the pregnant female can have an increased likelihood of preterm birth. In some embodiments, the magnitude of a pregnant female's risk score, or the amount by which it exceeds a reference risk score, can be indicative of or correlated to that pregnant female's level of risk.

As exemplified herein, the PreTRM™ Classifier is defined as the natural log of the SIS normalized intensities of the IBP4 peptide transition (QCHPALDGQR_394.5_475.2 (SEQ ID NO: 2)) and the SHBG peptide transition (IALGGLLFPASNLR_481.3_657.4 (SEQ ID NO: 18)). Score=ln(P¹_n/P²_n), where P¹_nand P²_ndenote the SIS normalized peak area values for the IBP4 and SHBG transitions, respectively. SIS normalization is defined as the relative ratio of the endogenous peak area divided by the corresponding SIS peak area: e.g. P¹_n=P¹_e/P¹_SIS, where P¹_e=the peak area for the IBP4 endogenous transition and P¹_SIS=the peak area for IBP4 SIS transition. From the identified association between the distribution of PreTRM™ scores and the corresponding prevalence adjusted positive predictive value a probability of sPTB can be assigned to an unknown subject based on the determination of their score”. This relationship or association is shown in FIG. 25, and connects a laboratory measurement with a clinical prediction.

While the PreTRM™ Classifier is defined as the natural log of the SIS normalized intensities of the IBP4 peptide transition (QCHPALDGQR_394.5_475.2 (SEQ ID NO: 2)) and the SHBG peptide transition (IALGGLLFPASNLR_481.3_657.4 (SEQ ID NO: 18)), the invention also comprises classifiers that include multiple reversals. Improved performance can be achieved by constructing predictors formed from more than one reversal. In additional embodiments, the invention methods therefore comprise multiple reversals that have a strong predictive performance for example, for separate GABD windows, preterm premature rupture of membranes (PPROM) versus preterm labor in the absence of PPROM (PTL), fetal gender, primigravida versus multigravida. This embodiment is exemplified in Example 10, and Table 61, for either reversals that produced strong predictive performance either early (e.g. weeks 17-19) or later (e.g. weeks 19-21) in the gestational age range. As exemplified, performance of predictors formed from combinations (SumLog) of multiple reversals were evaluated for the entire blood draw range and a predictor score was derived from summing the Log values of the individual reversal (SumLog). One skilled in the art can select other models (e.g. logistic regression) to construct a predictor formed from more than one reversal.

The methods of the invention further include classifiers that contain an indicator variable that selects one or a subset of reversals based on known clinical factors, for example, blood draw period, fetal gender, gravidity as well as any other knowable patient features and/or risk factors described throughout this application. This embodiment is exemplified in Example 10, Tables 61 through 64, which exemplify reversal performance (weeks 17-21) independently for two different phenotypes of sPTB, PPROM and PTL. This embodiment is similarly exemplified in Example 10, Tables 76 and 77 and FIGS. 108 and 109, which exemplify reversal performance (weeks 19-21) independently for two different phenotypes of sPTB, preterm premature rupture of membranes (PPROM) and preterm labor in the absence of PPROM (PTL). The methods of the invention thus include selection of reversals to build independent predictors of PPROM and PTL, or to maximize performance overall with the combination of more than one reversal in a single predictor as described above. This embodiment is further exemplified in Example 10, Tables 65-68, which exemplify reversal performance (weeks 17-21) independently for two different types of sPTB, primigravida and multigravida. This embodiment is further exemplified in Example 10, Tables 69-72 and FIG. 106, which exemplify reversal performance (weeks 17-21) independently for two different types of sPTB based on fetal gender. While exemplified with regard to PPROM and PTL, gravidity and fetal gender, the methods of the invention include classifiers that contain an indicator variable that selects one or a subset of reversals based on GABD or any known clinical factors/risk factors described herein or otherwise known to those of skill in the art. As an alternative to having a classifier that includes an indicator variable, the invention further provides separate classifiers that are tailored to subsets of pregnant women based on GABD or any known clinical factors/risk factors described herein or otherwise known to those of skill in the art. For example, this embodiment encompasses separate classifiers for consecutive and/or overlapping time windows for GABD that are based on the best performing reversals for each time window.

As exemplified herein, the predictive performance of the claimed methods can be improved with a BMI stratification of greater than 22 and equal or less than 37 kg/m². Accordingly, in some embodiments, the methods of the invention can be practiced with samples obtained from pregnant females with a specified BMI. Briefly, BMI is an individual's weight in kilograms divided by the square of height in meters. BMI does not measure body fat directly, but research has shown that BMI is correlated with more direct measures of body fat obtained from skinfold thickness measurements, bioelectrical impedance, densitometry (underwater weighing), dual energy x-ray absorptiometry (DXA) and other methods. Furthermore, BMI appears to be as strongly correlated with various metabolic and disease outcome as are these more direct measures of body fatness. Generally, an individual with a BMI below 18.5 is considered underweight, an individual with a BMI of equal or greater than 18.5 to 24.9 normal weight, while an individual with a BMI of equal or greater than 25.0 to 29.9 is considered overweight and an individual with a BMI of equal or greater than 30.0 is considered obese. In some embodiments, the predictive performance of the claimed methods can be improved with a BMI stratification of equal or greater than 18, equal or greater than 19, equal or greater than 20, equal or greater than 21, equal or greater than 22, equal or greater than 23, equal or greater than 24, equal or greater than 25, equal or greater than 26, equal or greater than 27, equal or greater than 28, equal or greater than 29 or equal or greater than 30. In other embodiments, the predictive performance of the claimed methods can be improved with a BMI stratification of equal or less than 18, equal or less than 19, equal or less than 20, equal or less than 21, equal or less than 22, equal or less than 23, equal or less than 24, equal or less than 25, equal or less than 26, equal or less than 27, equal or less than 28, equal or less than 29 or equal or less than 30.

In the context of the present invention, the term “biological sample,” encompasses any sample that is taken from pregnant female and contains one or more of the biomarkers disclosed herein. Suitable samples in the context of the present invention include, for example, blood, plasma, serum, amniotic fluid, vaginal secretions, saliva, and urine. In some embodiments, the biological sample is selected from the group consisting of whole blood, plasma, and serum. In a particular embodiment, the biological sample is serum. As will be appreciated by those skilled in the art, a biological sample can include any fraction or component of blood, without limitation, T cells, monocytes, neutrophils, erythrocytes, platelets and microvesicles such as exosomes and exosome-like vesicles. In a particular embodiment, the biological sample is serum.

As used herein, the term “preterm birth” refers to delivery or birth at a gestational age less than 37 completed weeks. Other commonly used subcategories of preterm birth have been established and delineate moderately preterm (birth at 33 to 36 weeks of gestation), very preterm (birth at <33 weeks of gestation), and extremely preterm (birth at ≤28 weeks of gestation). With regard to the methods disclosed herein, those skilled in the art understand that the cut-offs that delineate preterm birth and term birth as well as the cut-offs that delineate subcategories of preterm birth can be adjusted in practicing the methods disclosed herein, for example, to maximize a particular health benefit. In various embodiments of the invention, cut-off that delineate preterm birth include, for example, birth at ≤37 weeks of gestation, ≤36 weeks of gestation, ≤35 weeks of gestation, ≤34 weeks of gestation, ≤33 weeks of gestation, ≤32 weeks of gestation, ≤30 weeks of gestation, ≤29 weeks of gestation, ≤28 weeks of gestation, ≤27 weeks of gestation, ≤26 weeks of gestation, ≤25 weeks of gestation, ≤24 weeks of gestation, ≤23 weeks of gestation or ≤22 weeks of gestation. In some embodiments, the cut-off delineating preterm birth is ≤35 weeks of gestation. It is further understood that such adjustments are well within the skill set of individuals considered skilled in the art and encompassed within the scope of the inventions disclosed herein. Gestational age is a proxy for the extent of fetal development and the fetus's readiness for birth. Gestational age has typically been defined as the length of time from the date of the last normal menses to the date of birth. However, obstetric measures and ultrasound estimates also can aid in estimating gestational age. Preterm births have generally been classified into two separate subgroups. One, spontaneous preterm births are those occurring subsequent to spontaneous onset of preterm labor or preterm premature rupture of membranes regardless of subsequent labor augmentation or cesarean delivery. Two, medically indicated preterm births are those occurring following induction or cesarean section for one or more conditions that the woman's caregiver determines to threaten the health or life of the mother and/or fetus. In some embodiments, the methods disclosed herein are directed to determining the probability for spontaneous preterm birth or medically indicated preterm birth. In some embodiments, the methods disclosed herein are directed to determining the probability for spontaneous preterm birth. In additional embodiments, the methods disclosed herein are directed to medically indicated preterm birth. In additional embodiments, the methods disclosed herein are directed to predicting gestational age at birth.

As used herein, the term “estimated gestational age” or “estimated GA” refers to the GA determined based on the date of the last normal menses and additional obstetric measures, ultrasound estimates or other clinical parameters including, without limitation, those described in the preceding paragraph. In contrast the term “predicted gestational age at birth” or “predicted GAB” refers to the GAB determined based on the methods of the invention as disclosed herein. As used herein, “term birth” refers to birth at a gestational age equal or more than 37 completed weeks.

In some embodiments, the pregnant female is between 17 and 28 weeks of gestation at the time the biological sample is collected, also referred to as GABD (Gestational Age at Blood Draw). In other embodiments, the pregnant female is between 16 and 29 weeks, between 17 and 28 weeks, between 18 and 27 weeks, between 19 and 26 weeks, between 20 and 25 weeks, between 21 and 24 weeks, or between 22 and 23 weeks of gestation at the time the biological sample is collected. In further embodiments, the pregnant female is between about 17 and 22 weeks, between about 16 and 22 weeks between about 22 and 25 weeks, between about 13 and 25 weeks, between about 26 and 28, or between about 26 and 29 weeks of gestation at the time the biological sample is collected. Accordingly, the gestational age of a pregnant female at the time the biological sample is collected can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 weeks. In particular embodiments, the biological sample is collected between 19 and 21 weeks of gestational age. In particular embodiments, the biological sample is collected between 19 and 22 weeks of gestational age. In particular embodiments, the biological sample is collected between 19 and 21 weeks of gestational age. In particular embodiments, the biological sample is collected between 19 and 22 weeks of gestational age. In particular embodiments, the biological sample is collected at 18 weeks of gestational age. In further embodiments, the highest performing reversals for consecutive or overlapping time windows can be combined in a single classifier to predict the probability of sPTB over a wider window of gestational age at blood draw.

The term “amount” or “level” as used herein refers to a quantity of a biomarker that is detectable or measurable in a biological sample and/or control. The quantity of a biomarker can be, for example, a quantity of polypeptide, the quantity of nucleic acid, or the quantity of a fragment or surrogate. The term can alternatively include combinations thereof. The term “amount” or “level” of a biomarker is a measurable feature of that biomarker.

The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of the biomarker pairs specified in any of Tables 1 through 77 and FIGS. 1 through 111 in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent.

The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of the biomarker pairs specified in Tables 27 through 59, 61 through 72, 76 and 77 in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent.

The invention also provides a method of detecting a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, VTNC/VTDB, VTNC/SHBG, CATD/SHBG, PSG2/ITIH4, CHL1/ITIH4, PSG2/C1QB, PSG2/FBLN3, HPX/IBP4, and HPX/PTGDS in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether the pair of isolated biomarkers is present in the biological sample by contacting the biological sample with a first capture agent that specifically binds a first member of said pair and a second capture agent that specifically binds a second member of said pair; and detecting binding between the first biomarker of said pair and the first capture agent and between the second member of said pair and the second capture agent. In one embodiment the invention provides a method of detecting IBP4 and SHBG in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; b. detecting whether IBP4 and SHBG are present in the biological sample by contacting the biological sample with a capture agent that specifically binds IBP4 and a capture agent that specifically binds SHBG; and c. detecting binding between IBP4 and the capture agent and between SHBG and the capture agent. In one embodiment, the method comprises measuring a reversal value for the pair of biomarkers. In a further embodiment, the existence of a change in reversal value between the pregnant female and a term control indicates the probability for preterm birth in the pregnant female. In one embodiment, the sample is obtained between 19 and 21 weeks of gestational age. In a further embodiment, the capture agent is selected from the group consisting of and antibody, antibody fragment, nucleic acid-based protein binding reagent, small molecule or variant thereof. In an additional embodiment, the method is performed by an assay selected from the group consisting of enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (MA).

In one embodiment the invention provides a method of detecting IBP4 and SHBG in a pregnant female, said method comprising the steps of a. obtaining a biological sample from the pregnant female; and b. detecting whether the pair of isolated biomarkers is present in the biological sample comprising subjecting the sample to a proteomics work-flow comprised of mass spectrometry quantification.

A “proteomics work-flow” generally encompasses one or more of the following steps: Serum samples are thawed and depleted of the 14 highest abundance proteins by immune-affinity chromatography. Depleted serum is digested with a protease, for example, trypsin, to yield peptides. The digest is subsequently fortified with a mixture of SIS peptides and then desalted and subjected to LC-MS/MS with a triple quadrapole instrument operated in MRM mode. Response ratios are formed from the area ratios of endogenous peptide peaks and the corresponding SIS peptide counterpart peaks. Those skilled in the art appreciate that other types of MS such as, for example, MALDI-TOF, or ESI-TOF, can be used in the methods of the invention. In addition, one skilled in the art can modify a proteomics work-flow, for example, by selecting particular reagents (such as proteases) or omitting or changing the order of certain steps, for example, it may not be necessary to immunodeplete, the SIS peptide could be added earlier or later and stable isotope labeled proteins could be used as standards instead of peptides.

Any existing, available or conventional separation, detection and quantification methods can be used herein to measure the presence or absence (e.g., readout being present vs. absent; or detectable amount vs. undetectable amount) and/or quantity (e.g., readout being an absolute or relative quantity, such as, for example, absolute or relative concentration) of biomarkers, peptides, polypeptides, proteins and/or fragments thereof and optionally of the one or more other biomarkers or fragments thereof in samples. In some embodiments, detection and/or quantification of one or more biomarkers comprises an assay that utilizes a capture agent. In further embodiments, the capture agent is an antibody, antibody fragment, nucleic acid-based protein binding reagent, small molecule or variant thereof. In additional embodiments, the assay is an enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (MA). In some embodiments, detection and/or quantification of one or more biomarkers further comprises mass spectrometry (MS). In yet further embodiments, the mass spectrometry is co-immunoprecitipation-mass spectrometry (co-IP MS), where coimmunoprecipitation, a technique suitable for the isolation of whole protein complexes is followed by mass spectrometric analysis.

As used herein, the term “mass spectrometer” refers to a device able to volatilize/ionize analytes to form gas-phase ions and determine their absolute or relative molecular masses. Suitable methods of volatilization/ionization are matrix-assisted laser desorption ionization (MALDI), electrospray, laser/light, thermal, electrical, atomized/sprayed and the like, or combinations thereof. Suitable forms of mass spectrometry include, but are not limited to, ion trap instruments, quadrupole instruments, electrostatic and magnetic sector instruments, time of flight instruments, time of flight tandem mass spectrometer (TOF MS/MS), Fourier-transform mass spectrometers, Orbitraps and hybrid instruments composed of various combinations of these types of mass analyzers. These instruments can, in turn, be interfaced with a variety of other instruments that fractionate the samples (for example, liquid chromatography or solid-phase adsorption techniques based on chemical, or biological properties) and that ionize the samples for introduction into the mass spectrometer, including matrix-assisted laser desorption (MALDI), electrospray, or nanospray ionization (ESI) or combinations thereof.

Generally, any mass spectrometric (MS) technique that can provide precise information on the mass of peptides, and preferably also on fragmentation and/or (partial) amino acid sequence of selected peptides (e.g., in tandem mass spectrometry, MS/MS; or in post source decay, TOF MS), can be used in the methods disclosed herein. Suitable peptide MS and MS/MS techniques and systems are well-known per se (see, e.g., Methods in Molecular Biology, vol. 146: “Mass Spectrometry of Proteins and Peptides”, by Chapman, ed., Humana Press 2000; Biemann 1990. Methods Enzymol 193: 455-79; or Methods in Enzymology, vol. 402: “Biological Mass Spectrometry”, by Burlingame, ed., Academic Press 2005) and can be used in practicing the methods disclosed herein. Accordingly, in some embodiments, the disclosed methods comprise performing quantitative MS to measure one or more biomarkers. Such quantitative methods can be performed in an automated (Villanueva, et al., Nature Protocols (2006) 1(2):880-891) or semi-automated format. In particular embodiments, MS can be operably linked to a liquid chromatography device (LC-MS/MS or LC-MS) or gas chromatography device (GC-MS or GC-MS/MS). Other methods useful in this context include isotope-coded affinity tag (ICAT), tandem mass tags (TMT), or stable isotope labeling by amino acids in cell culture (SILAC), followed by chromatography and MS/MS.

As used herein, the terms “multiple reaction monitoring (MRM)” or “selected reaction monitoring (SRM)” refer to an MS-based quantification method that is particularly useful for quantifying analytes that are in low abundance. In an SRM experiment, a predefined precursor ion and one or more of its fragments are selected by the two mass filters of a triple quadrupole instrument and monitored over time for precise quantification. Multiple SRM precursor and fragment ion pairs can be measured within the same experiment on the chromatographic time scale by rapidly toggling between the different precursor/fragment pairs to perform an MRM experiment. A series of transitions (precursor/fragment ion pairs) in combination with the retention time of the targeted analyte (e.g., peptide or small molecule such as chemical entity, steroid, hormone) can constitute a definitive assay. A large number of analytes can be quantified during a single LC-MS experiment. The term “scheduled,” or “dynamic” in reference to MRM or SRM, refers to a variation of the assay wherein the transitions for a particular analyte are only acquired in a time window around the expected retention time, significantly increasing the number of analytes that can be detected and quantified in a single LC-MS experiment and contributing to the selectivity of the test, as retention time is a property dependent on the physical nature of the analyte. A single analyte can also be monitored with more than one transition. Finally, included in the assay can be standards that correspond to the analytes of interest (e.g., same amino acid sequence), but differ by the inclusion of stable isotopes. Stable isotopic standards (SIS) can be incorporated into the assay at precise levels and used to quantify the corresponding unknown analyte. An additional level of specificity is contributed by the co-elution of the unknown analyte and its corresponding SIS and properties of their transitions (e.g., the similarity in the ratio of the level of two transitions of the unknown and the ratio of the two transitions of its corresponding SIS).

Mass spectrometry assays, instruments and systems suitable for biomarker peptide analysis can include, without limitation, matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS; MALDI-TOF post-source-decay (PSD); MALDI-TOF/TOF; surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF) MS; electrospray ionization mass spectrometry (ESI-MS); ESI-MS/MS; ESI-MS/(MS)_n(n is an integer greater than zero); ESI 3D or linear (2D) ion trap MS; ESI triple quadrupole MS; ESI quadrupole orthogonal TOF (Q-TOF); ESI Fourier transform MS systems; desorption/ionization on silicon (DIOS); secondary ion mass spectrometry (SIMS); atmospheric pressure chemical ionization mass spectrometry (APCI-MS); APCI-MS/MS; APCI-(MS)_n; ion mobility spectrometry (IMS); inductively coupled plasma mass spectrometry (ICP-MS) atmospheric pressure photoionization mass spectrometry (APPI-MS); APPI-MS/MS; and APPI-(MS)_n. Peptide ion fragmentation in tandem MS (MS/MS) arrangements can be achieved using manners established in the art, such as, e.g., collision induced dissociation (CID). As described herein, detection and quantification of biomarkers by mass spectrometry can involve multiple reaction monitoring (MRM), such as described among others by Kuhn et al. Proteomics 4: 1175-86 (2004). Scheduled multiple-reaction-monitoring (Scheduled MRM) mode acquisition during LC-MS/MS analysis enhances the sensitivity and accuracy of peptide quantitation. Anderson and Hunter, Molecular and Cellular Proteomics 5(4):573 (2006). As described herein, mass spectrometry-based assays can be advantageously combined with upstream peptide or protein separation or fractionation methods, such as for example with the chromatographic and other methods described herein below. As further described herein, shotgun quantitative proteomics can be combined with SRM/MRM-based assays for high-throughput identification and verification of prognostic biomarkers of preterm birth.

A person skilled in the art will appreciate that a number of methods can be used to determine the amount of a biomarker, including mass spectrometry approaches, such as MS/MS, LC-MS/MS, multiple reaction monitoring (MRM) or SRM and product-ion monitoring (PIM) and also including antibody based methods such as immunoassays such as Western blots, enzyme-linked immunosorbant assay (ELISA), immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, and FACS. Accordingly, in some embodiments, determining the level of the at least one biomarker comprises using an immunoassay and/or mass spectrometric methods. In additional embodiments, the mass spectrometric methods are selected from MS, MS/MS, LC-MS/MS, SRM, PIM, and other such methods that are known in the art. In other embodiments, LC-MS/MS further comprises 1D LC-MS/MS, 2D LC-MS/MS or 3D LC-MS/MS. Immunoassay techniques and protocols are generally known to those skilled in the art (Price and Newman, Principles and Practice of Immunoassay, 2nd Edition, Grove's Dictionaries, 1997; and Gosling, Immunoassays: A Practical Approach, Oxford University Press, 2000.) A variety of immunoassay techniques, including competitive and non-competitive immunoassays, can be used (Self et al., Curr. Opin. Biotechnol., 7:60-65 (1996).

In further embodiments, the immunoassay is selected from Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay (MA), dot blotting, and FACS. In certain embodiments, the immunoassay is an ELISA. In yet a further embodiment, the ELISA is direct ELISA (enzyme-linked immunosorbent assay), indirect ELISA, sandwich ELISA, competitive ELISA, multiplex ELISA, ELISPOT technologies, and other similar techniques known in the art. Principles of these immunoassay methods are known in the art, for example John R. Crowther, The ELISA Guidebook, 1st ed., Humana Press 2000, ISBN 0896037282. Typically ELISAs are performed with antibodies but they can be performed with any capture agents that bind specifically to one or more biomarkers of the invention and that can be detected. Multiplex ELISA allows simultaneous detection of two or more analytes within a single compartment (e.g., microplate well) usually at a plurality of array addresses (Nielsen and Geierstanger 2004. J Immunol Methods 290: 107-20 (2004) and Ling et al. 2007. Expert Rev Mol Diagn 7: 87-98 (2007)).

In some embodiments, Radioimmunoassay (RIA) can be used to detect one or more biomarkers in the methods of the invention. RIA is a competition-based assay that is well known in the art and involves mixing known quantities of radioactively-labelled (e.g., ¹²⁵I or ¹³¹I-labelled) target analyte with antibody specific for the analyte, then adding non-labeled analyte from a sample and measuring the amount of labeled analyte that is displaced (see, e.g., An Introduction to Radioimmunoassay and Related Techniques, by Chard T, ed., Elsevier Science 1995, ISBN 0444821198 for guidance).

A detectable label can be used in the assays described herein for direct or indirect detection of the biomarkers in the methods of the invention. A wide variety of detectable labels can be used, with the choice of label depending on the sensitivity required, ease of conjugation with the antibody, stability requirements, and available instrumentation and disposal provisions. Those skilled in the art are familiar with selection of a suitable detectable label based on the assay detection of the biomarkers in the methods of the invention. Suitable detectable labels include, but are not limited to, fluorescent dyes (e.g., fluorescein, fluorescein isothiocyanate (FITC), Oregon Green™, rhodamine, Texas red, tetrarhodimine isothiocynate (TRITC), Cy3, Cy5, etc.), fluorescent markers (e.g., green fluorescent protein (GFP), phycoerythrin, etc.), enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, etc.), nanoparticles, biotin, digoxigenin, metals, and the like.

For mass-spectrometry based analysis, differential tagging with isotopic reagents, e.g., isotope-coded affinity tags (ICAT) or the more recent variation that uses isobaric tagging reagents, iTRAQ (Applied Biosystems, Foster City, Calif.), or tandem mass tags, TMT, (Thermo Scientific, Rockford, IL), followed by multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS/MS) analysis can provide a further methodology in practicing the methods of the invention.

A chemiluminescence assay using a chemiluminescent antibody can be used for sensitive, non-radioactive detection of protein levels. An antibody labeled with fluorochrome also can be suitable. Examples of fluorochromes include, without limitation, DAPI, fluorescein, Hoechst 33258, R-phycocyanin, B-phycoerythrin, R-phycoerythrin, rhodamine, Texas red, and lissamine. Indirect labels include various enzymes well known in the art, such as horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase, urease, and the like. Detection systems using suitable substrates for horseradish-peroxidase, alkaline phosphatase, and beta-galactosidase are well known in the art.

A signal from the direct or indirect label can be analyzed, for example, using a spectrophotometer to detect color from a chromogenic substrate; a radiation counter to detect radiation such as a gamma counter for detection of ¹²⁵I; or a fluorometer to detect fluorescence in the presence of light of a certain wavelength. For detection of enzyme-linked antibodies, a quantitative analysis can be made using a spectrophotometer such as an EMAX Microplate Reader (Molecular Devices; Menlo Park, Calif.) in accordance with the manufacturer's instructions. If desired, assays used to practice the invention can be automated or performed robotically, and the signal from multiple samples can be detected simultaneously.

In some embodiments, the methods described herein encompass quantification of the biomarkers using mass spectrometry (MS). In further embodiments, the mass spectrometry can be liquid chromatography-mass spectrometry (LC-MS), multiple reaction monitoring (MRM) or selected reaction monitoring (SRM). In additional embodiments, the MRM or SRM can further encompass scheduled MRM or scheduled SRM.

As described above, chromatography can also be used in practicing the methods of the invention. Chromatography encompasses methods for separating chemical substances and generally involves a process in which a mixture of analytes is carried by a moving stream of liquid or gas (“mobile phase”) and separated into components as a result of differential distribution of the analytes as they flow around or over a stationary liquid or solid phase (“stationary phase”), between the mobile phase and said stationary phase. The stationary phase can be usually a finely divided solid, a sheet of filter material, or a thin film of a liquid on the surface of a solid, or the like. Chromatography is well understood by those skilled in the art as a technique applicable for the separation of chemical compounds of biological origin, such as, e.g., amino acids, proteins, fragments of proteins or peptides, etc.

Chromatography can be columnar (i.e., wherein the stationary phase is deposited or packed in a column), preferably liquid chromatography, and yet more preferably high-performance liquid chromatography (HPLC), or ultra high performance/pressure liquid chromatography (UHPLC). Particulars of chromatography are well known in the art (Bidlingmeyer, Practical HPLC Methodology and Applications, John Wiley & Sons Inc., 1993). Exemplary types of chromatography include, without limitation, high-performance liquid chromatography (HPLC), UHPLC, normal phase HPLC (NP-HPLC), reversed phase HPLC (RP-HPLC), ion exchange chromatography (IEC), such as cation or anion exchange chromatography, hydrophilic interaction chromatography (HILIC), hydrophobic interaction chromatography (HIC), size exclusion chromatography (SEC) including gel filtration chromatography or gel permeation chromatography, chromatofocusing, affinity chromatography such as immuno-affinity, immobilized metal affinity chromatography, and the like. Chromatography, including single-, two- or more-dimensional chromatography, can be used as a peptide fractionation method in conjunction with a further peptide analysis method, such as for example, with a downstream mass spectrometry analysis as described elsewhere in this specification.

Further peptide or polypeptide separation, identification or quantification methods can be used, optionally in conjunction with any of the above described analysis methods, for measuring biomarkers in the present disclosure. Such methods include, without limitation, chemical extraction partitioning, isoelectric focusing (IEF) including capillary isoelectric focusing (CIEF), capillary isotachophoresis (CITP), capillary electrochromatography (CEC), and the like, one-dimensional polyacrylamide gel electrophoresis (PAGE), two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), capillary gel electrophoresis (CGE), capillary zone electrophoresis (CZE), micellar electrokinetic chromatography (MEKC), free flow electrophoresis (FFE), etc.

In the context of the invention, the term “capture agent” refers to a compound that can specifically bind to a target, in particular a biomarker. The term includes antibodies, antibody fragments, nucleic acid-based protein binding reagents (e.g. aptamers, Slow Off-rate Modified Aptamers (SOMAmer™)), protein-capture agents, natural ligands (i.e. a hormone for its receptor or vice versa), small molecules or variants thereof.

Capture agents can be configured to specifically bind to a target, in particular a biomarker. Capture agents can include but are not limited to organic molecules, such as polypeptides, polynucleotides and other non polymeric molecules that are identifiable to a skilled person. In the embodiments disclosed herein, capture agents include any agent that can be used to detect, purify, isolate, or enrich a target, in particular a biomarker. Any art-known affinity capture technologies can be used to selectively isolate and enrich/concentrate biomarkers that are components of complex mixtures of biological media for use in the disclosed methods.

Antibody capture agents that specifically bind to a biomarker can be prepared using any suitable methods known in the art. See, e.g., Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies: A Laboratory Manual (1988); Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986). Antibody capture agents can be any immunoglobulin or derivative thereof, whether natural or wholly or partially synthetically produced. All derivatives thereof which maintain specific binding ability are also included in the term. Antibody capture agents have a binding domain that is homologous or largely homologous to an immunoglobulin binding domain and can be derived from natural sources, or partly or wholly synthetically produced. Antibody capture agents can be monoclonal or polyclonal antibodies. In some embodiments, an antibody is a single chain antibody. Those of ordinary skill in the art will appreciate that antibodies can be provided in any of a variety of forms including, for example, humanized, partially humanized, chimeric, chimeric humanized, etc. Antibody capture agents can be antibody fragments including, but not limited to, Fab, Fab′, F(ab′)2, scFv, Fv, dsFv diabody, and Fd fragments. An antibody capture agent can be produced by any means. For example, an antibody capture agent can be enzymatically or chemically produced by fragmentation of an intact antibody and/or it can be recombinantly produced from a gene encoding the partial antibody sequence. An antibody capture agent can comprise a single chain antibody fragment. Alternatively or additionally, antibody capture agent can comprise multiple chains which are linked together, for example, by disulfide linkages; and, any functional fragments obtained from such molecules, wherein such fragments retain specific-binding properties of the parent antibody molecule. Because of their smaller size as functional components of the whole molecule, antibody fragments can offer advantages over intact antibodies for use in certain immunochemical techniques and experimental applications.

Suitable capture agents useful for practicing the invention also include aptamers. Aptamers are oligonucleotide sequences that can bind to their targets specifically via unique three dimensional (3-D) structures. An aptamer can include any suitable number of nucleotides and different aptamers can have either the same or different numbers of nucleotides. Aptamers can be DNA or RNA or chemically modified nucleic acids and can be single stranded, double stranded, or contain double stranded regions, and can include higher ordered structures. An aptamer can also be a photoaptamer, where a photoreactive or chemically reactive functional group is included in the aptamer to allow it to be covalently linked to its corresponding target. Use of an aptamer capture agent can include the use of two or more aptamers that specifically bind the same biomarker. An aptamer can include a tag. An aptamer can be identified using any known method, including the SELEX (systematic evolution of ligands by exponential enrichment), process. Once identified, an aptamer can be prepared or synthesized in accordance with any known method, including chemical synthetic methods and enzymatic synthetic methods and used in a variety of applications for biomarker detection. Liu et al., Curr Med Chem. 18(27):4117-25 (2011). Capture agents useful in practicing the methods of the invention also include SOMAmers (Slow Off-Rate Modified Aptamers) known in the art to have improved off-rate characteristics. Brody et al., J Mol Biol. 422(5):595-606 (2012). SOMAmers can be generated using any known method, including the SELEX method.

It is understood by those skilled in the art that biomarkers can be modified prior to analysis to improve their resolution or to determine their identity. For example, the biomarkers can be subject to proteolytic digestion before analysis. Any protease can be used. Proteases, such as trypsin, that are likely to cleave the biomarkers into a discrete number of fragments are particularly useful. The fragments that result from digestion function as a fingerprint for the biomarkers, thereby enabling their detection indirectly. This is particularly useful where there are biomarkers with similar molecular masses that might be confused for the biomarker in question. Also, proteolytic fragmentation is useful for high molecular weight biomarkers because smaller biomarkers are more easily resolved by mass spectrometry. In another example, biomarkers can be modified to improve detection resolution. For instance, neuraminidase can be used to remove terminal sialic acid residues from glycoproteins to improve binding to an anionic adsorbent and to improve detection resolution. In another example, the biomarkers can be modified by the attachment of a tag of particular molecular weight that specifically binds to molecular biomarkers, further distinguishing them. Optionally, after detecting such modified biomarkers, the identity of the biomarkers can be further determined by matching the physical and chemical characteristics of the modified biomarkers in a protein database (e.g., SwissProt).

It is further appreciated in the art that biomarkers in a sample can be captured on a substrate for detection. Traditional substrates include antibody-coated 96-well plates or nitrocellulose membranes that are subsequently probed for the presence of the proteins. Alternatively, protein-binding molecules attached to microspheres, microparticles, microbeads, beads, or other particles can be used for capture and detection of biomarkers. The protein-binding molecules can be antibodies, peptides, peptoids, aptamers, small molecule ligands or other protein-binding capture agents attached to the surface of particles. Each protein-binding molecule can include unique detectable label that is coded such that it can be distinguished from other detectable labels attached to other protein-binding molecules to allow detection of biomarkers in multiplex assays. Examples include, but are not limited to, color-coded microspheres with known fluorescent light intensities (see e.g., microspheres with xMAP technology produced by Luminex (Austin, Tex.); microspheres containing quantum dot nanocrystals, for example, having different ratios and combinations of quantum dot colors (e.g., Qdot nanocrystals produced by Life Technologies (Carlsbad, Calif.); glass coated metal nanoparticles (see e.g., SERS nanotags produced by Nanoplex Technologies, Inc. (Mountain View, Calif.); barcode materials (see e.g., sub-micron sized striped metallic rods such as Nanobarcodes produced by Nanoplex Technologies, Inc.), encoded microparticles with colored bar codes (see e.g., CellCard produced by Vitra Bioscience, vitrabio.com), glass microparticles with digital holographic code images (see e.g., CyVera microbeads produced by Illumina (San Diego, Calif.); chemiluminescent dyes, combinations of dye compounds; and beads of detectably different sizes.

In another aspect, biochips can be used for capture and detection of the biomarkers of the invention. Many protein biochips are known in the art. These include, for example, protein biochips produced by Packard BioScience Company (Meriden Conn.), Zyomyx (Hayward, Calif.) and Phylos (Lexington, Mass.). In general, protein biochips comprise a substrate having a surface. A capture reagent or adsorbent is attached to the surface of the substrate. Frequently, the surface comprises a plurality of addressable locations, each of which location has the capture agent bound there. The capture agent can be a biological molecule, such as a polypeptide or a nucleic acid, which captures other biomarkers in a specific manner. Alternatively, the capture agent can be a chromatographic material, such as an anion exchange material or a hydrophilic material. Examples of protein biochips are well known in the art.

The present disclosure also provides methods for predicting the probability of pre-term birth comprising measuring a change in reversal value of a biomarker pair. For example, a biological sample can be contacted with a panel comprising one or more polynucleotide binding agents. The expression of one or more of the biomarkers detected can then be evaluated according to the methods disclosed below, e.g., with or without the use of nucleic acid amplification methods. Skilled practitioners appreciate that in the methods described herein, a measurement of gene expression can be automated. For example, a system that can carry out multiplexed measurement of gene expression can be used, e.g., providing digital readouts of the relative abundance of hundreds of mRNA species simultaneously.

In some embodiments, nucleic acid amplification methods can be used to detect a polynucleotide biomarker. For example, the oligonucleotide primers and probes of the present invention can be used in amplification and detection methods that use nucleic acid substrates isolated by any of a variety of well-known and established methodologies (e.g., Sambrook et al., Molecular Cloning, A laboratory Manual, pp. 7.37-7.57 (2nd ed., 1989); Lin et al., in Diagnostic Molecular Microbiology, Principles and Applications, pp. 605-16 (Persing et al., eds. (1993); Ausubel et al., Current Protocols in Molecular Biology (2001 and subsequent updates)). Methods for amplifying nucleic acids include, but are not limited to, for example the polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR) (see e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; 4,965,188), ligase chain reaction (LCR) (see, e.g., Weiss, Science 254:1292-93 (1991)), strand displacement amplification (SDA) (see e.g., Walker et al., Proc. Natl. Acad. Sci. USA 89:392-396 (1992); U.S. Pat. Nos. 5,270,184 and 5,455,166), Thermophilic SDA (tSDA) (see e.g., European Pat. No. 0 684 315) and methods described in U.S. Pat. No. 5,130,238; Lizardi et al., BioTechnol. 6:1197-1202 (1988); Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173-77 (1989); Guatelli et al., Proc. Natl. Acad. Sci. USA 87:1874-78 (1990); U.S. Pat. Nos. 5,480,784; 5,399,491; US Publication No. 2006/46265.

In some embodiments, measuring mRNA in a biological sample can be used as a surrogate for detection of the level of the corresponding protein biomarker in a biological sample. Thus, any of the biomarkers, biomarker pairs or biomarker reversal panels described herein can also be detected by detecting the appropriate RNA. Levels of mRNA can measured by reverse transcription quantitative polymerase chain reaction (RT-PCR followed with qPCR). RT-PCR is used to create a cDNA from the mRNA. The cDNA can be used in a qPCR assay to produce fluorescence as the DNA amplification process progresses. By comparison to a standard curve, qPCR can produce an absolute measurement such as number of copies of mRNA per cell. Northern blots, microarrays, Invader assays, and RT-PCR combined with capillary electrophoresis have all been used to measure expression levels of mRNA in a sample. See Gene Expression Profiling: Methods and Protocols, Richard A. Shimkets, editor, Humana Press, 2004.

Some embodiments disclosed herein relate to diagnostic and prognostic methods of determining the probability for preterm birth in a pregnant female. The detection of the level of expression of one or more biomarkers and/or the determination of a ratio of biomarkers can be used to determine the probability for preterm birth in a pregnant female. Such detection methods can be used, for example, for early diagnosis of the condition, to determine whether a subject is predisposed to preterm birth, to monitor the progress of preterm birth or the progress of treatment protocols, to assess the severity of preterm birth, to forecast the outcome of preterm birth and/or prospects of recovery or birth at full term, or to aid in the determination of a suitable treatment for preterm birth.

The quantitation of biomarkers in a biological sample can be determined, without limitation, by the methods described above as well as any other method known in the art. The quantitative data thus obtained is then subjected to an analytic classification process. In such a process, the raw data is manipulated according to an algorithm, where the algorithm has been pre-defined by a training set of data, for example as described in the examples provided herein. An algorithm can utilize the training set of data provided herein, or can utilize the guidelines provided herein to generate an algorithm with a different set of data.

In some embodiments, analyzing a measurable feature to determine the probability for preterm birth in a pregnant female encompasses the use of a predictive model. In further embodiments, analyzing a measurable feature to determine the probability for preterm birth in a pregnant female encompasses comparing said measurable feature with a reference feature. As those skilled in the art can appreciate, such comparison can be a direct comparison to the reference feature or an indirect comparison where the reference feature has been incorporated into the predictive model. In further embodiments, analyzing a measurable feature to determine the probability for preterm birth in a pregnant female encompasses one or more of a linear discriminant analysis model, a support vector machine classification algorithm, a recursive feature elimination model, a prediction analysis of microarray model, a logistic regression model, a CART algorithm, a flex tree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, a machine learning algorithm, a penalized regression method, or a combination thereof. In particular embodiments, the analysis comprises logistic regression.

An analytic classification process can use any one of a variety of statistical analytic methods to manipulate the quantitative data and provide for classification of the sample. Examples of useful methods include linear discriminant analysis, recursive feature elimination, a prediction analysis of microarray, a logistic regression, a CART algorithm, a FlexTree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, machine learning algorithms; etc.

For creation of a random forest for prediction of GAB one skilled in the art can consider a set of k subjects (pregnant women) for whom the gestational age at birth (GAB) is known, and for whom N analytes (transitions) have been measured in a blood specimen taken several weeks prior to birth. A regression tree begins with a root node that contains all the subjects. The average GAB for all subjects can be calculated in the root node. The variance of the GAB within the root node will be high, because there is a mixture of women with different GAB's. The root node is then divided (partitioned) into two branches, so that each branch contains women with a similar GAB. The average GAB for subjects in each branch is again calculated. The variance of the GAB within each branch will be lower than in the root node, because the subset of women within each branch has relatively more similar GAB's than those in the root node. The two branches are created by selecting an analyte and a threshold value for the analyte that creates branches with similar GAB. The analyte and threshold value are chosen from among the set of all analytes and threshold values, usually with a random subset of the analytes at each node. The procedure continues recursively producing branches to create leaves (terminal nodes) in which the subjects have very similar GAB's. The predicted GAB in each terminal node is the average GAB for subjects in that terminal node. This procedure creates a single regression tree. A random forest can consist of several hundred or several thousand such trees.

Classification can be made according to predictive modeling methods that set a threshold for determining the probability that a sample belongs to a given class. The probability preferably is at least 50%, or at least 60%, or at least 70%, or at least 80% or higher. Classifications also can be made by determining whether a comparison between an obtained dataset and a reference dataset yields a statistically significant difference. If so, then the sample from which the dataset was obtained is classified as not belonging to the reference dataset class. Conversely, if such a comparison is not statistically significantly different from the reference dataset, then the sample from which the dataset was obtained is classified as belonging to the reference dataset class.

The predictive ability of a model can be evaluated according to its ability to provide a quality metric, e.g. AUROC (area under the ROC curve) or accuracy, of a particular value, or range of values. Area under the curve measures are useful for comparing the accuracy of a classifier across the complete data range. Classifiers with a greater AUC have a greater capacity to classify unknowns correctly between two groups of interest. In some embodiments, a desired quality threshold is a predictive model that will classify a sample with an accuracy of at least about 0.5, at least about 0.55, at least about 0.6, at least about 0.7, at least about 0.75, at least about 0.8, at least about 0.85, at least about 0.9, at least about 0.95, or higher. As an alternative measure, a desired quality threshold can refer to a predictive model that will classify a sample with an AUC of at least about 0.7, at least about 0.75, at least about 0.8, at least about 0.85, at least about 0.9, or higher.

As is known in the art, the relative sensitivity and specificity of a predictive model can be adjusted to favor either the selectivity metric or the sensitivity metric, where the two metrics have an inverse relationship. The limits in a model as described above can be adjusted to provide a selected sensitivity or specificity level, depending on the particular requirements of the test being performed. One or both of sensitivity and specificity can be at least about 0.7, at least about 0.75, at least about 0.8, at least about 0.85, at least about 0.9, or higher.

The raw data can be initially analyzed by measuring the values for each biomarker, usually in triplicate or in multiple triplicates. The data can be manipulated, for example, raw data can be transformed using standard curves, and the average of triplicate measurements used to calculate the average and standard deviation for each patient. These values can be transformed before being used in the models, e.g. log-transformed, Box-Cox transformed (Box and Cox, Royal Stat. Soc., Series B, 26:211-246(1964). The data are then input into a predictive model, which will classify the sample according to the state. The resulting information can be communicated to a patient or health care provider.

To generate a predictive model for preterm birth, a robust data set, comprising known control samples and samples corresponding to the preterm birth classification of interest is used in a training set. A sample size can be selected using generally accepted criteria. As discussed above, different statistical methods can be used to obtain a highly accurate predictive model. Examples of such analysis are provided in Example 2.

In one embodiment, hierarchical clustering is performed in the derivation of a predictive model, where the Pearson correlation is employed as the clustering metric. One approach is to consider a preterm birth dataset as a “learning sample” in a problem of “supervised learning.” CART is a standard in applications to medicine (Singer, Recursive Partitioning in the Health Sciences, Springer (1999)) and can be modified by transforming any qualitative features to quantitative features; sorting them by attained significance levels, evaluated by sample reuse methods for Hotelling's T²statistic; and suitable application of the lasso method. Problems in prediction are turned into problems in regression without losing sight of prediction, indeed by making suitable use of the Gini criterion for classification in evaluating the quality of regressions.

This approach led to what is termed FlexTree (Huang, Proc. Nat. Acad. Sci. U.S.A 101:10529-10534(2004)). FlexTree performs very well in simulations and when applied to multiple forms of data and is useful for practicing the claimed methods. Software automating FlexTree has been developed. Alternatively, LARTree or LART can be used (Turnbull (2005) Classification Trees with Subset Analysis Selection by the Lasso, Stanford University). The name reflects binary trees, as in CART and FlexTree; the lasso, as has been noted; and the implementation of the lasso through what is termed LARS by Efron et al. (2004) Annals of Statistics 32:407-451 (2004). See, also, Huang et al., Proc. Natl. Acad. Sci. USA. 101(29):10529-34 (2004). Other methods of analysis that can be used include logic regression. One method of logic regression Ruczinski, Journal of Computational and Graphical Statistics 12:475-512 (2003). Logic regression resembles CART in that its classifier can be displayed as a binary tree. It is different in that each node has Boolean statements about features that are more general than the simple “and” statements produced by CART.

Another approach is that of nearest shrunken centroids (Tibshirani, Proc. Natl. Acad. Sci. U.S.A 99:6567-72(2002)). The technology is k-means-like, but has the advantage that by shrinking cluster centers, one automatically selects features, as is the case in the lasso, to focus attention on small numbers of those that are informative. The approach is available as PAM software and is widely used. Two further sets of algorithms that can be used are random forests (Breiman, Machine Learning 45:5-32 (2001)) and MART (Hastie, The Elements of Statistical Learning, Springer (2001)). These two methods are known in the art as “committee methods,” that involve predictors that “vote” on outcome.

To provide significance ordering, the false discovery rate (FDR) can be determined. First, a set of null distributions of dissimilarity values is generated. In one embodiment, the values of observed profiles are permuted to create a sequence of distributions of correlation coefficients obtained out of chance, thereby creating an appropriate set of null distributions of correlation coefficients (Tusher et al., Proc. Natl. Acad. Sci. U.S.A 98, 5116-21 (2001)). The set of null distribution is obtained by: permuting the values of each profile for all available profiles; calculating the pair-wise correlation coefficients for all profile; calculating the probability density function of the correlation coefficients for this permutation; and repeating the procedure for N times, where N is a large number, usually 300. Using the N distributions, one calculates an appropriate measure (mean, median, etc.) of the count of correlation coefficient values that their values exceed the value (of similarity) that is obtained from the distribution of experimentally observed similarity values at given significance level.

The FDR is the ratio of the number of the expected falsely significant correlations (estimated from the correlations greater than this selected Pearson correlation in the set of randomized data) to the number of correlations greater than this selected Pearson correlation in the empirical data (significant correlations). This cut-off correlation value can be applied to the correlations between experimental profiles. Using the aforementioned distribution, a level of confidence is chosen for significance. This is used to determine the lowest value of the correlation coefficient that exceeds the result that would have obtained by chance. Using this method, one obtains thresholds for positive correlation, negative correlation or both. Using this threshold(s), the user can filter the observed values of the pair wise correlation coefficients and eliminate those that do not exceed the threshold(s). Furthermore, an estimate of the false positive rate can be obtained for a given threshold. For each of the individual “random correlation” distributions, one can find how many observations fall outside the threshold range. This procedure provides a sequence of counts. The mean and the standard deviation of the sequence provide the average number of potential false positives and its standard deviation.

In an alternative analytical approach, variables chosen in the cross-sectional analysis are separately employed as predictors in a time-to-event analysis (survival analysis), where the event is the occurrence of preterm birth, and subjects with no event are considered censored at the time of giving birth. Given the specific pregnancy outcome (preterm birth event or no event), the random lengths of time each patient will be observed, and selection of proteomic and other features, a parametric approach to analyzing survival can be better than the widely applied semi-parametric Cox model. A Weibull parametric fit of survival permits the hazard rate to be monotonically increasing, decreasing, or constant, and also has a proportional hazards representation (as does the Cox model) and an accelerated failure-time representation. All the standard tools available in obtaining approximate maximum likelihood estimators of regression coefficients and corresponding functions are available with this model.

In addition the Cox models can be used, especially since reductions of numbers of covariates to manageable size with the lasso will significantly simplify the analysis, allowing the possibility of a nonparametric or semi-parametric approach to prediction of time to preterm birth. These statistical tools are known in the art and applicable to all manner of proteomic data. A set of biomarker, clinical and genetic data that can be easily determined, and that is highly informative regarding the probability for preterm birth and predicted time to a preterm birth event in said pregnant female is provided. Also, algorithms provide information regarding the probability for preterm birth in the pregnant female.

Accordingly, one skilled in the art understands that the probability for preterm birth according to the invention can be determined using either a quantitative or a categorical variable. For example, in practicing the methods of the invention the measurable feature of each of N biomarkers can be subjected to categorical data analysis to determine the probability for preterm birth as a binary categorical outcome. Alternatively, the methods of the invention may analyze the measurable feature of each of N biomarkers by initially calculating quantitative variables, in particular, predicted gestational age at birth. The predicted gestational age at birth can subsequently be used as a basis to predict risk of preterm birth. By initially using a quantitative variable and subsequently converting the quantitative variable into a categorical variable the methods of the invention take into account the continuum of measurements detected for the measurable features. For example, by predicting the gestational age at birth rather than making a binary prediction of preterm birth versus term birth, it is possible to tailor the treatment for the pregnant female. For example, an earlier predicted gestational age at birth will result in more intensive prenatal intervention, i.e. monitoring and treatment, than a predicted gestational age that approaches full term.

Among women with a predicted GAB of j days plus or minus k days, p(PTB) can estimated as the proportion of women in the PAPR clinical trial (see Example 1) with a predicted GAB of j days plus or minus k days who actually deliver before 37 weeks gestational age. More generally, for women with a predicted GAB of j days plus or minus k days, the probability that the actual gestational age at birth will be less than a specified gestational age, p(actual GAB<specified GAB), was estimated as the proportion of women in the PAPR clinical trial with a predicted GAB of j days plus or minus k days who actually deliver before the specified gestational age.

In the development of a predictive model, it can be desirable to select a subset of markers, i.e. at least 3, at least 4, at least 5, at least 6, up to the complete set of markers. Usually a subset of markers will be chosen that provides for the needs of the quantitative sample analysis, e.g. availability of reagents, convenience of quantitation, etc., while maintaining a highly accurate predictive model. The selection of a number of informative markers for building classification models requires the definition of a performance metric and a user-defined threshold for producing a model with useful predictive ability based on this metric. For example, the performance metric can be the AUC, the sensitivity and/or specificity of the prediction as well as the overall accuracy of the prediction model.

As will be understood by those skilled in the art, an analytic classification process can use any one of a variety of statistical analytic methods to manipulate the quantitative data and provide for classification of the sample. Examples of useful methods include, without limitation, linear discriminant analysis, recursive feature elimination, a prediction analysis of microarray, a logistic regression, a CART algorithm, a FlexTree algorithm, a LART algorithm, a random forest algorithm, a MART algorithm, and machine learning algorithms. Various methods are used in a training model. The selection of a subset of markers can be for a forward selection or a backward selection of a marker subset. The number of markers can be selected that will optimize the performance of a model without the use of all the markers. One way to define the optimum number of terms is to choose the number of terms that produce a model with desired predictive ability (e.g. an AUC>0.75, or equivalent measures of sensitivity/specificity) that lies no more than one standard error from the maximum value obtained for this metric using any combination and number of terms used for the given algorithm.

In yet another aspect, the invention provides kits for determining probability of preterm birth. The kit can include one or more agents for detection of biomarkers, a container for holding a biological sample isolated from a pregnant female; and printed instructions for reacting agents with the biological sample or a portion of the biological sample to detect the presence or amount of the isolated biomarkers in the biological sample. The agents can be packaged in separate containers. The kit can further comprise one or more control reference samples and reagents for performing an immunoassay.

The kit can comprise one or more containers for compositions contained in the kit. Compositions can be in liquid form or can be lyophilized. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. The kit can also comprise a package insert containing written instructions for methods of determining probability of preterm birth.

From the foregoing description, it will be apparent that variations and modifications can be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

The following examples are provided by way of illustration, not limitation.

EXAMPLES
Example 1. Development of Sample Set for Discovery and Validation of Biomarkers for Preterm Birth

A standard protocol was developed governing conduct of the Proteomic Assessment of Preterm Risk (PAPR) clinical study. Specimens were obtained from women at 11 Institutional Review Board (IRB) approved sites across the United States. After providing informed consent, serum and plasma samples were obtained, as well as pertinent information regarding the patient's demographic characteristics, past medical and pregnancy history, current pregnancy history and concurrent medications. Following delivery, data were collected relating to maternal and infant conditions and complications. Serum and plasma samples were processed according to a protocol that requires standardized refrigerated centrifugation, aliquoting of the samples into 2-D bar-coded cryovials and subsequent freezing at −80° C.

Following delivery, preterm birth cases were individually reviewed to determine their status as either a spontaneous preterm birth or a medically indicated preterm birth. Only spontaneous preterm birth cases were used for this analysis. For discovery of biomarkers of preterm birth, serum samples from 86 preterm cases and 172 controls were analyzed covering gestational ages at blood draw (GABD) of 17 weeks and 0 days (17.0) to 28 weeks and 6 days (28.6). A separate sample set was also analyzed for purposes of verification and was composed of serum from 50 preterm cases and 100 controls, across the same gestational age range. The two controls for each case were matched by GABD and selected from several randomly generated panels of controls that matched the distribution of births reported in the 2012 National Vital Statistics Report. A protocol was instituted to ensure that laboratory staff were blinded to gestation age at birth and case vs control status of subjects used for both sample sets. Informatics staff were also blinded to the verification sample set until analytical analysis of samples was complete.

Serum samples were depleted of high abundance proteins using the Human 14 Multiple Affinity Removal System (MARS 14), which removes 14 of the most abundant proteins that are treated as uninformative with regard to the identification for disease-relevant changes in the serum proteome. To this end, equal volumes (50 μl) of each clinical, pooled human serum sample (HGS) sample, or a human pooled pregnant women serum sample (pHGS) were diluted with 150 μl Agilent column buffer A and filtered on a Captiva filter plate to remove precipitates. Filtered samples were depleted using a MARS-14 column (4.6×100 mm, Cat. #5188-6558, Agilent Technologies), according to manufacturer's protocol. Samples were chilled to 4° C. in the autosampler, the depletion column was run at room temperature, and collected fractions were kept at 4° C. until further analysis. The unbound fractions were collected for further analysis.

Depleted serum samples were, reduced with dithiothreitol, alkylated using iodoacetamide, and then digested with 5.0 μg Trypsin Gold-Mass Spec Grade (Promega) at 37° C. for 17 hours(±1 hour). Following trypsin digestion, a mixture of 187 Stable Isotope Standard (SIS) peptides were added to the samples and half of each sample was desalted on an Empore C18 96-well Solid Phase Extraction Plate (3M Bioanalytical Technologies). The plate was conditioned according to the manufacture's protocol. Peptides were washed with 300 μl 1.5% trifluoroacetic acid, 2% acetonitrile, eluted with 250 μl 1.5% trifluoroacetic acid, 95% acetonitrile, frozen at −80° C. for 30 minutes, and then lyophilized to dryness. Lyophilized peptides were reconstituted with 2% acetontile/0.1% formic acid containing three non-human internal standard (IS) peptides. Peptides were separated with a 30 min acetonitrile gradient at 400 μl/min on an Agilent Poroshell 120 EC-C18 column (2.1×100 mm, 2.7 μm) at 40° C. and injected into an Agilent 6490 Triple Quadrapole mass spectrometer.

Depleted and trypsin digested samples were analyzed using a scheduled Multiple Reaction Monitoring method (sMRM). The sMRM assay monitored 898 transitions that measured 259 biological peptides and 190 IS peptides (187 SIS+3 IS), representing 148 proteins. Chromatographic peaks were integrated using Mass Hunter Quantitative Analysis software (Agilent Technologies).

Data Analysis

Analysis of discovery and verification sample data was performed in two phases. In the first phase robust biomarkers were identified by selection using the discovery samples and confirmation using the independent verification sample set. In the second phase the discovery and verification data were combined and used to identify best analytes and panels of analytes for classifier development.

Phase I: Blinded Analysis

Initial classifier development focused on gestational ages 17.0 to 25.6. Using discovery samples a set of peptides corresponding to 62 proteins were selected based on preanalytic and analytic criteria. Analyte diagnostic performance was assessed in a series of narrow GABD windows that span three weeks with two weeks of overlap between adjacent windows. Based on consistency in diagnostic performance (up and down regulation in cases vs controls across GABD), a subset of 43 analytes was selected for further analysis.

For each narrow GABD window a set of reversals was formed using all the combinations of up and down regulated analytes within the narrow window. A reversal value is the ratio of the relative peak area of an up regulated analyte over the relative peak area of a down regulated analyte and serves to both normalize variability and amplify diagnostic signal. Out of all the possible reversals within a narrow window, a subset was selected based on their individual univariate performance (AUC>=0.6).

For each window reversal panels of varying sizes were formed (sizes of 2, 3, 4, 6, 8). For each panel size within a window, a Monte Carlo Cross Validation (MCCV) was performed by training and testing a logistic classifier iteratively 1,000 times on 70% and 30% of the samples, respectively. A panel size of 4, determined to be optimal by mean MCCV AUC, was subsequently used for identification of candidate reversals that perform well on panels. Candidate reversals were identified by frequency of occurrence on top performing logistic classifiers of panels of size 4 in MCCV analysis. For each window, three sets of reversal frequency tables were created using performance measures of either AUC, or partial AUC (pAUC) for sensitivity ranging from 0.7 to 1, or correlation of the classifier output score to time to birth value (TTB) (difference in days between GABD and gestational age at birth). From each of these reversal lists, the top 15 reversals were selected for further analysis.

For each GABD narrow window, reversal panels of size 2, 3, 4 were formed from each of the three lists (AUC, pAUC, and TTB) and based on the performance of a MCCV analysis, the top 15 panels for each panel size in each window were selected. Along with the top 15 reversals from each of the three lists (AUC, pAUC, and TTB) for each window, these top 15 panels of size 2, 3, 4, were used to train logistic classifiers on the discovery samples and the classification scores were generated for verification samples in a blinded fashion.

A third party statistician assessed the performance of all reversals and classifier panels and the AUC, pAUC for ROC curves and the TTB correlation of the classifier scores were reported.

Phase II: Unblinded Analysis

Following unblinding, discovery and verification data sets were combined and reanalyzed. Because the expression of diagnostic proteins may change across pregnancy we examined the levels of proteins as a function of GABD. A median smoothing window of +/−10 days was applied to generate the kinetic plots. Relative levels of proteins were expressed as the ratio of the endogenous peptide peak area over its corresponding SIS standard (relative ratio). Examples of proteins with levels that increase in pregnancy but are not different in PTB cases and controls are shown in FIGS. 3, 4 and 10. Measurement of the levels of such proteins could be useful in accurate dating of pregnancy (e.g. a pregnancy “clock”). The pregnancy clock predicts gestational age from the relative abundance of one or more proteins (transitions). Alternatively, in this same analysis we identified proteins whose levels change across GABD but show differences between PTB cases and controls FIG. 5. These proteins are obvious diagnostic candidates for PTB classifier development. The impact of forming a reversal using the ratio of an overexpressed protein over that of an underexpressed protein was also exemplified (FIGS. 8 and 21). It is clear that this results in an increase in separation of PTB cases and controls. Previous analysis suggested that levels of some analytes may be influenced by pre-pregnancy body weight index (BMI). CLIN. CHEM. 37/5, 667-672 (1991); European Journal of Endocrinology (2004) 150 161-171. For this reason the impact of BMI on separation was explored by expressing the reversal value across gestation in only those patients whose BMI is less than 35 (FIG. 21). This results in a further improvement in separation.

Reversal selection and classifier development in the combined discovery and verification data set mirrored earlier studies. We focused on the 3rd overlapping GABD window (Days 133-153) to exemplify analysis. MCCV analysis was performed to identify candidate reversals. To assess performance of panels, reversal values were combined in a simple LogSum classifier. The LogSum classifier assigns a score to each sample based on the sum of the logs of each reversal's relative ratio value for that sample. The lack of coefficients in a classifier of this type helps to avoid problems of overfitting. Anyone skilled in the art can derive an equivalent logistic classifier using the same analytes with well-established techniques. Multivariate performance of a panel of three top reversals formed from four proteins is shown as a histogram of AUC values obtained by cross validation and in ROC curves in FIG. 8. Previous analysis suggested that levels of some analytes may be influenced by pre-pregnancy body weight index (BMI).

We determined proteins and/or reversals, exemplified here by using ITIH4/CSH, that are strong predictors of time to birth (TTB) (FIG. 10). TTB is defined as the difference between the GABD the gestational age at birth (GAB). This has potential to enable prediction, either individually or in mathematical combination of such analytes to clinically estimate TTB (or GAB).

Example 2. Validation of the IBP4/SHBG sPTB Predictor

This example demonstrates validation of the IBP4/SHBG sPTB predictor identified in a large maternal serum proteomics effort in asymptomatic women early in pregnancy.

Subjects

The Proteomic Assessment of Preterm Risk (PAPR) study was conducted under a standardized protocol at eleven Institutional Review Board (IRB)-approved sites across the U.S. (Clinicaltrials.gov identifier: NCT01371019). Subjects were enrolled between 17 0/7 and 28 6/7 weeks GA. Dating was established using a predefined protocol of menstrual dating confirmed by early ultrasound biometry, or ultrasound alone, to provide the best clinically estimated gestational age. Body mass index (BMI) was derived from height and pre-pregnancy self-reported weight. Pregnancies with multiple gestations and with known or suspected major fetal anomalies were excluded. Pertinent information regarding subject demographic characteristics, past medical and pregnancy history, current pregnancy history and concurrent medications was collected and entered into an electronic case report form. Following delivery, data were collected for maternal and infant outcomes and complications. All deliveries were adjudicated as term (≥37 0/7 weeks GA), spontaneous preterm (including preterm premature rupture of membranes) or medically indicated preterm births. As indicated, discrepancies were clarified with the Principal Investigator at the study site. Adjudication was completed and the data locked prior to validation studies.

Sample Collection

Maternal blood was collected and processed as follows: a 10 minute room temperature clotting period, followed by immediate refrigerated centrifugation or placement on an ice water bath at 4-8° C. until centrifugation. Blood was centrifuged within 2.5 hours of collection and 0.5 ml serum aliquots were stored at −80° C. until analyzed.

Predictor Development Principles

Development of the IBP4/SHBG predictor included independent and sequential discovery, verification and validation steps consistent with Institute of Medicine (TOM) guidelines for best practices in ‘omics’ research. IOM (Institute of Medicine). Evolution of Translation Omics: Lessons Learned and the Path Forward. (Micheel C M, Nass S J, Omenn GS, eds.). Washington, D.C.: The National Academies Press.; 2012:1-355. Analytical validation preceded clinical validation sample analysis and included assessment of inter- and intra-batch precision, carryover and limit of detection.

The validation nested case/control analysis was performed on prespecified sPTB cases and control specimens independent of discovery and verification. sPTB cases included samples from nine sites in total, with two sites being unique to validation. Validation cases and controls underwent 100% on-site source document verification with each subject's medical record prior to mass spectrometry (MS) serum analysis. This process ensured that all subjects satisfied the inclusion and exclusion criteria, as well as confirmed medical/pregnancy complications and GA at birth assignments for all subjects at time of sample collection and delivery. Detailed analysis protocols, including the validation study design, analysis plan and a blinding protocol were pre-established. Personnel were blinded to subject case, control and GA at birth data assignments with the exception of the Director of Clinical Operations (DCO) and Clinical Data Manager. The data analysis plan included prespecified validation claims and a protocol for double independent external analyses. Predictor scores, calculated as described below, were determined for all subject samples by a blinded statistician. Case, control and GA data, linked to the predictor scores by the DCO, were subjected to independent external statistical analysis. Area under the receiver operating characteristic curve (AUROC) and significance testing results were then transferred back to the DCO. Transfer of data incorporated the use of the SUMPRODUCT function (Microsoft. Microsoft Excel. 2013) to ensure maintenance of data integrity. To provide an audit trail of data from each subject through to validation results, real-time digital time-stamping was applied to analytical data, plans and reports.

Validation Study Design

In the primary analysis, sPTB cases were defined as subjects with deliveries due to preterm premature rupture of the membranes (PPROM) or spontaneous onset of labor <37 0/7 weeks GA. Controls were subjects who delivered at ≥37 0/7 weeks GA. Prior discovery and verification analyses investigated 44 candidate biomarkers using serum samples collected across broad gestational age (17 0/7 through 25 6/7 weeks GA) (Supplementary Material). Discovery and verification identified an optimal narrow GA at blood draw interval (19 0/7 through 21 6/7 weeks) and two proteins, IBP4 and SHBG, used in a ratio (IBP4/SHBG) as the best predictor by AUROC for sPTB (Supplementary Material). In discovery and verification, subjects without extreme BMI values had improved classification performance by IBP4/SHBG (Supplementary Results). Following discovery and verification analyses, we proceeded to analytical and clinical validation.

Validation sPTB cases totaled 18 subjects collected between 19 0/7 through 21 6/7 weeks GA at blood draw (GABD), from a total available of 81 subjects across 17 0/7 through 28 6/7 weeks GA. Sets of controls, comprising two controls per sPTB case matched by GABD, were randomly selected using R Statistical program (R 3.0.2) (Team R C. R: a Language and Environment for Statistical Computing. Vienna, Austria; 2014. 2015; Matei A, Tiné Y. The R “sampling” package. European Conference on Quality in Survey Statistics. 2006) and compared to the term delivery distribution as outlined in the 2012 National Vital Statistics Report (Martin J A, Hamilton B E, Osterman M J, Curtin S C, Mathews T J. Births: Final Data for 2012. National Vital Statistics Reports. 2014; 63(09):1-86) using Chi-Square test. Randomly created control sets (in groups of 10) were examined for sets yielding a p-value approaching 1.0.

The primary objective was to validate the performance of the IBP4/SHBG ratio as a predictor for sPTB using AUROC (Team R C. R: a Language and Environment for Statistical Computing. Vienna, Austria; 2014. 2015; Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005; 21(20):7881). To control the overall multiple testing error rate (α=0.05), the fixed sequence approach (Dmitrienko A, Tamhane A C, Bretz F, eds. Multiple Testing Problems in Pharmaceutical Statistics. Boca Raton, Florida: CRC Press; 2009:1-320; Dmitrienko A, D'Agostino R B, Huque M F. Key multiplicity issues in clinical drug development. Stat Med. 2012; 32(7):1079-111. doi:10.1002/sim.5642.) was applied to GABD increments within the optimal interval (19 0/7 through 21 6/7 weeks GA) identified in discovery and verification with and without the application of a BMI stratification (see Supplementary Material). Significance was assessed by the Wilcoxon-Mann-Whitney statistic that tests equivalence to AUROC=0.5 (random chance). (Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. Journal of mathematical psychology. 1975; 12(4):387-415. doi:10.1016/0022-2496(75)90001-2; Mason S J, Graham N E. Areas beneath the relative operating characteristics (ROC) and relative operating levels (ROL) curves: Statistical significance and interpretation. QJR Meteorol Soc. 2002; 128(584):2145-2166. doi:10.1256/003590002320603584.) For determinations of classification performance at GA boundaries other than <37 0/7 vs. ≥37 0/7 weeks GA (e.g. <36 0/7 vs. ≥36 0/7, <35 0/7 vs. ≥35 0/7), cases and controls were redefined as all subjects below and equal to/above the specific boundary, respectively.

Laboratory Methods

A systems biology approach was employed to generate a highly multiplexed multiple reaction monitoring (MRM) MS assay (Supplementary Methods and Results). The validation assay quantified proteotypic peptides specific to predictor proteins IBP4 and SHBG and other controls. Samples were processed in batches of 32, which were comprised of clinical subjects (24), pooled serum standards from healthy non-pregnant donors (HGS)(3), pooled serum standards from healthy pregnant donors (pHGS)(3) and phosphate buffered saline that served as process controls (2). For all analyses, serum samples were first depleted of high abundance and non-diagnostic proteins using MARS-14 immuno-depletion columns (Agilent Technologies), reduced with dithiothreitol, alkylated with iodoacetamide, and digested with trypsin. Heavy-labeled stable isotope standard (SIS) peptides were then added to samples, which were subsequently desalted and analyzed by reversed-phase liquid chromatography (LC)/MRM-MS. SIS peptides were used for normalization by generating response ratios (RR), where the peak area of a peptide fragment ion (i.e. transition) measured in serum was divided by that of the corresponding SIS transition spiked into the same serum sample.

The IBP4/SHBG Predictor

The predictor score was defined as the natural log of the ratio of the IBP4 and SHBG peptide transition response ratios:

$S = \ln (\frac{{RR}_{IBP 4}}{{RR}_{SHEG}}),$

where RR are the measured response ratios of the respective peptides.

Results

FIG. 23 summarizes the distribution of study subjects in PAPR. Between March, 2011 and August, 2013, 5,501 subjects were enrolled. As predefined in the protocol, 410 (6.7%) subjects were excluded from analysis due to receiving progestogen therapy after the first trimester of pregnancy. An additional 120 (2.2%) subjects were excluded due to early discontinuation, and 146 (2.7%) were lost to follow-up. A total of 4,825 subjects were available for analysis. There were 533 PTBs; 248 (4.7%) spontaneous and 285 (5.9%) medically indicated. Compared to those who delivered at term, subjects with a sPTB were more likely to have had one or more prior PTBs and to have experienced bleeding after 12 weeks of gestation in the study pregnancy (Table 1). Characteristics of sPTB cases and term controls selected for validation were not significantly different from each other, with the exception that there were significantly more Hispanic controls (47.5% vs. 33.3% p=0.035). Similarly, subjects selected for validation were largely representative of the study cohort as a whole (Table 1), with the exception of ethnicity of term controls.

Validation Analysis

In discovery and verification analyses the ratio of IBP4/SHBG and the interval between 19 0/7 through 21 6/7 weeks GA was identified as the best performing sPTB predictor by AUROC and GA interval, respectively (Supplementary Results, below). For validation, a predefined fixed sequence approach validated the IBP4/SHBG predictor with and without BMI stratification, with optimal performance identified for the GA interval of 19 1/7 through 20 6/7 weeks. Without taking BMI into consideration, validated performance was AUROC=0.67 (p=0.02) (Supplementary Results). However, as expected, performance was improved with a BMI stratification of >22 and ≤37 kg/m²which corresponded to an AUROC of 0.75 (p=0.016, 95% CI 0.56-0.91) (FIG. 24). More detailed characterization of BMI stratification can be found in Supplementary Results. Performance measures of sensitivity, specificity, AUROC and odds ratios (ORs) were determined at varied case vs. control boundaries (Table 2). For sPTB vs. term birth (<37 0/7 vs. ≥37 0/7 weeks), the sensitivity and specificity was 0.75 and 0.74, respectively, with an odds ratio (OR) of 5.04 (95% CI 1.4-18). The results at other boundaries are summarized in Table 2. Accuracy of the test improved at lower GA boundaries.

The prevalence adjusted positive predictive value (PPV), a measure of clinical risk, is shown as a function of predictor score in FIG. 25. Stratification of subjects with increasing predictor score occurs as PPV increases from a background value (population sPTB rate of 7.3% for singleton births in the U.S.)(Martin et al., Births: final data for 2013. Natl Vital Stat Rep. 2015; 64(1):1-65 Martin J A, Hamilton B E, Osterman M J, Curtin S C, Matthews T J. Births: final data for 2013. Natl Vital Stat Rep. 2015; 64(1):1-65) to relative risks of 2× (14.6%) and 3× (21.9%) (dashed lines) and higher (FIG. 25). The distribution of IBP4/SHBG predictor score values for subjects color coded by GA at birth category are shown in box plots in FIG. 25. The earliest sPTB cases (<35 0/7 weeks GA) have higher predictor scores than late term controls (≥39 0/7 weeks GA) while the scores for late sPTB cases (≥35 0/7 through <37 0/7 weeks GA) overlap with early term controls (≥37 0/7 through <39 0/7 weeks GA) (FIG. 25). Validation subjects were identified as high or low risk according to a predictor score cut-off corresponding to 2× relative risk (PPV of 14.6%). The rate of births for the high and low risk groups were then displayed as events in a Kaplan Meier analysis (FIG. 26). From this analysis, those classified as high risk generally delivered earlier than those classified as low risk (p=0.0004).

Post Validation Analyses

Predictor performance was measured using a combination of subjects from the blinded verification (Supplementary data, below) and validation analyses within the optimal BMI and GA interval. The ROC curve for the combined sample set is shown and corresponds to an AUROC of 0.72 (p=0.013) (FIG. 27).

Using an 'omics approach we developed a maternal serum predictor comprised of the ratio of IBP4/SHBG levels at 19-20 weeks with a BMI interval of >22 and ≤37 kg/m2 that identified 75% of women destined for sPTB. Prior history of sPTB (Goldenberg et al., Epidemiology and causes of preterm birth. Lancet. 2008; 371(9606):75-84. doi:10.1016/50140-6736(08)60074-4, Petrini et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005; 105(2):267-272) and cervical length measurements (Jams et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med. 1996; 334(9):567-72; Hassan et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011; 38(1):18-31) are considered the best measures of clinical risk to date; however, either individually or in combination they fail to predict the majority of sPTBs.

An ideal sPTB prediction tool would be minimally invasive, performed early in gestation coinciding with timing of routine obstetrical visits, and would accurately identify those at highest risk. Current 'omics studies suggest that perturbations in the physiological state of pregnancy can be detected in maternal serum analytes measured in sPTB subjects. 'Omics discovery studies in PTB have included proteomic (Gravett et al. Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J Proteome Res. 2007; 6(1):89-96; Goldenberg et al. The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health. 1998; 88(2):233-8; Gravett et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA. 2004; 292(4):462-469; Pereira et al. Insights into the multifactorial nature of preterm birth: proteomic profiling of the maternal serum glycoproteome and maternal serum peptidome among women in preterm labor. Am J Obstet Gynecol. 2010; 202(6):555.e1-10; 32. Pereira et al. Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. J Proteome Res. 2007; 6(4):1269-76; Dasari et al. Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res. 2007; 6(4):1258-1268; Esplin et al. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2010; 204(5):391.e1-8), transcriptomic (Weiner et al. Human effector/initiator gene sets that regulate myometrial contractility during term and preterm labor. Am J Obstet Gynecol. 2010; 202(5):474.e1-20; Chim et al. Systematic identification of spontaneous preterm birth-associated RNA transcripts in maternal plasma. PLoS ONE. 2012; 7(4):e34328. Enquobahrie et al. Early pregnancy peripheral blood gene expression and risk of preterm delivery: a nested case control study. BMC Pregnancy Childbirth. 2009; 9(1):56), genomic (Bezold et al. The genomics of preterm birth: from animal models to human studies. Genome Med. 2013; 5(4):34; Romero et al. Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol. 2010; 202(5):431.e1-34; Swaggart et al. Genomics of preterm birth. Cold Spring Harb Perspect Med. 2015; 5(2):a023127; Haataja et al. Mapping a new spontaneous preterm birth susceptibility gene, IGF1R, using linkage, haplotype sharing, and association analysis. PLoS Genet. 2011; 7(2):e1001293; McElroy et al. Maternal coding variants in complement receptor 1 and spontaneous idiopathic preterm birth. Hum Genet. 2013; 132(8):935-42), and metabolomic (Menon et al. Amniotic fluid metabolomic analysis in spontaneous preterm birth. Reprod Sci. 2014; 21(6):791-803) approaches. However, to date none of these approaches have produced validated testing methods to reliably predict the risk of sPTB in asymptomatic women.

The current invention is the result of a large prospective and contemporaneous clinical study that allowed independent discovery, verification and validation analyses, while adhering to TOM guidelines regarding omics' test development. It involved construction of a large and standardized multiplexed proteomic assay to probe biological pathways of relevance in pregnancy. The study size and relatively broad blood collection window (17 0/7 through 28 6/7 weeks GA) also enabled the identification of a GA interval where there were marked alterations in protein concentrations between sPTB cases and term controls. Use of a low complexity predictor model (i.e. the ratio of two proteins) limited the pitfalls of overfitting.

Application of the proteomic assay and model building led to the identification of a pair of critical proteins (IBP4 and SHBG) with consistently good predictive performance for sPTB. Despite the challenges of building a classifier for a condition attributed to multiple etiologies, the predictor demonstrated good performance at a cutoff of <37 0/7 vs. ≥37 0/7 weeks GA with an AUROC of 0.75. Importantly, accuracy of the predictor improves for earlier sPTBs (e.g. <35 0/7 weeks GA), enabling the detection of those sPTBs with the greatest potential for morbidity. Subjects determined to be at high risk for sPTB using the IBP4/SHBG predictor delivered significantly earlier than subjects identified as low risk. Our findings suggest that IBP4 and SHBG may perform important functions related to the etiologies of sPTB and/or act as convergence points in relevant biological pathways.

Universal transvaginal ultrasound (TVU) measurement of cervical length (CL) was not performed routinely at the majority of our study centers and was available for less than 1/3 of study subjects. It will be of interest to assess whether CL measurements improve upon the proteomic predictor in future studies or alternatively, if risk stratification by the IBP4/SHBG classifier identifies women that benefit most from serial CL measurements. Finally it will be intriguing to investigate the performance of the molecular predictor together with a BMI variable, or perhaps in combination with other medical/pregnancy history and sociodemographic characteristics.

In conclusion, a predefined predictive test for sPTB based on serum measurements of IBP4 and SHBG in asymptomatic parous and nulliparous women was validated in a completely independent set of subjects. Further functional studies on these proteins, their gene regulation and related pathways may help to elucidate the molecular and physiological underpinnings of sPTB. Application of this predictor should enable early and sensitive detection of women at risk of sPTB. This may improve pregnancy outcomes through increased clinical surveillance as well as to accelerate the development of clinical interventions for PTB prevention.

Supplementary Materials and Methods

Discovery and Verification Subjects

Discovery and verification subjects were derived from the PAPR study described above in this Example.

Discovery and Verification Principles

sPTB cases were defined as described above in this Example. Discovery and verification of the predictor was conducted according to guidelines for best practices in ‘omics’ research. (IOM (Institute of Medicine). Evolution of Translation Omics: Lessons Learned and the Path Forward. (Micheel C M, Nass S J, Omenn G S, eds.). Washington, DC: The National Academies Press.; 2012:1-355). Nested case/control analyses used sample sets completely independent of each other. Cases and controls selected for discovery and verification underwent central review for within-subject data discrepancies; no source document verification (SDV) with the medical record was performed. All sPTB cases and controls for discovery and verification were individually adjudicated by the Chief Medical Officer and discrepancies were clarified with the PI at the clinical site. Detailed analysis protocols, including study designs, analysis plans and a verification blinding protocol were pre-established. Laboratory and data analysis personnel were blinded to verification subject's case, control and GA data assignments. Predictor scores, calculated as described below, were assigned to all subjects by an internal blinded statistician. Case, control and GA data, linked to the predictor scores by the DCO, were provided to an independent external statistician for analysis. AUROC results were then transferred back to the DCO. Transfer of data utilized a SUMPRODUCT (Microsoft. Microsoft Excel. 2013) function in Excel to ensure maintenance of data integrity. To provide an audit trail of data from subjects through to verification results, digital timestamping was applied to analytical data, plans and reports.

Discovery and Verification Study Design

Discovery and verification sPTB cases totaled 86 and 50 subjects, respectively, collected across 17 0/7 through 28 6/7 weeks GA at blood draw (GABD). Subjects used in discovery and verification were completely independent of each other and independent from those used in validation. Matched controls were identified for sPTB cases in discovery and verification as described above in this Example.

Prevalence Analyses

Following discovery, verification and validation analyses, additional term controls, not used in prior studies, were selected from the PAPR database and processed in the laboratory using the MRM-MS assay applied in validation and described above in this Example. Using the Sampling package in R Statistical software (version 3.0.3) (Team R C. R: a Language and Environment for Statistical Computing. Vienna, Austria; 2014. 2015; Matei A, Tillé Y. The R “sampling” package. European Conference on Quality in Survey Statistics. 2006), sets of 187 subjects were randomly selected from the validated GA blood draw interval and compared via univariate statistical analyses (Chi-Square Test) against the gestational age at birth (GAB) data from the 2012 National Vital Statistics Report (NVSR). Martin et al.: Final Data for 2012. National Vital Statistics Reports. 2014; 63(09):1-86 Sets of controls most closely approximating the distribution of deliveries in the 2012 NVSR based on the best p value (approaching 1.0 with minimum acceptable value of 0.950) were then selected for comparison against the BMI distribution in the PAPR study as a whole. Using univariate statistical analyses (Chi-Square Test) against the BMI data from the PAPR study database, the sets of controls most closely approximating the distribution of BMI (approaching 1.0 with minimum acceptable value of 0.950) and the distribution of delivery timing in the NVSR were selected and compared to the GABD of the validated blood draw samples. The set that most closely approximated all three distributions was selected as the subject set for the Prevalence Study. Predictor score values for verification, validation and prevalence within the validation GABD interval and BMI restriction totaled 150 subjects. This composite dataset was used to obtain the best estimates of confidence intervals about the PPV curve in FIG. 25. Confidence intervals about the PPV were calculated with the normal approximation of the error for binomial proportions. Brown et al. Interval estimation for a binomial proportion. Statistical science. 2001; 16(2):101-133.

Laboratory Methods

A systems biology approach was employed to generate a highly multiplexed multiple reaction monitoring (MRM) mass spectrometry (MS) assay by iterative application of: literature curation, targeted and un-targeted proteomic discovery and small scale MRM-MS analyses of subject samples. The mature MRM-MS assay, measuring 147 proteins, was applied in discovery and verification studies. For all analyses, serum samples were processed in the laboratory as described above in this Example. Aliquots of pooled serum controls (pHGS) were used to calculate the inter-batch analytical coefficient of variation (CV) for IBP4 and SHBG.

General Predictor Development Strategy

A strategy was developed to avoid over-fitting and to overcome the dilution of biomarker performance expected across broad gestational age ranges due to the dynamic nature of protein expression during pregnancy. Ratios of up-regulated over down-regulated analyte intensities were employed in predictor development. Such “reversals” are similar to the top-scoring pair and 2-gene classifier strategies. (Geman et al. Classifying gene expression profiles from pair wise mRNA comparisons. Stat Appl Genet Mol Biol. 2004; 3(1):Article19; Price et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci USA. 2007; 104(9):3414-9) This approach allowed amplification of the diagnostic signal and self-normalization as both proteins in a “reversal” underwent the same pre-analytical and analytical processing steps. As a strategy to normalize peptide intensity measures in complex proteomics workflows, reversals are also similar to a recently introduced approach termed “endogenous protein normalization (EPN)”. (Li et al. An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples. Clin Proteomics. 2015; 12(1):3; Li et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013; 5(207):207ra142) The number of candidate analytes used for model building was reduced by analytic criteria. Analytic filters included: cut-offs for analytical precision, intensity, evidence of interference, sample processing order dependence and pre-analytical stability. The total number of analytes in any one predictor was limited to a single reversal, thus avoiding complex mathematical models. Predictor scores were defined as the natural log of a single reversal value, where the reversal itself was a response ratio (defined above in this Example). Lastly, predictive performance was investigated in narrow overlapping 3-week intervals of gestation.

Receiver Operating Characteristic Curves

AUROC values and associated p-values were calculated for reversals as described above in this Example. The distribution and mean value for predictor AUROC in the combined discovery and verification set was calculated using a bootstrap sampling performed iteratively by selecting random sets of samples with replacement. Efron B, Tibshirani R J. An Introduction to the Bootstrap. Boca Raton, Florida: Chapman and Hall/CRC Press; 1994. The total number of selected samples at each iteration corresponded to the total available in the starting pool.

Supplementary Results

Discovery, verification and validation subject characteristics are summarized in Table 3. The percentage of subjects with one or more prior sPTBs in discovery sPTB cases were higher than in verification or validation, and other characteristics were largely consistent across the studies.

Discovery and Verification Analyses

Forty-four proteins were either up- or down-regulated in overlapping 3-week GA intervals and passed analytic filters (FIG. 28). Reversals were formed from the ratio of up-over down-regulated proteins and predictive performance tested in samples in each of the overlapping 3-week GA intervals. Performance for a subset of reversals displaying representative patterns is shown in FIG. 29. Waves of performance were evident: IBP4/SHBG and APOH/SHBG reversals possessed better AUROC values in early windows, while ITIH4/BGH3 and PSG2/BGH3 peaked later in gestation (FIG. 24). Some reversals had a consistent but moderate performance across the entire gestational age range (PSG2/PRG2) (FIG. 29). The top performing reversal overall, IBP4/SHBG, had an AUROC=0.74 in the interval from 19 0/7 through 21 6/7 (FIG. 29). AUROC performance of the IBP4/SHBG predictor increased to 0.79 when subjects were stratified by pre-pregnancy BMI<35 (kg/m2) (Table 4). Because of its consistently strong performance early in gestation (i.e. 17 0/7 through 22 6/7 weeks GA) (FIG. 29) and potentially desirable clinical utility the IBP4/SHBG predictor was selected for verification analysis.

The blinded IBP4/SHBG AUROC performance on verification samples was 0.77 and 0.79 for all subjects and BMI stratified subjects, respectively, in good agreement with performance obtained in discovery (Table 5). Following blinded verification, discovery and verification samples were combined for a bootstrap performance determination. A mean AUROC of 0.76 was obtained from 2,000 bootstrap iterations (FIG. 30).

BMI Validation Analyses

The performance of the IBP4/SHBG predictor was evaluated at several cut-offs of BMI in the validation samples (Table 5). AUROC measured performance modestly improved by elimination of either very high (e.g. >37 kg/m2) or low BMI (e.g. ≤22 kg/m2). Stratification by a combination of those two cut-offs gave an AUROC of 0.75 (Table 5).

Example 3. Correlation of Mass Spectrometry and Immunoassay Data

This example demonstrates results of a Myriad RBM screen identifying IBP4 and other biomarkers individual biomarkers for sPTB in the early, middle, and late gestational age collection windows, (2) correlation of MS and immunoassay results for SHBG/IBP4, and (3) clinical data relating to SHBG as a biomarker for sPTB.

RBM Data

Briefly, RBM assayed 40 cases and 40 controls from PAPR (20/20 from Early Window), 10/10 from Middle Window, 10/10 from Late Window). RBM used the Human Discovery MAP 250+ v2.0 (Myriad RBM, Austin, TX). The objective of these analyses is to develop multivariate models to predict PTB using multiple analytes. We used four modeling methods: random forest (rf), boosting, lasso, and logistic (logit). We perform a first round of variable selection in which each method independently selects the 15 best variables for that method. From the 15, the best analytes were selected independently by each of the four modeling methods using backward stepwise selection and estimation of area under the ROC curve (AUC) using out-of-bag bootstrap samples. Table 6 shows the top hits from several multivariable models. Table 7 shows Early Window (GABD 17-22 wks) Analyte Ranking by Different Multivariate Models. Table 8 shows Middle Window (GABD 23-25 wks) Analyte Ranking by Different Multivariate Models. Table 9 shows Late Window (GABD 26-28 weeks) Analyte Ranking by Different Multivariate Model.

Identifying Commercial ELISA Kits that Correlate With Mass Spec Data

Briefly, ELISA versus MS comparisons involved multiple studies using PAPR samples and ranging in size from 30-40 subjects. Each ELISA was performed according to the manufacture's protocol. The predicted concentration of each analyte by ELISA was then compared to MS derived relative ratios from identical samples. A Person's r correlation value was then generated for comparison. ELISA versus MS comparisons involved multiple studies using PAPR samples and ranging in size from 30-40 subjects. Each ELISA was performed according to the manufacture's protocol. The predicted concentration of each analyte by ELISA was then compared to MS derived relative ratios from identical samples. A Person's r correlation value was then generated for comparison. Table 10 provides epitope and clonality information for kits tested for analytes IBP4_HUMAN and SHBG_HUMAN. Table 11 shows that not all ELISA kits correlate with MS, even for proteins where correlation exists. See for example: IBP4, CHL1, ANGT, PAPP1.

One hundred and twenty previously frozen serum samples with known outcomes from the PAPR study were selected for comparison between ELISA and MS assays. These samples have a Gestational Age at Blood Draw (GABD) between 119 and 180 days. Samples were not excluded due to maternal BMI. ELISA's were performed on commercially available kits for IBP4 (AL-126, ANSCH Labs Webster, Texas), and SHBG (DSHBGOB, R&D Systems Minneapolis, Minnesota). Assays were run according to the manufactures' protocols. Internal standards were used for plate-to-plate normalization. The score was calculated from the ELISA concentration values according to LN([IBP4]/[SHBG]), and by MS according to LN(IBP4^RR/SHBG^RR), where RR refers to the relative ratio of endogenous peptide to SIS peptide peak areas. Scores derived from the two approaches were compared in case versus control separation (p values derived from unpaired t-tests assuming equal standard deviations) (FIG. 31).

Fifty seven previously frozen serum samples (19 sPTB cases, 38 term controls) with known outcomes from the PAPR study were selected for comparison between ELISA and MS assays. These samples have a Gestational Age at Blood Draw (GABD) between 133 and 148 days. ELISA's were performed on commercially available kits for IBP4 (AL-126, ANSCH Labs Webster, Texas), and SHBG (DSHBGOB, R&D Systems Minneapolis, Minnesota). Assays were run according to the manufactures' protocols. Samples run on different plates were normalized using internal standards. The score was calculated from the ELISA concentration values according to LN([IBP4]/[SHBG]), and by MS according to LN(IBP4^RR/SHBG^RR), where RR refers to the relative ratio of endogenous peptide to SIS peptide peak areas. Performance of the immunoassay by area under the receiver operating characteristic curve (AUC) was then determined and compared to the MS derived AUC on the same sample sets (FIG. 32). AUC values were also determined after applying a BMI stratification to the samples (BMI>22 ≤37) resulting in 34 total samples (13 sPTB cases, 21 term controls) (FIG. 33).

Sixty previously frozen serum samples with known outcomes from the PAPR study were analyzed by ELISA and MS assays. These samples have a predicted Gestational Age at Blood Draw (GABD) between 133 and 146 days. Correlation analyses were performed for samples at all BMI (FIG. 34, right panel) or for the subset of samples with a BMI >22 or ≤37 (FIG. 34, left panel). ELISA's were performed on commercially available kits for IBP4 (AL-126, ANSCH Labs Webster, Texas), and SHBG (DSHBGOB, R&D Systems Minneapolis, Minnesota). Assays were run according to the manufactures' protocols. Internal standards were used for plate-to-plate normalization. The score was calculated from the ELISA concentration values according to LN([IBP4]/[SHBG]), and by MS according to LN(IBP4^RR/SHBG^RR), where RR refers to the relative ratio of endogenous peptide to SIS peptide peak areas. Scores derived from the two approaches were compared by correlation and in case versus control separation (p values derived from unpaired t-tests assuming equal standard deviations). Table 12 shows IBP4 and SHBG ELISA Kits Demonstrating sPTB vs Control Separation (univariate).

Comparison of SHBG Measurements by Mass Spectrometry and Clinical Analyzers

Thirty five samples from individual subjects and serum pools of pregnant and non-pregnant women were simultaneously analyzed at Sera Prognostics and two independent reference laboratories, ARUP Laboratories and Intermountain Laboratory Services. Aliquots were transported refrigerated to each laboratory and shipping was coordinated so testing would begin on the same date for all three laboratories. ARUP utilizes a Roche cobas e602 analyzer and Intermountain uses the Abbott Architect CMIA, both semi-automated immunoassay instruments. Sera Prognostics employs a unique proteomic analysis method involving immuno-depletion of samples, enzymatic digestion and analyzed on an Agilent 6490 Mass Spectrometer. Results from both ARUP and IHC were reported in nmol/L while Sera uses the Relative Ratio (RR) of heavy and light peptide surrogates. Data from ARUP and Intermountain were compared to each other to determine accuracy (FIG. 39). Linearity and precision matched well throughout the broad range of results with a linearity slope of 1.032 and r²value of 0.990. Each reference laboratory's data was then compared to Sera's RR and a linear regression plot (FIGS. 37 and 38). Data compared well to Sera results with ARUP having an r²value of 0.937 and Intermountain having an r²value of 0.934.

Example 4. SNPs, Insertions and Deletions and Structural Variants within the PreTRM IBP4 and SHBG Peptides

This example shows the known SNPs, insertions and deletions (indels) and structural variants within the PreTRM IBP4 and SHBG peptides.

Table 13 and Table 14 detail the known SNPs, insertions and deletions (indels) and structural variants within the PreTRM IBP4 and SHBG peptides. The information is derived from the Single Nucleotide Polymorphism database (dbSNP) Build 146. A single missense variation (G>C) in SHBG, A179P (dbSNP id: rs115336700) has the highest overall allelic frequency of 0.0048. While this allelic frequency is low, several subpopulations studied in the 1000 genomes project had significantly higher frequencies. These populations (allele frequencies) are; Americans of African Ancestry in SW USA (0.0492); African Carribbeans in Barbados (0.0313); Yourba in Ibadan, Nigeria (0.0278); Luhya in Webuye, Kenya (0.0101); Esan in Nigeria (0.0101); Colombians from Medellin, Colombia (0.0053); Gambian in Western Divisions in The Gambia (0.0044). All other studied subpopulations had no variation in this nucleotide position. The table header includes the cluster id—(dbSNP rs number), Heterozygosity—average heterozygosity, Validation—validation method (or blank with no validation), MAF—Minor Allele Frequency, Function—functional characteristic of the polymorphism, dbSNP allele—identity of allelic nucleotide, Protein residue—residue resulting from allele, Codon pos—position in codon, NP_001031.2 Amino acid pos—amino acid position in reference sequence NP_001031.2, and NM_001040.2 mRNA pos—nucleotide position in a reference sequence NM_001040.2.

Example 5. IBP4/SHBG Reversal Amplifies Diagnostic Signal for sPTB and Reduces Analytical Variability

This example demonstrates the amplification of diagnostic signal and reduction of variability obtained employing the IBP4/SHBG reversal strategy.

Shown are the levels of IBP4 and SHBG determined by MS across the indicated gestation age range for sPTB cases and term controls separately (FIG. 44 and FIG. 45). Curves were generated by a mean smoothing of the peptide relative ratios (endogenous peptide peak area over corresponding SIS peak area). Case versus control signal corresponds to an approximate maximal 10% difference for IBP4 and SHBG. When the score calculated as ln(IBP4RR/SHBGRR) is plotted an amplification of signal is evident (maximal difference of approximately 20%) (FIG. 46). These data demonstrate the amplification of diagnostic signal obtained employing the IBP4/SHBG reversal strategy.

Forming the ratio of the levels of two proteins may reduce the variability because each protein experiences the same analytical and preanalytical processing steps. To examine the impact on variability the CVs were determined for the individual proteins (RR of IBP4 and SHBG) and for IBP4 RR/SHBG RR ratio in pooled control serum samples from pregnant donors (pHGS). Pooled control samples, free of biological variability, were analyzed in multiple batches and across several days. Reversal variability is less than the variability associated with the individual proteins. (FIG. 48)

To investigate whether formation of reversals in general amplifies diagnostic signal we examined ROC performance (AUC) performance of high performing reversals (AUC >0.6) formed by the ratio of many proteins. Shown in the top panel of FIG. 47 is the range of AUC values (sPTB case vs term control) using datasets from samples collected between 19/0 weeks and 21/6 weeks gestation. The adjacent box plots show the range in ROC performance for the individual up-regulated and down-regulated proteins used to form the associated reversals. Similarly, p values derived from a Wilcoxon test (sPTB case vs. term controls) for reversals are more significant than those for the corresponding individual proteins (FIG. 47, bottom).

To investigate whether formation of reversals more generally reduces variability we examined the analytical variability for 72 different reversal values (i.e. ratio of relative peak areas versus the analytical variability of the individual proteins that comprise the reversals in pooled control serum samples from pregnant donors (pHGS). Pooled control samples, free of biological variability, were analyzed in multiple batches and across several days. Reversal variability is less than the variability associated with the individual proteins (FIG. 49).

Generalizability of the Reversal Strategy to Reduce Analytic Variability.

FIG. 48 reports the CVs calculated for pHGS specimens (pooled pregnant samples) analyzed in the lab in several batches, days and instruments. Because the CVs were calculated using pHGS specimens that are devoid of biological variability, they correspond to the measure of analytic variability introduced in the lab processing of samples. The analytic variability of associated with the ratioed value for 72 reversals is lower than the analytic variability of the relative peak areas of individual up-regulated and down-regulated proteins used to form the reversals FIG. 49.

Example 6. Medically Indicated PTB Analysis

This example confirms that the classifier is sensitive to a component of medically indicated PTB based on conditions such as preeclampsia or gestational diabetes.

PreTRM™ was developed and validated as a predictor for spontaneous PTB. About 75% of all PTB in the U.S. are spontaneous, the remaining are medically indicated due to some maternal or fetal complication (e.g. preeclampsia, intrauterine growth restriction, infection). 41 medically indicated PTB samples from the PAPR biobank were analyzed in the lab and PreTRM scores were calculated. The PreTRM™ scores were compared for those subjects annotated as medically indicated for preeclampsia versus other indications were compared. Subjects medically indicated for preterm delivery because of preeclampsia had significantly higher scores than others (FIG. 50).

FIG. 52 shows a reversal intensity heatmap with diabetes annotation. The red arrows show diabetes subjects. The samples are listed on the bottom with PTB cases on the right and term births on the left side of the screen. The diabetes patients are clustered on the right, showing that reversals can be identified that stratify gestational diabetes and thus that it is possible to build a diagnostic test from the biomarkers to predict gestational diabetes.

Example 7. Other Transitions and Peptides

Table 16 shows comparative IBP4 peptide and transition MS data. Four different heavy labeled peptides (R*+10 daltons) exemplify various transitions and their relative intensities that could be monitored to quantify IBP4. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify IBP4.

Table 17 shows comparative IBP4 peptide and transition MS data. IBP4 tryptic peptides derived from recombinant protein was analyzed by MRM-MS to identify candidate surrogate peptide and their transitions. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify IBP4. IBP4 was identified in RBM (above), then the synthetic peptide was ordered to build the assay.

Table 18 shows Comparative SHBG peptide and transition MS data. SHBG tryptic peptides derived from recombinant protein or pooled pregnant serum was analyzed by MRM-MS to identify candidate surrogate peptide and their transitions. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify SHBG. Also shown are isoform specific peptides identified in serum.

Table 19 shows proteins with altered serum levels across 17-25 weeks GA in PTB samples. * Additional proteins limited to weeks 19-21 GA in PTB. LC-MS (MRM) assay of 148 proteins from multiple pathways and analyzed serum samples from gestational age (GA) weeks 17-25 from 312 women (104 sPTB cases, 208 term controls). MRM peak area data was analyzed by hierarchical clustering, t-tests, and relationship to GA. Following analytic filtering, 25 proteins exhibited significant differences (p<0.05) in sPTB vs term subjects (Table 1). Levels of 14 proteins were higher and 3 were lower in sPTB samples across the entire GA range. Other proteins were found to be dynamically regulated in sub-intervals of the GA period. For example, in GA weeks 19-21, an additional 7 proteins were elevated and 1 was lower in sPTB.

Table 20 lists 44 proteins meeting analytical filters that were up- or down-regulated in sPTB vs. term controls.

Example 8. Mechanistic Insights from Serum Proteomic Biomarkers Predictive of Spontaneous Preterm Birth

This example demonstrates that, as specific protein expression changes dynamically throughout pregnancy, biomarker performance varies considerably across GA. Differentially expressed proteins have functions in steroid metabolism, placental development, immune tolerance, angiogenesis and maintenance of pregnancy. FIGS. 55, 57-59. These protein profile differences seen in sPTB reflect impaired developmental transitions within the fetal/placental compartment during the second trimester.

Briefly, the objective of the study described in this example was to gain insight into the physiological basis for biomarker association with spontaneous preterm birth (sPTB) prediction.

Study Design

Pathways such as inflammation, infection and bleeding have been implicated in the etiology of preterm birth. However, less is known about which proteins are measurable in blood and when in gestation they are disrupted. To answer these questions we created an LC-MS (MRM) assay of 148 proteins from multiple pathways and analyzed serum samples from gestational age (GA) weeks 17-25 from 312 women (104 sPTB cases, 208 term controls).

Briefly, serum samples were depleted of high abundance proteins, digested with trypsin and fortified with heavy-labeled stable isotope standard (SIS) peptides for nearly all of the proteins. SIS peptides were used for normalization by generating response ratios, where the peak area of a peptide fragment ion (i.e. transition) measured in serum was divided by that of the corresponding SIS transition. Response ratios of MRM peak area data were analyzed by hierarchical clustering, t-tests and relationship to GA.

As shown in FIG. 53, multiple peptides to the same protein are well correlated. Discrete branches (grouped by color) correspond to identifiable functional categories such as: acute-phase proteins, apolipoproteins and known pregnancy specific proteins. Protein complexes important in reproductive biology such as: PAPP1:PRG2, INHBE:INHBC, and IGF2:IBP3:ALS are evident. These quality assessments and highlighted relationships validate the highly multiplexed MRM-MS assay described in this application for use in probing the biology of pregnancy and the discovery of analytes predictive of sPTB.

FIG. 54 shows differentially expressed proteins that function in extracellular matrix interactions. TENX activates latent TGF-b and is localized to fetal and maternal stroma at transition points of cytotrophoblast differentiation. Alcaraz, L., et al. 2014 J. Cell Biol. 205(3) 409-428; Damsky, C., et al. 1992 J. Clin. Invest. 89(1) 210-222. Reduced serum TENX levels in sPTB indicate blood vessel defects or reduced TGF-b activity in placenta. NCAM1(CD56) is highly expressed on neural cells and natural killer cells. NCAM1 is also expressed by endovascular trophoblasts, but is reduced or absent in PE placentas. Red-Horse, K., et al. 2004 J. Clin. Invest. 114:744-754. Inverted serum NCAM1 levels in sPTB cases can reflect poor spiral artery remodeling and/or defective immunoregulation. CHL1 is homologous to NCAM1 and directs integrin-mediated cell migration. BGH3(TGFBI), a cell adhesion molecule expressed in vascular endothelial cells, and inhibits angiogenesis via specific interactions with av/03 integrin. Son, H-N., et al. 2013 Biochimica et Biophysica Acta 1833(10) 2378-2388. Elevated TGFBI in sPTB cases may indicate reduced placental angiogenesis.

FIG. 55 shows kinetic plots of differentially expressed proteins with functions in the IGF-2 pathway that show maximum separation at 18 weeks. IGF2 stimulates proliferation, differentiation and endometrial invasion by extravillous trophoblasts in early pregnancy. IBP4 binds and modulates the bioavailability of IGF2 at maternal-fetal interface. Elevated IBP4 and reduced IGF2 during the 1st trimester are correlated with IUGR and SGA, respectively. Qiu, Q., et al. 2012 J. Clin. Endocrino.l Metab. 97(8):E1429-39; Demetriou, C., et al. 2014 PLOS 9(1): e85454. PAPP1 is a placental-specific protease that cleaves IBP4 and releases active IGF2. Low serum PAPP1 levels early in pregnancy are associated with IUGR, PE and PTB. Huynh, L., et al. 2014 Canadian Family Physician 60(10) 899-903.PRG2 (proMBP) is expressed in placenta and covalently binds and inactivates PAPP1. The PRG2:PAPP1 inactive complex circulates in maternal serum. Huynh, L., et al. 2014 Canadian Family Physician 60(10) 899-903. Perturbed pathway regulation is consistent with compromised IGF2 activity in sPTB cases that may result in abnormal placentation. FIG. 56 A shows a schematic of the dynamic regulation and bioavailability of the aforementioned proteins during sPTB.

FIG. 56 B shows a schematic of intracellular signals preferentially activated by insulin binding to the IR-B and by insulin and IGFs binding to either IR-A or IGF1R. Belfiore and Malaguarnera, Endocrine-Related Cancer (2011) 18 R125-R147. IR-A and IGF1R activation by insulin and IGFs leads to the predominance of growth and proliferative signals through the phosphorylation of IRS1/2 and Shc proteins. Shc activation leads to the recruitment of Grb2/Sos complex with subsequent activation of Ras/Raf/MEK1 and Erk1/2. This latter kinase translocates to the nucleus and induces the transcription of several genes involved in cell proliferation and survival. Phosphorylation of IRS1/2 induces the activation of the PI3K/PDK1/AKT pathway. Besides its role in metabolic effects, AKT leads to the activation of effectors involved in the control of apoptosis and survival (BAD, Mdm2, FKHR, NFkB, and JNK) and protein synthesis and cell growth (mTOR).

FIG. 57 shows kinetic plots of differentially expressed proteins with functions in metabolic hormone balance. Sex hormone-binding globulin (SHBG), a placental protein, increases during pregnancy and determines bioavailability and metabolism of sex steroid hormones. Decreased SHBG levels result in higher free androgen and estrogen levels. Free androgens can be converted to estrogen by placental aromatase activity. Progesterone opposing activity of estrogens accelerate gestation/labor. Thyroxine-binding globulin (THBG) is induced by estrogen and increases ˜2.5-fold by mid-pregnancy. The elevated serum THBG levels in sPTB cases may result in reduced free thyroid hormone. Hypothyroidism in pregnancy is associated with increased risk of miscarriage and preterm birth. Stagnaro-Green A. and Pearce E. 2012 Nat. Rev. Endocrinol. 8(11):650-8. Angiotensinogen is increased ˜3-fold by estrogen by mid-pregnancy to stimulate the ˜40% increase in plasma volume. Up-regulation of ANGT could lead to gestational hypertension, a condition associated with increased risk of sPTB.

FIG. 58 shows kinetic plots of differentially expressed proteins with functions in angiogenesis. TIE1, an inhibitory co-receptor of the TIE2 angiopoietin receptor, blocks the ability of Ang-2 to stimulate angiogenesis. Seegar, T., et al. 2010 Mol. Cell. 37(5): 643-655. Pigment epithelial derived factor (PEDF), an anti-angiogenesis factor expressed in placenta, stimulates cleavage and inactivation of VEGFR-1 by gamma-secretase.10 Cathepsin D (CATD) cleaves prolactin to generate vasoinhibins that inhibit angiogenesis. Elevated serum CATD and vasoinhibins are associated with preeclampsia. Nakajima, R., et al. 2015 Hypertension Research 38, 899-901. Leucine-rich alpha-2-glycoprotein (LRG1/A2GL) promotes TGF-β signaling through binding co-receptor, endoglin. TGF-β activates endothelial cell mitogenesis and angiogenesis by the Smad1/5/8 signaling pathway. Wang, X., et al. 2013 Nature 499(7458). PSG3 induces anti-inflammatory cytokines from monocytes and macrophages, and stimulates angiogenesis through binding TGF-β. Low levels of PSGs are associated with IUGR. Moore, T., and Dveksler, G. 2014 Int. J. Dev. Biol. 58: 273-280. ENPP2(autotaxin), an ectoenzyme with lysophospholipase D activity, produces lysophosphatidic acid (LPA). LPA acts on placental receptors to stimulate angiogenesis and chemotaxis of NK cells and monocytes. Levels of Autotaxin are reduced in cases of PIH and early onset PE. Chen, S-U., et al. 2010 Endocrinology 151(1):369-379.

FIG. 59 shows kinetic plots of differentially expressed proteins with functions in innate immunity. LBP presents bacterial LPS to the Toll-like receptor-4 via its co-receptor CD14 to induce the inflammatory response of the innate immunity pathway. Fetuin-A (alpha-2-HS-glycoprotein) is a carrier protein for fatty acids in blood and the FetA-FA complex can bind and activate TLR4 receptor. Pal, D., et al. 2012 Nature Med. 18(8):1279-85.

FIG. 60 shows kinetic plots of differentially expressed proteins with functions in coagulation.

FIG. 61 shows kinetic plots of differentially expressed serum/secreted proteins.

FIG. 62 shows kinetic plots of differentially expressed PSGs/IBPs.

FIG. 63 shows kinetic plots of differentially expressed ECM/cell surface proteins.

FIG. 64 shows kinetic plots of differentially expressed complement/acute phase proteins-1.

FIG. 65 shows kinetic plots of differentially expressed complement/acute phase proteins-2.

FIG. 66 shows kinetic plots of differentially expressed complement/acute phase proteins-3.

FIG. 67 shows kinetic plots of differentially expressed complement/acute phase proteins-4.

Example 9. SDT4/SV4 Kinetic Analysis

This example provides kinetic analysis for all analytes initially exemplified in Example 1, supra, with data from 17 weeks 0 days, through 28 weeks, 6 days.

For FIGS. 68-85, average relative ratios for each peptide transition are plotted using the R ggplot2 package against GABD using a mean average smoothing function (window=+/−10 days). Graphs feature separate plots for case vs. control using two different gestational age at birth cutoffs (<37 0/7 vs >=37 0/7 weeks and <35 0/7 vs >=35 0/7 weeks). Plot titles display a protein short name, underscore, and the peptide sequence. Analyte sequences may have been trimmed for titles to fit on the plots.

The kinetic analyses exemplified herein serve several purposes. These analyses demonstrate whether analyte levels are changing during pregnancy and in which direction, whether they change differently for cases and controls, and illustrate diagnostic differences as a function of gestational age. In some cases, the diagnostic signal is located in a narrow gestational age range, and increases or decreases across time. The shape of kinetic plots also provides visual guidance for selection of proteins that pair well in reversals.

Analytes that were discovered to show significant case versus control separation in an early window, e.g. sample collection between 18 and 20 weeks of gestational age, include, for example, AFAM, B2M, CATD, CAH1, C1QB, C1S, F13A, GELS, FETUA, HEMO, LBP, PEDF, PEPD, PLMN, PRG2, SHBG, TENX, THRB, and VCAM1. Analytes that were discovered to show significant case versus control separation in a later window, e.g. sample collection between 26 and 28 weeks of gestational age, include, for example, ITIH4, HEP2, IBP3, IGF2, KNG1, PSG11, PZP, VASN, and VTDB. Separation of cases versus controls improved using cutoff of less than 35 0/7 versus greater or equal to 35 0/7 weeks versus less than 37 0/7 versus greater or equal to 37 0/7 weeks, as seen for analytes including, for example, AFAM, APOH, CAH1, CATD, CD14, CLUS, CRIS3, F13B, IBP6, ITIH4, LYAM1, PGRP2, PRDX, PSG2, PTGDS, SHBG and SPRL1. It was discovered that many inflammatory and immuno-modulatory molecules show improved separation using the lower gestational at birth cutoff. One skilled in the art will appreciate that any of the analytes showing significant separation between cases and controls shown in the accompanying Figures for a given time window are candidates for use in a reversal pair of the present inventions, as a single biomarker or as part of a biomarker panel of analytes.

Lastly, kinetic plots for analytes that lack a case versus control difference, but demonstrate changes in analyte intensity across pregnancy, are useful in a pregnancy clock according to the methods of the invention. These analytes, also referred to herein as “clock proteins”, can be used to date a pregnancy in the absence of or in conjunction with other dating methods (e.g. date of last menstrual period, ultrasound dating). Table 60 provides a list of clock proteins useful in a pregnancy clock of the invention.

Example 10. Discovery 2 Analysis of sPTB Cases

This example describes analysis of all previously analyzed sPTB cases as described in the preceding examples, their matched controls (2 per every case) and 2 new controls. This analysis described in this example expanded the commercial blood draw window beyond weeks 19 and 20, generated additional data with regards to prediction of sPTB <35 weeks based on larger number of samples from all previous examples, led to discovery of new analytes and reversals, defined molecular clock proteins, clarified risk thresholds and formed accurate validation claims for future clinical studies.

Sample Processing Methods

A standard protocol was developed governing conduct of the Proteomic Assessment of Preterm Risk (PAPR) clinical study. This protocol also specified that the samples and clinical information could be used to study other pregnancy complications. Specimens were obtained from women at 11 Internal Review Board (IRB) approved sites across the United States. After providing informed consent, serum and plasma samples were obtained, as well as pertinent information regarding the patient's demographic characteristics, past medical and pregnancy history, current pregnancy history and concurrent medications. Following delivery, data were collected relating to maternal and infant conditions and complications. Serum and plasma samples were processed according to a protocol that requires standardized refrigerated centrifugation, aliquoting of the samples into 0.5 ml 2-D bar-coded cryovials and subsequent freezing at −80° C.

The serum samples were subsequently depleted of high abundance proteins using the Human 14 Multiple Affinity Removal System (MARS-14), which removes 14 of the most abundant proteins. Equal volumes of each clinical sample or replicates of two quality control serum pools were diluted with column buffer and filtered to remove precipitates. Filtered samples were depleted using a MARS-14 column (4.6×100 mm, Agilent Technologies). Samples were chilled to 4° C. in the autosampler, the depletion column was run at room temperature, and collected fractions were kept at 4° C. until further analysis. The unbound fractions were collected for further analysis.

Depleted serum samples were reduced with dithiothreitol, alkylated using iodoacetamide, and then digested with trypsin. Following trypsin digestion, samples were fortified with a pool of stable isotope standards at concentrations that approximated the concentration of the surrogate peptide analyte. SIS fortified samples were mixed and split into two equal volumes. Each split was placed in −80° C. storage until ready to continue the work process. One frozen split from each sample was retrieved from −80° C. storage, allowed to thaw, and then desalted on a C18 solid phase extraction plate (Empore, 3M). Eluted peptides were lyophilized to dryness. The lyophilized samples were resolubilized in a reconstitution solution containing internal standards that monitor quality of the LC-MS step only (IS Recon).

Fully processed samples were analyzed using a dynamic Multiple Reaction Monitoring method (dMRM). The peptides were separated on a 2.1×100 mm Poroshell EC-C18, 2.7μ particle size column at a flow rate of 0.4 mL/min using an Agilent 1290 UPLC and eluted using an acetonitrile gradient into an Agilent 6490 triple quadrupole mass spectrometer with an electrospray source, operating in positive ion mode. The dMRM assay measured 442 transitions that correspond to 119 peptides and 77 proteins serving both diagnostic and quality roles. Chromatographic peaks were integrated using MassHunter Quantitative Analysis software (Agilent Technologies). Ratios of the chromatographic peak area of the surrogate peptide analyte to the corresponding SIS chromatographic peak area were reported.

A summary of the proteins, peptides and transitions for serum analytes, SIS transitions and IS Recon standards measured in the dMRM method is shown in Table 21. MARS-14 Depletion proteins identify analytes targeted by the MARS-14 immunodepletion column and are measured for quality control purposes. Quant transitions are used for relative response ratios and qual transitions serve quality control purposes. The asterisk (*) denotes name changes. CSH denotes that the peptide corresponds to both CSH1 and CSH2. HLAG now referred to as HLACI since the peptide is conserved in several class I HLA isotypes. LYAM3 now referred to as LYAM1 because, while the peptide sequence is present in each, it is only derived by trypsin cleavage from LYAM1. SOM2 now referred to as SOM2.CSH as the peptides are specific to both SOM2 and CSH.

Significant Protein and Reversal Selection

For each analyte, in each of the two week and three week overlapping window, with and without the BMI restriction, and with two SPTB definitions (37/37 and 35/35), the fold change value that denotes if the mean of the SPTB case samples was higher or lower than the mean of the TERM control samples, was calculated. Tables 22 and 23 show protein/transition AUROC for two week gestational age windows overlapping by one week (e.g. 119-132 refers to days 119-132 of pregnancy which equals gestational weeks 17 and 18). Performance in each two week window is reported for two different case vs control cut-offs (<37 0/7 vs >=37 0/7, <35 0/7 vs >=35 0/7) and with (rBMI) and without (aBMI) a BMI stratification. Tables 24 and 25 show protein/transition AUROC for three week gestational windows overlapping by two weeks (show in days, e.g. “119-139” refers to days 119-139 of pregnancy which equals gestational weeks 17, 18 and 19). Performance in each three week window is reported for two different case vs control cut-offs (<37 0/7 vs >=37 0/7, <35 0/7 vs >=35 0/7) and with (rBMI) and without (aBMI) a BMI stratification.

FIGS. 86 to 95 show kinetic plots of various peptide transitions for case vs. control using gestational age at birth cutoff of <37 0/7 vs >=37 0/7 weeks. FIGS. 96 to 105 show kinetic plots of various peptide transitions for case vs. control using gestational age at birth cutoff of <35 0/7 vs >=35 0/7 weeks. Briefly, average relative ratios for each peptide transition are plotted using the R ggplot2 package against GABD using a mean average smoothing function (window=+/−10 days). Graphs feature separate plots for case vs. control using two different gestational age at birth cutoffs (<37 0/7 vs >=37 0/7 weeks and <35 0/7 vs >=35 0/7 weeks). Plot titles display a protein short name, underscore, and the peptide sequence. Analyte sequences may have been trimmed for titles to fit on the plots.

Based on the fold change value, which denotes if the mean of the SPTB case samples was higher or lower than the mean of the TERM control samples, each analyte was marked as up or down regulated for each of the combinations (i.e. overlapping 2 or 3 week window, BMI restriction, and SPTB definition) and if an analyte had majority of the combinations marked as up regulated it was called an overall up regulated analyte and vice versa. This is shown in Table 26.

Based on these up and down regulation assignments (55 up regulated and 30 down regulated), reversals were created by dividing each of the up regulated analyte relative ratio value by that of a down regulated analyte and taking the natural logarithm of the result. This results in 1650 reversals (55×30=1650). For each reversal, an area under the ROC curve (AUCROC) denoting SPTB and TERM separation and a p-value denoting if the AUCROC value is significantly different from AUCROC=0.5 (i.e. no significant SPTB and TERM separation) was calculated. Performance of each reversal was tabulated for different conditions (e.g. gestational windows, with and without BMI restriction, and the two sPTB cut-offs), for those reversals with an AUCROC>0.6 and a p-value<0.05. Tables 27 to 42 show reversal classification performance for gestational weeks 17 and 18. Tables 47 to 58 show reversal classification performance for gestational weeks 17, 18 and 19. Tables 43 to 46 show reversal classification performance for gestational weeks 17 through 21. Additional reversals of potential significance are shown in Table 59.

Also demonstrated, was improved performance of predictors formed from more than one reversal (weeks 17-21). Briefly, reversals that gave strong predictive performance either early (e.g. weeks 17-19) or later (e.g. weeks 19-21) in this gestational age range were combined and performance was evaluated of predictors formed from combinations (SumLog) of multiple reversals for the entire blood draw range. This is shown in Table 61. Predictor score was derived from summing the Log values of the individual reversal (SumLog) but one skilled in the art could select other models (e.g. logistic regression). It is also contemplated to apply this multiple reversal approach to combinations of reversals specific to preterm premature rupture of membranes (PPROM) versus preterm labor in the absence of PPROM (PTL), fetal gender and gravidity. It is further contemplated that the predictor could contain an indicator variable that selects a subset of reversals to be used given knowledge of the blood draw period, fetal gender or gravidity.

FIG. 110 shows the relationships between the Predictor Score (ln IBP4/SHBG) and the prevalence adjusted relative risk of sPTB (Positive Predictive Value), using a cut-off of <37 0/7 weeks vs >=37 0/7 weeks gestation. Samples were drawn between 19 1/7 weeks and 20 6/7 weeks with BMI >22 <=37. The relative risk increases as predictor score increases from the background rate of 7.3% (average population risk of sPTB in singleton pregnancies) to approximately 50%. The screen positive rate curve for all score thresholds is superimposed. Confidence intervals (gray shade) were calculated assuming the binomially distributed observations and approximating the distribution of error with a normal distribution. Sample distribution by classifier score is shown by bar graph according to the color scheme in the figure legend.

FIG. 111 shows the relationships between the Predictor Score (ln IBP4/SHBG) and the prevalence adjusted relative risk of sPTB (Positive Predictive Value), using a cut-off of <35 0/7 weeks vs >=35 0/7 weeks gestation. Samples were drawn between 19 1/7 weeks and 20 6/7 weeks. The relative risk increases as predictor score increases from the background rate of 4.4% (average population risk of sPTB (<35) in singleton pregnancies) to approximately 50%. The screen positive rate curve for all score thresholds is superimposed. Confidence intervals (gray shade) were calculated assuming the binomially distributed observations and approximating the distribution of error with a normal distribution. Sample distribution by classifier score is shown by bar graph according to the color scheme in the figure legend.

Clinical Observations: sPTB, PPROM and PTL

Reversal performance (GABD weeks 17-21) was evaluated independently for two different phenotypes of sPTB, PPROM and PTL. PPROM more often occurs early and is associated with infection or inflammation. PTL can occur later and is generally considered a less severe phenotype. There were more significant reversals and with higher performance for PPROM and those reversals are populated with proteins known to be involved in inflammation and infection. Selection of reversals to build independent testing methods of PPROM and PTL, or to maximize performance overall with the combination of more than one reversal in a single predictor is contemplated. In the analysis shown in Tables 61 to 64, an AUC>0.65 and p<0.05 for either PPROM or PTL was required.

Table 61 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >37 0/7 weeks, without BMI stratification, separately for PPROM and PTL. Table 62 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22 <=37), separately for PPROM and PTL. Table 63 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately for PPROM and PTL. Table 64 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37), separately for PPROM and PTL.

The best performing analytes for PTL and best performing analytes for PPROM for GABD weeks 19-20 were also determined and several reversals were constructed from the strongest performers. IBP4 is present as a good performer in both PTL and PPROM enabling its utility in general for sPTB. Table 76 lists transition AUROC for gestational weeks 19 1/7 through 20 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, for PTL. Table 77 lists transition AUROC for gestational weeks 19 1/7 through 20 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, for PPROM. FIG. 108 exemplifies reversals with good performance in weeks 19-20 in PTL. FIG. 109 exemplifies reversals with good performance in weeks 19-20 in PPROM.

Clinical Observations: Primigravida and Multigravida

Reversal performance (weeks 17-21) was further evaluated independently for two different phenotypes of sPTB, primigravida and multigravida. In Tables 65-68, the top performing reversals (weeks 17-21) are shown for primigravida (first time mothers) and multigravida subjects separately. First time mothers are most in need of a test to predict probability of PTB because they have no pregnancy history for physicians to determine/estimate risk. These results enable a test independent for these two groups, or to combine high performing reversals in a single classifier to predict risk for both. In the analysis shown in Tables 65-68, an AUC >0.65 and p<0.05 for either primigravida or multigravida was required.

Table 65 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, separately for primigravida and multigravida. Table 66 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22<=37), separately for primigravida and multigravida. Table 67 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately for primigravida and multigravida. Table 68 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37), separately for primigravida and multigravida.

Clinical Observations: Fetal Gender

Reversal performance (weeks 17-21) was further evaluated independently for subjects pregnant with a male vs a female fetus. Some reversals were discovered to have fetal gender specific predictive performance. FIG. 106 demonstrates fetal gender specific IBP4 and SHBG analyte and score (IBP4/SHBG) differences. IBP4 is significant higher in subjects with male fetuses. Performance of the reversal remains comparable for gestational age weeks 19-21 without BMI stratification (FIG. 106). Additionally, in the PAPR clinical trial male fetuses were discovered to be at increased risk of sPTB with a p value of 0.0002 and an odds ratio of 1.6. Lastly, fetal gender can be incorporated into a predictor (e.g. a reversal value plus fetal gender). In the analysis shown in Tables 69-72, an AUC>0.65 and p<0.05 for either male or female fetuses was required.

Table 69 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification, separately by fetal gender. Table 70 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22 <=37), separately by fetal gender. Table 71 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately by fetal gender. Table 72 shows reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37), separately by fetal gender.

Example 11. Correlation of Mass Spectrometry and Immunoassay Data

This example demonstrates implementation of an immunoassays using an MSD platform (e.g. MSD data correlating with commercial ELISA data and MS data for IBP4 and SHBG).

Materials

The following antibodies were used: sex hormone binding globulin (Biospacific Catalog #s 6002-100051 and 6001-100050; R&D Systems Catalog #s MAB2656 and AF2656), IGFBP-4 (Ansh Catalog #s AB-308-A1039 and AB-308-A1042). SHBG proteins from Origene (Catalog #TP328307), Biospacific (Catalog 065200), NIBSC (code: 95/560), and R&D Systems (only available as part of the ELISA SHBG kit) were tested as calibrator. Recombinant Human IGFBP-4 (Ansh, Catalog #AG-308-A1050) was used as a calibrator.

Creating Individual U-PLEX-Coupled Antibody Solutions

Each biotinylated antibody was diluted to 10 μg/mL in Diluent 100 for a final volume of >200 μL. Biotinylated antibody was then added to 300 μL of assigned U-PLEX Linker. (A different linker was used for each biotinylated antibody). Samples were vortexed and incubated at room temperature for 30 minutes. Stop Solution (200 μl) was added to each tube. Tubes were vortexed and incubated at room temperature for 30 minutes.

Preparation of Multiplex Coating Solution

Each U-PLEX-coupled antibody (600 μL) solution was combined into a single tube and vortexed to mix. When combining fewer than 10 antibodies, the solution volume was brought to up to 6 mL with stop solution to result in a final 1× concentration. Note that in these experiments, there was only a single antibody per well.

Coating the U-PLEX Plate.

Multiplex Coating Solution (50 μL) was added to each well. Plates were sealed with adhesive plate seal and incubated at room temperature for 1 hour or at 2-8° C. for overnight, with shaking at around 700 rpm. After washing 3 times with at least 1504, of 1× MSD wash buffer, plates were ready to use.

Sample Analysis

Aliquots, 50 μl, of sample or calibrator were added to each well. The plate was sealed and incubated at room temperature for 1 hour with shaking at around 700 rpm. The plate was then washed 3 times with at least 150 μL of 1×MSD wash buffer*. Detection antibody solution, 50 μL, was added to each well. After sealing, the plate was incubated at room temperature for 1 hour with shaking at around 700 rpm. The plate was washed 3 times with at least 150 μL of 1×MSD wash buffer. After addition of 150 μL of 2× Read Buffer to each well, the plate was read immediately on an MSD instrument.

SHBG Antibody and Calibrator Screening

All antibodies were tested in both capture-detector orientations, all pair wise combinations. Capture antibodies were prepared at 10 μg/mL, coupled to U-PLEX linkers, and coated onto the U-PLEX plate. The SHBG R&D Systems calibrator was diluted in Diluent 43 to create a 7-point standard curve with assay diluent blank. Samples were diluted as follows in Diluent 43 and tested in the assays: Sera SHBG “high” and “low” samples: 100- and 500-fold dilutions, and the Sera Pregnant pool: 100-, 200-, 400-, 800-fold dilutions. Detection antibodies were tested at 1 μg/mL in Diluent 3. Standard curves and binding to native analyte in serum were evaluated. Top analyte pairs were then tested with the NIB SC and Biospacific calibrators, with dilutions made as above.

IGFBP-4 Antibody and Calibrator Screening.

The two antibodies were tested in both capture-detector orientations. Capture antibodies were prepared at 10 μg/mL, coupled to U-PLEX linkers, and coated onto the U-PLEX plate. IGFBP-4 calibrator was diluted in Diluent 12 and to create a 7-point standard curve with assay diluent blank. Samples were diluted as follows in Diluent 12 and tested in the assays: Sera IGFBP-4 “high” and “low” samples: 5-fold, Sera Pregnant pool: 2-fold dilutions from 2- to 64-fold, and 2 individual human serum samples (MSD samples): 2-, 4-, 8- and 16-fold. Detection antibodies were tested at 1 μg/mL in Diluent 12. Standard curves and binding to native analyte in serum were evaluated.

SHBG and IGFBP-4 Testing Using 60 Sera Samples.

Antibody pair 12 was selected to measure SHBG in 60 plasma samples in duplicate from Sera. For IGFBP-4, pair 2 was selected. Plasma samples were diluted 1:1000 and 1:20 for SHBG and IGFBP-4, respectively. Results from the MSD ELISA were compared to commercial ELISA kits and to MS-MRM data.

Results:

SHBG Antibody Screen

Only antibody pair 1 (R&D mono capture, poly detection), gave a strong signal with the Origene calibrator, suggesting that this calibrator may represent a subpopulation of the endogenous SHBG analyte. Thus, additional calibrators were tested in subsequent studies to identify a calibrator that works with all pairs. Nevertheless, all antibody pairs recognized native analyte in the Sera High, Low, and Pregnant pool samples. R&D poly AF2656 and Biospacific mono 6001-100050 gave similar performance. Pairs 2, 3, and 12 showed roughly linear titration with sample dilution (Table 73). The top four antibody pairs were then tested for performance with three additional calibrators. Good calibrator curves were achieved for the 4 top pairs across the 3 calibrators (Table 74). Differences in signal may be in part due to differences in assigned concentration.

The bottom panel shows that the NIBSC or Biospacific signals relative to the R&D calibrator varied depending on antibody pair. Pairs 3 and 10 (same antibodies with the capture-detection orientation flipped) had a similar profile. Pair 2 gave lower signals for NIBSC and Biospacific (compare with Pair 3, same capture). Pair 12 gave higher signals for Biospacific and more than 3-fold higher signals for the NIBSC standard.

IGFBP-4 Antibody Screen

The antibody pair 2 standard curve gave 4-6 fold higher specific calibrator signals and background compared to Pair 1 (Table 75). Serum sample signals fell in the linear range for most dilutions tested; the pregnant pool approached background at the 32 and 64-fold dilutions. Pair 2 gave ˜12 fold higher signals for samples resulting in a 2-4 fold difference in quantification. Signal CVs were generally <5% for both pairs.

Measurement of SHBG and IGFBP-4 in 60 Serum Samples

For SHBG, with the 1000-fold dilution, samples fell between calibrator standards 1-3. The median measured concentration was 58.4 μg/mL. CVs of duplicate measurements were low with a median CV 2.4%. The median measured concentration for IGFBP-4 was 234 ng/ml and the median CV between duplicate samples was 2.2%. As shown in FIG. 107, good correlation was seen with both proteins in the MSD assay as compared to commercial ELISA kits and the MS-MRM assay.

TABLE 1

Maternal Characteristics and Pregnancy Outcomes Stratified by Timing of Delivery (sPTB and Term)

PAPR
Validation

Cases
Controls

Case
Control

PAPR vs. Validation

N (%)
N (%)

N (%)
N (%)

p-value
p-value

(N = 217)
(N = 4,292)
p-value
(N = 81)
(N = 162)
p-value
(Cases)
(Controls)

Maternal Characteristics

Maternal Age at Enrollment, y

0.245

0.239
0.741
0.226

18-22 yrs
58 (26.7)
990 (23.1)

22 (27.2)
47 (29.0)

23-27 yrs
56 (25.8)
1,222 (28.5)

17 (21.0)
41 (25.3)

28-32 yrs
54 (24.9)
1,154 (26.9)

25 (30.9)
34 (21.0)

33-37 yrs
31 (14.3)
692 (16.1)

9 (11.1)
30 (18.5)

38 or More
18 (8.3)
234 (5.5)

8 (9.9)
10 (6.2)

Mean
28
28

28
28

Median
27
27

28
27

Interquartile Range
22-32
23-32

21-32
22-32

Body Mass Index, kg/m2

0.380

0.802
0.630
0.191

Less than 18.5
10 (4.7)
129 (3.1)

1 (1.3)
2 (1.3)

18.5-24.9
78 (36.8)
1,789 (42.3)

25 (31.3)
55 (34.6)

25.0-29.9
54 (25.5)
1,091 (25.8)

26 (32.5)
46 (28.9)

30.0-34.9
39 (18.4)
617 (15.6)

17 (21.3)
25 (15.7)

35.0-39.9
17 (8.0)
320 (7.6)

6 (7.5)
17 (10.7)

Greater than 40.0
14 (6.6)
286 (6.7)

5 (6.3)
14 (8.8)

Mean
27.8
27.5

28.4
29.1

Median
26.5
25.7

27.4
27.8

Interquartile Range
22.7-31.8
22.3-31.1

23.6-32.0
23.4-32.4

Education Level

<0.0002

0.201
0.711
0.094

Graduate Degree
13 (6.0)
461 (10.9)

6 (7.7)
14 (8.7)

College Diploma
34 (15.8)
701 (16.6)

10 (12.6)
22 (13.8)

Some College
51 (23.7)
936 (22.2)

19 (24.0)
23 (14.4)

High School
46 (21.4)
1,032 (24.5)

16 (20.2)
50 (31.3)

Diploma/Equivalent

Some High School
53 (24.6)
774 (18.4)

25 (31.6)
36 (22.5)

9 Grade or less
12 (5.8)
292 (6.9)

3 (3.8)
14 (8.7)

Other
6 (2.8)
23 (0.6)

0
1 (0.6)

Ethnicity

0.157

0.035
0.226
0.003

Hispanic or Latino
89 (41.0)
1,557 (36.3)

27 (33.3)
77 (47.5)

Non-Hispanic or Latino
128 (59.0)
2,735 (63.7)

54 (66.7)
85 (52.5)

Race

0.887

0.811
0.953
0.071

American Indian/Alaskan
1 (0.5)
29 (0.7)

0
2 (1.2)

Native

Asian
4 (1.8)
131 (3.1)

1 (1.2)
1 (0.6)

Black or African-American
45 (20.7)
838 (19.5)

19 (23.5)
37 (22.8)

Native Hawaiian or Other
0
12 (0.30)

0
2 (1.2)

Pacific Islander

White
156 (71.9)
3,101 (72.3)

58 (71.6)
114 (70.4)

Other
11 (5.1)
193 (4.5)

3 (3.7)
6 (3.7)

Obstetrical Characteristics

Primigravida
64 (29.5)
1,212 (28.2)
0.689
27 (33.3)
39 (24.1)
0.126
0.522
0.247

Multigravida
153 (70.5)
3,080 (71.8)

54 (66.7)
123 (75.9)

Number of prior full-term

0.007

0.326
0.816
0.881

deliveries

1 or More
113 (73.8)
2,538 (82.4)

40 (74.5)
102 (82.9)

None
40 (26.2)
542 (17.6)

13 (24.5)
21 (17.1)

Number of prior Spontaneous

<0.0001

0.221
0.337
0.472

PTBs

1 or More
35 (22.9)
339 (11.0)

9 (16.7)
11 (8.9)

None
118 (77.1)
2,741 (89.0)

45 (83.3)
112 (91.1)

Lifestyle Characteristics

Smoking

0.412

0.719
0.555
0.283

Yes
34 (15.7)
588 (13.7)

15 (18.5)
27 (16.7)

No
183 (84.3)
3,704 (86.3)

66 (81.5)
135 (83.3)

Illicit Drugs

0.283

0.628
0.992
0.052

Yes
16 (7.4)
242 (5.6)

6 (7.4)
15 (9.3)

No
201 (92.6)
4,050 (94.4)

75 (92.6)
147 (90.7)

Alcohol

0.096

0.628
0.622
0.141

Yes
20 (9.2)
273 (6.4)

6 (7.4)
15 (9.3)

No
197 (90.8)
4,018 (93.6)

75 (92.6)
147 (90.7)

Alcohol Use

0.108

0.592
0.880
0.317

Yes (amount unknown)
3 (1.4)
39 (0.9)

0
2 (1.2)

Social (occasional)
16 (7.4)
230 (5.4)

6 (7.4)
13 (8.0)

Heavy (daily)
1 (0.5)
4 (0.09)

0
0

No
197 (90.8)
4,018 (93.6)

75 (92.6)
147 (90.7)

Medical Characteristics

Bleeding During Pregnancy

0.006

0.360
0.785
0.892

after 12 Wks

Yes
21 (9.7)
228 (5.3)

7 (8.6)
9 (5.6)

No
196 (90.3)
4,064 (94.7)

74 (91.4)
153 (94.4)

sPTB, spontaneous preterm birth; PTB, preterm birth; N, number of subjects.

Comparisons of clinical data between cases and controls were performed using Chi-square test or Fisher exact test or Mann-Whitney test, as appropriate (SAS System 9.4) and R (3.1.0).

Missing values are excluded in the frequency tables.

TABLE 2

GA

Boundary
AUC
Sensitivity
Specificity
OR (95% CI)

<37 vs. ≥ 37
0.75 (p = 0.016)
0.75
0.74
5.04 (1.4-18)

<36 vs. ≥ 36
0.79 (p = 0.027)
0.83
0.83
17.33 (2.2-138)

<35 vs. ≥ 35
0.93 (p = 0.001)
1.00
0.83
34.47 (1.7-699)

TABLE 3

Maternal Characteristics and Pregnancy Outcomes Stratified by Timing of Delivery (sPTD and Term)

Entire Validation Cohort
Validated Window

PAPR Study
(17 0/7- 28 weeks)
(191/7-206/7)

Cases
Controls

Cases
Controls

Cases
Controls

N (%)
N (%)

N (%)
N (%)

N (%)
N (%)

Variables
(N = 217)
(N = 4,292)
P Value
(N = 81)
(N = 162)
P Value
(N = 18)
(N = 36)
P Value

Maternal Characteristics

Maternal Age at Enrollment, y

0.245

0.239

0.387

18-22 yrs
58 (26.7)
990 (23.1)

22 (27.2)
47 (29.0)

6 (33.3)
13 (36.1)

23-27 yrs
56 (25.8)
1,222 (28.5)

17 (21.0)
41 (25.3)

6 (33.3)
9 (25.0)

28-32 yrs
54 (24.9)
1,154 (26.9)

25 (30.9)
34 (21.0)

5 (27.8)
5 (13.9)

33-37 yrs
31 (14.3)
692 (16.1)

9 (11.1)
30 (18.5)

1 (5.6)
7 (19.4)

38 or More
18 (8.3)
234 (5.5)

8 (9.9)
10 (6.2)

0
2 (5.6)

Mean
28
28

28
28

25
27

Median
27
27

28
27

25
25

Interquartile Range
22-32
23-32

21-32
22-32

21-30
22-33

Body Mass Index, kg/m2

0.380

0.802

0.959

Less than 18.5
10 (4.7)
129 (3.1)

1 (1.3)
2 (1.3)

0
0

18.5-24.9
78 (36.8)
1,789 (42.3)

25 (31.3)
55 (34.6)

8 (44.4)
16 (45.7)

25.0-29.9
54 (25.5)
1,091 (25.8)

26 (32.5)
46 (28.9)

4 (22.2)
9 (25.7)

30.0-34.9
39 (18.4)
617 (15.6)

17 (21.3)
25 (15.7)

3 (16.7)
4 (11.4)

35.0-39.9
17 (8.0)
320 (7.6)

6 (7.5)
17 (10.7)

2 (11.1)
5 (14.3)

Greater than 40.0
14 (6.6)
286 (6.7)

5 (6.3)
14 (8.8)

1 (5.6)
1 (2.9)

Mean
27.8
27.5

28.4
29.1

28.2
27.4

Median
26.5
25.7

27.4
27.8

26.5
27

Interquartile Range
22.7-31.8
22.3-31.1

23.6-32.0
23.4-32.4

23.8-33.7
22.3-30.6

Education Level

<0.0002

0.201

0.263

Graduate Degree
13 (6.0)
461 (10.9)

6 (7.7)
14 (8.7)

0
2 (5.7)

College Diploma
34 (15.8)
701 (16.6)

10 (12.6)
22 (13.8)

2 (11.1)
5 (14.3)

Some College
51 (23.7)
936 (22.2)

19 (24.0)
23 (14.4)

1 (5.6)
5 (14.3)

High School
46 (21.4)
1,032 (24.5)

16 (20.2)
50 (31.3)

5 (27.8)
14 (40.0)

Diploma/Equivalent

Some High School
53 (24.6)
774 (18.4)

25 (31.6)
36 (22.5)

9 (50.0)
6 (17.1)

9 Grade or less
12 (5.8)
292 (6.9)

3 (3.8)
14 (8.7)

1 (5.6)
3 (8.6)

Other
6 (2.8)
23 (0.6)

0
1 (0.6)

0
0

Ethnicity

0.157

0.035

0.844

Hispanic or Latino
89 (41.0)
1,557 (36.3)

27 (33.3)
77 (47.5)

7 (38.9)
15 (41.7)

Non-Hispanic or Latino
128 (59.0)
2,735 (63.7)

54 (66.7)
85 (52.5)

11 (61.1)
21 (58.3)

Race

0.887

0.811

0.319

American Indian/Alaskan
1 (0.5)
29 (0.7)

0
2 (1.2)

0
1 (2.8)

Native

Asian
4 (1.8)
131 (3.1)

1 (1.2)
1 (0.6)

0
1 (2.8)

Black or African-American
45 (20.7)
838 (19.5)

19 (23.5)
37 (22.8)

2 (11.1)
11 (30.6)

Native Hawaiian or Other
0
12 (0.30)

0
2 (1.2)

0
1 (2.8)

Pacific Islander

White
156 (71.9)
3,101 (72.3)

58 (71.6)
114 (70.4)

16 (88.9)
22 (61.1)

Other
11 (5.1)
193 (4.5)

3 (3.7)
6 (3.7)

0
0

Obstetrical Characteristics

Primigravida
64 (29.5)
1,212 (28.2)
0.689
27 (33.3)
39 (24.1)
0.126
5 (27.8)
8 (22.2)
0.652

Multigravida
153 (70.5)
3,080 (71.8)

54 (66.7)
123 (75.9)

13 (72.2)
28 (77.8)

Number of prior full-term deliveries

0.007

0.326

0.790

1 or More
113 (73.8)
2,538 (82.4)

40 (74.5)
102 (82.9)

10 (76.9)
22 (78.6)

None
40 (26.2)
542 (17.6)

13 (24.5)
21 (17.1)

3 (23.1)
6 (21.4)

Number of prior Spontaneous PTDs

<0.0001

0.221

0.524

1 or More
35 (22.9)
339 (11.0)

9 (16.7)
11 (8.9)

1 (7.7)
6 (21.4)

None
118 (77.1)
2,741 (89.0)

45 (83.3)
112 (91.1)

12 (92.3)
22 (78.6)

Lifestyle Characteristics

Smoking

0.412

0.719

1.000

Yes
34 (15.7)
588 (13.7)

15 (18.5)
27 (16.7)

3 (16.7)
6 (16.7)

No
183 (84.3)
3,704 (86.3)

66 (81.5)
135 (83.3)

15 (83.3)
30 (83.3)

Illicit Drugs

0.283

0.628

0.739

Yes
16 (7.4)
242 (5.6)

6 (7.4)
15 (9.3)

2 (11.1)
3 (8.3)

No
201 (92.6)
4,050 (94.4)

75 (92.6)
147 (90.7)

16 (88.9)
33 (91.7)

Alcohol

0.096

0.628

0.278

Yes
20 (9.2)
273 (6.4)

6 (7.4)
15 (9.3)

4 (22.2)
4 (11.1)

No
197 (90.8)
4,018 (93.6)

75 (92.6)
147 (90.7)

14 (77.8)
32 (88.9)

Alcohol Use

0.108

0.592

0.278

Yes (amount unknown)
3 (1.4)
39 (0.9)

0
2 (1.2)

0
0

Social (occasional)
16 (7.4)
230 (5.4)

6 (7.4)
13 (8.0)

4 (22.2)
4 (11.1)

Heavy (daily)
1 (0.5)
4 (0.09)

0
0

0
0

No
197 (90.8)
4,018 (93.6)

75 (92.6)
147 (90.7)

14 (77.8)
32 (88.9)

Medical Characteristics

Bleeding During Pregnancy after 12 Wks

0.006

0.360

0.308

Yes
21 (9.7)
228 (5.3)

7 (8.6)
9 (5.6)

0
2 (5.6)

No
196 (90.3)
4,064 (94.7)

74 (91.4)
153 (94.4)

18 (100.0)
34 (94.4)

sPTD, spontaneous preterm delivery; PTD, preterm delivery; N, number of subjects.

Comparisons of clinical data between cases and controls were performed using Chi-square test or Fisher exact test or Mann-Whitney test, as appropriate (SAS System 9.4) and R (3.1.0).

Missing values are excluded in the frequency tables.

TABLE 4

Discovery
Verification
Validation

Sample #
86, 172
50, 100
81, 162

(17-28 wks)*

Sample #
22, 44†
9, 18†
18, 36‡

(All BMI)*

AUC
0.74 (p = 8e−4)†
0.77 (p = 0.01)†
0.67 (p = 0.02)‡

(All BMI)

Sample #
17, 33†
6, 17†
15, 29‡

(BMI < 35)*

AUC
0.79 (p = 3e−4)†
0.79 (p = 0.015)†
0.70 (p = 0.02)‡

(BMI < 35)

p values test equivalence to AUC = 0.5 by one-sided Wilcoxon-Mann-Whitney statistic

*Number of Cases , Number of Controls

†GA at blood draw weeks 19/0-21/6

‡Optimal GA at blood draw interval from fixed sequence validation (19/1-20/6)

TABLE 5

BMI (kg/m²)
AUROC

All BMI
0.67 (p = 0.044)

BMI Less or equal to 45
0.67 (p = 0.047)

BMI Less or equal 40
0.68 (p = 0.048)

BMI Less or equal 37
0.71 (p = 0.020)

BMI Larger than 18
0.67 (p = 0.047)

BMI Larger than 20
0.65 (p = 0.087)

BMI Larger than 22
0.69 (p = 0.048)

BMI larger than 22 and less or equal to 37
0.75 (p = 0.016)

p-values determined by Wilcoxon-Mann-Whitney statistic

GA at Blood Draw 19/1-20/6 weeks

TABLE 6

RBM Screen

Early Window (17-22 weeks)
Middle Window (23-25 weeks)
Late Window (26-28 weeks)

ANALYTE
AUC
ANALYTE
AUC
ANALYTE
AUC

Fibrinogen
0.76
Vascular.Cell.Adhesion.Molecule.1..VCAM.1.
0.96
Apolipoprotein.C.III..Apo.C.III.
0.97

Antileukoproteinase..ALP.
0.75
Epidermal.Growth.Factor.Receptor..EGFR.
0.79
Apolipoprotein.B..Apo.B.
0.85

Kidney.Injury.Molecule.1..KIM.1.
0.73
Carcinoembryonic.antigen.related.cell.ad-
0.78
Apolipoprotein.E..Apo.E.
0.85

Tissue.Inhibitor.of.Metallo-
0.72
hesion.molecule.1..CEACAM1.

Glutathione.S.Transferase.alpha..
0.82

proteinases.1..TIMP.1.

Carcinoembryonic.antigen.related.cell.ad-
0.76
GST.alpha.

Beta.2.Microglobulin..B2M.
0.69
hesion.molecule.6..CEACAM6.

Insulin.like.Growth.Factor.Binding.
0.81

Trefoil.Factor.3..TFF3.
0.69
Angiotensinogen
0.75
Protein.6..IGFBP6.

Tyrosine.kinase.with.Ig.and.EGF.ho-
0.69
Interleukin.6.receptor.subunit.beta..IL.6R.beta.
0.75
Tyrosine.kinase.with.Ig.and.EGF.
0.78

mology.domains.2..TIE.2.

CD5.Antigen.like..CD5L.
0.72
homology.domains.1..Tie.1.

Angiotensinogen
0.67
Pulmonary.surfactant.associated.protein.D..SP.D.
0.7
Insulin.like.Growth.Factor.Binding.
0.78

P.Selectin
0.67
Cathepsin.B..pro...CTSB.
0.7
Protein.4..IGFBP4.

Pepsinogen.I..PGI.
0.66
Growth.Hormone..GH.
0.69
Stem.Cell.Factor..SCF.
0.77

Prostate.Specific.Antigen..total..tPSA.
0.66
Beta.microseminoprotein..PSP94.
0.69
Phosphoserine.Aminotransferase..PSAT.
0.76

Pulmonary.and.Activation.Regulated.
0.66
Serotransferrin..Transferrin.
0.68
Trefoil.Factor.3..TFF3.
0.72

Chemokine..PARC.

Neuronal.Cell.Adhesion.Molecule..Nr.CAM.
0.67
Chemokine.CC.4..HCC.4.
0.71

Serum.Amyloid.P.Component..SAP.
0.66
Urokinase.type.Plasminogen.Activator..uPA.
0.67
Macrophage.Colony.Stimulating.Factor.
0.7

Tumor Necrosis.Factor.Receptor.I..
0.66
Vitronectin
0.65
1..M.CSF.

TNF.RI.

von.Willebrand.Factor..vWF.
0.65
Complement.Factor.H...Related.Protein.
0.7

Vascular.endothelial.growth.factor.re-
0.66
Testosterone..Total
0.65
1..CFHR1.

ceptor.3..VEGFR.3.

Lipocalin.1..LCN1.
0.65
Tyrosine.kinase.with.Ig.and.EGF.
0.69

Cathepsin.D
0.65
Squamous.Cell.Carcinoma.Antigen.1..SCCA.1.
0.64
homology.domains.2..TIE.2.

Fetuin.A
0.65
Monocyte.Chemotactic.Protein.1..MCP.1.
0.64
Prostate.Specific.Antigen..total..tPSA.
0.68

Platelet.endothelial.cell.adhesion.mo-
0.65
Tenascin.C..TN.C.
0.63
Glucagon.like.Peptide.1..total..GLP.1.
0.68

lecule..PECAM.1.

Complement.C3..C3.
0.63
total.

Cadherin.1..E.Cad.
0.64
Tamm.Horsfall.Urinary.Glycoprotein..THP
0.63
FASLG.Receptor..FAS.
0.67

Cancer.Antigen.15.3..CA.15.3.
0.64
Neuropilin.1
0.63
Insulin.like.Growth.Factor.Binding.
0.67

Progesterone
0.64
Midkine
0.62
Protein.5..IGFBP5.

Tenascin.C..TN.C.
0.64
Cortisol..Cortisol.
0.62
Urokinase.type.plasminogen.activator.
0.66

Aldose.Reductase
0.63
Immunoglobulin.M..IgM.
0.62
receptor..uPAR.

Angiopoietin.1..ANG.1.
0.63
Receptor.for.advanced.glycosylation.end.
0.62
Haptoglobin
0.66

Apolipoprotein.A.II..Apo.A.II.
0.63
products..RAGE.

Insulin.like.Growth.Factor.Binding.
0.66

Osteoprotegerin..OPG.
0.63
N.terminal.prohormone.of.brain.natriuretic.
0.62
Protein.2..IGFBP.2.

Follicle.Stimulating.Hormone..FSH.
0.62
peptide..NT.proBNP.

Kallikrein.5
0.66

Growth.Regulated.alpha.protein..
0.62
Macrophage.inflammatory.protein.3.beta..
0.62
Tenascin.C..TN.C.
0.65

GRO.alpha.

MIP.3.beta.

Cathepsin.D
0.65

Matrix.Metalloproteinase.7..MMP.7.
0.62
Kidney.Injury.Molecule.1..KIM.1.
0.61
Tumor Necrosis.Factor.Receptor.I..
0.65

Phosphoserine.Aminotransferase..PSAT.
0.62
Matrix.Metalloproteinase.9..total..MMP.9..total.
0.61
TNF.RI.

Serotransferrin..Transferrin.
0.62
Cellular.Fibronectin..cFib.
0.6
Interleukin.1.receptor.antagonist..IL.1ra.
0.64

Apolipoprotein.C.III..Apo.C.III.
0.61
Mesothelin..MSLN.
0.6
Proinsulin..Intact
0.64

Carbonic.anhydrase.9..CA.9.
0.61
Transthyretin..TTR.
0.6
Proinsulin..Total
0.64

Complement.C3..C3.
0.61
Collagen.IV
0.6
Matrix.Metalloproteinase.9..MMP.9.
0.64

Cystatin.C
0.61

Myeloid.Progenitor.Inhibitory.Factor.1.
0.64

Insulin.like.Growth.Factor.Binding.Pro-
0.61

MPIF.1.

tein.4..IGFBP4.

Angiopoietin.2..ANG.2.
0.64

Intercellular.Adhesion.Molecule.1..
0.61

von.Willebrand.Factor..vWF.
0.63

ICAM.1.

Cystatin.B
0.63

Macrophage.Colony.Stimulating.Fac-
0.61

Complement.C3..C3.
0.62

tor.1..M.CSF.

Midkine
0.62

Midkine
0.61

Matrix.Metalloproteinase.9..total..
0.62

Angiogenin
0.6

MMP.9..total.

C.Reactive.Protein..CRP.
0.6

Monokine.Induced.by.Gamma.Inter.
0.62

CD.40.antigen..CD40.
0.6

feron..MIG.

Cellular.Fibronectin..cFib.
0.6

Pulmonary.and.Activation.Regulated.
0.62

Interleukin.2.receptor.alpha..IL.2.re-
0.6

Chemokine..PARC.

ceptor.alpha.

Interleukin.2.receptor.alpha..IL.2.
0.62

Thrombospondin.4..TSP4.
0.6

receptor.alpha.

Interleukin.6.receptor.subunit.beta..
0.61

IL.6R.beta.

CD5.Antigen.like..CD5L.
0.61

Hepsin
0.61

Fetuin.A
0.61

B.Lymphocyte.Chemoattractant..BLC.
0.61

Antileukoproteinase..ALP.
0.61

Alpha.2.Macroglobulin..A2Macro.
0.61

Tissue.Inhibitor.of.Metalloproteinases.
0.61

1..TIMP.1.

Receptor.for.advanced.glycosylation.
0.6

end.products..RAGE.

Pancreatic.secretory.trypsin.inhibitor..
0.6

TATI.

Adiponectin
0.6

Lumican
0.6

Apolipoprotein.C.I..Apo.C.I.
0.6

Apolipoprotein.H..Apo.H.
0.6

Hepatocyte.Growth.Factor..HGF.
0.6

TABLE 7

Early Window (GABD 17-22 wks) Analyte Ranking by Different Multivariate Models

rank
rf
boosting
lasso
logit

1
B.cell.activating.factor..BAFF.
Macrophage.inflammatory.pro-
Antileukoproteinase..ALP.
Apolipoprotein.A.II..Apo.A.

tein.3.beta..MIP.3.beta.

II.

2
Macrophage.inflammatory.pro-
B.cell.activating.factor..BAFF
Angiotensinogen
Apolipoprotein.a...Lp.a..

tein.3.beta..MIP.3.beta.

3
Fibrinogen
Kidney.Injury.Molecule.1..
Kidney.Injury.Molecule.1..KIM.1
Apolipoprotein.A.IV..Apo.A.

KIM.1.

IV.

4
Kidney.Injury.Molecule.1..
Fibrinogen
Progesterone
Apolipoprotein.B..Apo.B.

KIM.1.

5
Tissue.Inhibitor.of.Metallopro-
Beta.2.Microglobulin..B2M.
Monocyte.Chemotactic.Protein.1.
Apolipoprotein.C.III..Apo.C.

teinases.1..TIMP.1.

MCP.1.
III.

6
Tumor.necrosis.factor.ligand.
Tissue.Inhibitor.of.Metallopro-
Follicle.Stimulating.Hormone..
Apolipoprotein.H..Apo.H.

superfamily.member.12..Tweak
teinases.1..TIMP.1.
FSH.

7
Pulmonary.and.Activation.Reg-
N.terminal.prohormone.of.
Serotransferrin..Transferrin.
Angiotensin.Converting.En-

ulated.Chemokine..PARC.
brain.natriuretic.peptide..NT.

zyme..ACE.

proBNP.

8
Pancreatic.Polypeptide..PPP.
Antileukoproteinase..ALP.
Tyrosine.kinase.with.Ig.and.EGF.
Apolipoprotein.C.I..Apo.C.I.

homology.domains.2..TIE.2.

9
Angiotensinogen
Prostate.Specific.Antigen..total..
Thyroglobulin..TG.
B.Lymphocyte.Chemo-

tPSA.

attractant..BLC.

10
Prostate.Specific.Antigen..total..
Pancreatic.Polypeptide..PPP.
Cancer.Antigen.15.3..CA.15.3.
Adiponectin

tPSA.

11
Antileukoproteinase..ALP.
Collagen.IV
Pulmonary.and.Activation.
Angiotensinogen

Regulated.Chemokine..PARC.

12
Tyrosine.kinase.with.Ig.and.EGF.
Tyrosine.kinase.with.Ig.and.EGF.
Trefoil.Factor.3..TFF3.
AXL.Receptor.Tyrosine.

homology.domains.2..TIE.2.
homology.domains.2..TIE.2.

Kinase..AXL.

13
Cathepsin.D
Angiotensinogen
Midkine
Angiogenin

14
Beta.2.Microglobulin..B2M.
Cathepsin.D
Beta.2.Microglobulin..B2M.
Aldose.Reductase

TABLE 8

Middle Window (GABD 23-25 wks) Analyte Ranking by Different Multivariate Models

rank
rf
boosting
lasso
logit

1
Vascular.Cell.Adhesion.Mole-
Vascular.Cell.Adhesion.Mole-
Vascular.Cell.Adhesion.Mole-
Alpha.Fetoprotein..AFP.

cule.1..VCAM.1.
cule.1..VCAM.1.
cule.1..VCAM.1.

2
Aldose.Reductase
Aldose.Reductase
Osteoprotegerin..OPG.
Adiponectin

3
Osteoprotegerin..OPG.
Osteoprotegerin..OPG.
Apolipoprotein.E..Apo.E.
Angiogenin

4
Insulin.like.Growth.Factor.
Angiotensinogen
Aldose.Reductase
Alpha.1.Antitrypsin..AAT.

Binding.Protein.3..IGFBP.3.

5
Carcinoembryonic.antigen.re-
Apolipoprotein.E..Apo.E.
Cancer.Antigen.72.4..CA.72.4
Angiotensin.Converting.En-

lated.cell.adhesion.molecule.1.

zyme..ACE.

CEACAM1.

6
Angiotensinogen
Interleukin.16..IL.16.
Epidermal.Growth.Factor.Re-
Alpha.1.Microglobulin..

ceptor..EGFR.
A1Micro.

7
Interleukin.16..IL.16.
Epidermal.Growth Factor.
Progesterone
Alpha.1.Antichymotrypsin..

Receptor..EGFR.

AACT.

8
Insulin.like.Growth.Factor.
Alpha.Fetoprotein..AFP.
Human.Chorionic.Gonado-
Alpha.2.Macroglobulin..

Binding.Protein.4..IGFBP4.

tropin.beta..hCG.
A2Macro.

9
Epidermal.Growth.Factor.Re-
Alpha.2.Macroglobulin..
Tissue.Inhibitor.of.Metallopro-
Aldose.Reductase

ceptor..EGFR.
A2Macro.
teinases.1..TIMP.1.

10
Carcinoembryonic.antigen.re-
Angiopoietin.2..ANG.2.
Alpha.Fetoprotein..AFP.
X6Ckine

lated.cell.adhesion.molecule.6.

CEACAM6.

11
Urokinase.type.Plasminogen.
Apolipoprotein.a...Lp.a..
Carcinoembryonic.antigen.re-
Angiopoietin.2..ANG.2.

Activator..uPA.

lated.cell.adhesion.molecule.1.

CEACAM1.

12
Tissue.Inhibitor.of.Metallopro-
Alpha.1.Microglobulin..
Insulin.like.Growth.Factor.Bi-
MHC.class.I.chain.related.pro-

teinases.1..TIMP.1.
A1Micro.
nding.Protein.5..IGFBP5.
tein.A..MICA.

13
Progesterone
Angiogenin
Lectin.Like.Oxidized.LDL.Re-
Neutrophil.Gelatinase.

ceptor.1..LOX.1.
Associated.Lipocalin..NGAL.

14
Interleukin.6.receptor.subunit.
B.cell.activating.factor..BAFF
FASLG.Receptor..FAS.
P.Selectin

beta..IL.6R.beta.

15
Thrombospondin.4..TSP4.
Adiponectin
Serotransferrin..Transferrin.
Tissue.Inhibitor.of.Metallopro-

teinases.2..TIMP.2.

TABLE 9

Late Window (GABD 26-28 weeks) Analyte Ranking by Different Multivariate Models

rank
rf
boosting

1
Apolipoprotein.C.III..Apo.C.III.
Apolipoprotein.C.III..Apo.C.III.

2
Apolipoprotein.E..Apo.E.
Apolipoprotein.E..Apo.E.

3
Insulin.like.Growth.Factor.Binding.Protein.4..IGFBP4.
EN.RAGE

4
Insulin.like.Growth.Factor.Binding.Protein.6..IGFBP6.
Alpha.Fetoprotein..AFP.

5
Apolipoprotein.B..Apo.B.
Apolipoprotein.B..Apo.B.

6
Interleukin.18..IL.18.
Angiotensinogen

7
Glutathione.S.Transferase.alpha..GST.alpha.
Angiotensin.Converting.Enzyme..ACE.

8
Stem.Cell.Factor..SCF.
Aldose.Reductase

9
Phosphoserine.Aminotransferase..PSAT.
Apolipoprotein.a...Lp.a..

10
Tyrosine.kinase.with.Ig.and.EGF.homology.domains.1..Tie.1.
Angiopoietin.2..ANG.2.

11
EN.RAGE
X6Ckine

12
Vascular.Endothelial.Growth.Factor.Receptor.1..VEGFR.1.
Alpha.2.Macroglobulin..A2Macro.

13
Insulin.like.Growth.Factor.Binding.Protein.2..IGFBP.2.
Angiogenin

14
Chemokine.CC.4..HCC.4.
Alpha.1.Antichymotrypsin..AACT.

15
Tyrosine.kinase.with.Ig.and.EGF.homology.domains.2..TIE.2.
Adiponectin

rank
lasso
logit

1
Apolipoprotein.C.III..Apo.C.III.
Alpha.1.Microglobulin..A1Micro.

2
Interleukin.18..IL.18.
Aldose.Reductase

3
Apolipoprotein.B..Apo.B.
Angiogenin

4
Glutathione.S.Transferase.alpha..GST.alpha.
Alpha.Fetoprotein..AFP.

5
Tyrosine.kinase.with.Ig.and.EGF.homology.domains.1..Tie.1.
Alpha.1.Antichymotrypsin..AACT.

6
Trefoil.Factor.3..TFF3.
Alpha.1.Antitrypsin..AAT.

7
Apolipoprotein.E..Apo.E.
X6Ckine

8
Insulin.like.Growth.Factor.Binding.Protein.4..IGFBP4.
Alpha.2.Macroglobulin..A2Macro.

9
FASLG.Receptor..FAS.
Adiponectin

10
Tyrosine.kinase.with.Ig.and.EGF.homology.domains.2..TIE.2.
Chromogranin.A..CgA.

11
Creatine.Kinase.MB..CK.MB.
Macrophage.Inflammatory.Protein.1.beta..MIP.1.beta.

12
Stem.Cell.Factor..SCF.
Angiopoietin.2..ANG.2.

13
Chemokine.CC.4..HCC.4.
Angiotensin.Converting.Enzyme..ACE.

14
Complement.Factor.H...Related.Protein.1..CFHR1.
Angiotensinogen

15
Alpha.2.Macroglobulin..A2Macro.
Apolipoprotein.a...Lp.a..

TABLE 10

Table of epitope and clonality information for kits tested for analytes IBP4_HUMAN and

SHBG_HUMAN when available.

Person's r

Correlation

Value

Catalog
Capture
Detection

ELISA

Analyte
Vendor
Number
Antibody
Antibody
Epitopes
vs MS

IBP4_HUMAN
ANSCH
Webster,
AL-126
Monoclonal
Monoclonal
C-terminal
0.8631

Labs
Texas

SHBG_HUMAN
R&D
Minneapolis,
DSHBGOB
Monoclonal
Monoclonal
Unmapped
0.9228

Systems
Minnesota

SHBG_HUMAN
Raybiotech
Norcross,
ELH-SHBG
Monoclonal
Monoclonal
Unmapped
0.8675

Georgia

IBP4_HUMAN
ABNOVA
Taipei,
KA1873
Monoclonal
Polyclonal
Unknown
0.2635

Taiwan

IBP4_HUMAN
ABCAM
Cambridge,
ab 100542
Monoclonal
Polyclonal
Asp22-
0.3439

Massachusetts

Glu258

IBP4_HUMAN
ANSCH
Webster,
AL-128
Monoclonal
Monoclonal
N-terminus
0.2954

Labs
Texas

and

C-terminus

TABLE 11

Analytes showing kits that either correlate with MS data or do not.

Correlating Data
Non-Correlating Data

Person's r

Person's r

Analyte
Correlation Value
Analyte
Correlation Value

(ELISA Kit #)
ELISA vs MS
(ELISA Kit #)
ELISA vs MS

ANGT_HUMAN #1
0.6192
A2GL_HUMAN
−0.2933

B2MG_HUMAN
0.8414
ANGT_HUMAN #2
−0.01351

BGH3_HUMAN
0.7159
APOH_HUMAN
0.2669

C06_HUMAN
0.8045
CHL1_HUMAN
0.0795

CD14_HUMAN
0.8004
CLUS_HUMAN
0.3132

CHL1_HUMAN
0.9271
CPN1_HUMAN
0.1775

FETUA_HUMAN
0.7259
CSH_HUMAN
−0.3172

IBP4_HUMAN#1
0.8631
FBLN1_HUMAN
0.1141

IGF2_HUMAN
0.6346
IBP4_HUMAN #2
0.3439

LBP_HUMAN
0.7389
IBP4_HUMAN #3
0.2365

PAPP1_HUMAN #1
0.9163
IBP4_HUMAN #4
0.2954

SHBG_HUMAN #1
0.9228
PAPP1_HUMAN #2
0.04381

SHBG_HUMAN #2
0.8675
PRG2_HUMAN #1
0.2699

PSG2_HUMAN #2
−0.06944

PTGDS_HUMAN
0.1627

TENX_HUMAN
−0.1116

TIE1_HUMAN
0.0384

VTDB_HUMAN
−0.2459

VTNC_HUMAN
0.1243

TABLE 12

IBP4 and SHBG ELISA Kits Demonstrating sPTB vs Control Separation

(univariate)

Control vs

Case

Person's
Separation P-

Analyte
R
Value
Vendor

Catalogue #

IBP4_HUMAN
0.8631
0.0009
ANSCH Labs
Webster, Texas
AL-126

SHBG_HUMAN
0.8675
0.0374
R&D Systems
Minneapolis,
DSHBG0B

Minnesota

TABLE 13

dbSNP rs#
Hetero-

Protein
Codon
NP_001543.2
NM_001552.2

cluster id
zygosity
Validation
MAF
Function
dbSNP allele
residue
position
Amino acid pos
mRNA pos

rs757185079
0

missense
C
Pro [P]
2
214
953

contig reference
A
GIn [Q]
2
214

rs759609271
0

nonsense
T

1
222
976

contig reference
C
Gln [Q]
1
222

rs765360682
0

missense
A
His [H]
2
223
980

contig reference
G
Arg [R]
2
223

TABLE 14

NP_001031.2

dbSNP rs#
Hetero-

dbSNP
Protein
Codon
Amino acid
NM_001040.2

cluster id
zygosity
Validation
MAF
Function
allelle
residue
pos
pos
mRNA pos

rs751519873
0

missense
T
Val [V]
2
171
591

contig reference
C
Ala [A]
2
171

rs528701583
0
byCluster

synonymous
A
Ala [A]
3
171
592

contig reference
G
Ala [A]
3
171

rs201120578
0
byClusterWith1000-
0.0002
missense
T
Phe [F]
1
172
593

GenomeData

contig reference
C
Leu [L]
1
172

rs747379879
0

synonymous
C
Leu [L]
3
172
595

contig reference
T
Leu [L]
3
172

rs769030967
0

missense
C
Arg [R]
1
173
596

contig reference
G
Gly [G]
1
173

rs777068397
0

missense
C
Ala [A]
2
173
597

contig reference
G
Gly [G]
2
173

synonymous
C
Gly [G]
3
173

contig reference
G
Gly [G]
3
173

rs567677603
0
byCluster

synonymous
T
Pro [P]
3
178
613

contig reference
C
Pro [P]
3
178

rs115336700
0.01
byClusterbyFreqWith-
0.0048
missense
C
Pro [P]
1
179
614

1000GenomeData

contig reference
G
Ala [A]
1
179

rs765896254
0

missense
G
Ser [S]
2
181
621

contig reference
A
Asn [N]
2
181

rs143134553
0
byClusterWith1000-
0.0002
missense
A
Lys [K]
3
181
622

GenomeData

contig reference
C
Asn [N]
3
181

rs139379650
0

missense
T
Trp [W]
1
183
626

contig reference
C
Arg [R]
1
183

rs759318203
0

missense
A
Gln [Q]
2
183
627

contig reference
G
Arg [R]
2
183

rs367555757
0
byCluster

synonymous
A
Gly [G]
3
173
598

TABLE 15

Discovery_BMI > 22 ≤ 37
Discovery_AllBMI
Discovery_BMI < 35

GABD

MW

MW

MW

(days)
AUC
p-value
Cases
Control
AUC
p-value
Cases
Control
AUC
p-value
Cases
Control

133:143
0.822
0.0018
10
18
0.719
0.0064
16
32
0.788
0.0023
12
22

133:144
0.791
0.0031
11
20
0.702
0.0089
17
34
0.763
0.0037
13
24

133:145
0.786
0.0027
12
21
0.711
0.0053
18
36
0.766
0.0023
14
26

133:146
0.788
0.0023
12
22
0.726
0.0025
19
38
0.773
0.0016
14
28

133:147
0.804
0.001
13
22
0.730
0.0016
20
40
0.791
0.0006
15
29

133:148
0.804
0.001
13
22
0.730
0.0016
20
40
0.791
0.0006
15
29

133:149
0.804
0.001
13
22
0.730
0.0016
20
40
0.791
0.0006
15
29

133:150
0.804
0.001
13
22
0.730
0.0016
20
40
0.791
0.0006
15
29

133:151
0.773
0.0003
14
23
0.722
0.0018
21
42
0.778
0.0007
16
31

133:152
0.773
0.0023
14
23
0.722
0.0018
21
42
0.778
0.0007
16
31

133:153
0.787
0.0009
15
25
0.736
0.0008
22
44
0.790
0.0003
17
33

Verification_BMI > 22 ≤ 37
Verification_AllBMI
Verification_BMI < 35

GABD

MW

MW

MW

(days)
AUC
p-value
Cases
Control
AUC
p-value
Cases
Control
AUC
p-value
Cases
Control

133:143
0.889
0.0364
2
9
0.750
0.0415
6
12
0.818
0.0278
4
11

133:144
0.889
0.0364
2
9
0.750
0.0415
6
12
0.818
0.0278
4
11

133:145
0.867
0.0245
3
10
0.765
0.023
7
14
0.815
0.0175
5
13

133:146
0.867
0.0245
3
10
0.765
0.023
7
14
0.815
0.0175
5
13

133:147
0.867
0.0245
3
10
0.765
0.023
7
14
0.815
0.0175
6
13

133:148
0.813
0.0291
4
12
0.727
0.0351
8
16
0.767
0.0274
6
15

133:149
0.839
0.0173
4
14
0.772
0.01
9
18
0.794
0.0149
6
17

133:150
0.839
0.0173
4
14
0.772
0.01
9
18
0.794
0.0149
6
17

133:151
0.839
0.0173
4
14
0.772
0.01
9
18
0.794
0.0149
6
17

133:152
0.839
0.0173
4
14
0.772
0.01
9
18
0.794
0.0149
6
17

133:153
0.839
0.0173
4
14
0.772
0.01
9
18
0.794
0.0149
6
17

Validation_BMI > 22 ≤ 37
Validation_AllBMI
Validation_BMI < 35

GABD

MW

MW

MW

(days)
AUC
p-value
Cases
Control
AUC
p-value
Cases
Control
AUC
p-value
Cases
Control

133-143
0.867
0.0051
7
15
0.698
0.0572
12
24
0.766
0.0248
9
19

133-144
0.768
0.0185
10
19
0.670
0.058
16
32
0.695
0.0501
13
26

133-145
0.788
0.0073
11
21
0.685
0.0342
17
34
0.707
0.0305
14
28

133-146
0.750
0.0157
12
23
0.670
0.0438
18
36
0.697
0.0342
15
29

133-147
0.750
0.0157
12
23
0.670
0.0438
18
36
0.697
0.0342
15
29

133-148
0.750
0.0157
12
23
0.670
0.0438
18
36
0.697
0.0342
15
29

133-149
0.684
0.0157
14
26
0.623
0.127
20
40
0.649
0.091
17
32

133-150
0.684
0.0587
14
26
0.623
0.127
20
40
0.649
0.091
17
32

133-151
0.609
0.0587
16
27
0.555
0.4782
22
43
0.598
0.2489
19
33

133-152
0.628
0.1582
17
28
0.573
0.3327
23
46
0.609
0.1897
20
34

133-153
0.646
0.0988
18
29
0.574
0.3152
24
48
0.609
0.1897
20
34

GABD (days) refers to the interval of gestation age at blood draw in days

MW p-value tests equivalence to AUC = 0.5 by a one-sided Wilcoxon Mann Whitney statistic

TABLE 16

Summary of peak areas for transitions to four IBP4_HUMAN synthetic heavy peptides

SEQ

Peptide
ID
Protein
Precursor
Precursor
Product
Product
Fragment
Retention

Sequence
NO:
Name
Mz
Charge
Mz
Charge
Ion
Time
Area

LPGGLEPK
1
IBP4_HUMAN
409.75
2
211.14
1
b2
4.62
252768

LPGGLEPK
1
IBP4_HUMAN
409.75
2
325.19
1
b4
4.66
76266

LPGGLEPK
1
IBP4_HUMAN
409.75
2
705.40
1
y7
4.66
844128

LPGGLEPK
1
IBP4_HUMAN
409.75
2
608.35
1
y6
4.66
866360

LPGGLEPK
1
IBP4_HUMAN
409.75
2
551.33
1
y5
4.62
96412

LPGGLEPK
1
IBP4_HUMAN
409.75
2
252.18
1
y2
4.66
939572

LPGGLEPK
1
IBP4_HUMAN
409.75
2
353.20
2
y7
4.66
3489414

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
289.10
1
b2
1.85
9703

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
426.16
1
b3
1.85
14713

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
822.36
1
b7
1.85
2136

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
903.47
1
y8
1.85
17798

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
766.41
1
y7
1.85
73221

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
669.36
1
y6
1.85
5019

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
598.32
1
y5
1.85
4078

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
485.23
1
y4
1.85
4383

QCHPALDGQR
2
IBP4_HUMAN
596.28
2
370.21
1
y3
1.85
25859

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
289.10
1
b2
1.85
57043

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
426.16
1
b3
1.85
109467

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
523.21
1
b4
1.85
12019

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
594.25
1
b5
1.85
30122

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
213.58
2
b3
1.85
7249

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
262.11
2
b4
1.85
11989

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
297.63
2
b5
1.85
71677

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
354.17
2
b6
1.85
10532

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
411.68
2
b7
1.85
8062

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
766.41
1
y7
1.85
118740

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
669.36
1
y6
1.85
79410

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
598.32
1
y5
1.85
235615

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
485.23
1
y4
1.85
637333

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
370.21
1
y3
1.85
440794

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
313.19
1
y2
1.85
26708

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
532.25
2
y9
1.85
52271

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
452.24
2
y8
1.85
24399

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
383.71
2
y7
1.85
238180

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
335.18
2
y6
1.85
64484

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
299.66
2
y5
1.85
18478

QCHPALDGQR
2
IBP4_HUMAN
397.86
3
243.12
2
y4
1.85
50903

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
239.11
1
b2
8.25
35797

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
368.16
1
b3
8.25
15185

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
483.18
1
b4
8.25
14411

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
596.27
1
b5
8.25
19740

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
759.33
1
b6
8.25
35904

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
872.41
1
b7
8.25
38201

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
985.50
1
b8
8.25
38297

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
1195.64
1
b10
8.2
11054

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
1107.59
1
y9
8.25
22635

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
994.50
1
y8
8.25
33493

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
881.42
1
y7
8.25
98887

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
784.36
1
y6
8.25
2565

THEDLYIIPIPNCDR
3
IBP4_HUMAN
933.46
2
671.28
1
y5
8.25
31935

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
239.11
1
b2
8.25
13586

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
368.16
1
b3
8.25
6976

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
483.18
1
b4
8.25
12635

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
596.27
1
b5
8.25
36886

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
759.33
1
b6
8.25
138833

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
872.41
1
b7
8.25
190646

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
985.50
1
b8
8.25
54139

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
493.25
2
b8
8.25
13320

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
541.78
2
b9
8.25
6168

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
994.50
1
y8
8.25
5893

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
881.42
1
y7
8.25
297346

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
784.36
1
y6
8.25
14422

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
671.28
1
y5
8.25
212081

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
574.23
1
y4
8.25
10550

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
460.18
1
y3
8.25
4183

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
441.21
2
y7
8.25
59487

THEDLYIIPIPNCDR
3
IBP4_HUMAN
622.64
3
336.14
2
y5
8.25
48606

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
245.08
1
b2
2.94
1864

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
472.22
1
b4
2.94
7355

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
569.27
1
b5
2.94
1648

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
668.34
1
b6
2.94
30775

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
765.39
1
b7
2.94
1033

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
893.45
1
b8
2.94
6138

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
950.47
1
b9
2.94
4242

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
285.14
2
b5
2.94
680

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
334.67
2
b6
2.94
1704

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
383.20
2
b7
2.9
3561

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
447.23
2
b8
2.94
3333

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
475.74
2
b9
2.94
6911

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
1083.49
1
y9
2.94
11083

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
1026.47
1
y8
2.94
4195

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
939.43
1
y7
2.94
8994

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
779.40
1
y6
2.94
13897

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
651.34
1
y5
2.94
23600

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
564.31
1
y4
2.94
7164

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
435.27
1
y3
2.94
8441

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
322.19
1
y2
2.94
10343

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
866.43
2
y15
2.94
2751

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
830.91
2
y14
2.94
994

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
752.86
2
y13
2.94
2065

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
654.80
2
y11
2.94
26747

EDARPVPQGSCQSELHR
4
IBP4_HUMAN
659.31
3
542.25
2
y9
2.94
7872

Comparative IBP4 peptide and transition MS data. Four different heavy labelled peptides (R*+10 daltons) exemplify various transitions and their relative intensities that could be monitored to quantify IBP4. Those skilled in the art could select potentially any of these peptides or transitions or others not exemplified to quantify IBP4.

TABLE 17

Peak Area Summary for Transitions to IBP4_HUMAN Surveyed Using Recombinant Protein

SEQ

Peptide
ID

Precursor
Precursor
Product
Product
Fragment
Retention

Sequence
NO:
Protein Name
Mz
Charge
Mz
Charge
lon
Time
Area

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
317.14
1
b2
6.4
20339

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
414.19
1
b3
6.35
21220

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
610.31
1
b5
6.46
13132

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
667.33
1
b6
6.46
14894

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
207.60
2
b3
6.4
5605

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
256.13
2
b4
6.4
13853

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
414.19
2
b7
6.4
21460

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
862.41
1
y7
6.4
16655

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
805.39
1
y6
6.4
7047

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
645.36
1
y5
6.4
19298

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
516.31
1
y4
6.4
14093

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
387.27
1
y3
6.35
11771

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
274.19
1
y2
6.46
8168

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
578.29
2
y10
6.35
7367

CRPPVGCEELVR
5
sp|P22692|IBP4_HUMAN
491.24
3
403.20
2
y6
6.46
5605

VNGAPR
6
sp|P22692|IBP4_HUMAN
307.17
2
214.12
1
b2
1.28
227017

VNGAPR
6
sp|P22692|IBP4_HUMAN
307.17
2
220.12
2
b5
1.2
17711

VNGAPR
6
sp|P22692|IBP4_HUMAN
307.17
2
272.17
1
y2
1.16
9908

VNGAPR
6
sp|P22692|IBP4_HUMAN
307.17
2
257.64
2
y5
1.2
8484

VNGAPR
6
sp|P22692|IBP4_HUMAN
307.17
2
200.62
2
y4
1.2
3592

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
245.08
1
b2
5.45
1059

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
472.22
1
b4
5.35
1968

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
668.34
1
b6
5.45
7567

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
950.47
1
b9
5.35
908

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
519.25
2
b10
5.45
1513

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
1016.46
1
y8
5.45
757

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
929.43
1
y7
5.4
2876

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
641.34
1
y5
5.35
4389

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
312.18
1
y2
5.35
3481

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
649.80
2
y11
5.35
5449

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
537.24
2
y9
5.5
1513

EDARPVPQGSCQSELHR
4
sp|P22692|IBP4_HUMAN
655.98
3
321.17
2
y5
5.4
605

LAASQSR
7
sp|P22692|IBP4_HUMAN
366.70
2
343.20
1
b4
1.31
4692

LAASQSR
7
sp|P22692|IBP4_HUMAN
366.70
2
279.65
2
b6
1.31
45027

LAASQSR
7
sp|P22692|IBP4_HUMAN
366.70
2
262.15
1
y2
1.31
3481

LAASQSR
7
sp|P22692|IBP4_HUMAN
366.70
2
310.16
2
y6
1.26
8097

LAASQSR
7
sp|P22692|IBP4_HUMAN
366.70
2
274.64
2
y5
1.31
22173

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
483.18
1
b4
8.96
619

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
596.27
1
b5
8.96
1115

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
759.33
1
b6
9.08
1610

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
872.41
1
b7
8.96
3468

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
985.50
1
b8
9.04
3096

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
1097.58
1
y9
8.96
867

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
984.49
1
y8
9.04
1734

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
871.41
1
y7
9
4211

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
661.27
1
y5
8.96
2477

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
928.45
2
744.88
2
y12
9.04
743

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
239.11
1
b2
8.96
4211

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
368.16
1
b3
9
1486

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
483.18
1
b4
8.96
5511

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
596.27
1
b5
9.04
11580

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
759.33
1
b6
8.96
30343

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
872.41
1
b7
8.96
53318

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
985.50
1
b8
8.96
9660

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
380.17
2
b6
9
2353

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
436.71
2
b7
8.96
8174

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
493.25
2
b8
8.96
4830

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
541.78
2
b9
9.41
2477

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
984.49
1
y8
9
2229

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
871.41
1
y7
9
55981

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
774.36
1
y6
8.96
5202

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
661.27
1
y5
8.96
52141

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
564.22
1
y4
8.92
4582

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
492.75
2
y8
8.96
5264

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
436.21
2
y7
8.96
11147

THEDLYIIPIPNCDR
3
sp|P22692|IBP4_HUMAN
619.31
3
331.14
2
y5
8.96
10280

NGNFHPK
8
sp|P22692|IBP4_HUMAN
407.20
2
286.11
1
b3
1.41
26865

NGNFHPK
8
sp|P22692|IBP4_HUMAN
407.20
2
285.62
2
b5
1.41
21038

NGNFHPK
8
sp|P22692|IBP4_HUMAN
407.20
2
334.15
2
b6
1.36
1665

NGNFHPK
8
sp|P22692|IBP4_HUMAN
407.20
2
244.17
1
y2
1.31
1665

NGNFHPK
8
sp|P22692|IBP4_HUMAN
407.20
2
321.67
2
y5
1.36
2422

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
426.16
1
b3
4.96
2882

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
297.63
2
b5
4.96
2401

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
756.40
1
y7
4.96
4483

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
659.35
1
y6
4.91
2722

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
588.31
1
y5
4.96
4963

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
475.23
1
y4
4.96
23535

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
360.20
1
y3
4.96
13448

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
527.25
2
y9
5.02
640

QCHPALDGQR
2
sp|P22692|IBP4_HUMAN
394.52
3
378.70
2
y7
4.91
7204

CWCVDR
9
sp|P22692|IBP4_HUMAN
448.18
2
347.12
1
b2
6.46
2497

CWCVDR
9
sp|P22692|IBP4_HUMAN
448.18
2
735.32
1
y5
6.41
2573

CWCVDR
9
sp|P22692|IBP4_HUMAN
448.18
2
549.24
1
y4
6.46
14908

CWCVDR
9
sp|P22692|IBP4_HUMAN
448.18
2
389.21
1
y3
6.46
6584

CWCVDR
9
sp|P22692|IBP4_HUMAN
448.18
2
290.15
1
y2
6.46
4086

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
211.14
1
b2
6.81
24216

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
325.19
1
b4
6.81
16119

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
567.31
1
b6
6.76
8778

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
697.39
1
y7
6.76
71815

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
600.34
1
y6
6.76
141209

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
543.31
1
y5
6.76
17481

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
244.17
1
y2
6.81
149987

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
349.20
2
y7
6.76
370277

LPGGLEPK
1
sp|P22692|IBP4_HUMAN
405.74
2
243.65
2
y4
6.76
7265

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
300.16
1
b3
7.47
5764

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
575.21
1
b5
7.42
1121

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
712.27
1
b6
7.47
961

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
840.33
1
b7
7.53
6084

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
953.41
1
b8
7.42
3682

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
420.67
2
b7
7.47
3682

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
477.21
2
b8
7.42
3282

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
570.24
2
b10
7.42
961

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
973.49
1
y8
7.47
5764

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
836.43
1
y7
7.47
29618

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
708.37
1
y6
7.47
22734

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
595.28
1
y5
7.47
39705

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
524.25
1
y4
7.47
23535

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
409.22
1
y3
7.47
35862

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
322.19
1
y2
7.47
3682

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
681.32
2
y11
7.42
103024

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
624.77
2
y10
7.47
58757

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
567.26
2
y9
7.42
31860

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
487.25
2
y8
7.47
18411

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
354.69
2
y6
7.47
2401

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
298.15
2
y5
7.53
6084

GELDCHQLADSFR
10
sp|P22692|IBP4_HUMAN
516.57
3
262.63
2
y4
7.47
1601

TABLE 18

Peak area summary for the different transitions for SHBG HUMAN

Pooled

Pregnant

SEQ

Pre-
Pre-
Prod-
Prod-
Frag-
Reten-
rSHBG
Serum

ID

cursor
cursor
uct
uct
ment
tion
Peak
Peak

Peptide Sequence
NO:
Protein Name
Mz
Charge
Mz
Charge
Ion
Time
Area
Area

TSSSFEVR
11
sp|P04278|SHBG_HUMAN
456.72
2
811.39
1
y7
6.18
26852
96178

TSSSFEVR
11
sp|P04278|SHBG_HUMAN
456.72
2
724.36
1
y6
6.18
104140
406657

TSSSFEVR
11
sp|P04278|SHBG_HUMAN
456.72
2
637.33
1
y5
6.18
39819
152232

TSSSFEVR
11
sp|P04278|SHBG_HUMAN
456.72
2
550.30
1
y4
6.18
33489
134866

TSSSFEVR
11
sp|P04278|SHBG_HUMAN
456.72
2
403.23
1
y3
6.18
27156
91485

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
288.13
1
b2
9.44
28789
430926

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
403.16
1
b3
9.44
48399
551674

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
629.26
1
b5
9.44
5719
37766

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
686.28
1
b6
9.44
4288
48075

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
785.35
1
b7
9.44
19603
255484

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
898.43
1
b8
9.44
9799
106444

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
1045.50
1
b9
9.44
2959
34703

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
1153.59
1
y10
9.49
2043
48983

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
1054.52
1
y9
9.44
23075
403061

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
941.44
1
y8
9.44
17663
302129

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
794.37
1
y7
9.39
10616
212103

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
631.30
1
y6
9.44
13070
199732

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
574.28
1
y5
9.44
2040
35430

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
459.26
1
y4
9.49
5716
86862

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
358.21
1
y3
9.44
1836
39288

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
244.17
1
y2
9.49
11027
123399

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
776.37
2
y14
9.44
12561
174726

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
718.86
2
y13
9.44
38597
604225

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
919.93
2
287.65
2
y5
9.49
4901
88390

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
288.13
1
b2
9.44
8782
30219

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
403.16
1
b3
9.44
7759
81236

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
686.28
1
b6
9.44
8984
65110

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
785.35
1
b7
9.44
30014
161864

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
898.43
1
b8
9.44
12149
65219

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
1045.50
1
b9
9.44

20004

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
343.64
2
b6
9.44

22039

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
449.72
2
b8
9.44

13058

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
523.25
2
b9
9.49

10924

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
633.30
2
b11
9.39

27875

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
741.33
2
b13
9.44

23467

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
1054.52
1
y9
9.49

22048

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
941.44
1
y8
9.39
27157
111649

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
794.37
1
y7
9.44
43700
251500

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
631.30
1
y6
9.44
56356
290887

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
574.28
1
y5
9.39
7863
50921

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
459.26
1
y4
9.49
12457
66024

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
358.21
1
y3
9.39
8376
26955

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
244.17
1
y2
9.39
17667
74103

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
776.37
2
y14
9.49

22867

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
718.86
2
y13
9.44

11628

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
471.22
2
y8
9.44

21129

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
397.69
2
y7
9.39
9192
46444

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
316.16
2
y6
9.49

37345

TWDPEGVIFYGDTNPK
12
sp|P04278|SHBG_HUMAN
613.62
3
287.65
2
y5
9.44

17354

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
231.06
1
b2
10.57
2450
218844

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
417.14
1
b3
10.62
4085
660895

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
564.21
1
b4
10.67
2652
190972

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
695.25
1
b5
10.62

56841

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
922.50
1
y7
10.62

206072

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
736.42
1
y6
10.62
12655
1487537

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
589.35
1
y5
10.62
16227
1563060

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
458.31
1
y4
10.67
4489
681922

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
345.22
1
y3
10.57
7755
826140

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
288.20
1
y2
10.62

100631

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
519.27
2
y8
10.62

25104

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
576.78
2
461.75
2
y7
10.62

83186

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
384.86
3
417.14
1
b3
10.62

11229

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
384.86
3
564.21
1
b4
10.57

7349

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
384.86
3
589.35
1
y5
10.57

2450

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
384.86
3
458.31
1
y4
10.62

16538

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
384.86
3
345.22
1
y3
10.62

30524

DDWFMLGLR
13
sp|P04278|SHBG_HUMAN
384.86
3
288.20
1
y2
10.51

3880

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
329.16
1
b3
7.84
5943
24455

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
555.25
1
b5
7.72

8188

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
796.39
1
b7
7.84
3326
13408

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
909.48
1
b8
7.84
5227
15675

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
1046.54
1
b9
7.72

12351

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
1160.58
1
b10
7.84
5462
11163

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
523.77
2
b9
7.72

8555

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
580.79
2
b10
7.84
4630
24587

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
649.32
2
b11
7.78
8555
24107

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
742.36
2
b12
7.9
4753
20193

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
777.88
2
b13
7.9
8312
19238

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
841.91
2
b14
7.72

8551

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
898.45
2
b15
7.84
6656
29217

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
1062.54
2
b19
7.84
3328
6649

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
1155.63
1
y11
7.9
11995
32069

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
969.55
1
y10
7.84
16386
47509

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
898.51
1
y9
7.84
9025
26601

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
770.45
1
y8
7.78
6410
16278

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
657.37
1
y7
7.84
4990
21850

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
556.32
1
y6
7.9
3089
8193

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
457.25
1
y5
7.9
3324
9848

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
329.19
1
y3
7.9
7600
11648

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
1062.56
2
y19
7.78
3802
9572

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
646.85
2
y12
7.9
3328
7497

AGPR

DGRPEIQLHNHWAQLTVG
14
sp|P04278|SHBG_HUMAN
818.09
3
329.19
2
y7
7.84
10685
5422

AGPR

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
324.15
1
b2
5.82
95843
143834

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
452.20
1
b3
5.88
24228
30155

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
551.27
1
b4
5.82
10215
16269

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
680.32
1
b5
5.88
31354
35986

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
779.38
1
b6
5.82
8316
12828

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
739.41
1
y6
5.82
29929
37874

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
602.35
1
y5
5.82
57721
77194

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
246.18
1
y2
5.82
91450
141340

WHQVEVK
15
sp|P04278|SHBG_HUMAN
463.25
2
370.21
2
y6
5.82
88601
90134

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
324.15
1
b2
5.82
89310
94424

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
452.20
1
b3
5.88
82658
107490

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
551.27
1
b4
5.82
57008
47029

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
340.66
2
b5
5.82
47270
48456

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
602.35
1
y5
5.82
20904
24944

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
474.29
1
y4
5.82
43114
35632

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
246.18
1
y2
5.82
284438
306895

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
370.21
2
y6
5.82
431957
434922

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
301.68
2
y5
5.82
32539
42866

WHQVEVK
15
sp|P04278|SHBG_HUMAN
309.17
3
237.65
2
y4
5.82
24000
22570

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
261.09
1
b2
9.56
9976
176237

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
318.11
1
b3
9.5
4160
68533

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
433.14
1
b4
9.56
11047
235634

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
520.17
1
b5
9.44

89909

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
619.24
1
b6
9.56
21139
230412

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
732.32
1
b7
9.56
13304
236332

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
845.41
1
b8
9.56
12592
166750

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
974.45
1
b9
9.56
5708
94539

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
1073.52
1
b10
9.44

58323

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
1188.55
1
b11
9.44

32055

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
260.59
2
b5
9.44

29113

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
1158.60
1
y10
9.5
20897
448830

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
1045.52
1
y9
9.56
32183
563430

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
916.47
1
y8
9.56
29571
345839

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
817.41
1
y7
9.62
26010
438470

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
702.38
1
y6
9.56
13669
211762

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
645.36
1
y5
9.5
4037
32785

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
516.31
1
y4
9.56
5585
68764

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
387.27
1
y3
9.56
5459
81359

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
945.46
2
288.20
1
y2
9.5
9506
114023

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
261.09
1
b2
9.56
6062
51794

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
433.14
1
b4
9.5
9495
42761

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
619.24
1
b6
9.38
12348
65809

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
732.32
1
b7
9.5
21619
85170

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
974.45
1
b9
9.5

22572

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
366.67
2
b7
9.56
4985
27676

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
423.21
2
b8
9.44

36344

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
487.73
2
b9
9.5

20069

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
1045.52
1
y9
9.56
9148
74821

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
916.47
1
y8
9.56
21496
135854

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
817.41
1
y7
9.5
57831
380769

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
702.38
1
y6
9.56
46795
236942

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
645.36
1
y5
9.56
8320
42640

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
516.31
1
y4
9.62
21264
102732

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
387.27
1
y3
9.5
9267
84073

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
288.20
1
y2
9.32
12234
53912

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
685.88
2
y12
9.44

17945

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
458.74
2
y8
9.44

19110

MEGDSVLLEVDGEEVLR
16
sp|P04278|SHBG_HUMAN
630.64
3
323.18
2
y5
9.56

24717

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
228.13
1
b2
5.86
11214
57191

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
788.45
1
y8
5.86
2990
19062

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
689.38
1
y7
5.86
61053
282713

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
602.35
1
y6
5.86
22679
104538

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
545.33
1
y5
5.86
27536
123604

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
448.28
1
y4
5.86
5233
26420

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
335.19
1
y3
5.86
29403
111637

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
234.14
1
y2
5.86
21802
79995

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
345.20
2
y7
5.86
14455
58815

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
301.68
2
y6
5.86
2990
18189

QVSGPLTSK
17
sp|P04278|SHBG_HUMAN
458.76
2
273.17
2
y5
5.86
16948
89586

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
298.21
1
b3
10.65
6981
63802

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
355.23
1
b4
10.72
4236
56059

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
412.26
1
b5
10.65
25923
402833

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
525.34
1
b6
10.65
41881
404680

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
638.42
1
b7
10.59
14960
144040

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
785.49
1
b8
10.65
10219
105535

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
1144.65
1
y11
10.65
22931
282840

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
1087.63
1
y10
10.65
10465
140548

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
1030.60
1
y9
10.72
6483
125959

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
917.52
1
y8
10.65
49362
594214

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
804.44
1
y7
10.65
76280
973633

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
657.37
1
y6
10.65
93730
1204642

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
560.32
1
y5
10.59
3242
53952

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
489.28
1
y4
10.65

49330

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
402.25
1
y3
10.65

23177

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
288.20
1
y2
10.65

18686

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
629.37
2
y12
10.65
5481
73517

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
572.83
2
y11
10.72

11466

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
402.72
2
y7
10.65

20181

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
329.19
2
y6
10.65

21538

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
721.43
2
245.14
2
y4
10.65

6485

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
298.21
1
b3
10.65

15331

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
412.26
1
b5
10.65
13956
193878

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
525.34
1
b6
10.65
24679
323212

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
638.42
1
b7
10.65
11589
110026

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
785.49
1
b8
10.59
2494
16200

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
319.72
2
b7
10.65

14451

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
393.25
2
b8
10.59
3745
12199

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
917.52
1
y8
10.65

21931

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
804.44
1
y7
10.65
7478
96064

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
657.37
1
y6
10.65
79020
937227

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
560.32
1
y5
10.65
19940
364330

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
489.28
1
y4
10.65
14459
185782

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
402.25
1
y3
10.59
4236
37877

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
288.20
1
y2
10.59

15698

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
402.72
2
y7
10.59
9968
81983

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
329.19
2
y6
10.65
67299
722053

IALGGLLFPASNLR
18
sp|P04278|SHBG_HUMAN
481.29
3
245.14
2
y4
10.72

16079

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
211.14
1
b2
9.72
142292
756192

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
324.23
1
b3
9.72
160489
866724

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
423.30
1
b4
9.66
194131
842302

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
212.15
2
b4
9.66
3491
131435

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
296.20
2
b6
9.66
4983
68644

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
1113.61
1
y10
9.72
24667
97571

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
1000.52
1
y9
9.66
27161
108785

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
901.46
1
y8
9.72
469991
1998965

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
804.40
1
y7
9.66
9969
74638

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
733.37
1
y6
9.66
9723
52218

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
620.28
1
y5
9.66
9966
75133

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
505.26
1
y4
9.72
28658
150379

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
605.83
2
y11
9.66
39377
199487

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
500.77
2
y9
9.66
11339
51218

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
451.23
2
y8
9.66
47221
214689

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
662.38
2
310.64
2
y5
9.66
48970
270761

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
211.14
1
b2
9.72
3988
4863

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
324.23
1
b3
9.72
3235
20432

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
423.30
1
b4
9.66
12709
38129

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
591.39
1
b6
9.72
20185
50468

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
704.47
1
b7
9.72

4615

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
260.68
2
b5
9.66
2987
5981

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
733.37
1
y6
9.66
3988
9096

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
620.28
1
y5
9.66
23677
67284

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
505.26
1
y4
9.66
19692
45854

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
448.23
1
y3
9.66
2243
8470

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
367.19
2
y6
9.72

5484

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
310.64
2
y5
9.59
4736
6356

LPLVPALDGCLR
19
sp|P04278|SHBG_HUMAN
441.92
3
253.13
2
y4
9.72
3491
8842

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
203.07
1
b2
7.1
36632

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
389.15
1
b3
7.1
2990

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
648.34
1
y5
7.1
10216

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
561.30
1
y4
7.1
59060

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
375.22
1
y3
7.1
75758

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
262.14
1
y2
7.1
71394

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
324.67
2
y5
7.1
11711

DSWLDK
20
sp|P04278|SHBG_HUMAN
382.18
2
281.16
2
y4
7.1
7726

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
200.10
1
b2
6.84
126856
265599

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
329.15
1
b3
6.84
225724
470069

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
442.23
1
b4
6.8
64901
134361

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
529.26
1
b5
6.84
20563
41566

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
600.30
1
b6
6.88
15019
27276

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
687.33
1
b7
6.84
7335
19406

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
758.37
1
b8
6.84
8226
19758

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
1131.60
1
y11
6.84
80998
171464

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
1002.56
1
y10
6.84
83503
195346

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
889.47
1
y9
6.84
365275
865394

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
802.44
1
y8
6.84
170577
346969

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
731.40
1
y7
6.84
184606
420174

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
644.37
1
y6
6.84
99233
217518

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
573.34
1
y5
6.84
204455
471407

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
476.28
1
y4
6.8
9298

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
375.24
1
y3
6.8
9116

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
288.20
1
y2
6.84
7689

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
566.30
2
y11
6.8
7063

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
665.85
2
501.78
2
y10
6.84
8043

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
200.10
1
b2
6.84
4738
70979

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
329.15
1
b3
6.8
8223
26541

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
442.23
1
b4
6.84
9478
15644

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
529.26
1
b5
6.8
6614

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
600.30
1
b6
6.8
5900
23599

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
687.33
1
b7
6.75
2859

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
344.17
2
b7
6.84
2682

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
731.40
1
y7
6.84
7869

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
644.37
1
y6
6.88
12335

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
573.34
1
y5
6.84
138213
82159

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
476.28
1
y4
6.8
33434
19037

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
375.24
1
y3
6.88
18686
11795

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
288.20
1
y2
6.8

139993

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
445.24
2
y9
6.84
1789
8675

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
401.72
2
y8
6.75

75276

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
322.69
2
y6
6.84
4828

QAEISASAPTSLR
21
sp|P04278|SHBG_HUMAN
444.24
3
287.17
2
y5
6.8
99236
33965

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
248.07
1
b2
9.75
42019
101416

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
363.10
1
b3
9.7
85912
184040

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
462.17
1
b4
9.7
38534
77277

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
591.21
1
b5
9.7
40944
79511

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
678.24
1
b6
9.7
23602
59566

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
792.28
1
b7
9.75
48097
86937

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
946.36
1
b9
9.75
58289
107231

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
1059.44
1
b10
9.7
53017
96052

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
445.17
2
b8
9.75
12607
47034

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
473.68
2
b9
9.7
50063
86740

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
530.22
2
b10
9.7
36838
58848

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
603.76
2
b11
9.7
11442
36577

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
660.30
2
b12
9.75
15913
24059

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
757.35
2
b14
9.7
25030
42298

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
1132.57
1
y10
9.7
110857
213116

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
1035.52
1
y9
9.7
34689
70918

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
978.50
1
y8
9.66
13408
29510

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
877.45
1
y7
9.75
21816
44261

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
749.39
1
y6
9.7
44877
76365

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
678.36
1
y5
9.7
30398
67608

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
549.31
1
y4
9.75
29679
77350

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
288.20
1
y2
9.7

24322

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
878.97
2
y16
9.75
10731
14845

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
671.86
2
y12
9.75
8226
15831

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
615.32
2
y11
9.7
754906
1053051

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
566.79
2
y10
9.7
83146
139155

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
375.20
2
y6
9.7
10192
19233

NLR

SCDVESNPGIFLPPGTQAEF
22
sp|P04278|SHBG_HUMAN
850.08
3
275.16
2
y4
9.79

19761

NLR

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
229.12
1
b2
10.33

5965

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
326.17
1
b3
10.46

11667

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
454.23
1
b4
10.4

8742

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
551.28
1
b5
10.4

6984

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
688.34
1
b6
10.33

16485

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
759.38
1
b7
10.33

19657

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
888.42
1
b8
10.4

38546

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
1171.55
1
b10
10.4

8234

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
276.14
2
b5
10.52

7732

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
586.28
2
b10
10.46

6088

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
695.33
2
b12
10.46

5961

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
738.85
2
b13
10.4

8373

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
852.90
2
b15
10.4

6596

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
909.45
2
b16
10.27

7093

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
937.96
2
b17
10.4

12049

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
994.50
2
b18
10.4

6720

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
963.55
1
y9
10.46

8243

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
892.51
1
y8
10.4

28277

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
745.45
1
y7
10.4

17877

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
658.41
1
y6
10.33

6455

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
545.33
1
y5
10.33

15214

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
430.30
1
y4
10.4

51478

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
317.22
1
y3
10.4

24348

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
260.20
1
y2
10.4

11287

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
1010.04
2
y18
10.33

67074

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
953.50
2
y17
10.4

226206

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
904.97
2
y16
10.33

7357

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
840.94
2
y15
10.4

137962

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
792.41
2
y14
10.4

11410

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
688.37
2
y12
10.33

12934

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
575.32
2
y10
10.33

3557

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
373.23
2
y7
10.33

16856

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
1067.55
2
215.65
2
y4
10.27

6851

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
229.12
1
b2
10.33

54641

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
888.42
1
b8
10.33

15214

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
1149.63
1
y10
10.33

11157

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
963.55
1
y9
10.33
3928
87243

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
892.51
1
y8
10.38
8027
165351

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
745.45
1
y7
10.33
6318
159006

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
658.41
1
y6
10.33

67207

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
545.33
1
y5
10.33
2393
59596

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
430.30
1
y4
10.38
3584
86992

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
317.22
1
y3
10.33
2390
60223

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
260.20
1
y2
10.33

19028

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
953.50
2
y17
10.38
6828
77604

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
840.94
2
y15
10.38
9905
125911

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
792.41
2
y14
10.33

17238

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
688.37
2
y12
10.4

8880

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
623.85
2
y11
10.38
4778
57062

DIPQPHAEPWAFSLDLGLK
23
sp|P04278|SHBG_HUMAN
712.04
3
446.76
2
y8
10.33

28150

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
312.23
1
b3
12.14

14018

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
399.26
1
b4
12.09

13357

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
486.29
1
b5
12.09

10441

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
543.31
1
b6
12.14

15143

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
630.35
1
b7
12.17
3930
14951

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
687.37
1
b8
12.13
3925
26904

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
784.42
1
b9
12.09

7900

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
841.44
1
b10
12.13
3930
10719

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
954.53
1
b11
12.13
2903
25772

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
1069.55
1
b12
12.13
4955
16747

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
1182.64
1
b13
12.04
4099
31707

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
535.28
2
b12
12.04

5641

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
936.55
2
b20
12.04

13640

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
1190.79
1
y11
12.13
17593
91335

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
1093.73
1
y10
12.09

8089

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
980.65
1
y9
12.09

21070

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
881.58
1
y8
12.08
18961
80043

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
768.50
1
y7
12.13
18444
102065

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
711.48
1
y6
12.08
3074
21355

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
598.39
1
y5
12.08
47057
292259

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
501.34
1
y4
12.09

3760

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
388.26
1
y3
12.08
2732
21073

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
260.20
1
y2
12.04
3074
11477

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
1087.64
2
y22
12.08
3077
21073

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
1031.10
2
y21
12.09

15240

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
987.59
2
y20
12.09

8371

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
944.07
2
y19
12.13
3415
11761

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
915.56
2
y18
12.14

8558

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
872.04
2
y17
12.13
4609
19566

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
843.53
2
y16
12.04

15899

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
766.49
2
y14
12.14

4141

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
652.44
2
y12
12.14

8088

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
1186.71
2
441.29
2
y8
12.09

6774

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
312.23
1
b3
12.13
42888
65949

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
399.26
1
b4
12.13
21029
43367

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
486.29
1
b5
12.07
7286
7151

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
543.31
1
b6
12.18
9370
12223

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
630.35
1
b7
12.13
18326
24266

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
687.37
1
b8
12.13
19156
21728

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
784.42
1
b9
12.13
11660
23424

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
841.44
1
b10
12.13
16347
20317

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
954.53
1
b11
12.13
15821
19379

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
1069.55
1
b12
12.07
46738
71574

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
1182.64
1
b13
12.13
47885
64624

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
421.22
2
b10
12.13
5101
13732

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
477.77
2
b11
12.18
5206
6681

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
535.28
2
b12
12.13
11661
18625

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
591.82
2
b13
12.07
30187
42141

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
640.35
2
b14
12.13
52254
63769

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
696.89
2
b15
12.13
16655
17121

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
746.42
2
b16
12.13
8535
10155

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
936.55
2
b20
12.07
5000
8561

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
1190.79
1
y11
12.13
51215
73554

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
1093.73
1
y10
12.07
23529
31977

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
980.65
1
y9
12.07
51626
77042

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
881.58
1
y8
12.13
153018
225474

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
768.50
1
y7
12.07
369345
512663

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
711.48
1
y6
12.13
64333
87008

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
598.39
1
y5
12.13
329370
537778

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
501.34
1
y4
12.13
10510
16372

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
388.26
1
y3
12.13
30707
60384

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
260.20
1
y2
12.07
18529
33308

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
872.04
2
y17
12.13
4166
6771

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
766.49
2
y14
12.07
12077
14396

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
652.44
2
y12
12.07
7494
10257

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
595.90
2
y11
12.07
33522
42701

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
547.37
2
y10
12.13
3954
4984

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
441.29
2
y8
12.13
7701
15425

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
356.24
2
y6
12.07
6871
8751

LQLK

VVLSSGSGPGLDLPLVLGLP
24
sp|P04278|SHBG_HUMAN
791.48
3
299.70
2
y5
12.07
7701
9689

LQLK

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
312.23
1
b3
5.25
14004
16657

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
584.34
1
b6
5.22

9128

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
718.41
1
y7
5.25
101369
154048

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
619.34
1
y6
5.25
860577
1157529

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
506.26
1
y5
5.21
168229
273074

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
419.22
1
y4
5.25
40477
58906

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
291.17
1
y3
5.25
56277
98421

VVLSQGSK
25
sp|P04278|SHBG_HUMAN
409.24
2
234.14
1
y2
5.3
18448
21652

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
229.12
1
b2
7.22
175928

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
328.19
1
b3
7.22
30537
50598

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
443.21
1
b4
7.22
24914

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
571.27
1
b5
7.18
8188

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
642.31
1
b6
7.06

27320

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
869.44
1
b8
7.06

22459

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
435.22
2
b8
7.06

24039

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
930.46
1
y8
7.22
66345
99621

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
815.44
1
y7
7.22
128600
224769

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
716.37
1
y6
7.22
176273
329489

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
601.34
1
y5
7.22
112569
239451

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
473.28
1
y4
7.18
84667
185259

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
402.25
1
y3
7.18
69746
100254

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
289.16
1
y2
7.22
55177
96879

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
408.22
2
y7
7.18
21442

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
358.69
2
y6
7.18
4997

LDVDQALNR
26
sp|P04278|SHBG_HUMAN
522.28
2
201.63
2
y3
7.22
10549

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
256.17
1
b3
12.18

79381

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
369.25
1
b4
12.12

20134

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
466.30
1
b5
12.23

11181

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
676.44
1
b7
12.12

14124

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
733.46
1
b8
12.07

12965

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
846.54
1
b9
12.18

19293

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
917.58
1
b10
12.18

14550

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
282.18
2
b6
12.07

7805

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
1069.59
1
y9
12.12

6538

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
842.46
1
y7
12.07

8531

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
656.38
1
y6
12.23

14766

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
585.35
1
y5
12.18

9813

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
457.25
1
y4
12.18

45762

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
1063.14
2
y20
12.12

8012

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
1027.62
2
y19
12.07

17082

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
971.08
2
y18
12.12

214978

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
922.55
2
y17
12.12

7694

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
1155.20
2
478.28
2
y8
12.12

7702

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
256.17
1
b3
12.07

842606

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
369.25
1
b4
12.12

82661

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
466.30
1
b5
12.07

17819

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
563.36
1
b6
12.02

10122

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
733.46
1
b8
12.12

9487

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
282.18
2
b6
12.07

48813

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
367.23
2
b8
12.07

11705

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
1182.67
1
y10
12.07

25519

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
1069.59
1
y9
12.12

53562

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
955.55
1
y8
12.12

29098

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
842.46
1
y7
12.07

164685

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
656.38
1
y6
12.12

180607

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
585.35
1
y5
12.07

93202

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
457.25
1
y4
12.12

285196

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
360.20
1
y3
12.12

8859

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
232.14
1
y2
12.12

13702

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
1027.62
2
y19
12.07

7692

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
971.08
2
y18
12.07

616149

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
922.55
2
y17
12.12

82239

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
874.02
2
y16
12.12

25832

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
817.48
2
y15
12.07

64945

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
788.97
2
y14
12.12

12867

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
732.43
2
y13
12.07

48079

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
696.91
2
y12
12.07

72642

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
648.38
2
y11
12.12

238495

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
591.84
2
y10
12.12

11281

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
535.30
2
y9
12.12

19196

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
478.28
2
y8
12.07

92887

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
421.74
2
y7
12.12

29947

QGR

ALALPPLGLAPLLNLWAKP
27
sp|P04278|SHBG_HUMAN
770.47
3
293.18
2
y5
12.02

12438

QGR

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
467.22
1
b4
7.56

7050

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
653.30
1
b5
7.46

43014

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
446.21
2
b7
7.61

9066

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
682.30
2
b11
7.41

6441

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
774.34
2
b13
7.46

6544

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
942.39
1
y10
7.46

4031

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
701.28
1
y7
7.41

8864

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
530.22
1
y5
7.41

6044

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
429.17
1
y4
7.46

13502

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
314.15
1
y3
7.41

19243

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
243.11
1
y2
7.51

46537

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
664.27
2
y13
7.41

9468

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
428.18
2
y9
7.51

13303

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
351.15
2
y7
7.46

6446

ASH

SHEIWTHSCPQSPGNGTD
28
sp|P04278|SHBG_HUMAN
768.99
3
215.09
2
y4
7.51

11478

ASH

Different Isoforms

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
211.14
1
b2
10.93

86522

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
282.18
1
b3
10.88

73637

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
411.22
1
b4
10.98

8856

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
682.38
1
b7
10.93

19344

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
840.45
1
b9
10.88

21252

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
937.50
1
b10
10.88

28413

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
341.69
2
b7
10.88

17422

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
385.21
2
b8
10.93

9772

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
573.34
1
y5
10.88

6857

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
476.28
1
y4
10.93

197840

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
288.20
1
y2
10.93

6351

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
445.24
2
y9
10.88

23775

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
706.89
2
287.17
2
y5
10.83

12993

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
211.14
1
b2
10.93

148281

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
282.18
1
b3
10.93

23973

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
411.22
1
b4
10.93

17728

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
524.31
1
b5
10.93

3629

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
682.38
1
b7
10.93

8865

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
840.45
1
b9
10.93

1614

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
937.50
1
b10
10.93

1914

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
341.69
2
b7
10.88

8765

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
385.21
2
b8
10.88

4734

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
469.25
2
b10
10.88

4633

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
563.29
2
b12
10.88

3025

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
644.37
1
y6
10.93

5434

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
476.28
1
y4
10.88

333632

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
288.20
1
y2
10.88

5642

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
650.35
2
y13
10.88

12993

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
566.30
2
y11
10.93

1813

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
445.24
2
y9
10.88

36867

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
366.21
2
y7
10.93

4734

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
322.69
2
y6
10.93

3424

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
287.17
2
y5
10.88

19746

5|SHBG_HUMAN

LPAEISASAPTSLR
29
sp|P04278-
471.60
3
238.64
2
y4
10.83

9876

5|SHBG_HUMAN

TLPPLFA
30
sp|P04278-
379.73
2
312.19
1
b3
5.99

99852

2|SHBG_HUMAN

TLPPLFA
30
sp|P04278-
379.73
2
350.21
1
y3
5.99

830722

2|SHBG_HUMAN

TLPPLFA
30
sp|P04278-
379.73
2
237.12
1
y2
5.99

1013802

2|SHBG_HUMAN

TLPPLFA
30
sp|P04278-
379.73
2
272.66
2
y5
5.99

2760482

2|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
389.13
1
b4
10.84

355452

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
476.16
1
b5
10.84

71118

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
577.21
1
b6
10.84

15469

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
289.11
2
b6
10.84

29667

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
332.62
2
b7
10.84

471567

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
406.16
2
b8
10.84

26243

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
486.17
2
b9
10.84

28271

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
542.72
2
b10
10.84

11031

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
599.74
2
b11
10.84

15214

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
628.25
2
b12
10.84

27636

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
813.35
2
b15
10.84

12932

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
858.46
1
y7
10.84

12672

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
745.37
1
y6
10.84

32451

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
488.26
1
y4
10.84

16233

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
360.20
1
y3
10.84

54774

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
819.40
2
y14
10.84

40433

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
651.82
2
y11
10.9

31186

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
515.26
2
y9
10.78

15092

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
458.24
2
y8
10.78

16351

R

4|SHBG_HUMAN

GEDSSTSFCLNGLWAQGQ
31
sp|P04278-
704.98
3
373.19
2
y6
10.84

39431

R

4|SHBG_HUMAN

TABLE 19

Proteins with altered serum levels across 17-25 weeks

GA in PTB samples

Protein
Change
Functional Category

THRB
up
coagulation/acute phase response

VTNC
up
cell adhesion/acute phase response

HEMO
up
heme transport/acute phase response

FETUA
up
inflammation/acute phase response

LBP
up
innate immunity/acute phase response

IBP4
up
growth factor regulation

CD14
up
innate immunity

HABP2
up
cell adhesion/migration

INHBC
up
growth factor regulation

CFAB
up
complement/acute phase response

ICAM1
up
cell adhesion/migration

IC1
up
complement/acute phase response

APOH
up
coagulation/autoimmunity

B2MG
up
MHC/immunity

C1S
up*
Complement

APOE
up*
cholesterol metabolism

APOC3
up*
triglyceride metabolism

PEDF
up*
angiogenesis

CATD
up*
ECM remodelling/cell migration

INHBE
up*
growth factor regulation

IBP6
up*
growth factor regulation

PRG2
down
growth factor regulation

SHBG
down
inflammation/steroid metabolism

GELS
down
actin binding/acute phase response

PSG4
down*
growth factor regulation

*Additional proteins limited to weeks 19-21 GA in PTB.

TABLE 20

44 Proteins Meeting Analytical Filters That Were Up- or Down-Regulated in sPTD

vs. Term Controls

Short

Uniprot ID
Name
Protein Name

A2GL_HUMAN
LRG1
Leucine-rich alpha-2-glycoprotein

AFAM_HUMAN
AFM
Afamin

ANGT_HUMAN
AGT
Angiotensinogen

APOC3_HUMAN
APOC3
Apolipoprotein C-III

APOH_HUMAN
APOH
Beta-2-glycoprotein 1

B2MG_HUMAN
B2M
Beta-2-microglobulin

BGH3_HUMAN
TGFBI
Transforming growth factor-beta-induced protein ig-h3

CATD_HUMAN
CTSD
Cathepsin D

CBPN_HUMAN
CPN1
Carboxypeptidase N catalytic chain

CD14_HUMAN
CD14
Monocyte differentiation antigen CD14

CFAB_HUMAN
CFB
Complement factor B

CHL1_HUMAN
CHL1
Neural cell adhesion molecule L1-like protein

CO5_HUMAN
C5
Complement C5

CO6_HUMAN
C6
Complement component C6

CO8A_HUMAN
C8A
Complement component C8 alpha chain

CRIS3_HUMAN
CRISP3
Cysteine-rich secretory protein 3

ENPP2_HUMAN
ENPP2
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2

F13B_HUMAN
F13B
Coagulation factor XIII B chain

FBLN3_HUMAN
EFEMP1
EGF-containing fibulin-like extracellular matrix protein 1

FETUA_HUMAN
AHSG
Alpha-2-HS-glycoprotein

HABP2_HUMAN
HABP2
Hyaluronan-binding protein 2

HEMO_HUMAN
HPX
Hemopexin

HLAG_HUMAN
HLA-G*
HLA class I histocompatibility antigen, alpha chain G

IBP2_HUMAN
IGFBP2
Insulin-like growth factor-binding protein 2

IBP3_HUMAN
IGFBP3
Insulin-like growth factor-binding protein 3

IBP4_HUMAN
IGFBP4
Insulin-like growth factor-binding protein 4

INHBC_HUMAN
INHBC
Inhibin beta C chain

ITIH3_HUMAN
ITIH3
Inter-alpha-trypsin inhibitor heavy chain H3

ITIH4_HUMAN
ITIH4
Inter-alpha-trypsin inhibitor heavy chain H4 N-term

ITIH4_HUMAN
ITIH4
Inter-alpha-trypsin inhibitor heavy chain H4 C-Term

KNG1_HUMAN
KNG1
Kininogen-1

LBP_HUMAN
LBP
Lipopolysaccharide-binding protein

LYAM3_HUMAN
SELP
P-selectin

PAPP1_HUMAN
PAPPA
Pappalysin-1

PEDF_HUMAN
SERPINF1
Pigment epithelium-derived factor

PGRP2_HUMAN
PGLYRP2
N-acetylmuramoyl-L-alanine amidase

PRG2_HUMAN
PRG2
Bone marrow proteoglycan

PSG11_HUMAN
PSG11
Pregnancy-specific beta-1-glycoprotein 11

PSG2_HUMAN
PSG2
Pregnancy-specific beta-1-glycoprotein 2

PSG9_HUMAN
PSG9
Pregnancy-specific beta-1-glycoprotein 9

SHBG_HUMAN
SHBG
Sex hormone-binding globulin

TENX_HUMAN
TNXB
Tenascin-X

TIE1_HUMAN
TIE1
Tyrosine-protein kinase receptor Tie-1

VTNC_HUMAN
VTN
Vitronectin

*peptide surrogate for HLA-G was not unique to this protein.

TABLE 21

SEQ
Trans-
MARS14

SEQ

ID
ition
Depleted

ID

Protein
Transition
NO:
Type
Protein
SIS Transition
NO:

A1AG1_HUMAN
NWGLSVYADKPETTK_570.3_301.1
32
quant
Depleted
IS_NWGLSVYADKPETTK_573.0_301.1
32

A1AG1_HUMAN
NWGLSVYADKPETTK_570.3_818.4
32
qual
Depleted
IS_NWGLSVYADKPETTK_573.0_826.4
32

A1AT_HUMAN
LSITGTYDLK_555.8_696.4
33
qual
Depleted
IS_LSITGTYDLK_559.8_704.4
33

A1AT_HUMAN
LSITGTYDLK_555.8_797.4
33
quant
Depleted
IS_LSITGTYDLK_559.8_805.4
33

A2GL_HUMAN
DLLLPQPDLR_590.3_229.1
34
qual

IS_DLLLPQPDLR_595.3_229.1
34

A2GL_HUMAN
DLLLPQPDLR_590.3_725.4
34
quant

IS_DLLLPQPDLR_595.3_735.4
34

A2GL_HUMAN
LQVLGK_329.2_204.1
35
qual

A2GL_HUMAN
LQVLGK_329.2_416.3
35
quant

A2MG_HUMAN
LHTEAQIQEEGTVVELTGR_704.0_674.4
36
qual
Depleted
IS_LHTEAQIQEEGTVVELTGR_707.4_680.3
36

A2MG_HUMAN
LHTEAQIQEEGTVVELTGR_704.0_680.3
36
quant
Depleted
IS_LHTEAQIQEEGTVVELTGR_707.4_684.4
36

AFAM_HUMAN
DADPDTFFAK_563.8_302.1
37
qual

IS_DADPDTFFAK_567.8_302.1
37

AFAM_HUMAN
DADPDTFFAK_563.8_825.4
37
quant

IS_DADPDTFFAK_567.8_833.4
37

AFAM_HUMAN
HFQNLGK_422.2_285.1
38
quant

IS_HFQNLGK_426.2_285.1
38

AFAM_HUMAN
HFQNLGK_422.2_527.2
38
qual

IS_HFQNLGK_426.2_527.2
38

ALBU_HUMAN
LVTDLTK_395.2_213.2
39
qual
Depleted
IS_LVTDLTK_399.2_213.2
39

ALBU_HUMAN
LVTDLTK_395.2_577.3
39
quant
Depleted
IS_LVTDLTK_399.2_585.3
39

ALS_HUMAN
IRPHTFTGLSGLR_485.6_432.3
40
quant

IS_IRPHTFTGLSGLR_488.9_442.3
40

ALS_HUMAN
IRPHTFTGLSGLR_485.6_545.3
40
qual

IS_IRPHTFTGLSGLR_488.9_555.3
40

ALS_HUMAN
LEYLLLSR_503.8_447.3
41
qual

ALS_HUMAN
LEYLLLSR_503.8_745.4
41
quant

ANGT_HUMAN
DPTFIPAPIQAK_433.2_461.2
42
qual

IS_DPTFIPAPIQAK_435.9_461.2
42

ANGT_HUMAN
DPTFIPAPIQAK_433.2_556.3
42
quant

IS_DPTFIPAPIQAK_435.9_564.4
42

ANGT_HUMAN
SLDFTELDVAAEK_719.4_316.2
43
quant

ANGT_HUMAN
SLDFTELDVAAEK_719.4_874.5
43
qual

APOA1_HUMAN
AKPALEDLR_506.8_288.2
44
qual
Depleted
IS_AKPALEDLR_511.8_298.2
44

APOA1_HUMAN
AKPALEDLR_506.8_813.5
44
quant
Depleted
IS_AKPALEDLR_511.8_823.5
44

APOA2_HUMAN
SPELQAEAK_486.8_659.4
45
qual
Depleted
IS_SPELQAEAK_490.8_667.4
45

APOA2_HUMAN
SPELQAEAK_486.8_788.4
45
quant
Depleted
IS_SPELQAEAK_490.8_796.4
45

APOC3_HUMAN
DYWSTVK_449.7_347.2
46
qual

APOC3_HUMAN
DYWSTVK_449.7_620.3
46
quant

APOC3_HUMAN
GWVTDGFSSLK_598.8_854.4
47
quant

IS_GWVTDGFSSLK_602.8_862.4
47

APOC3_HUMAN
GWVTDGFSSLK_598.8_953.5
47
qual

IS_GWVTDGFSSLK_602.8_961.5
47

APOH_HUMAN
ATVVYQGER_511.8_652.3
48
quant

IS_ATVVYQGER_516.8_662.3
48

APOH_HUMAN
ATVVYQGER_511.8_751.4
48
qual

IS_ATVVYQGER_516.8_761.4
48

APOH_HUMAN
EHSSLAFWK_552.8_267.1
49
qual

APOH_HUMAN
EHSSLAFWK_552.8_838.4
49
quant

B2MG_HUMAN
VEHSDLSFSK_383.5_234.1
50
qual

IS_VEHSDLSFSK_386.2_242.2
50

B2MG_HUMAN
VEHSDLSFSK_383.5_468.2
50
quant

IS_VEHSDLSFSK_386.2_476.3
50

B2MG_HUMAN
VNHVTLSQPK_374.9_244.2
51
qual

IS_VNHVTLSQPK_377.6_252.2
51

B2MG_HUMAN
VNHVTLSQPK_374.9_459.3
51
quant

IS_VNHVTLSQPK_377.6_467.3
51

BGH3_HUMAN
LTLLAPLNSVFK_658.4_804.5
52
quant

IS_LTLLAPLNSVFK_662.4_812.5
52

BGH3_HUMAN
LTLLAPLNSVFK_658.4_875.5
52
qual

IS_LTLLAPLNSVFK_662.4_883.5
52

BGH3_HUMAN
VLTDELK_409.2_605.3
53
quant

BGH3_HUMAN
VLTDELK_409.2_718.4
53
qual

C163A_HUMAN
INPASLDK_429.2_462.3
54
qual

IS_INPASLDK_433.2_470.3
54

C163A_HUMAN
INPASLDK_429.2_630.4
54
quant

IS_INPASLDK_433.2_638.4
54

C1QB_HUMAN
VPGLYYFTYHASSR_554.3_420.2
55
quant

IS_VPGLYYFTYHASSR_557.6_430.2
55

C1QB_HUMAN
VPGLYYFTYHASSR_554.3_720.3
55
qual

IS_VPGLYYFTYHASSR_557.6_730.4
55

CAH1_HUMAN
GGPFSDSYR_493.2_627.3
56
quant

IS_GGPFSDSYR_498.2_637.3
56

CAH1_HUMAN
GGPFSDSYR_493.2_774.3
56
qual

IS_GGPFSDSYR_498.2_784.3
56

CATD_HUMAN
VGFAEAAR_410.7_517.3
57
qual

IS_VGFAEAAR_415.7_527.3
57

CATD_HUMAN
VGFAEAAR_410.7_721.4
57
quant

IS_VGFAEAAR_415.7_731.4
57

CATD_HUMAN
VSTLPAITLK_521.8_642.4
58
quant

IS_VSTLPAITLK_525.8_650.4
58

CATD_HUMAN
VSTLPAITLK_521.8_856.6
58
qual

IS_VSTLPAITLK_525.8_864.6
58

CBPN_HUMAN
EALIQFLEQVHQGIK_585.0_526.3
59
qual

IS_EALIQFLEQVHQGIK_587.7_530.3
59

CBPN_HUMAN
EALIQFLEQVHQGIK_585.0_720.4
59
quant

IS_EALIQFLEQVHQGIK_587.7_724.4
59

CBPN_HUMAN
NNANGVDLNR_543.8_229.1
60
quant

IS_NNANGVDLNR_548.8_229.1
60

CBPN_HUMAN
NNANGVDLNR_543.8_858.4
60
qual

IS_NNANGVDLNR_548.8_868.5
60

CD14_HUMAN
LTVGAAQVPAQLLVGALR_8890_416.3
61
quant

IS_LTVGAAQVPAQLLVGALR_894.0_426.3
61

CD14_HUMAN
LTVGAAQVPAQLLVGALR_889.0_628.4
61
qual

IS_LTVGAAQVPAQLLVGALR_894.0_638.4
61

CD14_HUMAN
SWLAELQQWLKPGLK_599.7_274.1
62
quant

IS_SWLAELQQWLKPGLK_602.3_274.1
62

CD14_HUMAN
SWLAELQQWLKPGLK_599.7_670.4
62
qual

IS_SWLAELQQWLKPGLK_602.3_674.4
62

CFAB_HUMAN
VSEADSSNADWVTK_754.9_347.2
63
quant

CFAB_HUMAN
VSEADSSNADWVTK_754.9_533.3
63
qual

CFAB_HUMAN
YGLVTYATYPK_638.3_334.2
64
qual

IS_YGLVTYATYPK_642.3_334.2
64

CFAB_HUMAN
YGLVTYATYPK_638.3_843.4
64
quant

IS_YGLVTYATYPK_642.3_851.4
64

CHL1_HUMAN
TAVTANLDIR_537.3_288.2
65
qual

CHL1_HUMAN
TAVTANLDIR_537.3_802.4
65
quant

CHL1_HUMAN
VIAVNEVGR_478.8_574.3
66
qual

IS_VIAVNEVGR_483.8_584.3
66

CHL1_HUMAN
VIAVNEVGR_478.8_744.4
66
quant

IS_VIAVNEVGR_483.8_754.4
66

CLUS_HUMAN
ASSIIDELFQDR_697.4_678.4
67
qual

IS_ASSIIDELFQDR_702.4_688.4
67

CLUS_HUMAN
ASSIIDELFQDR_697.4_922.4
67
quant

IS_ASSIIDELFQDR_702.4_932.4
67

CLUS_HUMAN
LFDSDPITVTVPVEVSR_937.5_1086.6
68
quant

IS_LFDSDPITVTVPVEVSR_942.5_1096.6
68

CLUS_HUMAN
LFDSDPITVTVPVEVSR_937.5_985.6
68
qual

IS_LFDSDPITVTVPVEVSR_942.5_995.6
68

CO3_HUMAN
IHWESASLLR_606.3_251.2
69
quant
Depleted
IS_IHWESASLLR_611.3_251.2
69

CO3_HUMAN
IHWESASLLR_606.3_437.2
69
qual
Depleted
IS_IHWESASLLR_611.3_437.2
69

CO5_HUMAN
TLLPVSKPEIR_418.3_288.2
70
qual

IS_TLLPVSKPEIR_421.6_298.2
70

CO5_HUMAN
TLLPVSKPEIR_418.3_514.3
70
quant

IS_TLLPVSKPEIR_421.6_524.3
70

CO5_HUMAN
VFQFLEK_455.8_276.2
71
qual

IS_VFQFLEK_459.8_284.2
71

CO5_HUMAN
VFQFLEK_455.8_811.4
71
quant

IS_VFQFLEK_459.8_819.4
71

CO6_HUMAN
ALNHLPLEYNSALYSR_621.0_538.3
72
quant

IS_ALNHLPLEYNSALYSR_624.3_548.3
72

CO6_HUMAN
ALNHLPLEYNSALYSR_621.0_696.4
72
qual

IS_ALNHLPLEYNSALYSR_624.3_706.4
72

CO6_HUMAN
SEYGAALAWEK_612.8_788.4
73
qual

CO6_HUMAN
SEYGAALAWEK_612.8_845.5
73
quant

CO8A_HUMAN
SLLQPNK_400.2_358.2
74
qual

IS_SLLQPNK_404.2_366.2
74

CO8A_HUMAN
SLLQPNK_400.2_599.4
74
quant

IS_SLLQPNK_404.2_607.4
74

CO8A_HUMAN
YHFEALADTGISSEFYDNANDLL
75
quant

SK_940.8_761.4

CO8A_HUMAN
YHFEALADTGISSEFYDNANDLL
75
qual

SK_940.8_874.5

CO8B_HUMAN
QALEEFQK_496.8_551.3
76
qual

IS_QALEEFQK_500.8_559.3
76

CO8B_HUMAN
QALEEFQK_496.8_680.3
76
quant

IS_QALEEFQK_500.8_688.3
76

CO8B_HUMAN
SGFSFGFK_438.7_585.3
77
quant

CO8B_HUMAN
SGFSFGFK_438.7_732.4
77
qual

CRIS3_HUMAN
AVSPPAR_349.2_258.1
78
qual

IS_AVSPPAR_354.2_258.1
78

CRIS3_HUMAN
AVSPPAR_349.2_343.2
78
quant

IS_AVSPPAR_354.2_353.2
78

CRIS3_HUMAN
YEDLYSNCK_596.3_784.4
79
qual

IS_YEDLYSNCK_600.3_792.4
79

CRIS3_HUMAN
YEDLYSNCK_596.3_899.4
79
quant

IS_YEDLYSNCK_600.3_907.4
79

CSH_HUMAN*
AHQLAIDTYQEFEETYIPK_766.0_
80
qual

IS_AHQLAIDTYQEFEETYIPK_768.7_
80

521.3

521.3

CSH_HUMAN*
AHQLAIDTYQEFEETYIPK_766.0_
80
quant

IS_AHQLAIDTYQEFEETYIPK_768.7_
80

634.4

634.4

CSH_HUMAN*
ISLLLIESWLEPVR_834.5_371.2
81
qual

IS_ISLLLIESWLEPVR_839.5_381.2
81

CSH_HUMAN*
ISLLLIESWLEPVR_834.5_500.3
81
quant

IS_ISLLLIESWLEPVR_839.5_510.3
81

ENPP2_HUMAN
TEFLSNYLTNVDDITLVPGTLGR_
82
quant

IS_TEFLSNYLTNVDDITLVPGTLGR_
82

846.8_600.3

850.1_610.4

ENPP2_HUMAN
TEFLSNYLTNVDDITLVPGTLGR
82
qual

IS_TEFLSNYLTNVDDITLVPGTLGR_
82

846.8_699.4

850.1_709.4

ENPP2_HUMAN
TYLHTYESEI_628.3_1124.5
83
quant

IS_TYLHTYESEI_631.8_1124.5
83

ENPP2_HUMAN
TYLHTYESEI_628.3_908.4
83
qual

IS_TYLHTYESEI_631.8_908.4
83

F13B_HUMAN
GDTYPAELYITGSILR_885.0_1332.8
84
quant

IS_GDTYPAELYITGSILR_890.0_1342.8
84

F13B_HUMAN
GDTYPAELYITGSILR_885.0_274.1
84
qual

IS_GDTYPAELYITGSILR_890.0_274.1
84

F13B_HUMAN
IAQYYYTFK_598.8_395.2
85
qual

F13B_HUMAN
IAQYYYTFK_598.8_884.4
85
quant

FBLN1_HUMAN
TGYYFDGISR_589.8_694.4
86
qual

IS_TGYYFDGISR_594.8_704.4
86

FBLN1_HUMAN
TGYYFDGISR_589.8_857.4
86
quant

IS_TGYYFDGISR_594.8_867.4
86

FBLN3_HUMAN
IPSNPSHR_303.2_496.3
87
quant

IS_IPSNPSHR_306.5_506.3
87

FBLN3_HUMAN
IPSNPSHR_303.2_610.3
87
qual

IS_IPSNPSHR_306.5_620.3
87

FETUA_HUMAN
FSVVYAK_407.2_381.2
88
qual

IS_FSVVYAK_411.2_389.2
88

FETUA_HUMAN
FSVVYAK_407.2_579.4
88
quant

IS_FSVVYAK_411.2_587.4
88

FETUA_HUMAN
HTLNQIDEVK_598.8_951.5
89
qual

IS_HTLNQIDEVK_602.8_951.5
89

FETUA_HUMAN
HTLNQIDEVK_598.8_958.5
89
quant

IS_HTLNQIDEVK_602.8_966.5
89

FIBA_HUMAN
ESSSHHPGIAEFPSR_546.6_353.7
90
qual
Depleted
IS_ESSSHHPGIAEFPSR_549.9_358.7
90

FIBA_HUMAN
ESSSHHPGIAEFPSR_546.6_502.2
90
quant
Depleted
IS_ESSSHHPGIAEFPSR_549.9_502.2
90

FIBB_HUMAN
QGFGNVATNTDGK_654.8_319.2
91
qual
Depleted
IS_QGFGNVATNTDGK_658.8_327.2
91

FIBB_HUMAN
QGFGNVATNTDGK_654.8_706.3
91
quant
Depleted
IS_QGFGNVATNTDGK_658.8_714.4
91

HABP2_HUMAN
FLNWIK_410.7_560.3
92
quant

IS_FLNWIK_414.7_568.3
92

HABP2_HUMAN
FLNWIK_410.7_673.4
92
qual

IS_FLNWIK_414.7_681.4
92

HEMO_HUMAN
NFPSPVDAAFR_610.8_775.4
93
qual

IS_NFPSPVDAAFR_615.8_785.4
93

HEMO_HUMAN
NFPSPVDAAFR_610.8_959.5
93
quant

IS_NFPSPVDAAFR_615.8_969.5
93

HEMO_HUMAN
SGAQATWTELPWPHEK_613.3_510.3
94
qual

HEMO_HUMAN
SGAQATWTELPWPHEK_613.3_793.4
94
quant

HLAG_HUMAN*
WAAVVVPSGEEQR_714.4_428.2
95
qual

IS_WAAVVVPSGEEQR_719.4_428.2
95

HLAG_HUMAN*
WAAVVVPSGEEQR_714.4_802.4
95
quant

IS_WAAVVVPSGEEQR_719.4_812.4
95

HPT_HUMAN
TEGDGVYTLNNEK_720.3_403.2
96
qual
Depleted
IS_TEGDGVYTLNNEK_724.3_403.2
96

HPT_HUMAN
TEGDGVYTLNNEK_720.3_881.4
96
quant
Depleted
IS_TEGDGVYTLNNEK_724.3_889.5
96

IBP1_HUMAN
VVESLAK_373.2_547.3
97
quant

IS_VVESLAK_377.2_555.3
97

IBP1_HUMAN
VVESLAK_373.2_646.4
97
qual

IS_VVESLAK_377.2_654.4
97

IBP2_HUMAN
LIQGAPTIR_484.8_227.2
98
qual

IS_LIQGAPTIR_489.8_227.2
98

IBP2_HUMAN
LIQGAPTIR_484.8_742.4
98
quant

IS_LIQGAPTIR_489.8_752.4
98

IBP3_HUMAN
FLNVLSPR_473.3_472.3
99
qual

IS_FLNVLSPR_478.3_482.3
99

IBP3_HUMAN
FLNVLSPR_473.3_685.4
99
quant

IS_FLNVLSPR_478.3_695.4
99

IBP3_HUMAN
YGQPLPGYTTK_612.8_666.3
100
qual

IS_YGQPLPGYTTK_616.8_674.4
100

IBP3_HUMAN
YGQPLPGYTTK_612.8_876.5
100
quant

IS_YGQPLPGYTTK_616.8_884.5
100

IBP4_HUMAN
QCHPALDGQR_394.5_360.2
2
qual

IS_QCHPALDGQR_397.9_370.2
2

IBP4_HUMAN
QCHPALDGQR_394.5_475.2
2
quant

IS_QCHPALDGQR_397.9_485.2
2

IBP6_HUMAN
GAQTLYVPNCDHR_510.9_312.2
101
qual

IS_GAQTLYVPNCDHR_514.2_322.2
101

IBP6_HUMAN
GAQTLYVPNCDHR_510.9_637.8
101
quant

IS_GAQTLYVPNCDHR_514.2_642.8
101

IBP6_HUMAN
HLDSVLQQLQTEVYR_610.3_667.3
102
qual

IS_HLDSVLQQLQTEVYR_613.7_677.3
102

IBP6_HUMAN
HLDSVLQQLQTEVYR_610.3_795.4
102
quant

IS_HLDSVLQQLQTEVYR_613.7_805.4
102

IGF2_HUMAN
GIVEECCFR_585.3_771.3
103
qual

IS_GIVEECCFR_590.3_781.3
103

IGF2_HUMAN
GIVEECCFR_585.3_900.3
103
quant

IS_GIVEECCFR_590.3_910.3
103

IGF2_HUMAN
SCDLALLETYCATPAK_906.9_1040.5
104
qual

IGF2_HUMAN
SCDLALLETYCATPAK_906.9_1153.6
104
quant

IGHG3_HUMAN
ALPAPIEK_419.8_327.7
105
quant
Depleted
IS_ALPAPIEK_423.8_331.7
105

IGHG3_HUMAN
ALPAPIEK_419.8_654.4
105
qual
Depleted
IS_ALPAPIEK_423.8_662.4
105

IGHM_HUMAN
GFPSVLR_388.2_286.2
106
quant
Depleted
IS_GFPSVLR_393.2_291.2
106

IGHM_HUMAN
GFPSVLR_388.2_571.4
106
qual
Depleted
IS_GFPSVLR_393.2_581.4
106

INHBC_HUMAN
LDFHFSSDR_375.2_448.2
107
qual

IS_LDFHFSSDR_378.5_453.2
107

INHBC_HUMAN
LDFHFSSDR_375.2_611.3
107
quant

IS_LDFHFSSDR_378.5_621.3
107

IS_Recon
IS_ASSILAT_662.4_313.1
108
qual

IS_Recon
IS_ASSILAT_662.4_359.2
108
quant

IS_Recon
IS_ELWFSDDPDVTK_726.3_559.3
109
quant

IS_Recon
IS_ELWFSDDPDVTK_726.3_876.4
109
qual

IS_Recon
IS_NVDQSLLELHK_432.6_397.3
110
quant

IS_Recon
IS_NVDQSLLELHK_432.6_639.4
110
qual

ITIH3_HUMAN
ALDLSLK_380.2_185.1
111
qual

IS_ALDLSLK_384.2_185.1
111

ITIH3_HUMAN
ALDLSLK_380.2_575.3
111
quant

IS_ALDLSLK_384.2_583.4
111

ITIH4_HUMAN
ILDDLSPR_464.8_587.3
112
qual

IS_ILDDLSPR_469.8_597.3
112

ITIH4_HUMAN
ILDDLSPR_464.8_702.3
112
quant

IS_ILDDLSPR_469.8_712.4
112

ITIH4_HUMAN
NPLVWVHASPEHVVVTR_647.4_325.2
113
quant

IS_NPLVWVHASPEHVVVTR_650.7_325.2
113

ITIH4_HUMAN
NPLVWVHASPEHVVVTR_647.4_936.5
113
qual

IS_NPLVWVHASPEHVVVTR_650.7_946.5
113

ITIH4_HUMAN
QLGLPGPPDVPDHAAYHPF_676.7_263.1
114
quant

IS_QLGLPGPPDVPDHAAYHPF_680.0_273.2
114

ITIH4_HUMAN
QLGLPGPPDVPDHAAYHPF_676.7_299.2
114
qual

IS_QLGLPGPPDVPDHAAYHPF_680.0_299.2
114

ITIH4_HUMAN
VRPQQLVK_484.3_609.4
115
quant

ITIH4_HUMAN
VRPQQLVK_484.3_722.4
115
qual

KNG1_HUMAN
DIPTNSPELEETLTHTITK_713.7_756.4
116
quant

IS_DIPTNSPELEETLTHTITK_716.4_760.4
116

KNG1_HUMAN
DIPTNSPELEETLTHTITK_713.7_799.9
116
qual

IS_DIPTNSPELEETLTHTITK_716.4_803.9
116

KNG1_HUMAN
QVVAGLNFR_502.3_606.3
117
qual

IS_QVVAGLNFR_507.3_616.3
117

KNG1_HUMAN
QVVAGLNFR_502.3_677.4
117
quant

IS_QVVAGLNFR_507.3_687.4
117

LBP_HUMAN
ITGFLKPGK_320.9_301.2
118
quant

IS_ITGFLKPGK_323.5_309.2
118

LBP_HUMAN
ITGFLKPGK_320.9_429.3
118
qual

IS_ITGFLKPGK_323.5_437.3
118

LBP_HUMAN
ITLPDFTGDLR_624.3_288.2
119
qual

IS_ITLPDFTGDLR_629.3_298.2
119

LBP_HUMAN
ITLPDFTGDLR_624.3_920.5
119
quant

IS_ITLPDFTGDLR_629.3_930.5
119

LYAM3_HUMAN*
SYYWIGIR_529.3_644.4
120
qual

IS_SYYWIGIR_534.3_654.4
120

LYAM3_HUMAN*
SYYWIGIR_529.3_807.5
120
quant

IS_SYYWIGIR_534.3_817.5
120

NCAM1_HUMAN
GLGEISAASEFK_604.8_357.2
121
qual

IS_GLGEISAASEFK_608.8_357.2
121

NCAM1_HUMAN
GLGEISAASEFK_604.8_739.4
121
quant

IS_GLGEISAASEFK_608.8_747.4
121

PAPP1_HUMAN
DIPHWLNPTR_416.9_373.2
122
quant

IS_DIPHWLNPTR_420.2_383.2
122

PAPP1_HUMAN
DIPHWLNPTR_416.9_600.4
122
qual

IS_DIPHWLNPTR_420.2_610.4
122

PAPP1_HUMAN
LDGSTHLNIFFAK_488.3_739.4
123
quant

PAPP1_HUMAN
LDGSTHLNIFFAK_488.3_852.5
123
qual

PEDF_HUMAN
LQSLFDSPDFSK_692.3_329.2
124
qual

IS_LQSLFDSPDFSK_696.4_329.2
124

PEDF_HUMAN
LQSLFDSPDFSK_692.3_942.4
124
quant

IS_LQSLFDSPDFSK_696.4_950.4
124

PEDF_HUMAN
TVQAVLTVPK_528.3_428.3
125
qual

IS_TVQAVLTVPK_532.3_432.3
125

PEDF_HUMAN
TVQAVLTVPK_528.3_855.5
125
quant

IS_TVQAVLTVPK_532.3_863.5
125

PGRP2_HUMAN
AGLLRPDYALLGHR_518.0_369.2
126
quant

IS_AGLLRPDYALLGHR_521.3_379.2
126

PGRP2_HUMAN
AGLLRPDYALLGHR_518.0_595.4
126
qual

IS_AGLLRPDYALLGHR_521.3_605.4
126

PGRP2_HUMAN
DGSPDVTTADIGANTPDATK_973.5_
127
quant

531.3

PGRP2_HUMAN
DGSPDVTTADIGANTPDATK_973.5_
127
qual

844.4

PRDX2_HUMAN
GLFIIDGK_431.8_319.2
128
qual

IS_GLFIIDGK_435.8_327.2
128

PRDX2_HUMAN
GLFIIDGK_431.8_545.3
128
quant

IS_GLFIIDGK_435.8_553.3
128

PRG2_HUMAN
WNFAYWAAHQPWSR_607.3_545.3
129
quant

IS_WNFAYWAAHQPWSR_610.6_555.3
129

PRG2_HUMAN
WNFAYWAAHQPWSR_607.3_673.3
129
qual

IS_WNFAYWAAHQPWSR_610.6_683.3
129

PSG1_HUMAN
DLYHYITSYVVDGEIIIYGPAYSGR_
130
qual

955.5_650.3

PSG1_HUMAN
DLYHYITSYVVDGEIIIYGPAYSGR_
130
quant

955.5_707.3

PSG1_HUMAN
FQLPGQK_409.2_276.1
131
quant

IS_FQLPGQK_413.2_276.1
131

PSG1_HUMAN
FQLPGQK_409.2_429.2
131
qual

IS_FQLPGQK_413.2_437.3
131

PSG11_HUMAN
LFIPQITPK_528.8_261.2
132
qual

IS_LFIPQITPK_532.8_261.2
132

PSG11_HUMAN
LFIPQITPK_528.8_683.4
132
quant

IS_LFIPQITPK_532.8_691.4
132

PSG2_HUMAN
IHPSYTNYR_384.2_338.2
133
qual

IS_IHPSYTNYR_387.5_348.2
133

PSG2_HUMAN
IHPSYTNYR_384.2_452.2
133
quant

IS_IHPSYTNYR_387.5_462.2
133

PSG3_HUMAN
VSAPSGTGHLPGLNPL_758.9_229.2
134
quant

IS_VSAPSGTGHLPGLNPL_762.4_236.2
134

PSG3_HUMAN
VSAPSGTGHLPGLNPL_758.9_610.4
134
qual

IS_VSAPSGTGHLPGLNPL_762.4_617.4
134

PSG9_HUMAN
DVLLLVHNLPQNLPGYFWYK_810.4_
135
qual

IS_DVLLLVHNLPQNLPGYFWYK_813.1_
135

328.2

328.2

PSG9_HUMAN
DVLLLVHNLPQNLPGYFWYK_810.4_
135
quant

IS_DVLLLVHNLPQNLPGYFWYK_813.1_
135

960.5

968.5

PSG9_HUMAN
LFIPQITR_494.3_614.4
136
quant

IS_LFIPQITR_499.3_624.4
136

PSG9_HUMAN
LFIPQITR_494.3_727.4
136
qual

IS_LFIPQITR_499.3_737.5
136

PTGDS_HUMAN
GPGEDFR_389.2_322.2
137
qual

IS_GPGEDFR_394.2_332.2
137

PTGDS_HUMAN
GPGEDFR_389.2_623.3
137
quant

IS_GPGEDFR_394.2_633.3
137

SHBG_HUMAN
ALALPPLGLAPLLNLWAKPQGR_770.5_
27
quant

256.2

SHBG_HUMAN
ALALPPLGLAPLLNLWAKPQGR_770.5_
27
qual

457.3

SHBG_HUMAN
IALGGLLFPASNLR_481.3_412.3
18
qual

IS_IALGGLLFPASNLR_484.6_412.3
18

SHBG_HUMAN
IALGGLLFPASNLR_481.3_6574
18
quant

IS_IALGGLLFPASNLR_484.6_667.4
18

SOM2_HUMAN*
NYGLLYCFR_603.3_278.1
138
quant

IS_NYGLLYCFR_608.3_278.1
138

SOM2_HUMAN*
NYGLLYCFR_603.3_758.4
138
qual

IS_NYGLLYCFR_608.3_768.4
138

SOM2_HUMAN*
SVEGSCGF_421.7_223.1
139
qual

IS_SVEGSCGF_424.7_223.1
139

SOM2_HUMAN*
SVEGSCGF_421.7_383.1
139
quant

IS_SVEGSCGF_424.7_383.1
139

SPRL1_HUMAN
VLTHSELAPLR_412.6_512.3
140
quant

IS_VLTHSELAPLR_415.9_517.3
140

SPRL1_HUMAN
VLTHSELAPLR_412.6_568.8
140
qual

IS_VLTHSELAPLR_415.9_573.8
140

TENX_HUMAN
LNWEAPPGAFDSFLLR_917.0_414.2
141
qual

IS_LNWEAPPGAFDSFLLR_922.0_414.2
141

TENX_HUMAN
LNWEAPPGAFDSFLLR_917.0_614.3
141
quant

IS_LNWEAPPGAFDSFLLR_922.0_614.3
141

TENX_HUMAN
LSQLSVTDVTTSSLR_803.9_1165.6
142
quant

IS_LSQLSVTDVTTSSLR_808.9_1175.6
142

TENX_HUMAN
LSQLSVTDVTTSSLR_803.9_979.5
142
qual

IS_LSQLSVTDVTTSSLR_808.9_989.5
142

THBG_HUMAN
AVLHIGEK_289.5_292.2
143
qual

IS_AVLHIGEK_292.2_296.2
143

THBG_HUMAN
AVLHIGEK_289.5_348.7
143
quant

IS_AVLHIGEK_292.2_352.7
143

TIE1_HUMAN
VSWSLPLVPGPLVGDGFLLR_708.1_
144
qual

IS_VSWSLPLVPGPLVGDGFLLR_711.4_
144

543.8

548.8

TIE1_HUMAN
VSWSLPLVPGPLVGDGFLLR_708.1_
144
quant

IS_VSWSLPLVPGPLVGDGFLLR_711.4_
144

620.9

625.9

TRFE_HUMAN
YLGEEYVK_500.8_277.2
145
qual
Depleted
IS_YLGEEYVK_504.8_277.2
145

TRFE_HUMAN
YLGEEYVK_500.8_724.4
145
quant
Depleted
IS_YLGEEYVK_504.8_732.4
145

TTHY_HUMAN
VEIDTK_352.7_476.3
146
quant
Depleted
IS_VEIDTK_356.7_484.3
146

TTHY_HUMAN
VEIDTK_352.7_605.3
146
qual
Depleted
IS_VEIDTK_356.7_613.3
146

VTDB_HUMAN
ELPEHTVK_476.8_347.2
147
qual

IS_ELPEHTVK_480.8_355.2
147

VTDB_HUMAN
ELPEHTVK_476.8_710.4
147
quant

IS_ELPEHTVK_480.8_718.4
147

VTDB_HUMAN
VLEPTLK_400.3_458.3
148
qual

VTDB_HUMAN
VLEPTLK_400.3_587.3
148
quant

VTNC_HUMAN
GQYCYELDEK_652.8_1119.5
149
quant

IS_GQYCYELDEK_656.8_1127.5
149

VTNC_HUMAN
GQYCYELDEK_652.8_276.2
149
qual

IS_GQYCYELDEK_656.8_284.2
149

VTNC_HUMAN
VDTVDPPYPR_579.8_629.3
150
quant

IS_VDTVDPPYPR_584.8_639.3
150

VTNC_HUMAN
VDTVDPPYPR_579.8_744.4
150
qual

IS_VDTVDPPYPR_584.8_754.4
150

*Denotes name changes. CSH denotes that the peptide corresponds to both CSH1 and CSH2. HLAG now referred to as HLACI since the peptide is conserved in several class I HLA isotypes. LYAM3 now referred to as LYAM1 because, while the peptide sequence is present in each, it is only derived by trypsin cleavage from LYAM1. SOM2 now referred to as SOM2.CSH as the

peptides are specific to both SOM2 and CSH.

TABLE 22

119_
119_
119_
119_
126_
126_
126_
126_
133_
133_

SEQ
132_
132_
132_
1322_
139_
139_
139_
139_
146_
146_

ID
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_

Protein
Transition
NO:
37
37
35
35
37
37
35
35
37
37

A2GL
A2GL_DLLLPQPDLR
34
0.508
0.511
0.534
0.513
0.568
0.608
0.519
0.522
0.562
0.602

AFAM
AFAM_DADPDTFFAK
37
0.594
0.551
0.601
0.564
0.551
0.558
0.553
0.578
0.549
0.584

AFAM
AFAM_HFQNLGK
38
0.583
0.533
0.589
0.540
0.540
0.534
0.534
0.556
0.554
0.591

ALS
ALS_IRPHTFTGLSGLR
40
0.515
0.509
0.530
0.560
0.507
0.503
0.511
0.504
0.513
0.524

ANGT
ANGT_DPTFIPAPIQAK
42
0.577
0.622
0.666
0.685
0.574
0.608
0.573
0.616
0.507
0.544

APOC3
APOC3_GWVTDGFSSLK
47
0.582
0.576
0.510
0.548
0.605
0.611
0.607
0.593
0.635
0.617

APOH
APOH_ATVVYQGER
48
0.540
0.523
0.577
0.555
0.629
0.612
0.595
0.621
0.606
0.590

B2MG
B2MG_VEHSDLSFSK
50
0.533
0.566
0.502
0.507
0.522
0.505
0.512
0.521
0.558
0.548

B2MG
B2MG_VNHVTLSQPK
51
0.512
0.582
0.517
0.540
0.524
0.501
0.554
0.560
0.593
0.580

BGH3
BGH3_LTLLAPLNSVFK
52
0.562
0.575
0.557
0.610
0.509
0.512
0.531
0.538
0.522
0.557

C163A
C163A_INPASLDK
54
0.520
0.561
0.604
0.617
0.546
0.583
0.594
0.605
0.511
0.515

C1QB
C1QB_VPGLYYFTYHASSR
55
0.573
0.607
0.538
0.573
0.586
0.631
0.565
0.560
0.596
0.588

CAH1
CAH1_GGPFSDSYR
56
0.560
0.560
0.563
0.553
0.500
0.590
0.563
0.605
0.543
0.581

CATD
CATD_VGFAEAAR
57
0.516
0.523
0.585
0.555
0.501
0.546
0.545
0.553
0.550
0.507

CATD
CATD_VSTLPAITLK
58
0.525
0.512
0.606
0.613
0.515
0.550
0.540
0.536
0.542
0.530

CBPN
CBPN_EALIQFLEQVHQGIK
59
0.508
0.563
0.567
0.585
0.508
0.509
0.549
0.582
0.517
0.507

CBPN
CBPN_NNANGVDLNR
60
0.514
0.519
0.579
0.606
0.521
0.507
0.502
0.516
0.505
0.526

CD14
CD14_LTVGAAQVPAQLLVGALR
61
0.532
0.539
0.578
0.626
0.608
0.623
0.635
0.665
0.605
0.577

CD14
CD14_SWLAELQQWLKPGLK
62
0.550
0.547
0.540
0.549
0.589
0.594
0.599
0.608
0.594
0.567

CFAB
CFAB_YGLVTYATYPK
64
0.635
0.605
0.514
0.522
0.574
0.556
0.530
0.572
0.564
0.592

CHL1
CHL1_VIAVNEVGR
66
0.670
0.680
0.669
0.661
0.550
0.592
0.549
0.554
0.514
0.522

CLUS
CLUS_ASSIIDELFQDR
67
0.563
0.557
0.713
0.667
0.554
0.530
0.685
0.649
0.526
0.541

CLUS
CLUS_LFDSDPITVTVPVEVSR
68
0.559
0.529
0.643
0.562
0.557
0.525
0.687
0.623
0.522
0.514

CO5
CO5_TLLPVSKPEIR
70
0.590
0.610
0.613
0.632
0.570
0.606
0.541
0.563
0.567
0.592

CO5
CO5_VFQFLEK
71
0.568
0.588
0.533
0.560
0.555
0.571
0.542
0.526
0.576
0.579

CO6
CO6_ALNHLPLEYNSALYSR
72
0.619
0.647
0.721
0.795
0.553
0.537
0.592
0.621
0.524
0.541

CO8A
CO8A_SLLQPNK
74
0.512
0.536
0.515
0.537
0.574
0.566
0.561
0.547
0.610
0.638

CO8B
CO8B_QALEEFQK
76
0.528
0.522
0.522
0.500
0.576
0.563
0.546
0.501
0.605
0.633

CRIS3
CRIS3_AVSPPAR
78
0.513
0.543
0.592
0.626
0.508
0.562
0.567
0.587
0.530
0.577

CRIS3
CRIS3_YEDLYSNCK
79
0.530
0.539
0.631
0.654
0.529
0.574
0.596
0.616
0.544
0.602

CSH
CSH_AHQLAIDTYQEFEETYIPK
80
0.615
0.550
0.534
0.516
0.568
0.566
0.570
0.540
0.527
0.540

CSH
CSH_ISLLLIESWLEPVR
81
0.597
0.528
0.515
0.506
0.530
0.521
0.550
0.520
0.543
0.558

ENPP2
ENPP2_TEFLSNYLTNVDDITLVPGTLGR
82
0.547
0.522
0.795
0.795
0.501
0.532
0.593
0.674
0.560
0.565

ENPP2
ENPP2_TYLHTYESEI
83
0.557
0.508
0.762
0.772
0.506
0.548
0.597
0.673
0.567
0.553

F13B
F13B_GDTYPAELYITGSILR
84
0.563
0.557
0.528
0.533
0.569
0.576
0.588
0.623
0.503
0.516

FBLN1
FBLN1_TGYYFDGISR
86
0.609
0.585
0.506
0.560
0.594
0.581
0.562
0.519
0.536
0.550

FBLN3
FBLN3_IPSNPSHR
87
0.538
0.553
0.503
0.553
0.529
0.528
0.509
0.503
0.510
0.537

FETUA
FETUA_FSVVYAK
88
0.527
0.519
0.521
0.531
0.502
0.539
0.544
0.586
0.525
0.513

FETUA
FETUA_HTLNQIDEVK
89
0.532
0.506
0.559
0.599
0.503
0.528
0.587
0.618
0.523
0.514

HABP2
HABP2_FLNWIK
92
0.678
0.680
0.732
0.780
0.585
0.605
0.630
0.603
0.550
0.543

HEMO
HEMO_NFPSPVDAAFR
93
0.524
0.502
0.575
0.555
0.557
0.529
0.522
0.519
0.552
0.502

HLACI
HLACI_WAAVVVPSGEEQR
95
0.534
0.504
0.530
0.549
0.512
0.529
0.541
0.515
0.538
0.514

IBP1
IBP1_VVESLAK
97
0.578
0.556
0.559
0.516
0.546
0.528
0.557
0.542
0.516
0.518

IBP2
IBP2_LIQGAPTIR
98
0.539
0.525
0.521
0.518
0.505
0.507
0.517
0.563
0.501
0.500

IBP3
IBP3_FLNVLSPR
99
0.504
0.557
0.576
0.637
0.505
0.545
0.536
0.567
0.530
0.535

IBP3
IBP3_YGQPLPGYTTK
100
0.500
0.530
0.606
0.628
0.511
0.542
0.562
0.557
0.559
0.578

IBP4
IBP4_QCHPALDGQR
2
0.501
0.542
0.542
0.555
0.590
0.590
0.591
0.626
0.691
0.723

IBP6
IBP6_GAQTLYVPNCDHR
101
0.527
0.603
0.528
0.592
0.535
0.527
0.593
0.552
0.561
0.503

IBP6
IBP6_HLDSVLQQLQTEVYR
102
0.512
0.557
0.512
0.570
0.517
0.533
0.545
0.520
0.541
0.504

IGF2
IGF2_GIVEECCFR
103
0.523
0.545
0.704
0.743
0.542
0.558
0.627
0.667
0.567
0.573

INHBC
INHBC_LDFHFSSDR
107
0.575
0.534
0.573
0.643
0.586
0.595
0.530
0.522
0.619
0.665

ITIH3
ITIH3_ALDLSLK
111
0.525
0.534
0.522
0.564
0.529
0.527
0.516
0.518
0.544
0.519

ITIH4
ITIH4_ILDDLSPR
112
0.513
0.553
0.541
0.599
0.537
0.563
0.504
0.552
0.551
0.546

ITIH4
ITIH4_NPLVWVHASPEHVVVTR
113
0.501
0.532
0.586
0.595
0.573
0.589
0.505
0.514
0.587
0.556

ITIH4
ITIH4_QLGLPGPPDVPDHAAYHPF
114
0.518
0.506
0.537
0.565
0.547
0.538
0.523
0.568
0.526
0.520

KNG1
KNG1_DIPTNSPELEETLTHTITK
116
0.529
0.530
0.560
0.652
0.557
0.542
0.559
0.617
0.564
0.522

KNG1
KNG1_QVVAGLNFR
117
0.511
0.501
0.587
0.667
0.542
0.539
0.593
0.646
0.584
0.557

LBP
LBP_ITGFLKPGK
118
0.575
0.512
0.510
0.500
0.578
0.545
0.501
0.565
0.566
0.546

LBP
LBP_ITLPDFTGDLR
119
0.598
0.546
0.508
0.533
0.590
0.569
0.515
0.535
0.591
0.585

LYAM1
LYAM1_SYYWIGIR
120
0.550
0.600
0.574
0.654
0.567
0.623
0.666
0.720
0.542
0.580

NCAM1
NCAM1_GLGEISAASEFK
121
0.592
0.570
0.595
0.615
0.541
0.545
0.502
0.579
0.515
0.530

PAPP1
PAPP1_DIPHWLNPTR
122
0.571
0.505
0.531
0.524
0.505
0.520
0.525
0.569
0.533
0.512

PEDF
PEDF_LQSLFDSPDFSK
124
0.594
0.575
0.517
0.513
0.563
0.540
0.502
0.520
0.555
0.542

PEDF
PEDF_TVQAVLTVPK
125
0.604
0.607
0.574
0.603
0.584
0.598
0.561
0.601
0.560
0.557

PGRP2
PGRP2_AGLLRPDYALLGHR
126
0.581
0.575
0.590
0.577
0.539
0.583
0.528
0.592
0.507
0.527

PRDX2
PRDX2_GLFIIDGK
128
0.544
0.533
0.615
0.588
0.510
0.604
0.535
0.570
0.582
0.613

PRG2
PRG2_WNFAYWAAHQPWSR
129
0.564
0.527
0.507
0.538
0.545
0.507
0.515
0.511
0.590
0.535

PSG11
PSG11_LFIPQITPK
132
0.503
0.520
0.532
0.575
0.521
0.578
0.520
0.576
0.502
0.541

PSG1
PSG1_FQLPGQK
131
0.600
0.571
0.646
0.582
0.546
0.564
0.501
0.511
0.501
0.507

PSG2
PSG2_IHPSYTNYR
133
0.520
0.597
0.681
0.742
0.509
0.562
0.638
0.704
0.536
0.568

PSG3
PSG3_VSAPSGTGHLPGLNPL
134
0.650
0.577
0.568
0.533
0.604
0.603
0.549
0.546
0.606
0.634

PSG9
PSG9_DVLLLVHNLPQNLPGYFWYK
135
0.602
0.596
0.569
0.526
0.562
0.578
0.623
0.599
0.526
0.558

PSG9
PSG9_LFIPQITR
136
0.575
0.565
0.638
0.555
0.543
0.552
0.654
0.670
0.521
0.547

PTGDS
PTGDS_GPGEDFR
137
0.527
0.597
0.542
0.557
0.538
0.547
0.550
0.594
0.559
0.598

SHBG
SHBG_IALGGLLFPASNLR
18
0.580
0.567
0.563
0.641
0.575
0.574
0.562
0.532
0.588
0.586

SOM2.CSH
SOM2.CSH_NYGLLYCFR
138
0.604
0.535
0.547
0.509
0.531
0.515
0.525
0.517
0.554
0.590

SOM2.CSH
SOM2.CSH_SVEGSCGF
139
0.589
0.528
0.570
0.537
0.529
0.547
0.507
0.502
0.544
0.511

SPRL1
SPRL1_VLTHSELAPLR
140
0.534
0.545
0.528
0.526
0.516
0.583
0.533
0.504
0.530
0.557

TENX
TENX_LNWEAPPGAFDSFLLR
141
0.582
0.562
0.534
0.527
0.577
0.640
0.602
0.583
0.567
0.577

TENX
TENX_LSQLSVTDVTTSSLR
142
0.519
0.523
0.534
0.562
0.568
0.634
0.578
0.560
0.560
0.571

THBG
THBG_AVLHIGEK
143
0.558
0.571
0.503
0.564
0.506
0.521
0.509
0.507
0.550
0.554

TIE1
TIE1_VSWSLPLVPGPLVGDGFLLR
144
0.549
0.592
0.524
0.561
0.578
0.613
0.572
0.525
0.507
0.501

VTDB
VTDB_ELPEHTVK
147
0.557
0.538
0.516
0.586
0.506
0.515
0.517
0.530
0.529
0.512

VTNC
VTNC_GQYCYELDEK
149
0.663
0.674
0.641
0.694
0.612
0.638
0.618
0.641
0.582
0.606

VTNC
VTNC_VDTVDPPYPR
150
0.622
0.633
0.547
0.555
0.603
0.621
0.585
0.586
0.624
0.634

TABLE 23

133_
133_
140_
140_
140_
140_
119_
119_
119_
119_

SEQ
146_
146_
153_
153_
153_
153_
153_
153_
153_
153_

ID
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_
aBMI
rBMI_

Protein
Transition
NO:
35
35
37
37
35
35
37
37
35
35

A2GL
A2GL_DLLLPQPDLR
34
0.517
0.541
0.566
0.577
0.544
0.580
0.554
0.568
0.520
0.533

AFAM
AFAM_DADPDTFFAK
37
0.573
0.676
0.589
0.615
0.658
0.691
0.557
0.557
0.590
0.620

AFAM
AFAM_HFQNLGK
38
0.551
0.662
0.624
0.680
0.712
0.778
0.559
0.561
0.590
0.626

ALS
ALS_IRPHTFTGLSGLR
40
0.531
0.501
0.542
0.505
0.509
0.510
0.504
0.513
0.521
0.519

ANGT
ANGT_DPTFIPAPIQAK
42
0.567
0.547
0.557
0.601
0.555
0.586
0.549
0.589
0.558
0.593

APOC3
APOC3_GWVTDGFSSLK
47
0.672
0.596
0.674
0.635
0.591
0.501
0.622
0.599
0.587
0.539

APOH
APOH_ATVVYQGER
48
0.674
0.733
0.531
0.547
0.588
0.626
0.580
0.563
0.573
0.591

B2MG
B2MG_VEHSDLSFSK
50
0.519
0.591
0.599
0.596
0.553
0.503
0.543
0.520
0.536
0.508

B2MG
B2MG_VNHVTLSQPK
51
0.568
0.505
0.659
0.642
0.615
0.557
0.570
0.539
0.571
0.553

BGH3
BGH3_LTLLAPLNSVFK
52
0.562
0.621
0.595
0.623
0.532
0.553
0.542
0.564
0.516
0.518

C163A
C163A_INPASLDK
54
0.532
0.549
0.593
0.572
0.555
0.519
0.504
0.527
0.530
0.540

C1QB
C1QB_VPGLYYFTYHASSR
55
0.593
0.672
0.603
0.574
0.509
0.555
0.575
0.583
0.539
0.547

CAH1
CAH1_GGPFSDSYR
56
0.626
0.623
0.514
0.584
0.585
0.524
0.507
0.500
0.557
0.549

CATD
CATD_VGFAEAAR
57
0.660
0.637
0.693
0.686
0.819
0.817
0.576
0.547
0.626
0.634

CATD
CATD_VSTLPAITLK
58
0.674
0.719
0.671
0.692
0.802
0.866
0.564
0.549
0.623
0.651

CBPN
CBPN_EALIQFLEQVHQGIK
59
0.558
0.651
0.552
0.581
0.589
0.553
0.507
0.542
0.510
0.506

CBPN
CBPN_NNANGVDLNR
60
0.512
0.551
0.589
0.604
0.619
0.604
0.516
0.541
0.550
0.546

CD14
CD14_LTVGAAQVPAQLLVGALR
61
0.648
0.617
0.586
0.568
0.612
0.579
0.577
0.558
0.615
0.600

CD14
CD14_SWLAELQQWLKPGLK
62
0.635
0.583
0.585
0.560
0.638
0.579
0.577
0.554
0.601
0.569

CFAB
CFAB_YGLVTYATYPK
64
0.530
0.508
0.613
0.643
0.601
0.655
0.599
0.601
0.522
0.528

CHL1
CHL1_VIAVNEVGR
66
0.564
0.583
0.563
0.503
0.534
0.541
0.568
0.577
0.505
0.506

CLUS
CLUS_ASSIIDELFQDR
67
0.618
0.568
0.512
0.563
0.500
0.521
0.534
0.546
0.628
0.592

CLUS
CLUS_LFDSDPITVTVPVEVSR
68
0.669
0.615
0.512
0.517
0.562
0.611
0.521
0.511
0.610
0.543

CO5
CO5_TLLPVSKPEIR
70
0.528
0.540
0.580
0.560
0.531
0.566
0.577
0.589
0.548
0.525

CO5
CO5_VFQFLEK
71
0.547
0.522
0.599
0.568
0.556
0.515
0.577
0.575
0.540
0.511

CO6
CO6_ALNHLPLEYNSALYSR
72
0.508
0.517
0.516
0.508
0.591
0.637
0.554
0.566
0.549
0.560

CO8A
COSA_SLLQPNK
74
0.602
0.585
0.604
0.588
0.584
0.582
0.574
0.557
0.563
0.553

CO8B
CO8B_QALEEFQK
76
0.594
0.584
0.608
0.611
0.613
0.635
0.578
0.567
0.565
0.549

CRIS3
CRIS3_AVSPPAR
78
0.614
0.686
0.563
0.594
0.595
0.611
0.525
0.571
0.582
0.608

CRIS3
CRIS3_YEDLYSNCK
79
0.616
0.694
0.570
0.606
0.588
0.590
0.539
0.580
0.596
0.620

CSH
CSH_AHQLAIDTYQEFEETYIPK
80
0.582
0.539
0.571
0.570
0.517
0.541
0.526
0.509
0.535
0.513

CSH
CSH_ISLLLIESWLEPVR
81
0.569
0.525
0.542
0.542
0.525
0.533
0.515
0.505
0.531
0.511

ENPP2
ENPP2_TEFLSNYLTNVDDITLVPGTLGR
82
0.583
0.509
0.703
0.737
0.650
0.659
0.574
0.571
0.517
0.558

ENPP2
ENPP2_TYLHTYESEI
83
0.591
0.519
0.711
0.722
0.692
0.664
0.576
0.559
0.500
0.545

F13B
F13B_GDTYPAELYITGSILR
84
0.590
0.614
0.526
0.515
0.578
0.571
0.529
0.528
0.584
0.590

FBLN1
FBLN1_TGYYFDGISR
86
0.632
0.575
0.519
0.588
0.562
0.537
0.537
0.521
0.542
0.550

FBLN3
FBLN3_IPSNPSHR
87
0.575
0.670
0.528
0.524
0.617
0.649
0.523
0.506
0.545
0.559

FETUA
FETUA_FSVVYAK
88
0.568
0.692
0.658
0.652
0.659
0.660
0.552
0.534
0.530
0.517

FETUA
FETUA_HTLNQIDEVK
89
0.611
0.699
0.656
0.655
0.715
0.761
0.544
0.529
0.524
0.531

HABP2
HABP2_FLNWIK
92
0.605
0.517
0.623
0.587
0.516
0.541
0.595
0.592
0.591
0.544

HEMO
HEMO_NFPSPVDAAFR
93
0.509
0.587
0.634
0.658
0.502
0.514
0.567
0.536
0.501
0.538

HLACI
HLACI_WAAVVVPSGEEQR
95
0.537
0.538
0.574
0.591
0.604
0.552
0.527
0.543
0.502
0.508

IBP1
IBP1_VVESLAK
97
0.619
0.625
0.525
0.518
0.650
0.702
0.537
0.510
0.597
0.563

IBP2
IBP2_LIQGAPTIR
98
0.548
0.576
0.527
0.526
0.685
0.734
0.522
0.507
0.554
0.552

IBP3
IBP3_FLNVLSPR
99
0.514
0.532
0.525
0.574
0.581
0.611
0.532
0.566
0.507
0.514

IBP3
IBP3_YGQPLPGYTTK
100
0.525
0.525
0.548
0.617
0.505
0.521
0.547
0.581
0.552
0.540

IBP4
IBP4_QCHPALDGQR
2
0.600
0.624
0.677
0.688
0.530
0.568
0.608
0.606
0.539
0.530

IBP6
IBP6_GAQTLYVPNCDHR
101
0.569
0.557
0.501
0.524
0.593
0.562
0.522
0.533
0.526
0.505

IBP6
IBP6_HLDSVLQQLQTEVYR
102
0.519
0.539
0.521
0.514
0.559
0.523
0.520
0.521
0.511
0.506

IGF2
IGF2_GIVEECCFR
103
0.527
0.513
0.580
0.623
0.529
0.590
0.569
0.592
0.578
0.579

INHBC
INHBC_LDFHFSSDR
107
0.610
0.625
0.672
0.698
0.608
0.636
0.608
0.612
0.545
0.517

ITIH3
ITIH3_ALDLSLK
111
0.525
0.580
0.612
0.623
0.547
0.557
0.557
0.557
0.513
0.519

ITIH4
ITIH4_ILDDLSPR
112
0.500
0.546
0.538
0.510
0.521
0.626
0.531
0.537
0.501
0.508

ITIH4
ITIH4_NPLVWVHASPEHVVVTR
113
0.556
0.621
0.507
0.508
0.719
0.822
0.534
0.528
0.559
0.597

ITIH4
ITIH4_QLGLPGPPDVPDHAAYHPF
114
0.507
0.666
0.509
0.551
0.613
0.626
0.512
0.505
0.520
0.582

KNG1
KNG1_DIPTNSPELEETLTHTITK
116
0.522
0.599
0.609
0.593
0.512
0.588
0.558
0.535
0.523
0.525

KNG1
KNG1_QVVAGLNFR
117
0.581
0.528
0.664
0.653
0.634
0.548
0.562
0.554
0.602
0.602

LBP
LBP_ITGFLKPGK
118
0.521
0.593
0.640
0.645
0.542
0.615
0.587
0.559
0.505
0.565

LBP
LBP_ITLPDFTGDLR
119
0.524
0.581
0.672
0.681
0.505
0.550
0.609
0.588
0.524
0.521

LYAM1
LYAM1_SYYWIGIR
120
0.701
0.765
0.554
0.585
0.663
0.687
0.552
0.596
0.651
0.696

NCAM1
NCAM1_GLGEISAASEFK
121
0.587
0.501
0.515
0.505
0.535
0.553
0.536
0.531
0.501
0.557

PAPP1
PAPP1_DIPHWLNPTR
122
0.504
0.632
0.582
0.507
0.513
0.622
0.540
0.519
0.525
0.594

PEDF
PEDF_LQSLFDSPDFSK
124
0.560
0.580
0.616
0.659
0.615
0.649
0.577
0.571
0.545
0.565

PEDF
PEDF_TVQAVLTVPK
125
0.587
0.620
0.587
0.560
0.573
0.562
0.577
0.570
0.577
0.598

PGRP2
PGRP2_AGLLRPDYALLGHR
126
0.618
0.721
0.569
0.580
0.668
0.703
0.560
0.578
0.576
0.627

PRDX2
PRDX2_GLFIIDGK
128
0.620
0.598
0.551
0.537
0.609
0.542
0.525
0.530
0.547
0.536

PRG2
PRG2_WNFAYWAAHQPWSR
129
0.563
0.552
0.586
0.505
0.556
0.535
0.565
0.501
0.520
0.529

PSG11
PSG11_LFIPQITPK
132
0.570
0.523
0.562
0.544
0.517
0.604
0.511
0.516
0.500
0.501

PSG1
PSG1_FQLPGQK
131
0.606
0.524
0.558
0.577
0.510
0.548
0.524
0.509
0.508
0.535

PSG2
PSG2_IHPSYTNYR
133
0.592
0.721
0.551
0.544
0.515
0.537
0.522
0.563
0.597
0.660

PSG3
PSG3_VSAPSGTGHLPGLNPL
134
0.614
0.559
0.517
0.520
0.571
0.546
0.581
0.563
0.557
0.506

PSG9
PSG9_DVLLLVHNLPQNLPGYFWYK
135
0.535
0.516
0.525
0.604
0.605
0.669
0.546
0.567
0.547
0.500

PSG9
PSG9_LFIPQITR
136
0.527
0.541
0.506
0.585
0.573
0.617
0.528
0.541
0.571
0.554

PTGDS
PTGDS_GPGEDFR
137
0.603
0.671
0.567
0.595
0.535
0.521
0.536
0.532
0.537
0.545

SHBG
SHBG_IALGGLLFPASNLR
18
0.688
0.761
0.594
0.579
0.717
0.772
0.585
0.576
0.611
0.613

SOM2.CSH
SOM2.CSH_NYGLLYCFR
138
0.538
0.529
0.608
0.612
0.509
0.501
0.501
0.527
0.513
0.520

SOM2.CSH
SOM2.CSH_SVEGSCGF
139
0.538
0.579
0.531
0.539
0.612
0.684
0.525
0.539
0.542
0.565

SPRL1
SPRL1_VLTHSELAPLR
140
0.648
0.623
0.502
0.510
0.658
0.631
0.502
0.543
0.578
0.555

TENX
TENX_LNWEAPPGAFDSFLLR
141
0.622
0.569
0.614
0.530
0.531
0.682
0.576
0.573
0.550
0.519

TENX
TENX_LSQLSVTDVTTSSLR
142
0.606
0.546
0.571
0.519
0.644
0.825
0.550
0.542
0.508
0.588

THBG
THBG_AVLHIGEK
143
0.534
0.539
0.556
0.571
0.532
0.530
0.518
0.507
0.520
0.500

TIE1
TIE1_VSWSLPLVPGPLVGDGFLLR
144
0.551
0.526
0.578
0.559
0.527
0.515
0.513
0.531
0.536
0.502

VTDB
VTDB_ELPEHTVK
147
0.567
0.653
0.524
0.547
0.611
0.611
0.506
0.502
0.528
0.533

VTNC
VTNC_GQYCYELDEK
149
0.560
0.555
0.680
0.698
0.625
0.651
0.623
0.635
0.598
0.617

VTNC
VTNC_VDTVDPPYPR
150
0.595
0.566
0.673
0.670
0.568
0.533
0.625
0.629
0.574
0.553

TABLE 24

119_
119_
119_
119_
126_
126_
126_
126_

SEQ
139_
139_
139_
139_
146_
146_
146_
146_

ID
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_

Protein
Transition
NO:
37
37
35
35
37
37
35
35

A2GL
A2GL_DLLLPQPDLR
34
0.549
0.565
0.503
0.500
0.552
0.596
0.511
0.513

AFAM
AFAM_DADPDTFFAK
37
0.543
0.531
0.554
0.579
0.575
0.594
0.586
0.633

AFAM
AFAM_HFQNLGK
38
0.526
0.501
0.529
0.544
0.579
0.593
0.568
0.612

ALS
ALS_IRPHTFTGLSGLR
40
0.516
0.526
0.532
0.533
0.536
0.530
0.518
0.511

ANGT
ANGT_DPTFIPAPIQAK
42
0.541
0.564
0.565
0.590
0.561
0.616
0.534
0.578

APOC3
APOC3_GWVTDGFSSLK
47
0.596
0.579
0.582
0.557
0.624
0.627
0.626
0.605

APOH
APOH_ATVVYQGER
48
0.604
0.573
0.567
0.577
0.597
0.591
0.610
0.654

B2MG
B2MG_VEHSDLSFSK
50
0.510
0.528
0.521
0.519
0.529
0.520
0.506
0.556

B2MG
B2MG_VNHVTLSQPK
51
0.523
0.531
0.545
0.538
0.556
0.539
0.563
0.535

BGH3
BGH3_LTLLAPLNSVFK
52
0.516
0.531
0.507
0.502
0.534
0.553
0.537
0.551

C163A
C163A_INPASLDK
54
0.532
0.578
0.573
0.581
0.511
0.534
0.568
0.596

C1QB
C1QB_VPGLYYFTYHASSR
55
0.564
0.582
0.544
0.544
0.606
0.640
0.556
0.572

CAH1
CAH1_GGPFSDSYR
56
0.500
0.550
0.547
0.569
0.502
0.546
0.571
0.578

CATD
CATD_VGFAEAAR
57
0.519
0.534
0.531
0.531
0.525
0.512
0.580
0.572

CATD
CATD_VSTLPAITLK
58
0.511
0.534
0.537
0.530
0.514
0.503
0.572
0.593

CBPN
CBPN_EALIQFLEQVHQGIK
59
0.514
0.519
0.527
0.544
0.501
0.518
0.528
0.580

CBPN
CBPN_NNANGVDLNR
60
0.525
0.504
0.510
0.506
0.506
0.530
0.530
0.504

CD14
CD14_LTVGAAQVPAQLLVGALR
61
0.573
0.558
0.616
0.623
0.604
0.611
0.647
0.662

CD14
CD14_SWLAELQQWLKPGLK
62
0.570
0.552
0.579
0.570
0.591
0.593
0.624
0.614

CFAB
CFAB_YGLVTYATYPK
64
0.590
0.573
0.520
0.548
0.582
0.591
0.510
0.501

CHL1
CHL1_VIAVNEVGR
66
0.570
0.610
0.518
0.516
0.563
0.578
0.541
0.556

CLUS
CLUS_ASSIIDELFQDR
67
0.545
0.533
0.695
0.666
0.547
0.548
0.644
0.590

CLUS
CLUS_LFDSDPITVTVPVEVSR
68
0.539
0.507
0.697
0.635
0.547
0.531
0.657
0.584

CO5
CO5_TLLPVSKPEIR
70
0.580
0.603
0.560
0.584
0.565
0.596
0.541
0.512

CO5
CO5_VFQFLEK
71
0.564
0.576
0.537
0.527
0.566
0.577
0.547
0.509

CO6
CO6_ALNHLPLEYNSALYSR
72
0.572
0.582
0.604
0.643
0.547
0.555
0.573
0.599

CO8A
CO8A_SLLQPNK
74
0.557
0.538
0.547
0.527
0.590
0.593
0.585
0.587

CO8B
CO8B_QALEEFQK
76
0.563
0.544
0.535
0.512
0.587
0.590
0.578
0.563

CRIS3
CRIS3_AVSPPAR
78
0.509
0.559
0.579
0.608
0.526
0.568
0.596
0.640

CRIS3
CRIS3_YEDLYSNCK
79
0.528
0.564
0.603
0.632
0.544
0.585
0.613
0.657

CSH
CSH_AHQLAIDTYQEFEETYIPK
80
0.574
0.571
0.555
0.535
0.519
0.505
0.574
0.559

CSH
CSH_ISLLLIESWLEPVR
81
0.543
0.531
0.535
0.517
0.501
0.514
0.561
0.544

ENPP2
ENPP2_TEFLSNYLTNVDDITLVPGTLGR
82
0.511
0.522
0.611
0.700
0.550
0.543
0.535
0.606

ENPP2
ENPP2_TYLHTYESEI
83
0.509
0.535
0.607
0.689
0.553
0.528
0.529
0.609

F13B
F13B_GDTYPAELYITGSILR
84
0.557
0.557
0.585
0.605
0.527
0.543
0.572
0.593

FBLN1
FBLN1_TGYYFDGISR
86
0.568
0.536
0.537
0.532
0.578
0.533
0.601
0.509

FBLN3
FBLN3_IPSNPSHR
87
0.522
0.503
0.503
0.505
0.527
0.524
0.550
0.571

FETUA
FETUA_FSVVYAK
88
0.504
0.544
0.533
0.575
0.531
0.509
0.543
0.610

FETUA
FETUA_HTLNQIDEVK
89
0.510
0.546
0.564
0.596
0.536
0.530
0.567
0.600

HABP2
HABP2_FLNWIK
92
0.576
0.593
0.630
0.598
0.606
0.610
0.650
0.615

HEMO
HEMO_NFPSPVDAAFR
93
0.534
0.530
0.505
0.545
0.559
0.547
0.505
0.557

HLACI
HLACI_WAAVVVPSGEEQR
95
0.503
0.513
0.556
0.542
0.503
0.521
0.525
0.525

IBP1
IBP1_VVESLAK
97
0.543
0.528
0.574
0.508
0.540
0.509
0.584
0.540

IBP2
IBP2_LIQGAPTIR
98
0.519
0.501
0.505
0.540
0.507
0.515
0.532
0.519

IBP3
IBP3_FLNVLSPR
99
0.537
0.565
0.556
0.588
0.506
0.531
0.504
0.518

IBP3
IBP3_YGQPLPGYTTK
100
0.544
0.563
0.583
0.582
0.508
0.542
0.538
0.518

IBP4
IBP4_QCHPALDGQR
2
0.572
0.552
0.573
0.589
0.626
0.636
0.563
0.568

IBP6
IBP6_GAQTLYVPNCDHR
101
0.532
0.540
0.584
0.531
0.528
0.531
0.544
0.515

IBP6
IBP6_HLDSVLQQLQTEVYR
102
0.519
0.543
0.546
0.504
0.516
0.522
0.508
0.501

IGF2
IGF2_GIVEECCFR
103
0.566
0.577
0.636
0.681
0.528
0.546
0.577
0.584

INHBC
INHBC_LDFHFSSDR
107
0.575
0.564
0.511
0.551
0.613
0.637
0.566
0.546

ITIH3
ITIH3_ALDLSLK
111
0.531
0.526
0.501
0.504
0.534
0.529
0.522
0.544

ITIH4
ITIH4_ILDDLSPR
112
0.528
0.544
0.512
0.558
0.541
0.567
0.507
0.506

ITIH4
ITIH4_NPLVWVHASPEHVVVTR
113
0.546
0.536
0.523
0.529
0.572
0.587
0.523
0.545

ITIH4
ITIH4_QLGLPGPPDVPDHAAYHPF
114
0.514
0.520
0.532
0.547
0.547
0.555
0.506
0.587

KNG1
KNG1_DIPTNSPELEETLTHTITK
116
0.535
0.503
0.537
0.577
0.568
0.565
0.535
0.549

KNG1
KNG1_QVVAGLNFR
117
0.517
0.506
0.590
0.628
0.571
0.570
0.594
0.607

LBP
LBP_ITGFLKPGK
118
0.562
0.511
0.523
0.526
0.582
0.562
0.507
0.591

LBP
LBP_ITLPDFTGDLR
119
0.576
0.533
0.536
0.500
0.601
0.595
0.506
0.565

LYAM1
LYAM1_SYYWIGIR
120
0.558
0.603
0.646
0.691
0.548
0.594
0.672
0.739

NCAM1
NCAM1_GLGEISAASEFK
121
0.567
0.556
0.524
0.559
0.527
0.535
0.505
0.565

PAPP1
PAPP1_DIPHWLNPTR
122
0.518
0.524
0.539
0.582
0.548
0.510
0.515
0.555

PEDF
PEDF_LQSLFDSPDFSK
124
0.558
0.530
0.514
0.526
0.577
0.570
0.527
0.540

PEDF
PEDF_TVQAVLTVPK
125
0.571
0.569
0.575
0.606
0.586
0.597
0.574
0.609

PGRP2
PGRP2_AGLLRPDYALLGHR
126
0.554
0.574
0.525
0.574
0.524
0.553
0.548
0.610

PRDX2
PRDX2_GLFIIDGK
128
0.511
0.567
0.517
0.531
0.533
0.577
0.551
0.548

PRG2
PRG2_WNFAYWAAHQPWSR
129
0.555
0.505
0.502
0.519
0.577
0.518
0.563
0.511

PSG11
PSG11_LFIPQITPK
132
0.505
0.552
0.508
0.565
0.515
0.556
0.542
0.558

PSG1
PSG1_FQLPGQK
131
0.560
0.570
0.502
0.508
0.529
0.531
0.522
0.505

PSG2
PSG2_IHPSYTNYR
133
0.511
0.570
0.656
0.714
0.528
0.572
0.609
0.713

PSG3
PSG3_VSAPSGTGHLPGLNPL
134
0.615
0.611
0.547
0.538
0.615
0.603
0.603
0.561

PSG9
PSG9_DVLLLVHNLPQNLPGYFWYK
135
0.557
0.555
0.625
0.597
0.560
0.595
0.546
0.507

PSG9
PSG9_LFIPQITR
136
0.539
0.529
0.649
0.656
0.547
0.576
0.565
0.547

PTGDS
PTGDS_GPGEDFR
137
0.520
0.502
0.542
0.572
0.540
0.551
0.561
0.594

SHBG
SHBG_IALGGLLFPASNLR
18
0.576
0.578
0.541
0.509
0.584
0.570
0.613
0.613

SOM2.CSH
SOM2.CSH_NYGLLYCFR
138
0.546
0.526
0.523
0.506
0.502
0.529
0.546
0.516

SOM2.CSH
SOM2.CSH_SVEGSCGF
139
0.538
0.551
0.503
0.510
0.502
0.525
0.551
0.583

SPRL1
SPRL1_VLTHSELAPLR
140
0.508
0.559
0.536
0.515
0.523
0.571
0.585
0.548

TENX
TENX_LNWEAPPGAFDSFLLR
141
0.556
0.590
0.590
0.568
0.588
0.606
0.598
0.536

TENX
TENX_LSQLSVTDVTTSSLR
142
0.538
0.573
0.562
0.544
0.567
0.591
0.566
0.505

THBG
THBG_AVLHIGEK
143
0.502
0.536
0.512
0.502
0.507
0.520
0.521
0.508

TIE1
TIE1_VSWSLPLVPGPLVGDGFLLR
144
0.559
0.596
0.563
0.514
0.537
0.550
0.553
0.506

VTDB
VTDB_ELPEHTVK
147
0.505
0.528
0.513
0.504
0.501
0.501
0.561
0.580

VTNC
VTNC_GQYCYELDEK
149
0.602
0.604
0.599
0.611
0.624
0.662
0.605
0.635

VTNC
VTNC_VDTVDPPYPR
150
0.601
0.599
0.582
0.573
0.627
0.651
0.582
0.570

TABLE 25

133_
133_
133_
133_
119_
119_
119_
119_

SEQ
153_
153_
153_
153_
153_
153_
153_
153_

ID
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_
aBMI_
rBMI_

Protein
Transition
NO:
37
37
35
35
37
37
35
35

A2GL
A2GL_DLLLPQPDLR
34
0.581
0.597
0.538
0.549
0.554
0.568
0.520
0.533

AFAM
AFAM_DADPDTFFAK
37
0.539
0.561
0.584
0.647
0.557
0.557
0.590
0.620

AFAM
AFAM_HFQNLGK
38
0.549
0.584
0.595
0.679
0.559
0.561
0.590
0.626

ALS
ALS_IRPHTFTGLSGLR
40
0.503
0.515
0.517
0.503
0.504
0.513
0.521
0.519

ANGT
ANGT_DPTFIPAPIQAK
42
0.533
0.566
0.501
0.542
0.549
0.589
0.558
0.593

APOC3
APOC3_GWVTDGFSSLK
47
0.643
0.611
0.628
0.530
0.622
0.599
0.587
0.539

APOH
APOH_ATVVYQGER
48
0.601
0.584
0.632
0.656
0.580
0.563
0.573
0.591

B2MG
B2MG_VEHSDLSFSK
50
0.582
0.565
0.544
0.527
0.543
0.520
0.536
0.508

B2MG
B2MG_VNHVTLSQPK
51
0.613
0.599
0.582
0.551
0.570
0.539
0.571
0.553

BGH3
BGH3_LTLLAPLNSVFK
52
0.533
0.562
0.549
0.586
0.542
0.564
0.516
0.518

C163A
C163A_INPASLDK
54
0.524
0.505
0.509
0.515
0.504
0.527
0.530
0.540

C1QB
C1QB_VPGLYYFTYHASSR
55
0.579
0.564
0.577
0.613
0.575
0.583
0.539
0.547

CAH1
CAH1_GGPFSDSYR
56
0.522
0.531
0.610
0.598
0.507
0.500
0.557
0.549

CATD
CATD_VGFAEAAR
57
0.610
0.589
0.719
0.722
0.576
0.547
0.626
0.634

CATD
CATD_VSTLPAITLK
58
0.593
0.594
0.729
0.772
0.564
0.549
0.623
0.651

CBPN
CBPN_EALIQFLEQVHQGIK
59
0.504
0.530
0.516
0.552
0.507
0.542
0.510
0.506

CBPN
CBPN_NNANGVDLNR
60
0.529
0.549
0.533
0.510
0.516
0.541
0.550
0.546

CD14
CD14_LTVGAAQVPAQLLVGALR
61
0.600
0.567
0.620
0.582
0.577
0.558
0.615
0.600

CD14
CD14_SWLAELQQWLKPGLK
62
0.591
0.556
0.617
0.569
0.577
0.554
0.601
0.569

CFAB
CFAB_YGLVTYATYPK
64
0.579
0.596
0.529
0.523
0.599
0.601
0.522
0.528

CHL1
CHL1_VIAVNEVGR
66
0.515
0.519
0.564
0.573
0.568
0.577
0.505
0.506

CLUS
CLUS_ASSIIDELFQDR
67
0.518
0.539
0.591
0.560
0.534
0.546
0.628
0.592

CLUS
CLUS_LFDSDPITVTVPVEVSR
68
0.504
0.504
0.589
0.526
0.521
0.511
0.610
0.543

CO5
CO5_TLLPVSKPEIR
70
0.576
0.583
0.522
0.525
0.577
0.589
0.548
0.525

CO5
CO5_VFQFLEK
71
0.583
0.570
0.538
0.519
0.577
0.575
0.540
0.511

CO6
CO6_ALNHLPLEYNSALYSR
72
0.517
0.514
0.536
0.569
0.554
0.566
0.549
0.560

CO8A
CO8A_SLLQPNK
74
0.599
0.600
0.579
0.557
0.574
0.557
0.563
0.553

CO8B
CO8B_QALEEFQK
76
0.602
0.610
0.580
0.567
0.578
0.567
0.565
0.549

CRIS3
CRIS3_AVSPPAR
78
0.531
0.586
0.576
0.598
0.525
0.571
0.582
0.608

CRIS3
CRIS3_YEDLYSNCK
79
0.541
0.601
0.580
0.603
0.539
0.580
0.596
0.620

CSH
CSH_AHQLAIDTYQEFEETYIPK
80
0.523
0.533
0.550
0.513
0.526
0.509
0.535
0.513

CSH
CSH_ISLLLIESWLEPVR
81
0.531
0.546
0.548
0.511
0.515
0.505
0.531
0.511

ENPP2
ENPP2_TEFLSNYLTNVDDITLVPGTLGR
82
0.592
0.605
0.593
0.545
0.574
0.571
0.517
0.558

ENPP2
ENPP2_TYLHTYESEI
83
0.595
0.594
0.610
0.550
0.576
0.559
0.500
0.545

F13B
F13B_GDTYPAELYITGSILR
84
0.512
0.514
0.607
0.617
0.529
0.528
0.584
0.590

FBLN1
FBLN1_TGYYFDGISR
86
0.506
0.572
0.572
0.581
0.537
0.521
0.542
0.550

FBLN3
FBLN3_IPSNPSHR
87
0.515
0.524
0.571
0.622
0.523
0.506
0.545
0.559

FETUA
FETUA_FSVVYAK
88
0.562
0.558
0.532
0.508
0.552
0.534
0.530
0.517

FETUA
FETUA_HTLNQIDEVK
89
0.551
0.541
0.511
0.511
0.544
0.529
0.524
0.531

HABP2
HABP2_FLNWIK
92
0.556
0.546
0.539
0.562
0.595
0.592
0.591
0.544

HEMO
HEMO_NFPSPVDAAFR
93
0.588
0.552
0.526
0.528
0.567
0.536
0.501
0.538

HLACI
HLACI_WAAVVVPSGEEQR
95
0.522
0.564
0.518
0.513
0.527
0.543
0.502
0.508

IBP1
IBP1_VVESLAK
97
0.518
0.510
0.613
0.602
0.537
0.510
0.597
0.563

IBP2
IBP2_LIQGAPTIR
98
0.509
0.521
0.569
0.590
0.522
0.507
0.554
0.552

IBP3
IBP3_FLNVLSPR
99
0.545
0.568
0.525
0.541
0.532
0.566
0.507
0.514

IBP3
IBP3_YGQPLPGYTTK
100
0.573
0.608
0.529
0.501
0.547
0.581
0.552
0.540

IBP4
IBP4_QCHPALDGQR
2
0.674
0.694
0.571
0.570
0.608
0.606
0.539
0.530

IBP6
IBP6_GAQTLYVPNCDHR
101
0.549
0.502
0.541
0.529
0.522
0.533
0.526
0.505

IBP6
IBP6_HLDSVLQQLQTEVYR
102
0.540
0.501
0.515
0.524
0.520
0.521
0.511
0.506

IGF2
IGF2_GIVEECCFR
103
0.593
0.618
0.528
0.513
0.569
0.592
0.578
0.579

INHBC
INHBC_LDFHFSSDR
107
0.622
0.652
0.582
0.573
0.608
0.612
0.545
0.517

ITIH3
ITIH3_ALDLSLK
111
0.575
0.567
0.507
0.505
0.557
0.557
0.513
0.519

ITIH4
ITIH4_ILDDLSPR
112
0.542
0.524
0.518
0.559
0.531
0.537
0.501
0.508

ITIH4
ITIH4_NPLVWVHASPEHVVVTR
113
0.551
0.526
0.617
0.683
0.534
0.528
0.559
0.597

ITIH4
ITIH4_QLGLPGPPDVPDHAAYHPF
114
0.511
0.516
0.535
0.645
0.512
0.505
0.520
0.582

KNG1
KNG1_DIPTNSPELEETLTHTITK
116
0.575
0.535
0.508
0.552
0.558
0.535
0.523
0.525

KNG1
KNG1_QVVAGLNFR
117
0.596
0.582
0.596
0.559
0.562
0.554
0.602
0.602

LBP
LBP_ITGFLKPGK
118
0.595
0.582
0.504
0.590
0.587
0.559
0.505
0.565

LBP
LBP_ITLPDFTGDLR
119
0.619
0.613
0.526
0.543
0.609
0.588
0.524
0.521

LYAM1
LYAM1_SYYWIGIR
120
0.557
0.603
0.678
0.708
0.552
0.596
0.651
0.696

NCAM1
NCAM1_GLGEISAASEFK
121
0.505
0.512
0.541
0.535
0.536
0.531
0.501
0.557

PAPP1
PAPP1_DIPHWLNPTR
122
0.516
0.542
0.530
0.640
0.540
0.519
0.525
0.594

PEDF
PEDF_LQSLFDSPDFSK
124
0.568
0.565
0.570
0.600
0.577
0.571
0.545
0.565

PEDF
PEDF_TVQAVLTVPK
125
0.566
0.552
0.574
0.592
0.577
0.570
0.577
0.598

PGRP2
PGRP2_AGLLRPDYALLGHR
126
0.549
0.578
0.645
0.717
0.560
0.578
0.576
0.627

PRDX2
PRDX2_GLFIIDGK
128
0.561
0.562
0.619
0.595
0.525
0.530
0.547
0.536

PRG2
PRG2_WNFAYWAAHQPWSR
129
0.564
0.504
0.522
0.569
0.565
0.501
0.520
0.529

PSG11
PSG11_LFIPQITPK
132
0.527
0.507
0.522
0.529
0.511
0.516
0.500
0.501

PSG1
PSG1_FQLPGQK
131
0.519
0.544
0.555
0.516
0.524
0.509
0.508
0.535

PSG2
PSG2_IHPSYTNYR
133
0.528
0.550
0.558
0.624
0.522
0.563
0.597
0.660

PSG3
PSG3_VSAPSGTGHLPGLNPL
134
0.546
0.558
0.550
0.508
0.581
0.563
0.557
0.506

PSG9
PSG9_DVLLLVHNLPQNLPGYFWYK
135
0.516
0.553
0.529
0.505
0.546
0.567
0.547
0.500

PSG9
PSG9_LFIPQITR
136
0.502
0.528
0.542
0.552
0.528
0.541
0.571
0.554

PTGDS
PTGDS_GPGEDFR
137
0.568
0.602
0.568
0.592
0.536
0.532
0.537
0.545

SHBG
SHBG_IALGGLLFPASNLR
18
0.588
0.585
0.686
0.728
0.585
0.576
0.611
0.613

SOM2.CSH
SOM2.CSH_NYGLLYCFR
138
0.560
0.588
0.511
0.546
0.501
0.527
0.513
0.520

SOM2.CSH
SOM2.CSH_SVEGSCGF
139
0.509
0.532
0.549
0.573
0.525
0.539
0.542
0.565

SPRL1
SPRL1_VLTHSELAPLR
140
0.512
0.533
0.619
0.582
0.502
0.543
0.578
0.555

TENX
TENX_LNWEAPPGAFDSFLLR
141
0.576
0.578
0.558
0.519
0.576
0.573
0.550
0.519

TENX
TENX_LSQLSVTDVTTSSLR
142
0.564
0.554
0.504
0.599
0.550
0.542
0.508
0.588

THBG
THBG_AVLHIGEK
143
0.557
0.547
0.527
0.529
0.518
0.507
0.520
0.500

TIE1
TIE1_VSWSLPLVPGPLVGDGFLLR
144
0.512
0.506
0.542
0.528
0.513
0.531
0.536
0.502

VTDB
VTDB_ELPEHTVK
147
0.542
0.524
0.551
0.597
0.506
0.502
0.528
0.533

VTNC
VTNC_GQYCYELDEK
149
0.603
0.618
0.573
0.581
0.623
0.635
0.598
0.617

VTNC
VTNC_VDTVDPPYPR
150
0.629
0.626
0.583
0.552
0.625
0.629
0.574
0.553

TABLE 26

Up- and down-regulated proteins/transitions used for reversals

SEQ

ID

Protein
Transition
NO:
Reg

AFAM
AFAM_DADPDTFFAK
37
up

AFAM
AFAM_HFQNLGK
38
up

ANGT
ANGT_DPTFIPAPIQAK
42
up

APOC3
APOC3_GWVTDGFSSLK
47
up

APOH
APOH_ATVVYQGER
48
up

CD14
CD14_LTVGAAQVPAQLLVGALR
61
up

CD14
CD14_SWLAELQQWLKPGLK
62
up

CLUS
CLUS_ASSIIDELFQDR
67
up

CLUS
CLUS_LFDSDPITVTVPVEVSR
68
up

CO8A
CO8A_SLLQPNK
74
up

CO8B
CO8B_QALEEFQK
76
up

F13B
F13B_GDTYPAELYITGSILR
84
up

IBP4
IBP4_QCHPALDGQR
2
up

PEDF
PEDF_LQSLFDSPDFSK
124
up

PEDF
PEDF_TVQAVLTVPK
125
up

PRDX2
PRDX2_GLFIIDGK
128
up

PSG2
PSG2_IHPSYTNYR
133
up

PTGDS
PTGDS_GPGEDFR
137
up

VTNC
VTNC_GQYCYELDEK
149
up

VTNC
VTNC_VDTVDPPYPR
150
up

B2MG
B2MG_VNHVTLSQPK
51
up

BGH3
BGH3_LTLLAPLNSVFK
52
up

CBPN
CBPN_NNANGVDLNR
60
up

CO5
CO5_TLLPVSKPEIR
70
up

CO5
CO5_VFQFLEK
71
up

IBP6
IBP6_HLDSVLQQLQTEVYR
102
up

INHBC
INHBC_LDFHFSSDR
107
up

KNG1
KNG1_DIPTNSPELEETLTHTITK
116
up

KNG1
KNG1_QVVAGLNFR
117
up

THBG
THBG_AVLHIGEK
143
up

CATD
CATD_VGFAEAAR
57
up

CO6
CO6_ALNHLPLEYNSALYSR
72
up

ITIH4
ITIH4_NPLVWVHASPEHVVVTR
113
up

A2GL
A2GL_DLLLPQPDLR
34
up

CAH1
CAH1_GGPFSDSYR
56
up

CATD
CATD_VSTLPAITLK
58
up

CBPN
CBPN_EALIQFLEQVHQGIK
59
up

HABP2
HABP2_FLNWIK
92
up

CFAB
CFAB_YGLVTYATYPK
64
up

HEMO
HEMO_NFPSPVDAAFR
93
up

LBP
LBP_ITGFLKPGK
118
up

LBP
LBP_ITLPDFTGDLR
119
up

PAPP1
PAPP1_DIPHWLNPTR
122
up

FETUA
FETUA_FSVVYAK
88
up

FETUA
FETUA_HTLNQIDEVK
89
up

IBP6
IBP6_GAQTLYVPNCDHR
101
up

ITIH3
ITIH3_ALDLSLK
111
up

B2MG
B2MG_VEHSDLSFSK
50
up

ENPP2
ENPP2_TYLHTYESEI
83
up

HLACI
HLACI_WAAVVVPSGEEQR
95
up

ITIH4
ITIH4_QLGLPGPPDVPDHAAYHPF
114
up

C1QB
C1QB_VPGLYYFTYHASSR
55
up

ENPP2
ENPP2_TEFLSNYLTNVDDITLVPGTLGR
82
up

FBLN3
FBLN3_IPSNPSHR
87
up

PSG11
PSG11_LFIPQITPK
132
up

ITIH4
ITIH4_ILDDLSPR
112
down

PSG1
PSG1_FQLPGQK
131
down

CHL1
CHL1_VIAVNEVGR
66
down

CSH
CSH_ISLLLIESWLEPVR
81
down

NCAM1
NCAM1_GLGEISAASEFK
121
down

PRG2
PRG2_WNFAYWAAHQPWSR
129
down

SOM2.CSH
SOM2.CSH_NYGLLYCFR
138
down

ALS
ALS_IRPHTFTGLSGLR
40
down

FBLN1
FBLN1_TGYYFDGISR
86
down

PSG9
PSG9_LFIPQITR
136
down

CSH
CSH_AHQLAIDTYQEFEETYIPK
80
down

VTDB
VTDB_ELPEHTVK
147
down

IBP3
IBP3_FLNVLSPR
99
down

IBP3
IBP3_YGQPLPGYTTK
100
down

PSG9
PSG9_DVLLLVHNLPQNLPGYFWYK
135
down

TENX
TENX_LSQLSVTDVTTSSLR
142
down

IBP1
IBP1_VVESLAK
97
down

IBP2
IBP2_LIQGAPTIR
98
down

SOM2.CSH
SOM2.CSH_SVEGSCGF
139
down

SPRL1
SPRL1_VLTHSELAPLR
140
down

TENX
TENX_LNWEAPPGAFDSFLLR
141
down

TIE1
TIE1_VSWSLPLVPGPLVGDGFLLR
144
down

C163A
C163A_INPASLDK
54
down

IGF2
IGF2_GIVEECCFR
103
down

PSG3
PSG3_VSAPSGTGHLPGLNPL
134
down

CRIS3
CRIS3_AVSPPAR
78
down

CRIS3
CRIS3_YEDLYSNCK
79
down

LYAM1
LYAM1_SYYWIGIR
120
down

PGRP2
PGRP2_AGLLRPDYALLGHR
126
down

SHBG
SHBG_IALGGLLFPASNLR
18
down

TABLE 27

Reversal Classification Performance, weeks 17 and 18.

Reversal AUROC for gestational weeks 17 and 18 using

a case vs control cut-off of <37 0/7 vs >=37 0/7

weeks, without BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_CHL1_VIAVNEVGR
34 & 66
0.027
0.633

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.036
0.626

AFAM_DADPDTFFAK_vs_CHL1_VIAVNEVGR
37 & 66
0.005
0.669

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.001
0.699

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.020
0.640

AFAM_DADPDTFFAK_vs_VTDB_ELPEHTVK
37 & 147
0.043
0.622

AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR
38 & 66
0.003
0.679

AFAM_HFQNLGK_vs_NCAM1_GLGEISAASEFK
38 & 121
0.036
0.626

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.004
0.676

AFAM_HFQNLGK_vs_VTDB_ELPEHTVK
38 & 147
0.037
0.625

ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR
42 & 66
0.008
0.659

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.006
0.665

ANGT_DPTFIPAPIQAK_vs_CSH_ISLLLIESWLEPVR
42 & 81
0.023
0.637

ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR
42 & 86
0.025
0.635

ANGT_DPTFIPAPIQAK_vs_NCAM1_GLGEISAASEFK
42 & 121
0.040
0.624

ANGT_DPTFIPAPIQAK_vs_PSG1_FQLPGQK
42 & 131
0.036
0.626

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.004
0.675

ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
42 & 135
0.042
0.623

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_NYGLLYCFR
42 & 138
0.012
0.651

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.032
0.631

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.047
0.619

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.021
0.639

APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR
48 & 66
0.008
0.660

APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK
48 & 80
0.039
0.624

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.024
0.636

B2MG_VEHSDLSFSK_vs_CHL1_VIAVNEVGR
50 & 66
0.042
0.622

B2MG_VNHVTLSQPK_vs_CHL1_VIAVNEVGR
51 & 66
0.023
0.637

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL
51 & 134
0.046
0.620

BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR
52 & 66
0.006
0.666

BGH3_LTLLAPLNSVFK_vs_CSH_AHQLAIDTYQEFEETYIPK
52 & 80
0.014
0.648

BGH3_LTLLAPLNSVFK_vs_CSH_ISLLLIESWLEPVR
52 & 81
0.050
0.618

BGH3_LTLLAPLNSVFK_vs_FBLN1_TGYYFDGISR
52 & 86
0.020
0.640

BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL
52 & 134
0.024
0.636

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR
52 & 18
0.029
0.632

BGH3_LTLLAPLNSVFK_vs_SOM2.CSH_NYGLLYCFR
52 & 138
0.043
0.622

C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR
55 & 66
0.018
0.643

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.010
0.655

C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR
55 & 81
0.016
0.645

C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR
55 & 86
0.046
0.620

C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR
55 & 98
0.017
0.644

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.032
0.629

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.028
0.632

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.036
0.627

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 138
0.011
0.653

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF
55 & 139
0.048
0.621

CBPN_EALIQFLEQVHQGIK_vs_PSG3_VSAPSGTGHLPGLNPL
59 & 134
0.038
0.625

CBPN_EALIQFLEQVHQGIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
59 & 135
0.037
0.626

CBPN_NNANGVDLNR_vs_CHL1_VIAVNEVGR
60 & 66
0.044
0.621

CBPN_NNANGVDLNR_vs_PSG3_VSAPSGTGHLPGLNPL
60 & 134
0.044
0.622

CD14_LTVGAAQVPAQLLVGALR_vs_CHL1_VIAVNEVGR
61 & 66
0.011
0.652

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.046
0.620

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.032
0.629

CD14_SWLAELQQWLKPGLK_vs_CHL1_VIAVNEVGR
62 & 66
0.005
0.667

CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK
62 & 80
0.024
0.636

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.015
0.646

CFAB_YGLVTYATYPK_vs_C163A_INPASLDK
64 & 54
0.045
0.621

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.001
0.703

CFAB_YGLVTYATYPK_vs_CSH_AHQLAIDTYQEFEETYIPK
64 & 80
0.011
0.654

CFAB_YGLVTYATYPK_vs_CSH_ISLLLIESWLEPVR
64 & 81
0.024
0.636

CFAB_YGLVTYATYPK_vs_FBLN1_TGYYFDGISR
64 & 86
0.023
0.637

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.034
0.628

CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK
64 & 121
0.005
0.671

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.012
0.651

CFAB_YGLVTYATYPK_vs_PSG1_FQLPGQK
64 & 131
0.032
0.629

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.000
0.722

CFAB_YGLVTYATYPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
64 & 135
0.031
0.630

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.015
0.646

CFAB_YGLVTYATYPK_vs_SOM2.CSH_NYGLLYCFR
64 & 138
0.020
0.640

CFAB_YGLVTYATYPK_vs_SOM2.CSH_SVEGSCGF
64 & 139
0.027
0.635

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.031
0.630

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.012
0.652

CFAB_YGLVTYATYPK_vs_VTDB_ELPEHTVK
64 & 147
0.006
0.664

CLUS_ASSIIDELFQDR_vs_CHL1_VIAVNEVGR
67 & 66
0.002
0.682

CLUS_ASSIIDELFQDR_vs_CSH_AHQLAIDTYQEFEETYIPK
67 & 80
0.027
0.633

CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR
67 & 86
0.028
0.633

CLUS_ASSIIDELFQDR_vs_NCAM1_GLGEISAASEFK
67 & 121
0.042
0.622

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.007
0.664

CLUS_ASSIIDELFQDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
67 & 135
0.035
0.627

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.032
0.629

CLUS_LFDSDPITVTVPVEVSR_vs_CHL1_VIAVNEVGR
68 & 66
0.003
0.679

CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK
68 & 80
0.047
0.620

CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYFDGISR
68 & 86
0.028
0.633

CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL
68 & 134
0.014
0.648

CLUS_LFDSDPITVTVPVEVSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
68 & 135
0.034
0.628

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.038
0.625

CO5_TLLPVSKPEIR_vs_CHL1_VIAVNEVGR
70 & 66
0.002
0.683

CO5_TLLPVSKPEIR_vs_CSH_AHQLAIDTYQEFEETYIPK
70 & 80
0.021
0.640

CO5_TLLPVSKPEIR_vs_FBLN1_TGYYFDGISR
70 & 86
0.033
0.628

CO5_TLLPVSKPEIR_vs_NCAM1_GLGEISAASEFK
70 & 121
0.033
0.628

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.043
0.622

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.002
0.688

CO5_TLLPVSKPEIR_vs_SOM2.CSH_NYGLLYCFR
70 & 138
0.038
0.625

CO5_VFQFLEK_vs_CHL1_VIAVNEVGR
71 & 66
0.002
0.686

CO5_VFQFLEK_vs_CSH_AHQLAIDTYQEFEETYIPK
71 & 80
0.020
0.640

CO5_VFQFLEK_vs_FBLN1_TGYYFDGISR
71 & 86
0.033
0.628

CO5_VFQFLEK_vs_NCAM1_GLGEISAASEFK
71 & 121
0.034
0.628

CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR
71 & 126
0.046
0.620

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.002
0.685

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.043
0.622

CO5_VFQFLEK_vs_SOM2.CSH_NYGLLYCFR
71 & 138
0.038
0.625

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.047
0.619

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.000
0.723

CO6_ALNHLPLEYNSALYSR_vs_CSH_AHQLAIDTYQEFEETYIPK
72 & 80
0.010
0.655

CO6_ALNHLPLEYNSALYSR_vs_CSH_ISLLLIESWLEPVR
72 & 81
0.035
0.627

CO6_ALNHLPLEYNSALYSR_vs_FBLN1_TGYYFDGISR
72 & 86
0.013
0.649

CO6_ALNHLPLEYNSALYSR_vs_NCAM1_GLGEISAASEFK
72 & 121
0.010
0.656

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.049
0.619

CO6_ALNHLPLEYNSALYSR_vs_PSG1_FQLPGQK
72 & 131
0.043
0.622

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.001
0.699

CO6_ALNHLPLEYNSALYSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
72 & 135
0.041
0.623

CO6_ALNHLPLEYNSALYSR_vs_SOM2.CSH_NYGLLYCFR
72 & 138
0.019
0.641

CO6_ALNHLPLEYNSALYSR_vs_SOM2.CSH_SVEGSCGF
72 & 139
0.028
0.634

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.036
0.626

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.019
0.641

CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK
72 & 147
0.009
0.657

CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR
74 & 66
0.007
0.661

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.005
0.671

CO8B_QALEEFQK_vs_CHL1_VIAVNEVGR
76 & 66
0.019
0.642

CO8B_QALEEFQK_vs_CSH_AHQLAIDTYQEFEETYIPK
76 & 80
0.046
0.620

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.013
0.649

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3VSAPSGTGHLPGLNPL
82 & 134
0.033
0.629

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL
83 & 134
0.032
0.629

F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR
84 & 66
0.003
0.680

F13B_GDTYPAELYITGSILR_vs_CSH_AHQLAIDTYQEFEETYIPK
84 & 80
0.035
0.627

F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDGISR
84 & 86
0.035
0.627

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.007
0.663

FBLN3_IPSNPSHR_vs_CHL1_VIAVNEVGR
87 & 66
0.049
0.619

FETUA_FSVVYAK_vs_CHL1_VIAVNEVGR
88 & 66
0.009
0.658

FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGHR
88 & 126
0.042
0.623

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.009
0.658

FETUA_HTLNQIDEVK_vs_CHL1_VIAVNEVGR
89 & 66
0.009
0.657

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.017
0.643

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.000
0.739

HABP2_FLNWIK_vs_CSH_AHQLAIDTYQEFEETYIPK
92 & 80
0.002
0.687

HABP2_FLNWIK_vs_CSH_ISLLLIESWLEPVR
92 & 81
0.005
0.667

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.003
0.679

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.038
0.625

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.029
0.631

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.008
0.659

HABP2_FLNWIK_vs_ITIH4_ILDDLSPR
92 & 112
0.003
0.680

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.018
0.643

HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK
92 & 121
0.002
0.683

HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR
92 & 126
0.004
0.672

HABP2_FLNWIK_vs_PRG2_WNFAYWAAHQPWSR
92 & 129
0.027
0.633

HABP2_FLNWIK_vs_PSG1_FQLPGQK
92 & 131
0.014
0.649

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.000
0.750

HABP2_FLNWIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
92 & 135
0.015
0.646

HABP2_FLNWIK_vs_PSG9_LFIPQITR
92 & 136
0.043
0.622

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.010
0.655

HABP2_FLNWIK_vs_SOM2.CSH_NYGLLYCFR
92 & 138
0.004
0.674

HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF
92 & 139
0.005
0.673

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.016
0.645

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.004
0.673

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.000
0.711

HEMO_NFPSPVDAAFR_vs_CHL1_VIAVNEVGR
93 & 66
0.004
0.673

HEMO_NFPSPVDAAFR_vs_CSH_AHQLAIDTYQEFEETYIPK
93 & 80
0.047
0.619

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.016
0.645

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.023
0.637

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.021
0.640

IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL
102 & 134
0.032
0.629

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.010
0.655

INHBC_LDFHFSSDR_vs_CSH_AHQLAIDTYQEFEETYIPK
107 & 80
0.050
0.618

INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQPWSR
107 & 129
0.048
0.619

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.007
0.663

INHBC_LDFHFSSDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
107 & 135
0.049
0.619

ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL
111 & 134
0.041
0.623

KNG1_DIPTNSPELEETLTHTITK_vs_CHL1_VIAVNEVGR
116 & 66
0.013
0.650

KNG1_DIPTNSPELEETLTHTITK_vs_CSH_AHQLAIDTYQEFEETYIPK
116 & 80
0.032
0.629

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.007
0.661

KNG1_DIPTNSPELEETLTHTITK_vs_SOM2.CSHNYGLLYCFR
116 & 138
0.049
0.619

KNG1_QVVAGLNFR_vs_CHL1_VIAVNEVGR
117 & 66
0.023
0.637

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.041
0.623

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.024
0.636

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.011
0.654

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.008
0.661

LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
119 & 80
0.041
0.623

LBP_ITLPDFTGDLR_vs_FBLN1_TGYYFDGISR
119 & 86
0.049
0.619

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.046
0.620

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 & 121
0.042
0.623

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.006
0.665

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.047
0.619

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.049
0.620

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.019
0.641

PEDF_LQSLFDSPDFSK_vs_CHL1_VIAVNEVGR
124 & 66
0.003
0.681

PEDF_LQSLFDSPDFSK_vs_CSH_AHQLAIDTYQEFEETYIPK
124 & 80
0.020
0.640

PEDF_LQSLFDSPDFSK_vs_CSH_ISLLLIESWLEPVR
124 & 81
0.044
0.621

PEDF_LQSLFDSPDFSK_vs_FBLN1_TGYYFDGISR
124 & 86
0.026
0.634

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.050
0.618

PEDF_LQSLFDSPDFSK_vs_PSG1_FQLPGQK
124 & 131
0.025
0.635

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.006
0.666

PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
124 & 135
0.036
0.627

PEDF_LQSLFDSPDFSK_vs_SOM2.CSH_NYGLLYCFR
124 & 138
0.027
0.633

PEDF_LQSLFDSPDFSK_vs_SOM2.CSH_SVEGSCGF
124 & 139
0.049
0.620

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.043
0.622

PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK
124 & 147
0.025
0.635

PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR
125 & 66
0.004
0.675

PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK
125 & 80
0.015
0.646

PEDF_TVQAVLTVPK_vs_CSH_ISLLLIESWLEPVR
125 & 81
0.039
0.624

PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR
125 & 86
0.018
0.642

PEDF_TVQAVLTVPK_vs_NCAM1_GLGEISAASEFK
125 & 121
0.033
0.628

PEDF_TVQAVLTVPK_vs_PSG1_FQLPGQK
125 & 131
0.032
0.629

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.004
0.673

PEDF_TVQAVLTVPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
125 & 135
0.050
0.618

PEDF_TVQAVLTVPK_vs_SOM2.CSH_NYGLLYCFR
125 & 138
0.040
0.624

PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK
125 & 147
0.023
0.637

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.000
0.719

VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK
149 & 80
0.006
0.665

VTNC_GQYCYELDEK_vs_CSH_ISLLLIESWLEPVR
149 & 81
0.013
0.650

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.008
0.659

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.046
0.620

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.040
0.624

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.020
0.640

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.008
0.659

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.005
0.670

VTNC_GQYCYELDEK_vs_PSG1_FQLPGQK
149 & 131
0.021
0.639

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.000
0.743

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.029
0.631

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.014
0.648

VTNC_GQYCYELDEK_vs_SOM2.CSH_NYGLLYCFR
149 & 138
0.010
0.655

VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF
149 & 139
0.009
0.660

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.023
0.637

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.006
0.665

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.001
0.694

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.000
0.712

VTNC_VDTVDPPYPR_vs_CSH_AHQLAIDTYQEFEETYIPK
150 & 80
0.010
0.654

VTNC_VDTVDPPYPR_vs_CSH_ISLLLIESWLEPVR
150 & 81
0.029
0.631

VTNC_VDTVDPPYPR_vs_FBLN1_TGYYFDGISR
150 & 86
0.034
0.628

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.034
0.628

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.021
0.640

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.039
0.625

VTNC_VDTVDPPYPR_vs_PSG1_FQLPGQK
150 & 131
0.033
0.628

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.000
0.720

VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
150 & 135
0.035
0.627

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.043
0.622

VTNC_VDTVDPPYPR_vs_SOM2.CSH_NYGLLYCFR
150 & 138
0.023
0.637

VTNC_VDTVDPPYPR_vs_SOM2.CSH_SVEGSCGF
150 & 139
0.023
0.639

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.043
0.622

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.003
0.677

TABLE 28

Reversal Classification Performance, weeks 17 and 18.

Reversal AUROC for gestational weeks 17 and 18 using

a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks,

with BMI stratification (>22 <=37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_CHL1_VIAVNEVGR
37 & 66
0.040
0.647

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.030
0.656

AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR
38 & 66
0.022
0.664

ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR
42 & 66
0.017
0.671

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.037
0.650

ANGT_DPTFIPAPIQAK_vs_NCAM1_GLGEISAASEFK
42 & 121
0.043
0.645

ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
42 & 144
0.033
0.653

APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR
48 & 66
0.031
0.655

BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR
52 & 66
0.016
0.672

C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR
55 & 66
0.019
0.669

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.038
0.648

C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR
55 & 81
0.046
0.643

C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR
55 & 86
0.037
0.650

C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR
55 & 98
0.042
0.646

C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR
55 & 120
0.043
0.645

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.030
0.656

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.037
0.650

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 138
0.029
0.657

C1QB_VPGLYYFTYHASSR_vs_SPRL1_VLTHSELAPLR
55 & 140
0.034
0.652

CBPN_EALIQFLEQVHQGIK_vs_CHL1_VIAVNEVGR
59 & 66
0.047
0.642

CD14_SWLAELQQWLKPGLK_vs_CHL1_VIAVNEVGR
62 & 66
0.031
0.655

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.006
0.697

CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK
64 & 121
0.017
0.671

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.021
0.666

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.038
0.648

CLUS_ASSIIDELFQDR_vs_CHL1_VIAVNEVGR
67 & 66
0.014
0.675

CLUS_LFDSDPITVTVPVEVSR_vs_CHL1_VIAVNEVGR
68 & 66
0.022
0.664

CO5_TLLPVSKPEIR_vs_CHL1_VIAVNEVGR
70 & 66
0.006
0.696

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.044
0.644

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.038
0.648

CO5_VFQFLEK_vs_CHL1_VIAVNEVGR
71 & 66
0.005
0.701

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.048
0.642

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.038
0.648

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.001
0.741

CO6_ALNHLPLEYNSALYSR_vs_FBLN1_TGYYFDGISR
72 & 86
0.045
0.643

CO6_ALNHLPLEYNSALYSR_VS_LYAM1_SYYWIGIR
72 & 120
0.036
0.650

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.028
0.658

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.007
0.693

CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK
72 & 147
0.041
0.647

F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR
84 & 66
0.021
0.665

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.001
0.729

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.032
0.654

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.040
0.647

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.018
0.670

HABP2_FLNWIK_vs_ITIH4_ILDDLSPR
92 & 112
0.030
0.655

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.017
0.671

HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK
92 & 121
0.014
0.675

HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR
92 & 126
0.034
0.652

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.005
0.699

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.034
0.652

HABP2_FLNWIK_vs_SPRL1_VLTHSELAPLR
92 & 140
0.046
0.643

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.003
0.709

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.005
0.700

HEMO_NFPSPVDAAFR_vs_CHL1_VIAVNEVGR
93 & 66
0.020
0.667

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.034
0.652

KNG1_DIPTNSPELEETLTHTITK_vs_CHL1_VIAVNEVGR
116 & 66
0.022
0.664

PEDF_LQSLFDSPDFSK_vs_CHL1_VIAVNEVGR
124 & 66
0.008
0.691

PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR
125 & 66
0.009
0.688

PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK
125 & 147
0.049
0.641

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.021
0.665

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.012
0.680

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.025
0.660

PSG2_IHPSYTNYR_VS_NCAM1_GLGEISAASEFK
133 & 121
0.048
0.642

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.012
0.679

PSG2_IHPSYTNYR_vs_PSG9_LFIPQITR
133 & 136
0.033
0.653

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 & 147
0.043
0.645

VTNC_GQYCYELDEK_vs_C163A_INPASLDK
149 & 54
0.044
0.644

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.001
0.744

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.038
0.648

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.030
0.655

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.016
0.672

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.020
0.667

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.014
0.677

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.009
0.688

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.045
0.643

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.004
0.704

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.003
0.712

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.002
0.726

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.023
0.663

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.023
0.664

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.028
0.657

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.009
0.688

TABLE 29

Reversal Classification Performance, weeks 17 and 18.

Reversal AUROC for gestational weeks 17 and 18 using a

case vs control cut-off of <35 0/7 vs >=35 0/7 weeks,

without BMI stratification.

SEQ ID

Reversal
NO :
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.021
0.744

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.023
0.741

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.017
0.752

CLUS_ASSIIDELFQDR_vs_CHL1_VIAVNEVGR
67 & 66
0.018
0.749

CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR
67 & 99
0.043
0.713

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.005
0.795

CLUS_LFDSDPITVTVPVEVSR_vs_CHL1_VIAVNEVGR
68 & 66
0.046
0.710

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.012
0.765

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.048
0.709

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.018
0.750

CO6_ALNHLPLEYNSALYSR_vs_IBP3_YGQPLPGYTTK
72 & 100
0.047
0.710

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.007
0.787

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.040
0.717

CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK
72 & 147
0.034
0.724

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR
82 & 40
0.012
0.766

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISLLLIESWLEPVR
82 & 81
0.037
0.721

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1_TGYYFDGISR
82 & 86
0.026
0.735

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR
82 & 99
0.025
0.737

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK
82 & 100
0.029
0.731

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR
82 & 112
0.010
0.773

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK
82 & 121
0.007
0.785

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.012
0.767

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG1_FQLPGQK
82 & 131
0.011
0.769

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.043
0.713

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR
82 & 136
0.018
0.749

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_VS_SPRL1_VLTHSELAPLR
82 & 140
0.035
0.722

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR
82 & 141
0.046
0.710

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR
82 & 142
0.024
0.739

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
82 & 144
0.016
0.754

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDBELPEHTVK
82 & 147
0.008
0.781

ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR
83 & 40
0.026
0.735

ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR
83 & 112
0.028
0.732

ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK
83 & 121
0.021
0.744

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.013
0.762

ENPP2_TYLHTYESEI_vs_PSG1_FQLPGQK
83 & 131
0.021
0.744

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.034
0.723

ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR
83 & 142
0.038
0.719

ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
83 & 144
0.031
0.728

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.010
0.770

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.014
0.758

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.040
0.717

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.043
0.714

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.006
0.790

HABP2_FLNWIK_vs_ITIH4_ILDDLSPR
92 & 112
0.043
0.714

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.028
0.732

HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF
92 & 139
0.047
0.710

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.020
0.746

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.044
0.712

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.026
0.734

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.025
0.736

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.017
0.751

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.034
0.723

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.018
0.750

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.031
0.728

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.032
0.727

PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR
133 & 138
0.044
0.712

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.028
0.731

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.032
0.726

TABLE 30

Reversal Classification Performance, weeks 17 and 18.

Reversal AUROC for gestational weeks 17 and 18 using

a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks,

with BMI stratification (>22 <= 37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.042
0.749

ANGT_DPTFIPAPIQAK_vs_IBP3_FLNVLSPR
42 & 99
0.033
0.762

ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK
42 & 100
0.041
0.751

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.017
0.793

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.042
0.749

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.042
0.749

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.020
0.786

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.047
0.744

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.039
0.753

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.026
0.773

CO6_ALNHLPLEYNSALYSR_vs_IBP3_FLNVLSPR
72 & 99
0.016
0.795

CO6_ALNHLPLEYNSALYSR_vs_IBP3_YGQPLPGYTTK
72 & 100
0.025
0.775

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.005
0.842

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.025
0.775

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR
82 & 40
0.041
0.751

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISLLLIESWLEPVR
82 & 81
0.029
0.767

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR
82 & 112
0.019
0.788

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK
82 & 121
0.022
0.782

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.026
0.773

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG1_FQLPGQK
82 & 131
0.039
0.753

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.044
0.747

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_NYGLLYCFR
82 & 138
0.049
0.742

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR
82 & 142
0.029
0.767

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
82 & 144
0.015
0.799

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_ELPEHTVK
82 & 147
0.014
0.802

ENPP2_TYLHTYESEI_vs_CSH_ISLLLIESWLEPVR
83 & 81
0.047
0.744

ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR
83 & 112
0.038
0.755

ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK
83 & 121
0.034
0.760

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.033
0.762

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.044
0.747

ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR
83 & 142
0.033
0.762

ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
83 & 144
0.021
0.784

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.011
0.811

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.034
0.760

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.037
0.756

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.016
0.797

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.032
0.764

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.005
0.842

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.028
0.769

HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF
92 & 139
0.045
0.746

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CRIS3_YEDLYSNCK
114 & 79
0.046
0.745

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.033
0.762

KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR
117 & 99
0.018
0.791

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.027
0.771

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.006
0.839

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.030
0.766

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.023
0.778

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.008
0.826

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.010
0.817

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.037
0.756

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.014
0.800

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.015
0.799

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.022
0.780

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.005
0.842

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.008
0.828

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.028
0.769

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.040
0.752

THBG_AVLHIGEK_vs_IGF2_GIVEECCFR
143 & 103
0.042
0.749

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.042
0.749

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.015
0.799

TABLE 31

Reversal Classification Performance, weeks 18 and 19.

Reversal AUROC for gestational weeks 18 and 19 using a case vs

control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI

stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
34 & 80
0.030
0.603

A2GL_DLLLPQPDLR_vs_FBLN1_TGYYFDGISR
34 & 86
0.016
0.613

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.003
0.642

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.015
0.615

A2GL_DLLLPQPDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
34 & 144
0.024
0.607

AFAM_DADPDTFFAK_vs_FBLN1_TGYYFDGISR
37 & 86
0.034
0.600

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.015
0.615

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.009
0.623

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.025
0.606

AFAM_HFQNLGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
38 & 144
0.021
0.609

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.014
0.616

ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR
42 & 86
0.008
0.625

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.005
0.633

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.018
0.612

ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
42 & 144
0.010
0.621

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.018
0.612

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.002
0.648

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.033
0.601

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.022
0.608

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.014
0.616

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.007
0.627

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.022
0.608

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.012
0.619

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.017
0.613

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.026
0.605

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.016
0.614

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.032
0.601

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.009
0.623

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.028
0.604

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.026
0.605

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR
47 & 129
0.024
0.607

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.002
0.644

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.034
0.600

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.018
0.611

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.022
0.608

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.025
0.607

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.018
0.612

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.017
0.612

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.005
0.632

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.025
0.606

APOH_ATVVYQGER_vs_ALS_IRPHTFTGLSGLR
48 & 40
0.034
0.600

APOH_ATVVYQGER_vs_C163A_INPASLDK
48 & 54
0.023
0.607

APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK
48 & 80
0.011
0.620

APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR
48 & 86
0.002
0.645

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.024
0.607

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.017
0.613

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.025
0.606

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.001
0.664

APOH_ATVVYQGER_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
48 & 135
0.030
0.603

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.008
0.625

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.016
0.614

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 & 142
0.013
0.617

APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
48 & 144
0.002
0.645

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 & 147
0.030
0.602

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL
51 & 134
0.019
0.611

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.006
0.630

C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR
55 & 81
0.020
0.610

C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR
55 & 86
0.006
0.631

C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR
55 & 120
0.030
0.603

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.024
0.606

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.006
0.630

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.006
0.629

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 138
0.016
0.613

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.028
0.604

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.020
0.610

C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
55 & 144
0.013
0.618

CBPN_EALIQFLEQVHQGIK_vs_FBLN1_TGYYFDGISR
59 & 86
0.030
0.603

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.017
0.613

CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR
61 & 86
0.010
0.622

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.025
0.606

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.003
0.641

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.025
0.606

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.021
0.609

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.019
0.611

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.004
0.637

CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK
62 & 80
0.024
0.607

CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR
62 & 86
0.010
0.621

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.006
0.631

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.026
0.605

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.027
0.604

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.025
0.606

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.006
0.631

CFAB_YGLVTYATYPK_vs_C163A_INPASLDK
64 & 54
0.015
0.615

CFAB_YGLVTYATYPK_vs_CSH_AHQLAIDTYQEFEETYIPK
64 & 80
0.034
0.600

CFAB_YGLVTYATYPK_vs_FBLN1_TGYYFDGISR
64 & 86
0.032
0.601

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.006
0.631

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.028
0.604

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.003
0.642

CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR
67 & 86
0.021
0.609

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.013
0.618

CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYFDGISR
68 & 86
0.026
0.605

CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL
68 & 134
0.018
0.611

CO5_TLLPVSKPEIR_vs_FBLN1_TGYYFDGISR
70 & 86
0.020
0.610

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.011
0.620

CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
70 & 144
0.012
0.618

CO5_VFQFLEK_vs_FBLN1_TGYYFDGISR
71 & 86
0.020
0.610

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.024
0.607

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.011
0.620

CO6_ALNHLPLEYNSALYSR_vs_FBLN1_TGYYFDGISR
72 & 86
0.024
0.607

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.020
0.610

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.006
0.630

COSA_SLLQPNK_vs_CSH_AHQLAIDTYQEFEETYIPK
74 & 80
0.020
0.610

COSA_SLLQPNK_vs_FBLN1_TGYYFDGISR
74 & 86
0.021
0.609

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.007
0.627

COSA_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.021
0.609

COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.001
0.652

CO8B_QALEEFQK_vs_CSH_AHQLAIDTYQEFEETYIPK
76 & 80
0.016
0.614

CO8B_QALEEFQK_vs_FBLN1_TGYYFDGISR
76 & 86
0.034
0.600

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.007
0.627

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.019
0.611

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.024
0.607

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.001
0.654

F13B_GDTYPAELYITGSILR_VS_FBLN1_TGYYFDGISR
84 & 86
0.011
0.620

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.005
0.631

F13B_GDTYPAELYITGSILR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
84 & 144
0.023
0.607

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.031
0.602

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.025
0.606

FETUA_FSVVYAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
88 & 144
0.033
0.601

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.024
0.607

FETUA_HTLNQIDEVK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
89 & 144
0.033
0.601

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.013
0.617

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.004
0.635

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.024
0.607

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.029
0.603

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.010
0.622

HEMO_NFPSPVDAAFR_vs_FBLN1_TGYYFDGISR
93 & 86
0.024
0.607

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.008
0.624

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.030
0.602

HEMO_NFPSPVDAAFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
93 & 144
0.011
0.620

IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFEETYIPK
2 & 80
0.025
0.606

IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR
2 & 86
0.004
0.636

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.033
0.601

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.000
0.668

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.011
0.621

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.028
0.603

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.006
0.629

IBP6_GAQTLYVPNCDHR_vs_FBLN1_TGYYFDGISR
101 & 86
0.026
0.605

IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL
101 & 134
0.014
0.617

IBP6_HLDSVLQQLQTEVYR_vs_FBLN1_TGYYFDGISR
102 & 86
0.023
0.608

IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL
102 & 134
0.014
0.617

INHBC_LDFHFSSDR_vs_C163A_INPASLDK
107 & 54
0.013
0.617

INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR
107 & 86
0.016
0.614

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.005
0.634

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.012
0.618

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.020
0.610

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.011
0.620

ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL
111 & 134
0.033
0.601

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.024
0.606

ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR
113 & 86
0.018
0.612

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.015
0.615

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG3_VSAPSGTGHLPGLNPL
114 & 134
0.029
0.604

KNG1_DIPTNSPELEETLTHTITK_vs_CSH_AHQLAIDTYQEFEETYIPK
116 & 80
0.023
0.607

KNG1_DIPTNSPELEETLTHTITK_vs_FBLN1_TGYYFDGISR
116 & 86
0.018
0.612

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.005
0.634

KNG1_DIPTNSPELEETLTHTITK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
116 & 144
0.010
0.621

KNG1_QVVAGLNFR_Vs_FBLN1_TGYYFDGISR
117 & 86
0.022
0.608

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.014
0.616

KNG1_QVVAGLNFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
117 & 144
0.032
0.601

LBP_ITGFLKPGK_vs_C163A_INPASLDK
118 & 54
0.007
0.627

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.002
0.646

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.019
0.610

LBP_ITGFLKPGK_vs_SOM2.CSH_SVEGSCGF
118 & 139
0.032
0.602

LBP_ITGFLKPGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
118 & 144
0.022
0.608

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.004
0.635

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.027
0.605

LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
119 & 80
0.014
0.616

LBP_ITLPDFTGDLR_vs_FBLN1_TGYYFDGISR
119 & 86
0.017
0.612

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.031
0.602

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.001
0.652

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.013
0.618

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.018
0.612

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.015
0.615

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.034
0.600

PEDF_LQSLFDSPDFSK_vs_C163A_INPASLDK
124 & 54
0.033
0.601

PEDF_LQSLFDSPDFSK_vs_FBLN1_TGYYFDGISR
124 & 86
0.022
0.608

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.005
0.634

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.028
0.604

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.018
0.611

PEDF_LQSLFDSPDFSK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
124 & 144
0.014
0.616

PEDF_TVQAVLTVPK_vs_C163A_INPASLDK
125 & 54
0.021
0.609

PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK
125 & 80
0.027
0.605

PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR
125 & 86
0.010
0.622

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.003
0.643

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.019
0.611

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.018
0.612

PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
125 & 144
0.007
0.628

PTGDS_GPGEDFR_vs_FBLN1_TGYYFDGISR
137 & 86
0.023
0.607

PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL
137 & 134
0.013
0.618

VTNC_GQYCYELDEK_vs_C163A_INPASLDK
149 & 54
0.014
0.616

VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK
149 & 80
0.019
0.611

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.004
0.638

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.007
0.627

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.031
0.602

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.012
0.619

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.001
0.657

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.005
0.632

VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF
149 & 139
0.034
0.601

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.032
0.601

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.026
0.605

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.001
0.655

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.028
0.604

VTNC_VDTVDPPYPR_vs_FBLN1_TGYYFDGISR
150 & 86
0.014
0.616

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.012
0.618

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.001
0.650

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.015
0.615

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.004
0.637

TABLE 32

Reversal Classification Performance, weeks 18 and 19.

Reversal AUROC for gestational weeks 18 and 19 using a

case vs control cut-off of <37 0/7 vs >=37 0/7 weeks,

with BMI stratification (>22 <=37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_C163A_INPASLDK
34 & 54
0.021
0.634

A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR
34 & 78
0.049
0.614

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.041
0.619

A2GL_DLLLPQPDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
34 & 80
0.042
0.618

A2GL_DLLLPQPDLR_vs_FBLN1_TGYYFDGISR
34 & 86
0.034
0.623

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.011
0.648

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.020
0.636

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.010
0.651

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.018
0.637

A2GL_DLLLPQPDLR_vs_SPRL1_VLTHSELAPLR
34 & 140
0.019
0.637

A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR
34 & 141
0.021
0.634

A2GL_DLLLPQPDLR_vs_TENX_LSQLSVTDVTTSSLR
34 & 142
0.018
0.637

A2GL_DLLLPQPDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
34 & 144
0.010
0.651

AFAM_DADPDTFFAK_vs_C163A_INPASLDK
37 & 54
0.048
0.615

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.021
0.634

AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSFLLR
37 & 141
0.030
0.626

AFAM_DADPDTFFAK_vs_TENX_LSQLSVTDVTTSSLR
37 & 142
0.033
0.624

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.007
0.656

AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR
38 & 141
0.034
0.623

AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR
38 & 142
0.034
0.623

AFAM_HFQNLGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
38 & 144
0.030
0.626

ANGT_DPTFIPAPIQAK_vs_C163A_INPASLDK
42 & 54
0.032
0.625

ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR
42 & 66
0.026
0.629

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.043
0.618

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.038
0.621

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.006
0.658

ANGT_DPTFIPAPIQAK_vs_CSH_ISLLLIESWLEPVR
42 & 81
0.035
0.622

ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR
42 & 86
0.011
0.647

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.012
0.645

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.031
0.625

ANGT_DPTFIPAPIQAK_vs_PSG1_FQLPGQK
42 & 131
0.048
0.615

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.006
0.660

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.012
0.646

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_NYGLLYCFR
42 & 138
0.046
0.616

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.007
0.660

ANGT_DPTFIPAPIQAK_vs_SPRL1_VLTHSELAPLR
42 & 140
0.029
0.627

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.012
0.646

ANGT_DPTFIPAPIQAK_vs_TENX_LSQLSVTDVTTSSLR
42 & 142
0.008
0.654

ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
42 & 144
0.006
0.660

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.030
0.626

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.001
0.689

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.046
0.616

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.013
0.645

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.009
0.651

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.028
0.628

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.038
0.620

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.020
0.635

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.044
0.617

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.029
0.627

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.011
0.648

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.037
0.621

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 & 131
0.034
0.623

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.010
0.651

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.048
0.615

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.043
0.619

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.015
0.641

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.015
0.642

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.012
0.645

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.041
0.619

APOH_ATVVYQGER_vs_C163A_INPASLDK
48 & 54
0.032
0.625

APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR
48 & 66
0.049
0.614

APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK
48 & 80
0.040
0.619

APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR
48 & 86
0.019
0.636

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.017
0.638

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.031
0.626

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.013
0.644

APOH_ATVVYQGER_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
48 & 135
0.024
0.631

APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR
48 & 140
0.039
0.620

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.011
0.648

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 & 142
0.008
0.653

APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
48 & 144
0.015
0.642

C1QB_VPGLYYFTYHASSR_vs_ALS_IRPHTFTGLSGLR
55 & 40
0.030
0.626

C1QB_VPGLYYFTYHASSR_vs_C163A_INPASLDK
55 & 54
0.010
0.650

C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR
55 & 66
0.011
0.647

C1QB_VPGLYYFTYHASSR_vs_CRIS3_AVSPPAR
55 & 78
0.017
0.638

C1QB_VPGLYYFTYHASSR_vs_CRIS3_YEDLYSNCK
55 & 79
0.022
0.633

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.004
0.669

C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR
55 & 81
0.010
0.650

C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR
55 & 86
0.005
0.665

C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR
55 & 98
0.036
0.622

C1QB_VPGLYYFTYHASSR_vs_IBP3_FLNVLSPR
55 & 99
0.022
0.633

C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK
55 & 100
0.027
0.628

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.011
0.648

C1QB_VPGLYYFTYHASSR_vs_ITIH4_ILDDLSPR
55 & 112
0.024
0.631

C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR
55 & 120
0.004
0.668

C1QB_VPGLYYFTYHASSR_vs_NCAM1_GLGEISAASEFK
55 & 121
0.019
0.636

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.004
0.669

C1QB_VPGLYYFTYHASSR_vs_PSG1_FQLPGQK
55 & 131
0.020
0.636

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.004
0.665

C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
55 & 135
0.024
0.632

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.003
0.673

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 138
0.008
0.654

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF
55 & 139
0.010
0.652

C1QB_VPGLYYFTYHASSR_VS_SPRL1_VLTHSELAPLR
55 & 140
0.010
0.651

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.004
0.666

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.002
0.681

C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
55 & 144
0.004
0.666

C1QB_VPGLYYFTYHASSR_vs_VTDB_ELPEHTVK
55 & 147
0.034
0.623

CAH1_GGPFSDSYR_vs_C163A_INPASLDK
56 & 54
0.033
0.624

CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK
56 & 79
0.045
0.617

CAH1_GGPFSDSYR_vs_PSG1_FQLPGQK
56 & 131
0.046
0.616

CAH1_GGPFSDSYR_vs_PSG3_VSAPSGTGHLPGLNPL
56 & 134
0.029
0.627

CAH1_GGPFSDSYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
56 & 135
0.048
0.615

CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR
56 & 18
0.044
0.617

CAH1_GGPFSDSYR_vs_TENX_LNWEAPPGAFDSFLLR
56 & 141
0.038
0.621

CAH1_GGPFSDSYR_vs_TENX_LSQLSVTDVTTSSLR
56 & 142
0.026
0.630

CAH1_GGPFSDSYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
56 & 144
0.040
0.619

CBPN_EALIQFLEQVHQGIK_vs_FBLN1_TGYYFDGISR
59 & 86
0.050
0.614

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.030
0.626

CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPGAFDSFLLR
59 & 141
0.028
0.627

CBPN_EALIQFLEQVHQGIK_vs_TENX_LSQLSVTDVTTSSLR
59 & 142
0.029
0.627

CBPN_EALIQFLEQVHQGIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
59 & 144
0.049
0.614

CBPN_NNANGVDLNR_vs_FBLN1_TGYYFDGISR
60 & 86
0.045
0.617

CBPN_NNANGVDLNR_vs_TENX_LNWEAPPGAFDSFLLR
60 & 141
0.045
0.617

CD14_LTVGAAQVPAQLLVGALR_vs_C163A_INPASLDK
61 & 54
0.033
0.624

CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR
61 & 86
0.036
0.622

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.011
0.648

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.032
0.625

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.024
0.631

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.041
0.619

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.007
0.657

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.004
0.665

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.007
0.657

CD14_SWLAELQQWLKPGLK_vs_C163A_INPASLDK
62 & 54
0.037
0.621

CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR
62 & 86
0.034
0.623

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.026
0.630

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.043
0.618

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.010
0.649

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.006
0.661

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.012
0.646

CFAB_YGLVTYATYPK_vs_C163A_INPASLDK
64 & 54
0.025
0.630

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.040
0.620

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.011
0.648

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.043
0.618

CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR
67 & 141
0.030
0.626

CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTSSLR
67 & 142
0.023
0.632

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR
68 & 141
0.043
0.618

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR
68 & 142
0.041
0.619

CO5_TLLPVSKPEIR_vs_FBLN1_TGYYFDGISR
70 & 86
0.045
0.617

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.014
0.643

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.043
0.618

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.019
0.636

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.016
0.640

CO5_TLLPVSKPEIR_vs_TENX_LSQLSVTDVTTSSLR
70 & 142
0.011
0.647

CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
70 & 144
0.010
0.650

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.027
0.628

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.016
0.641

CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR
71 & 142
0.020
0.635

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.016
0.640

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.019
0.637

CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR
72 & 142
0.016
0.640

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.014
0.642

CO8A_SLLQPNK_vs_C163A_INPASLDK
74 & 54
0.036
0.622

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.035
0.623

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.030
0.626

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.007
0.656

CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.009
0.651

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.005
0.664

CO8B_QALEEFQK_vs_C163A_INPASLDK
76 & 54
0.049
0.614

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.037
0.621

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 & 140
0.046
0.616

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.005
0.663

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.006
0.659

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.005
0.664

F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR
84 & 66
0.031
0.625

F13B_GDTYPAELYITGSILR_vs_CSH_AHQLAIDTYQEFEETYIPK
84 & 80
0.035
0.623

F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDGISR
84 & 86
0.036
0.622

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.020
0.636

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.022
0.633

F13B_GDTYPAELYITGSILR_vs_TENX_LNWEAPPGAFDSFLLR
84 & 141
0.011
0.647

F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTDVTTSSLR
84 & 142
0.006
0.658

F13B_GDTYPAELYITGSILR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
84 & 144
0.024
0.631

HABP2_FLNWIK_vs_C163A_INPASLDK
92 & 54
0.027
0.628

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.040
0.620

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.028
0.628

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.022
0.633

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.016
0.640

HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF
92 & 139
0.048
0.617

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.014
0.642

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.012
0.646

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.008
0.654

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.042
0.618

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.049
0.614

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.017
0.639

HEMO_NFPSPVDAAFR_vs_TENX_LSQLSVTDVTTSSLR
93 & 142
0.028
0.628

HEMO_NFPSPVDAAFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
93 & 144
0.041
0.619

IBP4_QCHPALDGQR_vs_C163A_INPASLDK
2 & 54
0.031
0.625

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.042
0.618

IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFEETYIPK
2 & 80
0.048
0.615

IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR
2 & 86
0.030
0.626

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.019
0.636

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.020
0.635

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.008
0.654

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.033
0.624

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.041
0.619

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.013
0.645

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.011
0.648

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.007
0.656

INHBC_LDFHFSSDR_vs_C163A_INPASLDK
107 & 54
0.011
0.647

INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR
107 & 86
0.038
0.620

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.047
0.615

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.043
0.618

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.009
0.652

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.026
0.629

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.004
0.666

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.006
0.658

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.016
0.640

ITIH4_NPLVWVHASPEHVVVTR_vs_CHL1_VIAVNEVGR
113 & 66
0.044
0.617

ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_AVSPPAR
113 & 78
0.045
0.616

ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_YEDLYSNCK
113 & 79
0.035
0.622

ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_AHOLAIDTYQEFEETYIPK
113 & 80
0.042
0.618

ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR
113 & 86
0.041
0.619

ITIH4_NPLVWVHASPEHVVVTR_vs_LYAM1_SYYWIGIR
113 & 120
0.017
0.638

ITIH4_NPLVWVHASPEHVVVTR_vs_PGRP2_AGLLRPDYALLGHR
113 & 126
0.027
0.629

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.042
0.618

ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR
113 & 18
0.042
0.618

ITIH4_NPLVWVHASPEHVVVTR_vs_SOM2.CSHSVEGSCGF
113 & 139
0.045
0.618

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR
113 & 141
0.016
0.641

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR
113 & 142
0.011
0.647

ITIH4_NPLVWVHASPEHVVVTR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
113 & 144
0.044
0.617

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.042
0.618

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.049
0.614

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR
116 & 141
0.038
0.621

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR
116 & 142
0.024
0.631

KNG1_DIPTNSPELEETLTHTITK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
116 & 144
0.043
0.618

KNG1_QVVAGLNFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
117 & 144
0.044
0.617

LBP_ITGFLKPGK_vs_C163A_INPASLDK
118 & 54
0.037
0.621

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.028
0.628

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.021
0.634

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.045
0.617

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.017
0.639

PEDF_LQSLFDSPDFSK_vs_C163A_INPASLDK
124 & 54
0.042
0.618

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.034
0.623

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.044
0.617

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.019
0.636

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.009
0.651

PEDF_TVQAVLTVPK_vs_C163A_INPASLDK
125 & 54
0.009
0.652

PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR
125 & 66
0.025
0.630

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.049
0.614

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.044
0.617

PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK
125 & 80
0.039
0.620

PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR
125 & 86
0.041
0.619

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.012
0.646

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.011
0.647

PEDF_TVQAVLTVPK_vs_SOM2.CSH_SVEGSCGF
125 & 139
0.040
0.621

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.005
0.663

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.003
0.673

PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
125 & 144
0.006
0.658

PRDX2_GLFIIDGK_vs_C163A_INPASLDK
128 & 54
0.013
0.644

PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR
128 & 78
0.038
0.621

PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK
128 & 79
0.024
0.632

PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR
128 & 120
0.035
0.623

PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL
128 & 134
0.020
0.635

PRDX2_GLFIIDGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
128 & 135
0.047
0.615

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.029
0.627

PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR
128 & 141
0.022
0.633

PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR
128 & 142
0.021
0.634

PRDX2_GLFIIDGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
128 & 144
0.030
0.626

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.017
0.639

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.037
0.621

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.042
0.618

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.016
0.640

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR
133 & 141
0.041
0.619

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.026
0.629

PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL
137 & 134
0.048
0.615

PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR
137 & 141
0.036
0.622

PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR
137 & 142
0.043
0.618

PTGDS_GPGEDFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
137 & 144
0.028
0.628

VTNC_GQYCYELDEK_vs_C163A_INPASLDK
149 & 54
0.005
0.664

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.019
0.636

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.021
0.634

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.020
0.635

VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK
149 & 80
0.027
0.629

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.012
0.645

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.002
0.678

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.039
0.620

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.006
0.659

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.004
0.666

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.037
0.621

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.013
0.644

VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF
149 & 139
0.020
0.637

VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR
149 & 140
0.023
0.632

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.008
0.653

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.007
0.657

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.001
0.690

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.020
0.636

VTNC_VDTVDPPYPR_vs_C163A_INPASLDK
150 & 54
0.018
0.638

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.040
0.620

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.038
0.621

VTNC_VDTVDPPYPR_VS_FBLN1_TGYYFDGISR
150 & 86
0.040
0.619

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.004
0.666

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.027
0.629

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.007
0.658

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.030
0.626

VTNC_VDTVDPPYPR_vs_SOM2.CSH_SVEGSCGF
150 & 139
0.046
0.617

VTNC_VDTVDPPYPR_vs_SPRL1_VLTHSELAPLR
150 & 140
0.043
0.618

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.021
0.634

VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR
150 & 142
0.016
0.640

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.004
0.669

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.032
0.625

TABLE 33

Reversal Classification Performance, weeks 18 and 19.

Reversal AUROC for gestational weeks 18 and 19 using

a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks,

without BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.039
0.650

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.023
0.665

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.018
0.673

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.040
0.650

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.019
0.671

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.042
0.648

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.049
0.644

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.017
0.675

B2MG_VNHVTLSQPK_vs_C163A_INPASLDK
51 & 54
0.026
0.663

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.019
0.671

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.029
0.659

CBPN_EALIQFLEQVHQGIK_vs_PSG9_LFIPQITR
59 & 136
0.032
0.656

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.038
0.652

CD14_LTVGAAQVPAQLLVGALR_vs_C163A_INPASLDK
61 & 54
0.029
0.659

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.039
0.651

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.024
0.664

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.005
0.703

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.032
0.657

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.012
0.684

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.026
0.663

CD14_SWLAELQQWLKPGLK_vs_C163A_INPASLDK
62 & 54
0.036
0.653

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.047
0.645

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.018
0.672

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.022
0.667

CLUS_ASSIIDELFQDR_vs_C163A_INPASLDK
67 & 54
0.032
0.656

CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR
67 & 99
0.038
0.651

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.026
0.662

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.003
0.718

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.004
0.712

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.029
0.659

CLUS_LFDSDPITVTVPVEVSR_vs_C163A_INPASLDK
68 & 54
0.029
0.660

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.023
0.666

CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK
68 & 80
0.047
0.645

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR
68 & 99
0.017
0.674

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK
68 & 100
0.011
0.686

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.001
0.734

CLUS_LFDSDPITVTVPVEVSR_vs_ITIH4_ILDDLSPR
68 & 112
0.048
0.644

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.003
0.713

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR
68 & 141
0.030
0.658

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR
68 & 142
0.047
0.645

CLUS_LFDSDPITVTVPVEVSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
68 & 144
0.041
0.649

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.013
0.682

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.021
0.668

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.027
0.661

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.020
0.669

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.009
0.689

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.021
0.669

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.048
0.644

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.010
0.687

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.028
0.660

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.043
0.647

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.050
0.643

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR
82 & 136
0.027
0.662

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.050
0.643

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.028
0.660

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.045
0.646

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.017
0.674

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.006
0.700

FETUA_FSVVYAK_vs_PSG9_LFIPQITR
88 & 136
0.030
0.658

FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
89 & 135
0.037
0.652

FETUA_HTLNQIDEVK_vs_PSG9_LFIPQITR
89 & 136
0.017
0.673

HABP2_FLNWIK_vs_C163A_INPASLDK
92 & 54
0.021
0.668

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.030
0.658

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.015
0.677

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.049
0.644

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.021
0.668

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.037
0.652

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.045
0.647

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.035
0.654

IBP4_QCHPALDGQR_vs_C163A_INPASLDK
2 & 54
0.029
0.660

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.040
0.649

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.020
0.670

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.026
0.662

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.005
0.705

IBP6_GAQTLYVPNCDHR_vs_C163A_INPASLDK
101 & 54
0.015
0.678

IBP6_GAQTLYVPNCDHR_vs_IGF2_GIVEECCFR
101 & 103
0.035
0.654

IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR
101 & 120
0.025
0.664

IBP6_HLDSVLQQLQTEVYR_vs_C163A_INPASLDK
102 & 54
0.015
0.678

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.032
0.656

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.048
0.644

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.016
0.675

KNG1_QVVAGLNFR_vs_C163A_INPASLDK
117 & 54
0.049
0.643

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.040
0.650

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.010
0.687

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.007
0.697

KNG1_QVVAGLNFR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
117 & 144
0.043
0.648

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.046
0.646

PEDF_TVQAVLTVPK_VS_LYAM1_SYYWIGIR
125 & 120
0.021
0.668

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.024
0.665

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.021
0.668

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.013
0.681

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.020
0.670

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.041
0.649

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.010
0.688

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.041
0.649

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.030
0.659

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.007
0.696

PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK
133 & 121
0.050
0.643

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.024
0.664

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.033
0.655

PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR
133 & 138
0.037
0.652

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.043
0.648

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR
133 & 141
0.030
0.658

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.023
0.665

PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
133 & 144
0.037
0.652

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.045
0.646

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.036
0.653

VTNC_GQYCYELDEK_vs_C163A_INPASLDK
149 & 54
0.041
0.649

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.032
0.657

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.006
0.700

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.047
0.645

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.015
0.678

TABLE 34

Reversal Classification Performance, weeks 18 and 19.

Reversal AUROC for gestational weeks 18 and 19 using

a case vs control cut-off of <35 0/7 vs >=35 0/7

weeks, with BMI stratification (>22 <=37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.040
0.686

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.022
0.707

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.045
0.682

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.029
0.699

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.016
0.718

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.033
0.694

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.026
0.702

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.018
0.715

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.028
0.700

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.006
0.748

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.044
0.683

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.041
0.685

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.036
0.691

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.009
0.737

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.010
0.733

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.021
0.710

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.027
0.700

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.017
0.717

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.035
0.691

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.016
0.719

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.014
0.724

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.024
0.705

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.042
0.684

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR
82 & 136
0.011
0.731

ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK
83 & 121
0.047
0.680

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.042
0.684

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.012
0.727

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.037
0.689

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.009
0.737

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.006
0.748

FETUA_FSVVYAK_vs_PSG9_LFIPQITR
88 & 136
0.043
0.684

FETUA_HTLNQIDEVK_vs_PSG9_LFIPQITR
89 & 136
0.037
0.689

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.045
0.682

IBP4_QCHPALDGQR_vs_C163A_INPASLDK
2 & 54
0.048
0.679

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.043
0.684

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.010
0.733

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.004
0.759

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.020
0.710

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.010
0.734

KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR
117 & 99
0.029
0.698

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.034
0.692

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.004
0.760

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.007
0.746

LBP_ITGFLKPGK_vs_PSG9_LFIPQITR
118 & 136
0.044
0.682

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.046
0.681

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.018
0.714

PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR
133 & 40
0.038
0.688

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.012
0.728

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.036
0.691

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.008
0.741

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.007
0.743

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.024
0.705

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.044
0.683

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.017
0.716

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.019
0.712

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.025
0.704

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.010
0.733

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 & 112
0.026
0.702

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.002
0.777

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.032
0.694

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.010
0.733

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.028
0.699

PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR
133 & 138
0.036
0.690

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.045
0.682

PSG2_IHPSYTNYR_vs_TENX LNWEAPPGAFDSFLLR
133 & 141
0.024
0.705

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.018
0.715

PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
133 & 144
0.046
0.681

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 & 147
0.021
0.710

PTGDS_GPGEDFR_vs_C163A_INPASLDK
137 & 54
0.036
0.690

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 & 103
0.043
0.684

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.031
0.696

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.022
0.707

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.006
0.749

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.023
0.705

TABLE 35

Reversal Classification Performance, weeks 19 and 20.

Reversal AUROC for gestational weeks 19 and 20 using

a case vs control cut-off of <37 0/7 vs >=37 0/7

weeks, without BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_PRG2_WNFAYWAAHQPWSR
34 & 129
0.018
0.618

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.013
0.624

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.023
0.613

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.045
0.600

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.021
0.616

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.013
0.624

AFAM_HFQNLGK_vs_PRG2_WNFAYWAAHQPWSR
38 & 129
0.036
0.605

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.031
0.608

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.007
0.635

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.009
0.631

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.027
0.611

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.007
0.635

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.007
0.635

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.015
0.621

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.027
0.610

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.009
0.631

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.037
0.604

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.001
0.659

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.002
0.651

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.001
0.660

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.007
0.636

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.003
0.648

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.012
0.626

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.011
0.626

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR
47 & 129
0.004
0.642

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 & 131
0.031
0.608

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.001
0.659

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.044
0.601

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.042
0.602

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.004
0.645

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.028
0.610

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.028
0.610

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.008
0.634

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.005
0.641

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.005
0.640

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.006
0.638

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.005
0.641

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.043
0.601

APOH_ATVVYQGER_vs_IBP3_FLNVLSPR
48 & 99
0.031
0.608

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.012
0.626

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.004
0.646

APOH_ATVVYQGER_vs_PRG2_WNFAYWAAHQPWSR
48 & 129
0.033
0.606

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.003
0.650

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.014
0.622

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.025
0.612

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 & 142
0.021
0.615

B2MG_VEHSDLSFSK_vs_PSG3_VSAPSGTGHLPGLNPL
50 & 134
0.036
0.605

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.010
0.628

B2MG_VNHVTLSQPK_vs_PRG2_WNFAYWAAHQPWSR
51 & 129
0.020
0.617

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL
51 & 134
0.011
0.626

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.019
0.617

B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR
51 & 142
0.037
0.604

BGH3_LTLLAPLNSVFK_vs_PRG2_WNFAYWAAHQPWSR
52 & 129
0.035
0.605

BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL
52 & 134
0.043
0.601

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.022
0.614

C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR
55 & 129
0.011
0.627

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.008
0.633

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.012
0.625

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.031
0.608

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.040
0.602

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR
57 & 129
0.033
0.607

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.011
0.626

CD14_LTVGAAQVPAQLLVGALR_vs_PRG2_WNFAYWAAHQPWSR
61 & 129
0.028
0.610

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.008
0.633

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.022
0.615

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.027
0.611

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.028
0.610

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.034
0.606

CD14_SWLAELQQWLKPGLK_vs_PRG2_WNFAYWAAHQPWSR
62 & 129
0.033
0.607

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.014
0.622

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.034
0.606

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.042
0.602

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.030
0.609

CFAB_YGLVTYATYPK_vs_PRG2_WNFAYWAAHQPWSR
64 & 129
0.037
0.604

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.022
0.615

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.036
0.605

CO5_TLLPVSKPEIR_vs_PRG2_WNFAYWAAHQPWSR
70 & 129
0.037
0.604

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.017
0.619

CO5_VFQFLEK_vs_PRG2_WNFAYWAAHQPWSR
71 & 129
0.031
0.608

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.023
0.614

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.035
0.605

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.034
0.606

COSA_SLLQPNK_vs_IBP3_FLNVLSPR
74 & 99
0.044
0.600

COSA_SLLQPNK_vs_IBP3_YGQPLPGYTTK
74 & 100
0.026
0.611

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.004
0.643

CO8A_SLLQPNK_vs_PRG2_WNFAYWAAHQPWSR
74 & 129
0.021
0.615

COSA_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.009
0.631

COSA_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.019
0.617

COSA_SLLQPNK_vs_SPRL1_VLTHSELAPLR
74 & 140
0.035
0.605

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.024
0.613

COSA_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.019
0.617

COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.026
0.611

CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK
76 & 79
0.038
0.604

CO8B_QALEEFQK_vs_IBP3_FLNVLSPR
76 & 99
0.025
0.612

CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK
76 & 100
0.019
0.618

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.002
0.654

CO8B_QALEEFQK_vs_PRG2_WNFAYWAAHQPWSR
76 & 129
0.021
0.616

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.004
0.645

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.020
0.616

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 & 140
0.021
0.615

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.015
0.622

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.010
0.628

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.017
0.620

CO8B_QALEEFQK_vs_VTDB_ELPEHTVK
76 & 147
0.041
0.602

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2WNFAYWAAHQPWSR
82 & 129
0.033
0.607

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.033
0.606

ENPP2_TYLHTYESEI_vs_PRG2_WNFAYWAAHQPWSR
83 & 129
0.040
0.603

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL
83 & 134
0.044
0.601

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.036
0.605

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.038
0.604

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.031
0.608

FETUA_FSVVYAK_vs_PRG2_WNFAYWAAHQPWSR
88 & 129
0.033
0.606

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 1.34
0.017
0.619

FETUA_HTLNQIDEVK_vs_PRG2_WNFAYWAAHQPWSR
89 & 129
0.019
0.617

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.010
0.628

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.027
0.610

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.045
0.600

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.031
0.608

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.043
0.601

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.029
0.609

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.028
0.610

IBP4_QCHPALDGQR_vs_ALS_IRPHTFTGLSGLR
2 & 40
0.024
0.612

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.027
0.610

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.004
0.644

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.003
0.650

IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR
2 & 86
0.020
0.617

IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR
2 & 99
0.014
0.622

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.005
0.639

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.000
0.677

IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR
2 & 112
0.003
0.650

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.005
0.641

IBP4_QCHPALDGQR_vs_NCAM1_GLGEISAASEFK
2 & 121
0.027
0.610

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.011
0.627

IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQPWSR
2 & 129
0.002
0.658

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.000
0.710

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.001
0.673

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.004
0.646

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.002
0.655

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.005
0.641

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.004
0.645

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.002
0.658

IBP6_GAQTLYVPNCDHR_vs_PRG2_WNFAYWAAHQPWSR
101 & 129
0.038
0.604

IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL
101 & 134
0.024
0.613

IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR
101 & 18
0.045
0.600

IBP6_HLDSVLQQLQTEVYR_vs_PRG2_WNFAYWAAHQPWSR
102 & 129
0.032
0.607

IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL
102 & 134
0.023
0.613

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR
102 & 18
0.032
0.607

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.043
0.601

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.015
0.621

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.011
0.627

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.002
0.652

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.041
0.602

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.041
0.602

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.040
0.603

INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQPWSR
107 & 129
0.016
0.620

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.003
0.647

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.008
0.632

INHBC_LDFHFSSDR_VS_SPRL1_VLTHSELAPLR
107 & 140
0.035
0.605

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.007
0.634

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.009
0.630

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.024
0.612

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.025
0.612

ITIH3_ALDLSLK_vs_PRG2_WNFAYWAAHQPWSR
111 & 129
0.024
0.613

ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL
111 & 134
0.042
0.602

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.024
0.612

ITIH4_NPLVWVHASPEHVVVTR_vs_PRG2_WNFAYWAAHQPWSR
113 & 129
0.020
0.616

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.016
0.620

ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR
113 & 18
0.034
0.606

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.030
0.609

KNG1_DIPTNSPELEETLTHTITK_vs_PRG2_WNFAYWAAHQPWSR
116 & 129
0.032
0.607

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.020
0.617

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.041
0.602

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR
116 & 142
0.043
0.601

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.032
0.607

KNG1_QVVAGLNFR_vs_PRG2_WNFAYWAAHQPWSR
117 & 129
0.035
0.606

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.014
0.623

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.025
0.612

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.044
0.600

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.043
0.601

LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPWSR
118 & 129
0.022
0.615

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.006
0.637

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.033
0.606

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.024
0.613

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.018
0.618

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.024
0.613

LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR
119 & 129
0.011
0.628

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.002
0.652

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.011
0.628

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.015
0.621

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.045
0.600

PEDF_TVQAVLTVPK_vs_PRG2_WNFAYWAAHQPWSR
125 & 129
0.037
0.604

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.017
0.619

PRDX2_GLFIIDGK_vs_PRG2_WNFAYWAAHQPWSR
128 & 129
0.018
0.618

PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL
128 & 134
0.019
0.617

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.026
0.611

PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR
128 & 141
0.022
0.614

PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR
128 & 142
0.042
0.602

PTGDS_GPGEDFR_vs_PRG2_WNFAYWAAHQPWSR
137 & 129
0.026
0.611

PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL
137 & 134
0.028
0.610

THBG_AVLHIGEK_vs_PRG2_WNFAYWAAHQPWSR
143 & 129
0.029
0.609

THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL
143 & 134
0.018
0.618

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.033
0.606

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.030
0.609

VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQPWSR
149 & 129
0.018
0.618

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.014
0.622

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.009
0.631

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.033
0.607

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.013
0.624

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.033
0.606

VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQPWSR
150 & 129
0.014
0.623

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.004
0.642

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.004
0.643

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.032
0.607

VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR
150 & 142
0.043
0.601

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.015
0.621

TABLE 36

Reversal Classification Performance, weeks 19 and 20.

Reversal AUROC for gestational weeks 19 and 20 using

a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks,

with BMI stratification (>22 <= 37).

SEQ ID

ROC_

Reversal
NO:
pval
AUC

A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR
34 & 78
0.041
0.628

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.024
0.641

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 &
0.034
0.633

120

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLN
34 &
0.011
0.659

PL
134

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.030
0.636

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 &
0.044
0.626

100

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 &
0.036
0.631

103

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGL
37 &
0.028
0.637

NPL
134

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.040
0.628

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 &
0.018
0.647

100

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 &
0.018
0.648

103

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 &
0.014
0.654

134

AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR
38 &
0.047
0.624

141

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.047
0.624

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPG
42 &
0.025
0.640

LNPL
134

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.035
0.632

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.011
0.658

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.009
0.663

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.032
0.634

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 &
0.035
0.632

100

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 &
0.024
0.642

103

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 &
0.046
0.625

112

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 &
0.015
0.652

120

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLP
47 &
0.010
0.661

GLNPL
134

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASN
47 & 18
0.024
0.641

LR

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCG
47 &
0.049
0.623

F
139

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 &
0.049
0.623

140

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAF
47 &
0.048
0.624

DSFLLR
141

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTS
47 &
0.049
0.623

SLR
142

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 &
0.042
0.627

147

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.037
0.631

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 &
0.039
0.629

100

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 &
0.046
0.625

103

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLN
48 &
0.013
0.656

PL
134

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.025
0.640

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 &
0.038
0.630

103

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGL
51 &
0.028
0.637

NPL
134

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.036
0.631

BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGL
52 &
0.031
0.635

NPL
134

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHL
55 &
0.019
0.647

PGLNPL
134

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPAS
55 & 18
0.047
0.624

NLR

CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK
56 & 79
0.036
0.631

CAH1_GGPFSDSYR_vs_PSG3_VSAPSGTGHLPGLNP
56 &
0.028
0.637

L
134

CBPN_NNANGVDLNR_vs_PSG3_VSAPSGTGHLPGL
60 &
0.023
0.643

NPL
134

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYS
61 & 79
0.034
0.633

NCK

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPS
61 &
0.029
0.637

GTGHLPGLNPL
134

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTG
62 &
0.040
0.628

HLPGLNPL
134

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGL
64 &
0.020
0.646

NPL
134

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGL
67 &
0.027
0.638

NPL
134

CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR
70 & 78
0.049
0.623

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.039
0.629

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNP
70 &
0.010
0.661

L
134

CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK
71 & 79
0.041
0.628

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 &
0.028
0.637

134

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGH
72 &
0.050
0.623

LPGLNPL
134

COSA_SLLQPNK_vs_CRIS3_AVSPPAR
74 & 78
0.039
0.629

COSA_SLLQPNK_vs_CRIS3_YEDLYSNCK
74 & 79
0.016
0.651

CO8A_SLLQPNK_vs_IBP3_YGQPLPGYTTK
74 &
0.038
0.630

100

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 &
0.015
0.652

103

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 &
0.004
0.680

134

COSA_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.031
0.635

COSA_SLLQPNK_vs_SPRL1_VLTHSELAPLR
74 &
0.018
0.648

140

COSA_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 &
0.022
0.644

141

CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 &
0.017
0.650

142

CO8B_QALEEFQK_vs_ALS_IRPHTFTGLSGLR
76 & 40
0.035
0.632

CO8B_QALEEFQK_vs_CRIS3_AVSPPAR
76 & 78
0.017
0.649

CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK
76 & 79
0.008
0.665

CO8B_QALEEFQK_vs_IBP3_FLNVLSPR
76 & 99
0.028
0.638

CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK
76 &
0.017
0.649

100

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 &
0.005
0.677

103

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 &
0.039
0.629

120

CO8B_QALEEFQK_vs_NCAM1_GLGEISAASEFK
76 &
0.035
0.632

121

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 &
0.002
0.698

134

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.027
0.639

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 &
0.008
0.666

140

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSF
76 & 141
0.008
0.665

LLR

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.005
0.674

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVG
76 & 144
0.024
0.642

DGFLLR

CO8B_QALEEFQK_vs_VTDB_ELPEHTVK
76 & 147
0.020
0.645

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG
82 & 18
0.046
0.625

IALGGLLFPASNLR

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNC
84 & 79
0.040
0.628

K

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLN
88 & 134
0.038
0.630

PL

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLP
89 & 134
0.040
0.629

GLNPL

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.002
0.693

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.001
0.704

IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR
2 & 99
0.034
0.632

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.010
0.660

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.003
0.687

IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR
2 & 112
0.014
0.654

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.002
0.695

IBP4_QCHPALDGQR_VS_NCAM1_GLGEISAASEF
2 & 121
0.023
0.642

K

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL
2 & 126
0.016
0.651

GHR

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPG
2 & 134
0.000
0.741

LNPL

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNL
2 & 18
0.002
0.690

R

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.006
0.671

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFD
2 & 141
0.005
0.674

SFLLR

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSS
2 & 142
0.009
0.662

LR

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLV
2 & 144
0.012
0.657

GDGFLLR

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.003
0.686

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.024
0.642

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.029
0.637

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.015
0.652

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.007
0.669

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 &
0.005
0.674

100

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 &
0.002
0.695

103

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 &
0.033
0.633

112

INHBC_LDFHFSSDR_v_LYAM1_SYYWIGIR
107 &
0.030
0.636

120

INHBC_LDFHFSSDR_vs_NCAM1_GLGEISAASEF
107 &
0.047
0.624

K
121

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLG
107 &
0.036
0.631

HR
126

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGL
107 &
0.001
0.710

NPL
134

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNL
107 & 18
0.008
0.666

R

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 &
0.019
0.646

140

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDS
107 &
0.002
0.693

FLLR
141

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSS
107 &
0.003
0.689

LR
142

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLV
107 &
0.029
0.637

GDGFLLR
144

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 &
0.008
0.666

147

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.044
0.626

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YED
116 & 79
0.040
0.628

LYSNCK

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.049
0.623

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPG
117 &
0.033
0.633

LNPL
134

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNP
118 &
0.021
0.644

L
134

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.031
0.635

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.021
0.645

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGL
119 &
0.008
0.666

NPL
134

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.021
0.644

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLP
124 &
0.036
0.631

GLNPL
134

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPG
125 &
0.017
0.649

LNPL
134

PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR
128 & 78
0.019
0.647

PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK
128 & 79
0.012
0.658

PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR
128 &
0.028
0.637

120

PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGH
128 &
0.049
0.623

R
126

PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLN
128 &
0.005
0.676

PL
134

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.021
0.645

PRDX2_GLFIIDGK_vs_SPRL1_VLTHSELAPLR
128 &
0.049
0.623

140

PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFL
128 &
0.017
0.650

LR
141

PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR
128 &
0.030
0.636

142

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLN
133 &
0.044
0.626

PL
134

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.037
0.630

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 &
0.048
0.624

103

PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLN
137 &
0.020
0.645

PL
134

THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLN
143 &
0.026
0.639

PL
134

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.037
0.630

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPG
149 &
0.013
0.655

LNPL
134

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNL
149 & 18
0.024
0.641

R

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.032
0.634

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.023
0.643

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 &
0.036
0.631

120

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPG
150 &
0.005
0.675

LNPL
134

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN
150 & 18
0.013
0.656

LR

TABLE 37

Reversal Classification Performance, weeks 19 and 20.

Reversal AUROC for gestational weeks 19 and 20 using a

case vs control cut-off of <35 0/7 vs >=35 0/7 weeks,

without BMI stratification.

SEQ ID

ROC_

Reversal
NO:
pval
AUC

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 &
0.047
0.659

120

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.043
0.663

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 &
0.040
0.664

120

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.018
0.690

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.024
0.680

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.008
0.714

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.009
0.710

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEF
47 & 80
0.018
0.689

EETYIPK

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.025
0.680

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.017
0.691

APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK
47 & 97
0.022
0.683

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.019
0.688

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 &
0.020
0.686

100

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 &
0.026
0.679

103

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 &
0.016
0.694

112

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 &
0.001
0.756

120

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASE
47 &
0.031
0.673

FK
121

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALL
47 &
0.009
0.711

GHR
126

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 &
0.027
0.677

131

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLP
47 &
0.021
0.684

GLNPL
134

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASN
47 & 18
0.008
0.713

LR

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYC
47 &
0.029
0.675

FR
138

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCG
47 &
0.020
0.687

F
139

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 &
0.014
0.697

140

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAF
47 &
0.017
0.691

DSFLLR
141

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTS
47 &
0.015
0.694

SLR
142

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPL
47 &
0.012
0.702

VGDGFLLR
144

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 &
0.010
0.708

147

APOH_ATVVYQGER_vs_ALS_IRPHTFTGLSGLR
48 & 40
0.039
0.666

APOH_ATVVYQGER_vs_CRIS3_AVSPPAR
48 & 78
0.018
0.690

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.013
0.698

APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR
48 & 86
0.029
0.675

APOH_ATVVYQGER_vs_IBP1_VVESLAK
48 & 97
0.033
0.671

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 &
0.040
0.664

100

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 &
0.045
0.660

103

APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR
48 &
0.020
0.686

112

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 &
0.001
0.762

120

APOH_ATVVYQGER_vs_NCAM1_GLGEISAASEFK
48 &
0.047
0.659

121

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGH
48 &
0.003
0.736

R
126

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLN
48 &
0.005
0.725

PL
134

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.005
0.726

APOH_ATVVYQGER_VS_SPRL1_VLTHSELAPLR
48 &
0.007
0.718

140

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFL
48 &
0.010
0.705

LR
141

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 &
0.012
0.702

142

APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVG
48 &
0.041
0.664

DGFLLR
144

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 &
0.002
0.749

147

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 &
0.018
0.690

120

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.047
0.659

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.047
0.659

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 &
0.003
0.735

120

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLG
51 &
0.039
0.666

HR
126

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.019
0.688

B2MG_VNHVTLSQPK_vs_SPRL1_VLTHSELAPLR
51 &
0.037
0.667

140

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 &
0.025
0.679

120

CAH1_GGPFSDSYR_vs_CRIS3_AVSPPAR
56 & 78
0.026
0.679

CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK
56 & 79
0.029
0.675

CAH1_GGPFSDSYR_vs_IBP1_VVESLAK
56 & 97
0.036
0.668

CAH1_GGPFSDSYR_vs_LYAM1_SYYWIGIR
56 &
0.015
0.694

120

CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR
56 &
0.032
0.672

126

CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR
56 & 18
0.017
0.691

CAH1_GGPFSDSYR_vs_TENX_LNWEAPPGAFDSFLL
56 &
0.028
0.676

R
141

CAH1_GGPFSDSYR_vs_TENX_LSQLSVTDVTTSSLR
56 &
0.039
0.665

142

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.006
0.719

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.012
0.700

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.014
0.696

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIP
57 & 80
0.011
0.704

K

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.016
0.692

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.012
0.701

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.048
0.659

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 &
0.034
0.670

103

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 &
0.026
0.679

112

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 &
0.001
0.758

120

CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK
57 &
0.035
0.669

121

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 &
0.006
0.720

126

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWS
57 &
0.048
0.658

R
129

CATD_VGFAEAAR_vs_PSG1_FQLPGQK
57 &
0.008
0.713

131

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 &
0.015
0.695

134

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.006
0.719

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 &
0.028
0.676

138

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 &
0.020
0.687

139

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 &
0.007
0.716

140

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLL
57 &
0.004
0.730

R
141

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 &
0.004
0.733

142

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDG
57 &
0.016
0.693

FLLR
144

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 &
0.019
0.687

147

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.031
0.673

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.026
0.678

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.012
0.702

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.014
0.696

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYI
58 & 80
0.022
0.683

PK

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.034
0.670

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.011
0.704

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.033
0.671

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 &
0.029
0.675

100

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 &
0.014
0.697

103

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 &
0.030
0.674

112

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 &
0.002
0.749

120

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 &
0.024
0.681

121

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 &
0.005
0.727

126

CATD_VSTLPAITLK_vs_PSG1_FQLPGQK
58 &
0.025
0.679

131

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNP
58 &
0.009
0.710

L
134

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.005
0.723

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 &
0.039
0.665

138

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 &
0.046
0.660

139

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 &
0.006
0.720

140

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLL
58 &
0.003
0.741

R
141

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 &
0.003
0.737

142

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGD
58 &
0.026
0.679

GFLLR
144

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 &
0.007
0.717

147

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPA
59 & 18
0.038
0.667

SNLR

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 &
0.032
0.672

120

CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR
60 &
0.018
0.690

140

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPP
61 & 78
0.042
0.663

AR

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYS
61 & 79
0.036
0.668

NCK

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAI
61 & 80
0.043
0.663

DTYQEFEETYIPK

CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYF
61 & 86
0.022
0.684

DGISR

CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLA
61 & 97
0.044
0.661

K

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYW
61 &
0.001
0.759

IGIR
120

CD14_LTVGAAQVPAQLLVGALR_vs_NCAM1_GLGE
61 &
0.043
0.663

ISAASEFK
121

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLR
61 &
0.011
0.704

PDYALLGHR
126

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPS
61 &
0.020
0.687

GTGHLPGLNPL
134

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGL
61 & 18
0.008
0.713

LFPASNLR

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHS
61 &
0.015
0.695

ELAPLR
140

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEA
61 &
0.026
0.678

PPGAFDSFLLR
141

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSV
61 &
0.019
0.688

TDVTTSSLR
142

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLP
61 &
0.022
0.683

LVPGPLVGDGFLLR
144

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHT
61 &
0.005
0.727

VK
147

CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGI
62 & 86
0.033
0.671

SR

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGI
62 &
0.002
0.743

R
120

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLR
62 & 126
0.014
0.697

PDYALLGHR

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSG
62 & 134
0.031
0.673

TGHLPGLNPL

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGL
62 & 18
0.011
0.703

LFPASNLR

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSE
62 & 140
0.021
0.685

LAPLR

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEA
62 & 141
0.042
0.663

PPGAFDSFLLR

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSV
62 & 142
0.028
0.676

TDVTTSSLR

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPL
62 & 144
0.026
0.679

VPGPLVGDGFLLR

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHT
62 & 147
0.007
0.718

VK

CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR
67 & 86
0.048
0.658

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.004
0.728

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALL
67 & 126
0.036
0.668

GHR

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASN
67 & 18
0.008
0.713

LR

CLUS_ASSIIDELFQDR_vs_SPRL1_VLTHSELAPLR
67 & 140
0.031
0.673

CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTS
67 & 142
0.045
0.660

SLR

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.015
0.695

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPA
68 & 78
0.034
0.670

R

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYS
68 & 79
0.028
0.676

NCK

CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYF
68 & 86
0.036
0.668

DGISR

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWI
68 & 120
0.001
0.767

GIR

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLR
68 & 126
0.013
0.699

PDYALLGHR

CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSG
68 & 134
0.020
0.686

TGHLPGLNPL

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGL
68 & 18
0.004
0.730

LFPASNLR

CLUS_LFDSDPITVTVPVEVSR_vs_SPRL1_VLTHSE
68 & 140
0.012
0.702

LAPLR

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEA
68 & 141
0.021
0.684

PPGAFDSFLLR

CLUS_LFDSDPITVTVPVEVSR_v_TENX_LSQLSV
68 & 142
0.013
0.698

TDVTTSSLR

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHT
68 & 147
0.002
0.753

VK

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.009
0.710

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.027
0.677

CO5_TLLPVSKPEIR_vs_SPRL1_VLTHSELAPLR
70 & 140
0.028
0.676

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.013
0.699

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.030
0.674

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGI
72 & 120
0.017
0.692

R

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLF
72 & 18
0.040
0.665

PASNLR

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.009
0.711

COSA_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.045
0.661

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.033
0.671

COSA_SLLQPNK_vs_SPRL1_VLTHSELAPLR
74 & 140
0.036
0.668

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGD
74 & 144
0.040
0.665

GFLLR

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.009
0.711

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGL
76 & 134
0.035
0.669

NPL

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.036
0.668

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 & 140
0.025
0.679

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.043
0.662

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVG
76 & 144
0.032
0.672

DGFLLR

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.043
0.662

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.024
0.681

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNC
84 & 79
0.022
0.683

K

F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDG
84 & 86
0.046
0.660

ISR

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGI
84 & 120
0.001
0.754

R

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPD
84 & 126
0.037
0.667

YALLGHR

F13B_GDTYPAELYITGSILR_VS_SHBG_IALGGLLF
84 & 18
0.011
0.703

PASNLR

F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSEL
84 & 140
0.016
0.694

APLR

F13B_GDTYPAELYITGSILR_vs_TENX_LNWEAPP
84 & 141
0.046
0.660

GAFDSFLLR

F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTD
84 & 142
0.030
0.673

VTTSSLR

F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK
84 & 147
0.043
0.662

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.017
0.692

HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR
92 & 126
0.027
0.677

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.020
0.687

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLL
92 & 141
0.033
0.671

R

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.030
0.673

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.022
0.684

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.020
0.686

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPAS
93 & 18
0.022
0.684

NLR

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.006
0.720

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.009
0.708

IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR
2 & 86
0.040
0.664

IBP4_QCHPALDGQR_vs_IBP1_VVESLAK
2 & 97
0.038
0.666

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.001
0.761

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL
2 & 126
0.026
0.678

GHR

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLP
2 & 134
0.013
0.698

GLNPL

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASN
2 & 18
0.005
0.725

LR

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.007
0.715

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFD
2 & 141
0.047
0.659

SFLLR

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTS
2 & 142
0.044
0.661

SLR

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.033
0.671

IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR
101 &
0.049
0.657

120

IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFP
101 & 18
0.033
0.671

ASNLR

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIG
102 &
0.026
0.679

IR
120

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLF
102 & 18
0.033
0.671

PASNLR

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 &
0.038
0.666

120

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALL
107 &
0.044
0.661

GHR
126

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNL
107 & 18
0.043
0.662

R

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDS
107 &
0.047
0.659

FLLR
141

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSS
107 &
0.047
0.659

LR
142

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYY
116 &
0.013
0.700

WIGIR
120

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 &
0.003
0.734

120

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALL
117 &
0.048
0.659

GHR
126

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNL
117 & 18
0.012
0.702

R

KNG1_QVVAGLNFR_vs_SPRL1_VLTHSELAPLR
117 &
0.020
0.687

140

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.022
0.683

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.026
0.679

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 &
0.005
0.726

120

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPAS
124 & 18
0.045
0.660

NLR

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.023
0.683

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.024
0.681

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 &
0.003
0.736

120

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPG
125 &
0.047
0.659

LNPL
134

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNL
125 & 18
0.024
0.681

R

PEDF_TVQAVLTVPK_vs_SPRL1_VLTHSELAPLR
125 &
0.029
0.675

140

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSS
125 &
0.038
0.667

LR
142

PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK
125 &
0.036
0.668

147

PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR
128 & 78
0.032
0.672

PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK
128 & 79
0.029
0.675

PRDX2_GLFIIDGK_vs_IBP1_VVESLAK
128 & 97
0.033
0.671

PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR
128 &
0.013
0.700

120

PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGH
128 &
0.028
0.676

R
126

PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLN
128 &
0.047
0.659

PL
134

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.012
0.702

PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSF
128 &
0.020
0.687

LLR
141

PRDX2_GLFIIDGK_vs_TENX_LSQLSVTDVTTSSLR
128 &
0.028
0.676

142

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.023
0.682

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 &
0.043
0.662

120

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 &
0.049
0.657

140

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.031
0.673

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.035
0.669

PTGDS_GPGEDFR_vs_FBLN1_TGYYFDGISR
137 & 86
0.032
0.672

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 &
0.007
0.715

120

PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGH
137 &
0.044
0.661

R
126

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.033
0.671

PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF
137 &
0.041
0.664

139

PTGDS_GPGEDFR_VS_SPRL1_VLTHSELAPLR
137 &
0.016
0.692

140

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 &
0.013
0.698

120

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.041
0.664

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 &
0.015
0.696

120

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASN
149 & 18
0.031
0.672

LR

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 &
0.008
0.712

120

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALL
150 &
0.040
0.664

GHR
126

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN
150 & 18
0.014
0.696

LR

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 &
0.030
0.673

147

TABLE 38

Reversal Classification Performance, weeks 19 and 20.

Reversal AUROC for gestational weeks 19 and 20 using

a case vs control cut-off of <35 0/7 vs

>=35 0/7 weeks, with BMI stratification (>22 <= 37).

SEQ ID

ROC_

Reversal
NO:
pval
AUC

AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK
37 & 79
0.048
0.709

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 &
0.027
0.734

120

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLG
37 &
0.007
0.788

HR
126

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.010
0.771

AFAM_DADPDTFFAK_vs_VTDB_ELPEHTVK
37 &
0.027
0.734

147

AFAM_HFQNLGK_vs_IBP1_VVESLAK
38 & 97
0.045
0.726

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 &
0.021
0.744

120

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 &
0.012
0.766

126

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.016
0.756

AFAM_HFQNLGK_vs_VTDB_ELPEHTVK
38 &
0.036
0.722

147

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNL
42 & 18
0.025
0.737

R

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 &
0.033
0.726

120

APOH_ATVVYQGER_vs_CRIS3_AVSPPAR
48 & 78
0.020
0.746

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.013
0.762

APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR
48 &
0.043
0.714

112

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 &
0.003
0.816

120

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGH
48 &
0.001
0.855

R
126

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.003
0.819

APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR
48 &
0.043
0.714

140

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 &
0.001
0.839

147

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 &
0.008
0.782

120

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.022
0.742

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 &
0.028
0.732

120

BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLG
52 &
0.034
0.725

HR
126

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNL
52 & 18
0.027
0.734

R

BGH3_LTLLAPLNSVFK_vs_SOM2.CSH_SVEGSCGF
52 &
0.040
0.717

139

CAH1_GGPFSDSYR_vs_CRIS3_AVSPPAR
56 & 78
0.031
0.729

CAH1_GGPFSDSYR_vs_CRIS3_YEDLYSNCK
56 & 79
0.042
0.715

CAH1_GGPFSDSYR_VS_LYAM1_SYYWIGIR
56 &
0.033
0.726

120

CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR
56 &
0.045
0.712

126

CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR
56 & 18
0.020
0.747

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.035
0.723

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.029
0.731

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.038
0.720

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIP
57 & 80
0.028
0.733

K

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.038
0.720

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 &
0.006
0.789

120

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 &
0.018
0.751

126

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.013
0.762

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 &
0.044
0.713

139

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLL
57 &
0.045
0.712

R
141

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.016
0.754

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.014
0.760

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYI
58 & 80
0.029
0.731

PK

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.041
0.716

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 &
0.024
0.739

112

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 &
0.002
0.822

120

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 &
0.045
0.712

121

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 &
0.004
0.809

126

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.005
0.795

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 &
0.037
0.721

140

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLL
58 &
0.014
0.759

R
141

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 &
0.021
0.745

142

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 &
0.013
0.764

147

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNL
60 & 18
0.040
0.718

R

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPP
61 & 78
0.041
0.716

AR

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYS
61 & 79
0.028
0.732

NCK

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYW
61 &
0.005
0.799

IGIR
120

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLR
61 &
0.012
0.766

PDYALLGHR
126

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGL
61 & 18
0.011
0.768

LFPASNLR

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHT
61 &
0.016
0.756

VK
147

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGI
62 &
0.015
0.758

R
120

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPD
62 &
0.024
0.739

YALLGHR
126

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFP
62 & 18
0.017
0.752

ASNLR

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 &
0.034
0.725

147

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.035
0.723

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.040
0.718

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 &
0.018
0.751

120

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLG
67 &
0.042
0.715

HR
126

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.013
0.763

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 &
0.040
0.717

147

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.031
0.729

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNC
68 & 79
0.031
0.728

K

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGI
68 &
0.011
0.768

R
120

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPD
68 &
0.031
0.728

YALLGHR
126

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLL
68 & 18
0.009
0.776

FPASNLR

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHT
68 & 147
0.035
0.723

VK

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.033
0.726

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.018
0.750

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.031
0.728

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGI
72 & 120
0.041
0.716

R

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLF
72 & 18
0.024
0.739

PASNLR

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.029
0.731

CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.044
0.713

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.034
0.725

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.028
0.733

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.041
0.716

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.015
0.757

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNC
84 & 79
0.016
0.756

K

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGI
84 & 120
0.003
0.815

R

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPD
84 & 126
0.015
0.758

YALLGHR

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLF
84 & 18
0.004
0.801

PASNLR

F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK
84 & 147
0.023
0.740

FBLN3_IPSNPSHR_vs_CHL1_VIAVNEVGR
87 & 66
0.036
0.722

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPAS
93 & 18
0.036
0.722

NLR

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.008
0.780

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.012
0.766

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.001
0.861

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL
2 & 126
0.014
0.761

GHR

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNL
2 & 18
0.002
0.827

R

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.021
0.745

IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR
101 &
0.050
0.708

120

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGI
102 &
0.013
0.763

R
120

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLF
102 & 18
0.026
0.735

PASNLR

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLG
107 &
0.043
0.714

HR
126

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 &
0.013
0.762

120

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNL
117 & 18
0.033
0.726

R

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.048
0.709

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.045
0.712

PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPV
122 & 81
0.048
0.709

R

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 &
0.021
0.745

120

PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAH
122 &
0.033
0.726

QPWSR
129

PAPP1_DIPHWLNPTR_vs_PSG1_FQLPGQK
122 &
0.040
0.718

131

PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPAS
122 & 18
0.035
0.723

NLR

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCG
122 &
0.018
0.750

F
139

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 &
0.015
0.758

120

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPAS
124 & 18
0.024
0.739

NLR

PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK
124 &
0.048
0.709

147

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.047
0.710

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 &
0.008
0.783

120

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNL
125 & 18
0.009
0.777

R

PEDF_TVQAVLTVPK_vs_VTDB_ELPEHTVK
125 &
0.031
0.729

147

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.019
0.748

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.016
0.756

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.018
0.750

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.030
0.730

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.026
0.736

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 &
0.019
0.749

112

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 &
0.007
0.788

120

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGH
133 &
0.022
0.742

R
126

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLN
133 &
0.024
0.739

PL
134

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.005
0.794

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 &
0.036
0.722

139

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 &
0.022
0.743

140

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSF
133 &
0.028
0.733

LLR
141

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 &
0.029
0.731

142

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 &
0.013
0.764

147

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.020
0.747

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.019
0.749

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 &
0.003
0.814

120

PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGH
137 &
0.012
0.766

R
126

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.019
0.748

PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF
137 &
0.010
0.774

139

PTGDS_GPGEDFR_vs_VTDB_ELPEHTVK
137 &
0.027
0.734

147

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 &
0.024
0.739

120

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNL
149 & 18
0.030
0.730

R

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 &
0.025
0.738

120

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALL
150 &
0.046
0.711

GHR
126

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN
150 & 18
0.012
0.765

LR

68 & 18

TABLE 39

Reversal Classification Performance, weeks 20 and 21.

Reversal AUROC for gestational weeks 20 and 21 using

a case vs control cut-off of <37 0/7 vs >=37 0/7

weeks, without BMI stratification.

SEQ ID

ROC_

Reversal
NO:
pval
AUC

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.028
0.636

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.035
0.631

A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFL
34 & 141
0.035
0.631

LR

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.011
0.659

AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSF
37 & 141
0.027
0.638

LLR

AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR
38 & 66
0.036
0.631

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.028
0.636

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.008
0.666

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.001
0.713

AFAM_HFQNLGK_vs_PRG2_WNFAYWAAHQPWS
38 & 129
0.036
0.631

R

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.035
0.631

AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR
38 & 141
0.008
0.664

AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR
38 & 142
0.023
0.641

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDS
42 & 141
0.020
0.644

FLLR

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.014
0.653

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.045
0.625

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.010
0.660

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.006
0.669

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.006
0.670

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEF
47 & 80
0.013
0.654

EETYIPK

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.017
0.648

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.012
0.656

APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK
47 & 97
0.033
0.633

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.021
0.644

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.003
0.685

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.003
0.684

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.001
0.699

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.003
0.682

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.002
0.692

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASE
47 & 121
0.016
0.650

FK

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALL
47 & 126
0.001
0.699

GHR

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAH
47 & 129
0.006
0.670

QPWSR

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLP
47 & 134
0.010
0.660

GLNPL

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQ
47 & 135
0.018
0.647

NLPGYFWYK

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.018
0.647

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASN
47 & 18
0.002
0.688

LR

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYC
47 & 138
0.028
0.636

FR

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCG
47 & 139
0.011
0.658

F

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.008
0.665

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAF
47 & 141
0.002
0.693

DSFLLR

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTS
47 & 142
0.003
0.682

SLR

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPL
47 & 144
0.013
0.654

VGDGFLLR

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.003
0.683

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFL
48 & 141
0.042
0.627

LR

B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR
50 & 103
0.026
0.638

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.037
0.630

B2MG_VEHSDLSFSK_vs_PGRP2_AGLLRPDYALLGH
50 & 126
0.033
0.633

R

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.021
0.644

B2MG_VEHSDLSFSK_vs_TENX_LNWEAPPGAFDSF
50 & 141
0.008
0.664

LLR

B2MG_VEHSDLSFSK_vs_TENX_LSQLSVTDVTTSSLR
50 & 142
0.042
0.627

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.046
0.624

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.006
0.672

B2MG_VNHVTLSQPK_vs_ITIH4_ILDDLSPR
51 & 112
0.038
0.629

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.017
0.648

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLG
51 & 126
0.012
0.657

HR

B2MG_VNHVTLSQPK_vs_PRG2_WNFAYWAAHQP
51 & 129
0.050
0.622

WSR

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.009
0.662

B2MG_VNHVTLSQPK_vs_TENX_LNWEAPPGAFDS
51 & 141
0.005
0.675

FLLR

B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSL
51 & 142
0.030
0.635

R

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.023
0.641

BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR
52 & 103
0.009
0.662

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.048
0.623

BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLG
52 & 126
0.050
0.622

HR

BGH3_LTLLAPLNSVFK_vs_PRG2_WNFAYWAAHQ
52 & 129
0.043
0.626

PWSR

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNL
52 & 18
0.045
0.625

R

BGH3_LTLLAPLNSVFK_vs_TENX LNWEAPPGAFDS
52 & 141
0.011
0.658

FLLR

BGH3_LTLLAPLNSVFK_vs_TENX_LSQLSVTDVTTSS
52 & 142
0.039
0.628

LR

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.014
0.652

C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAA
55 & 129
0.049
0.623

HQPWSR

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPAS
55 & 18
0.040
0.628

NLR

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGA
55 & 141
0.009
0.663

FDSFLLR

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTT
55 & 142
0.038
0.629

SSLR

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.024
0.641

CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR
57 & 66
0.009
0.662

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.014
0.652

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.008
0.666

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIP
57 & 80
0.038
0.629

K

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.048
0.623

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.040
0.628

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.049
0.623

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.006
0.671

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.007
0.667

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.001
0.714

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.010
0.661

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.006
0.671

CATD_VGFAEAAR_VS_NCAM1_GLGEISAASEFK
57 & 121
0.026
0.639

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.003
0.685

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWS
57 & 129
0.002
0.688

R

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.008
0.666

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.009
0.662

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.039
0.629

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.012
0.656

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLL
57 & 141
0.000
0.739

R

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.001
0.713

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.008
0.666

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.037
0.630

CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR
58 & 66
0.009
0.663

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.022
0.643

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.013
0.655

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.049
0.623

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.034
0.632

CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR
58 & 98
0.037
0.630

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.006
0.671

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.010
0.660

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.001
0.712

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.014
0.653

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.011
0.659

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 & 121
0.031
0.634

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.002
0.691

CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPW
58 & 129
0.005
0.677

SR

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNP
58 & 134
0.012
0.657

L

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.005
0.677

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.028
0.637

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLL
58 & 141
0.000
0.731

R

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.001
0.710

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.019
0.646

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPA
59 & 18
0.037
0.630

SNLR

CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPG
59 & 141
0.027
0.637

AFDSFLLR

CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR
60 & 103
0.030
0.635

CBPN_NNANGVDLNR_vs_PGRP2_AGLLRPDYALLG
60 & 126
0.041
0.627

HR

CBPN_NNANGVDLNR_VS_SHBG_IALGGLLFPASNL
60 & 18
0.024
0.641

R

CBPN_NNANGVDLNR_vs_TENX_LNWEAPPGAFDS
60 & 141
0.011
0.657

FLLR

CBPN_NNANGVDLNR_vs_TENX_LSQLSVTDVTTSSL
60 & 142
0.031
0.634

R

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEEC
61 & 103
0.028
0.636

CFR

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGL
61 & 18
0.033
0.632

LFPASNLR

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEA
61 & 141
0.014
0.652

PPGAFDSFLLR

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFP
62 & 18
0.039
0.628

ASNLR

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPP
62 & 141
0.019
0.646

GAFDSFLLR

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.010
0.660

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLG
64 & 126
0.044
0.625

HR

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.049
0.623

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSF
64 & 141
0.015
0.651

LLR

CFAB_YGLVTYATYPK_vs_TENX_LSQLSVTDVTTSSL
64 & 142
0.047
0.623

R

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.047
0.623

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.041
0.627

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLL
70 & 141
0.021
0.644

R

CO5_VFQFLEK_vs_IGF2_GIVEECCFR
71 & 103
0.041
0.627

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.042
0.627

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.014
0.653

CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR
71 & 142
0.047
0.623

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGA
72 & 141
0.043
0.626

FDSFLLR

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.012
0.655

CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.032
0.633

COSA_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.048
0.623

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.009
0.662

COSA_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.021
0.644

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.009
0.663

CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR
76 & 126
0.040
0.628

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.045
0.625

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLL
76 & 141
0.006
0.670

R

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.012
0.655

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRP
82 & 40
0.002
0.695

HTFTGLSGLR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_C163A_I
82 & 54
0.036
0.631

NPASLDK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CHL1_V
82 & 66
0.002
0.690

IAVNEVGR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_A
82 & 78
0.005
0.673

VSPPAR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_Y
82 & 79
0.004
0.679

EDLYSNCK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_AH
82 & 80
0.012
0.656

QLAIDTYQEFEETYIPK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISL
82 & 81
0.014
0.652

LLIESWLEPVR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1
82 & 86
0.007
0.669

TGYYFDGISR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP1_V
82 & 97
0.027
0.638

VESLAK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP2_LI
82 & 98
0.008
0.664

QGAPTIR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FL
82 & 99
0.001
0.708

NVLSPR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_Y
82 & 100
0.001
0.708

GQPLPGYTTK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GI
82 & 103
0.000
0.736

VEECCFR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_IL
82 & 112
0.001
0.710

DDLSPR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1
82 & 120
0.001
0.704

SYYWIGIR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1
82 & 121
0.013
0.655

GLGEISAASEFK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2
82 & 126
0.001
0.708

AGLLRPDYALLGHR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2
82 & 129
0.003
0.684

WNFAYWAAHQPWSR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_V
82 & 134
0.004
0.681

SAPSGTGHLPGLNPL

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_D
82 & 135
0.016
0.650

VLLLVHNLPQNLPGYFWYK

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_L
82 & 136
0.027
0.637

FIPQITR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_I
82 & 18
0.000
0.720

ALGGLLFPASNLR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.C
82 & 138
0.032
0.633

SH_NYGLLYCFR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.C
82 & 139
0.020
0.645

SH_SVEGSCGF

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SPRL1
82 & 140
0.005
0.674

VLTHSELAPLR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_L
82 & 141
0.001
0.715

NWEAPPGAFDSFLLR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_L
82 & 142
0.001
0.700

SQLSVTDVTTSSLR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VS
82 & 144
0.006
0.671

WSLPLVPGPLVGDGFLLR

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_E
82 & 147
0.001
0.711

LPEHTVK

ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR
83 & 40
0.001
0.707

ENPP2_TYLHTYESEI_vs_C163A_INPASLDK
83 & 54
0.016
0.650

ENPP2_TYLHTYESEI_vs_CHL1_VIAVNEVGR
83 & 66
0.002
0.694

ENPP2_TYLHTYESEI_vs_CRIS3_AVSPPAR
83 & 78
0.004
0.680

ENPP2_TYLHTYESEI_vs_CRIS3_YEDLYSNCK
83 & 79
0.002
0.689

ENPP2_TYLHTYESEI_vs_CSH_AHQLAIDTYQEFEETY
83 & 80
0.006
0.670

IPK

ENPP2_TYLHTYESEI_vs_CSH_ISLLLIESWLEPVR
83 & 81
0.008
0.664

ENPP2_TYLHTYESEI_vs_FBLN1_TGYYFDGISR
83 & 86
0.007
0.669

ENPP2_TYLHTYESEI_vs_IBP1_VVESLAK
83 & 97
0.028
0.636

ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR
83 & 98
0.007
0.666

ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR
83 & 99
0.000
0.719

ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK
83 & 100
0.001
0.716

ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR
83 & 103
0.000
0.741

ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR
83 & 112
0.001
0.716

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.001
0.712

ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEF
83 & 121
0.010
0.660

K

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLG
83 & 126
0.001
0.714

HR

ENPP2_TYLHTYESEI_vs_PRG2_WNFAYWAAHQ
83 & 129
0.003
0.686

PWSR

ENPP2_TYLHTYESEI_vs_PSG1_FQLPGQK
83 & 131
0.047
0.623

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPG
83 & 134
0.004
0.678

LNPL

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQN
83 & 135
0.018
0.647

LPGYFWYK

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.027
0.637

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNL
83 & 18
0.000
0.722

R

ENPP2_TYLHTYESEI_vs_SOM2.CSH_NYGLLYCFR
83 & 138
0.019
0.646

ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF
83 & 139
0.010
0.661

ENPP2_TYLHTYESEI_vs_SPRL1_VLTHSELAPLR
83 & 140
0.003
0.686

ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDS
83 & 141
0.000
0.728

FLLR

ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSS
83 & 142
0.001
0.712

LR

ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLV
83 & 144
0.003
0.685

GDGFLLR

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.001
0.713

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.041
0.627

FETUA_FSVVYAK_vs_CHL1_VIAVNEVGR
88 & 66
0.016
0.650

FETUA_FSVVYAK_vs_CRIS3_AVSPPAR
88 & 78
0.030
0.635

FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK
88 & 79
0.017
0.648

FETUA_FSVVYAK_vs_IBP3_FLNVLSPR
88 & 99
0.018
0.646

FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK
88 & 100
0.014
0.652

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.001
0.701

FETUA_FSVVYAK_vs_ITIH4_ILDDLSPR
88 & 112
0.034
0.632

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.023
0.642

FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGH
88 & 126
0.011
0.659

R

FETUA_FSVVYAK_vs_PRG2_WNFAYWAAHQPW
88 & 129
0.012
0.657

SR

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLN
88 & 134
0.033
0.633

PL

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.010
0.660

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFL
88 & 141
0.002
0.694

LR

FETUA_FSVVYAK_vs_TENX_LSQLSVTDVTTSSLR
88 & 142
0.007
0.668

FETUA_FSVVYAK_vs_VTDB_ELPEHTVK
88 & 147
0.007
0.668

FETUA_HTLNQIDEVK_vs_CHL1_VIAVNEVGR
89 & 66
0.013
0.654

FETUA_HTLNQIDEVK_vs_CRIS3_AVSPPAR
89 & 78
0.046
0.624

FETUA_HTLNQIDEVK_vs_CRIS3_YEDLYSNCK
89 & 79
0.027
0.638

FETUA_HTLNQIDEVK_vs_IBP3_FLNVLSPR
89 & 99
0.036
0.630

FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK
89 & 100
0.041
0.627

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.004
0.681

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.041
0.627

FETUA_HTLNQIDEVK_vs_PGRP2_AGLLRPDYALL
89 & 126
0.024
0.640

GHR

FETUA_HTLNQIDEVK_vs_PRG2_WNFAYWAAH
89 & 129
0.015
0.651

QPWSR

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLP
89 & 134
0.037
0.630

GLNPL

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASN
89 & 18
0.009
0.662

LR

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAF
89 & 141
0.001
0.701

DSFLLR

FETUA_HTLNQIDEVK_vs_TENX_LSQLSVTDVTTS
89 & 142
0.005
0.673

SLR

FETUA_HTLNQIDEVK_vs_VTDB_ELPEHTVK
89 & 147
0.025
0.639

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.039
0.628

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.039
0.629

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.005
0.674

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.046
0.624

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLL
92 & 141
0.006
0.669

R

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.021
0.644

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.043
0.626

HEMO_NFPSPVDAAFR_vs_PGRP2_AGLLRPDYA
93 & 126
0.050
0.622

LLGHR

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPAS
93 & 18
0.017
0.648

NLR

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGA
93 & 141
0.013
0.654

FDSFLLR

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.023
0.642

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.027
0.638

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.013
0.655

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.005
0.676

IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR
2 & 112
0.014
0.653

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.013
0.654

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALL
2 & 126
0.005
0.674

GHR

IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQ
2 & 129
0.016
0.649

PWSR

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNL
2 & 18
0.003
0.685

R

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFD
2 & 141
0.001
0.702

SFLLR

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSS
2 & 142
0.016
0.649

LR

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.022
0.643

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.016
0.649

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.044
0.625

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.025
0.639

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.014
0.653

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 &
0.012
0.655

100

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 &
0.001
0.707

103

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 &
0.009
0.662

112

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 &
0.014
0.652

120

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLG
107 &
0.006
0.672

HR
126

INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQ
107 &
0.031
0.634

PWSR
129

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGL
107 &
0.019
0.646

NPL
134

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNL
107 & 18
0.006
0.672

R

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 &
0.035
0.631

140

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDS
107 &
0.003
0.684

FLLR
141

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSS
107 &
0.009
0.662

LR
142

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 &
0.008
0.666

147

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.043
0.626

ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR
111 &
0.037
0.630

103

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 &
0.034
0.632

120

ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR
111 &
0.008
0.665

126

ITIH3_ALDLSLK_vs_PRG2_WNFAYWAAHQPWS
111 &
0.035
0.631

R
129

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.010
0.660

ITIH3_ALDLSLK_vs_TENX_LNWEAPPGAFDSFLL
111 &
0.016
0.650

R
141

ITIH3_ALDLSLK_vs_TENX_LSQLSVTDVTTSSLR
111 &
0.049
0.622

142

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEEC
116 &
0.026
0.639

CFR
103

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGG
116 & 18
0.023
0.642

LLFPASNLR

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWE
116 &
0.006
0.671

APPGAFDSFLLR
141

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLS
116 &
0.032
0.634

VTDVTTSSLR
142

KNG1_QVVAGLNFR_vs_CHL1_VIAVNEVGR
117 & 66
0.037
0.630

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.049
0.622

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 &
0.014
0.653

103

KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR
117 &
0.026
0.638

112

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 &
0.024
0.641

120

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALL
117 &
0.016
0.649

GHR
126

KNG1_QVVAGLNFR_vs_PRG2_WNFAYWAAHQ
117 &
0.037
0.630

PWSR
129

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNL
117 & 18
0.005
0.675

R

KNG1_QVVAGLNFR_vs_TENX_LNWEAPPGAFDS
117 &
0.003
0.685

FLLR
141

KNG1_QVVAGLNFR_vs_TENX_LSQLSVTDVTTSS
117 &
0.032
0.634

LR
142

KNG1_QVVAGLNFR_vs_VTDB_ELPEHTVK
117 &
0.030
0.635

147

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.029
0.636

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.009
0.663

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.005
0.674

LBP_ITGFLKPGK_vs_IBP2_LIQGAPTIR
118 & 98
0.035
0.631

LBP_ITGFLKPGK_vs_IBP3_FLNVLSPR
118 & 99
0.022
0.642

LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK
118 &
0.012
0.657

100

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 &
0.003
0.684

103

LBP_ITGFLKPGK_vs_ITIH4_ILDDLSPR
118 &
0.020
0.645

112

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 &
0.008
0.664

120

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 &
0.014
0.653

126

LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPW
118 &
0.018
0.646

SR
129

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNP
118 &
0.016
0.650

L
134

LBP_ITGFLKPGK_vs_PSG9_DVLLLVHNLPQNLPG
118 &
0.045
0.625

YFWYK
135

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.009
0.662

LBP_ITGFLKPGK_vs_SPRL1_VLTHSELAPLR
118 &
0.024
0.640

140

LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLL
118 &
0.005
0.676

R
141

LBP_ITGFLKPGK_vs_TENX_LSQLSVTDVTTSSLR
118 &
0.019
0.646

142

LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK
118 &
0.010
0.659

147

LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR
119 & 40
0.019
0.646

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.009
0.663

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.003
0.686

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.002
0.696

LBP_ITLPDFTGDLR_vs_IBP1_VVESLAK
119 & 97
0.046
0.624

LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR
119 & 98
0.012
0.656

LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR
119 & 99
0.004
0.679

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 &
0.002
0.694

100

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 &
0.001
0.713

103

LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR
119 &
0.003
0.688

112

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 &
0.002
0.690

120

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 &
0.040
0.628

121

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLG
119 &
0.002
0.692

HR
126

LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQP
119 &
0.007
0.667

WSR
129

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGL
119 &
0.007
0.667

NPL
134

LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNL
119 &
0.025
0.639

PGYFWYK
135

LBP_ITLPDFTGDLR_vs_PSG9_LFIPQITR
119 &
0.037
0.630

136

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.002
0.690

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 &
0.032
0.634

139

LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR
119 &
0.007
0.668

140

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSF
119 &
0.001
0.705

LLR
141

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSL
119 &
0.004
0.678

R
142

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVG
119 &
0.020
0.645

DGFLLR
144

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 &
0.002
0.695

147

PAPP1_DIPHWLNPTR_vs_C163A_INPASLDK
122 & 54
0.050
0.622

PAPP1_DIPHWLNPTR_vs_CSH_AHQLAIDTYQEF
122 & 80
0.035
0.631

EETYIPK

PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPV
122 & 81
0.044
0.625

R

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYC
122 &
0.021
0.643

FR
138

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.030
0.635

PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR
124 &
0.011
0.658

103

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 &
0.036
0.631

120

PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYAL
124 &
0.033
0.632

LGHR
126

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAF
124 &
0.008
0.666

DSFLLR
141

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTT
124 &
0.035
0.631

SSLR
142

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 &
0.016
0.650

103

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFD
125 &
0.016
0.650

SFLLR
141

PSG11_LFIPQITPK_vs_PRG2_WNFAYWAAHQP
132 &
0.043
0.626

WSR
129

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.033
0.632

PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSF
137 &
0.015
0.651

LLR
141

PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR
137 &
0.046
0.624

142

THBG_AVLHIGEK_vs_TENX_LNWEAPPGAFDSFL
143 &
0.040
0.628

LR
141

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.038
0.629

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.049
0.623

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.017
0.648

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 &
0.020
0.645

100

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 &
0.002
0.689

103

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 &
0.024
0.641

112

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 &
0.039
0.629

120

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALL
149 &
0.028
0.636

GHR
126

VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQ
149 &
0.045
0.625

PWSR
129

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPG
149 &
0.039
0.629

LNPL
134

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNL
149 & 18
0.006
0.672

R

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFD
149 &
0.003
0.683

SFLLR
141

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSS
149 &
0.013
0.654

LR
142

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 &
0.005
0.673

147

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.025
0.640

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.050
0.622

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.040
0.628

VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR
150 & 99
0.021
0.644

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 &
0.023
0.641

100

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 &
0.003
0.686

103

VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR
150 &
0.017
0.648

112

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 &
0.018
0.646

120

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALL
150 &
0.020
0.645

GHR
126

VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQ
150 &
0.034
0.632

PWSR
129

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASN
150 & 18
0.005
0.675

LR

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFD
150 &
0.003
0.687

SFLLR
141

VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTS
150 &
0.013
0.654

SLR
142

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 &
0.003
0.686

147

TABLE 40

Reversal Classification Performance, weeks 20 and 21.

Reversal AUROC for gestational weeks 20 and 21 using a case

vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with BMI

stratification (>22 <= 37).

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.022
0.667

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.049
0.644

A2GL_DLLLPQPDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
34 & 135
0.044
0.647

A2GL_DLLLPQPDLR_vs_PSG9_LFIPQITR
34 & 136
0.043
0.648

AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR
37 & 99
0.032
0.656

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 & 100
0.005
0.703

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.004
0.710

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.026
0.662

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.038
0.651

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.003
0.718

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.000
0.757

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.000
0.775

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.045
0.646

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.025
0.664

AFAM_HFQNLGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
38 & 135
0.028
0.660

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.044
0.647

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.031
0.657

ANGT_DPTFIPAPIQAK_vs_IBP3_FLNVLSPR
42 & 99
0.037
0.653

ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK
42 & 100
0.011
0.686

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.007
0.697

ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
42 & 135
0.048
0.645

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.038
0.651

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.024
0.665

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.015
0.678

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.029
0.659

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.019
0.672

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.016
0.675

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.029
0.659

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.021
0.669

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.018
0.673

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.013
0.681

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.017
0.675

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.020
0.670

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.031
0.658

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.050
0.643

B2MG_VEHSDLSFSK_vs_CRIS3_AVSPPAR
50 & 78
0.049
0.644

B2MG_VEHSDLSFSK_vs_CRIS3_YEDLYSNCK
50 & 79
0.021
0.668

B2MG_VEHSDLSFSK_vs_IBP3_YGQPLPGYTTK
50 & 100
0.049
0.644

B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR
50 & 103
0.017
0.675

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.024
0.665

B2MG_VEHSDLSFSK_vs_PGRP2_AGLLRPDYALLGHR
50 & 126
0.043
0.648

B2MG_VEHSDLSFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
50 & 135
0.044
0.647

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.037
0.652

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.047
0.645

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.028
0.661

B2MG_VNHVTLSQPK_vs_IBP3_YGQPLPGYTTK
51 & 100
0.028
0.661

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.008
0.695

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.016
0.676

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR
51 & 126
0.020
0.670

B2MG_VNHVTLSQPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
51 & 135
0.028
0.660

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.019
0.671

BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR
52 & 78
0.033
0.656

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.006
0.700

BGH3_LTLLAPLNSVFK_vs_IBP3_YGQPLPGYTTK
52 & 100
0.028
0.660

BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR
52 & 103
0.010
0.688

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.031
0.657

BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLGHR
52 & 126
0.036
0.653

BGH3_LTLLAPLNSVFK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
52 & 135
0.028
0.660

BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR
52 & 141
0.047
0.645

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.041
0.649

C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
55 & 135
0.040
0.650

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.022
0.667

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.015
0.678

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.006
0.701

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.003
0.714

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.002
0.726

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.001
0.750

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.019
0.672

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.014
0.679

CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK
57 & 121
0.030
0.659

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.008
0.693

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR
57 & 129
0.041
0.649

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.031
0.657

CATD_VGFAEAAR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
57 & 135
0.011
0.686

CATD_VGFAEAAR_vs_PSG9_LFIPQITR
57 & 136
0.026
0.662

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.026
0.663

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.027
0.662

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.035
0.654

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.005
0.707

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.020
0.670

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.026
0.662

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.013
0.681

CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR
58 & 66
0.028
0.660

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.009
0.692

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.004
0.712

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.042
0.648

CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR
58 & 98
0.038
0.651

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.002
0.730

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.001
0.737

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.000
0.762

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.007
0.695

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.010
0.687

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 & 121
0.024
0.665

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.002
0.727

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.038
0.651

CATD_VSTLPAITLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
58 & 135
0.012
0.684

CATD_VSTLPAITLK_vs_PSG9_LFIPQITR
58 & 136
0.019
0.672

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.007
0.695

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.027
0.662

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.029
0.659

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.002
0.722

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.007
0.697

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.029
0.659

CBPN_EALIQFLEQVHQGIK_vs_IBP3_YGQPLPGYTTK
59 & 100
0.037
0.652

CBPN_EALIQFLEQVHQGIK_vs_IGF2_GIVEECCFR
59 & 103
0.028
0.660

CBPN_NNANGVDLNR_vs_CRIS3_YEDLYSNCK
60 & 79
0.043
0.648

CBPN_NNANGVDLNR_vs_IBP3_FLNVLSPR
60 & 99
0.032
0.656

CBPN_NNANGVDLNR_vs_IBP3_YGQPLPGYTTK
60 & 100
0.013
0.681

CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR
60 & 103
0.006
0.701

CBPN_NNANGVDLNR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
60 & 135
0.044
0.647

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR
60 & 18
0.038
0.651

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.033
0.656

CFAB_YGLVTYATYPK_vs_IBP3_FLNVLSPR
64 & 99
0.032
0.656

CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK
64 & 100
0.013
0.681

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.010
0.689

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.035
0.654

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.048
0.645

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.049
0.644

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.027
0.662

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.030
0.659

CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK
76 & 100
0.039
0.651

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.017
0.675

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR
82 & 40
0.001
0.737

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_C163A_INPASLDK
82 & 54
0.019
0.672

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CHL1_VIAVNEVGR
82 & 66
0.013
0.681

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_AVSPPAR
82 & 78
0.006
0.700

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_YEDLYSNCK
82 & 79
0.003
0.716

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_AHQLAIDTYQEFEETYIPK
82 & 80
0.011
0.686

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CSH_ISLLLIESWLEPVR
82 & 81
0.012
0.684

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1_TGYYFDGISR
82 & 86
0.037
0.653

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP2_LIQGAPTIR
82 & 98
0.008
0.692

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR
82 & 99
0.001
0.744

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK
82 & 100
0.000
0.758

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR
82 & 103
0.000
0.767

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR
82 & 112
0.001
0.748

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR
82 & 120
0.001
0.748

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK
82 & 121
0.010
0.687

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.001
0.742

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2_WNFAYWAAHQPWSR
82 & 129
0.033
0.656

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_VSAPSGTGHLPGLNPL
82 & 134
0.015
0.677

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.002
0.726

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR
82 & 136
0.005
0.703

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.001
0.747

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_NYGLLYCFR
82 & 138
0.030
0.659

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_SVEGSCGF
82 & 139
0.005
0.707

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SPRL1_VLTHSELAPLR
82 & 140
0.007
0.698

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR
82 & 141
0.005
0.706

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR
82 & 142
0.013
0.681

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
82 & 144
0.009
0.691

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_ELPEHTVK
82 & 147
0.002
0.722

ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR
83 & 40
0.001
0.733

ENPP2_TYLHTYESEI_vs_C163A_INPASLDK
83 & 54
0.015
0.678

ENPP2_TYLHTYESEI_vs_CHL1_VIAVNEVGR
83 & 66
0.018
0.673

ENPP2_TYLHTYESEI_vs_CRIS3_AVSPPAR
83 & 78
0.009
0.692

ENPP2_TYLHTYESEI_vs_CRIS3_YEDLYSNCK
83 & 79
0.003
0.716

ENPP2_TYLHTYESEI_vs_CSH_AHQLAIDTYQEFEETYIPK
83 & 80
0.007
0.695

ENPP2_TYLHTYESEI_vs_CSH_ISLLLIESWLEPVR
83 & 81
0.010
0.689

ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR
83 & 98
0.010
0.689

ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR
83 & 99
0.002
0.728

ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK
83 & 100
0.000
0.755

ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR
83 & 103
0.001
0.749

ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR
83 & 112
0.002
0.727

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.001
0.733

ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK
83 & 121
0.020
0.670

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.002
0.725

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL
83 & 134
0.025
0.664

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.004
0.712

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.008
0.693

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.001
0.747

ENPP2_TYLHTYESEI_vs_SOM2.CSH_NYGLLYCFR
83 & 138
0.028
0.661

ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF
83 & 139
0.003
0.716

ENPP2_TYLHTYESEI_vs_SPRL1_VLTHSELAPLR
83 & 140
0.009
0.691

ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDSFLLR
83 & 141
0.006
0.702

ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR
83 & 142
0.013
0.682

ENPP2_TYLHTYESEI_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
83 & 144
0.011
0.686

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.005
0.705

FETUA_FSVVYAK_vs_CRIS3_AVSPPAR
88 & 78
0.025
0.664

FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK
88 & 79
0.009
0.692

FETUA_FSVVYAK_vs_IBP3_FLNVLSPR
88 & 99
0.016
0.676

FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK
88 & 100
0.006
0.700

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.003
0.718

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.024
0.665

FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGHR
88 & 126
0.047
0.645

FETUA_FSVVYAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
88 & 135
0.026
0.663

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.040
0.650

FETUA_FSVVYAK_vs_VTDB_ELPEHTVK
88 & 147
0.049
0.644

FETUA_HTLNQIDEVK_vs_CRIS3_AVSPPAR
89 & 78
0.037
0.653

FETUA_HTLNQIDEVK_vs_CRIS3_YEDLYSNCK
89 & 79
0.015
0.678

FETUA_HTLNQIDEVK_vs_IBP3_FLNVLSPR
89 & 99
0.017
0.675

FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK
89 & 100
0.007
0.696

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.003
0.715

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.041
0.649

FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
89 & 135
0.029
0.659

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.029
0.659

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.044
0.647

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.024
0.664

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.018
0.673

HEMO_NFPSPVDAAFR_vs_CRIS3_AVSPPAR
93 & 78
0.047
0.645

HEMO_NFPSPVDAAFR_vs_CRIS3_YEDLYSNCK
93 & 79
0.025
0.664

HEMO_NFPSPVDAAFR_vs_IBP3_FLNVLSPR
93 & 99
0.045
0.646

HEMO_NFPSPVDAAFR_vs_IBP3_YGQPLPGYTTK
93 & 100
0.030
0.659

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.014
0.679

HEMO_NFPSPVDAAFR_vs_ITIH4_ILDDLSPR
93 & 112
0.017
0.674

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.048
0.645

HEMO_NFPSPVDAAFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
93 & 135
0.031
0.658

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.021
0.669

HLACI_WAAVVVPSGEEQR_vs_CRIS3_YEDLYSNCK
95 & 79
0.047
0.645

HLACI_WAAVVVPSGEEQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
95 & 135
0.007
0.695

HLACI_WAAVVVPSGEEQR_vs_PSG9_LFIPQITR
95 & 136
0.011
0.685

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.010
0.689

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.002
0.722

IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR
2 & 99
0.028
0.661

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.011
0.685

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.004
0.711

IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR
2 & 112
0.012
0.684

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.005
0.705

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.007
0.697

IBP4_QCHPALDGQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
2 & 135
0.019
0.672

IBP4_QCHPALDGQR_vs_PSG9_LFIPQITR
2 & 136
0.036
0.653

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.007
0.696

IBP4_QCHPALDGQR_vs_SOM2.CSH_SVEGSCGF
2 & 139
0.018
0.673

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.025
0.664

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.038
0.651

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.028
0.660

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.026
0.663

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.012
0.684

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.011
0.685

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.006
0.703

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.001
0.735

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.016
0.675

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.016
0.675

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.016
0.675

INHBC_LDFHFSSDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
107 & 135
0.019
0.671

INHBC_LDFHFSSDR_vs_PSG9_LFIPQITR
107 & 136
0.033
0.656

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.013
0.681

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.036
0.653

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.023
0.666

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.025
0.664

ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR
111 & 78
0.040
0.650

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.032
0.656

ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR
111 & 103
0.044
0.647

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.036
0.653

ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR
111 & 126
0.022
0.667

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.017
0.675

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK
116 & 79
0.023
0.666

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.019
0.672

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.049
0.644

KNG1_DIPTNSPELEETLTHTITK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
116 & 135
0.033
0.656

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.044
0.647

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.021
0.669

KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR
117 & 99
0.028
0.661

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.014
0.680

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.007
0.697

KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR
117 & 112
0.039
0.651

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.017
0.674

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.034
0.655

KNG1_QVVAGLNFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
117 & 135
0.028
0.660

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.031
0.657

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.018
0.673

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.006
0.700

LBP_ITGFLKPGK_vs_IBP3_FLNVLSPR
118 & 99
0.039
0.651

LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK
118 & 100
0.017
0.674

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.006
0.700

LBP_ITGFLKPGK_vs_ITIH4_ILDDLSPR
118 & 112
0.037
0.652

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.016
0.676

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 & 126
0.023
0.666

LBP_ITGFLKPGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
118 & 135
0.013
0.682

LBP_ITGFLKPGK_vs_PSG9_LFIPQITR
118 & 136
0.020
0.670

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.014
0.680

LBP_ITGFLKPGK_vs_SOM2.CSH_SVEGSCGF
118 & 139
0.024
0.664

LBP_ITGFLKPGK_vs_SPRL1_VLTHSELAPLR
118 & 140
0.044
0.647

LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK
118 & 147
0.031
0.658

LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR
119 & 40
0.031
0.657

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.004
0.710

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.002
0.727

LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR
119 & 98
0.031
0.658

LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR
119 & 99
0.007
0.698

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.003
0.717

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.001
0.733

LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR
119 & 112
0.004
0.710

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.003
0.716

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 & 121
0.045
0.646

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.002
0.722

LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
119 & 135
0.005
0.703

LBP_ITLPDFTGDLR_vs_PSG9_LFIPQITR
119 & 136
0.010
0.689

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.003
0.716

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.011
0.686

LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR
119 & 140
0.013
0.681

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.014
0.680

LBP ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.044
0.647

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.039
0.651

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.006
0.701

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.022
0.667

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.009
0.690

PEDF_LQSLFDSPDFSK_vs_IBP3_YGQPLPGYTTK
124 & 100
0.045
0.646

PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR
124 & 103
0.011
0.686

PEDF_LQSLFDSPDFSK_vs_ITIH4_ILDDLSPR
124 & 112
0.049
0.644

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.024
0.665

PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR
124 & 126
0.035
0.654

PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
124 & 135
0.037
0.653

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.037
0.652

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.041
0.649

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 & 103
0.024
0.665

THBG_AVLHIGEK_vs_CRIS3_YEDLYSNCK
143 & 79
0.050
0.643

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.047
0.645

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.024
0.665

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.011
0.686

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.003
0.718

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.003
0.719

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.017
0.675

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.026
0.663

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.042
0.648

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.028
0.660

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.013
0.681

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.037
0.653

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.037
0.652

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.022
0.667

VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR
150 & 99
0.015
0.677

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.006
0.699

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.004
0.710

VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR
150 & 112
0.037
0.653

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.018
0.673

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.044
0.647

VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
150 & 135
0.021
0.668

VTNC_VDTVDPPYPR_vs_PSG9_LFIPQITR
150 & 136
0.041
0.649

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.012
0.684

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.028
0.660

83 & 126

TABLE 41

Reversal Classification Performance, weeks 20 and 21.

Reversal AUROC for gestational weeks 20 and 21 using a case vs

control cut-offs of <35 0/7 vs >=35 0/7 weeks, without BMI

stratification.

Reversal
SEQ ID NO:
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_IBP2_LIQGAPTIR
37 & 98
0.042
0.703

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.045
0.701

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.036
0.709

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.020
0.732

AFAM_HFQNLGK_vs_IBP2_LIQGAPTIR
38 & 98
0.024
0.726

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.048
0.698

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.048
0.698

AFAM_HFQNLGK_vs_ITIH4_ILDDLSPR
38 & 112
0.033
0.714

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.031
0.715

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.017
0.738

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.029
0.719

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.017
0.738

AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF
38 & 139
0.048
0.698

AFAM_HFQNLGK_vs_SPRL1_VLTHSELAPLR
38 & 140
0.018
0.737

AFAM_HFQNLGK_vs_VTDB_ELPEHTVK
38 & 147
0.014
0.746

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.019
0.735

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.045
0.701

B2MG_VEHSDLSFSK_vs_IBP2_LIQGAPTIR
50 & 98
0.049
0.697

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.029
0.718

B2MG_VNHVTLSQPK_vs_IBP2_LIQGAPTIR
51 & 98
0.049
0.697

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.031
0.716

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR
51 & 126
0.035
0.711

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.028
0.720

B2MG_VNHVTLSQPK_vs_SOM2.CSH_SVEGSCGF
51 & 139
0.049
0.697

B2MG_VNHVTLSQPK_vs_SPRL1_VLTHSELAPLR
51 & 140
0.046
0.700

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.001
0.828

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.001
0.832

CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR
57 & 66
0.023
0.728

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.017
0.738

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.018
0.737

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.001
0.824

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.001
0.819

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.001
0.832

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.004
0.791

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.003
0.793

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.012
0.751

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.007
0.768

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.006
0.776

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.003
0.797

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.001
0.832

CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK
57 & 121
0.010
0.756

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.000
0.859

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR
57 & 129
0.001
0.822

CATD_VGFAEAAR_vs_PSG1_FQLPGQK
57 & 131
0.009
0.760

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.001
0.821

CATD_VGFAEAAR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
57 & 135
0.006
0.777

CATD_VGFAEAAR_vs_PSG9_LFIPQITR
57 & 136
0.014
0.747

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.003
0.802

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.001
0.823

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.001
0.831

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.000
0.864

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.001
0.819

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.006
0.776

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.005
0.779

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.000
0.855

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.001
0.826

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.012
0.752

CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR
58 & 66
0.023
0.727

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.029
0.718

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.028
0.720

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.003
0.798

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.003
0.800

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.001
0.838

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.004
0.791

CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR
58 & 98
0.003
0.797

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.006
0.774

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.006
0.774

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.005
0.779

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.008
0.767

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.002
0.805

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 & 121
0.012
0.750

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.001
0.844

CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR
58 & 129
0.004
0.785

CATD_VSTLPAITLK_vs_PSG1_FQLPGQK
58 & 131
0.016
0.740

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.001
0.831

CATD_VSTLPAITLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
58 & 135
0.018
0.736

CATD_VSTLPAITLK_vs_PSG9_LFIPQITR
58 & 136
0.033
0.714

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.002
0.803

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.003
0.796

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.003
0.796

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.001
0.830

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.001
0.820

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.008
0.767

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.009
0.760

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.001
0.819

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR
59 & 18
0.008
0.764

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR
60 & 18
0.016
0.740

CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR
60 & 140
0.037
0.709

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.034
0.712

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.027
0.721

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.038
0.708

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.029
0.718

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.026
0.722

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.021
0.731

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.045
0.701

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.045
0.701

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.032
0.715

ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR
83 & 40
0.031
0.715

ENPP2_TYLHTYESEI_vs_IBP1_VVESLAK
83 & 97
0.047
0.699

ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR
83 & 98
0.038
0.708

ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR
83 & 112
0.047
0.699

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.026
0.722

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.020
0.732

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.049
0.697

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.017
0.739

ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF
83 & 139
0.036
0.710

ENPP2_TYLHTYESEI_vs_SPRL1_VLTHSELAPLR
83 & 140
0.028
0.720

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.025
0.725

F13B_GDTYPAELYITGSILR_vs_IBP2_LIQGAPTIR
84 & 98
0.031
0.715

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.042
0.703

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.040
0.706

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.021
0.731

F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR
84 & 140
0.042
0.703

FETUA_FSVVYAK_vs_IBP2_LIQGAPTIR
88 & 98
0.026
0.722

FETUA_FSVVYAK_vs_ITIH4_ILDDLSPR
88 & 112
0.024
0.726

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.010
0.756

FETUA_FSVVYAK_vs_PGRP2_AGLLRPDYALLGHR
88 & 126
0.031
0.715

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.043
0.703

FETUA_FSVVYAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
88 & 135
0.045
0.701

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.021
0.731

FETUA_FSVVYAK_vs_SOM2.CSH_SVEGSCGF
88 & 139
0.031
0.716

FETUA_FSVVYAK_vs_SPRL1_VLTHSELAPLR
88 & 140
0.016
0.741

FETUA_FSVVYAK_vs_VTDB_ELPEHTVK
88 & 147
0.001
0.818

FETUA_HTLNQIDEVK_vs_ALS_IRPHTFTGLSGLR
89 & 40
0.033
0.713

FETUA_HTLNQIDEVK_vs_IBP2_LIQGAPTIR
89 & 98
0.018
0.737

FETUA_HTLNQIDEVK_vs_ITIH4_ILDDLSPR
89 & 112
0.022
0.729

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.012
0.751

FETUA_HTLNQIDEVK_vs_PGRP2_AGLLRPDYALLGHR
89 & 126
0.028
0.720

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.024
0.726

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.007
0.768

FETUA_HTLNQIDEVK_vs_SPRL1_VLTHSELAPLR
89 & 140
0.008
0.764

FETUA_HTLNQIDEVK_vs_VTDB_ELPEHTVK
89 & 147
0.003
0.792

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.038
0.708

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.036
0.709

IBP6_GAQTLYVPNCDHR_vs_TENX_LSQLSVTDVTTSSLR
101 & 142
0.044
0.702

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.021
0.732

ITIH4_NPLVWVHASPEHVVVTR_vs_ITIH4_ILDDLSPR
113 & 112
0.022
0.729

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.040
0.706

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.025
0.725

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.006
0.773

KNG1_QVVAGLNFR_vs_VTDB_ELPEHTVK
117 & 147
0.049
0.697

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.033
0.713

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.035
0.711

PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK
124 & 147
0.034
0.712

PRDX2_GLFIIDGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
128 & 135
0.049
0.697

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.035
0.711

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.041
0.704

THBG_AVLHIGEK_vs_VTDB_ELPEHTVK
143 & 147
0.023
0.728

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.026
0.723

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.032
0.715

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.033
0.714

TABLE 42

Reversal Classification Performance, weeks 20 and 21.

Reversal AUROC for gestational weeks 20 and 21 using a case vs

control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI

stratification (>22 <= 37).

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK
34 & 97
0.042
0.734

A2GL_DLLLPQPDLR_vs_IBP2_LIQGAPTIR
34 & 98
0.043
0.732

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.033
0.745

A2GL_DLLLPQPDLR_vs_SOM2.CSH_SVEGSCGF
34 & 139
0.048
0.727

AFAM_DADPDTFFAK_vs_IBP2_LIQGAPTIR
37 & 98
0.034
0.743

AFAM_DADPDTFFAK_vs_ITIH4_ILDDLSPR
37 & 112
0.032
0.747

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.023
0.761

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.032
0.747

AFAM_DADPDTFFAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
37 & 135
0.043
0.732

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.015
0.779

AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF
37 & 139
0.039
0.738

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.019
0.769

AFAM_HFQNLGK_vs_IBP1_VVESLAK
38 & 97
0.042
0.734

AFAM_HFQNLGK_vs_IBP2_LIQGAPTIR
38 & 98
0.014
0.781

AFAM_HFQNLGK_vs_ITIH4_ILDDLSPR
38 & 112
0.008
0.807

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.006
0.817

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.010
0.797

AFAM_HFQNLGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
38 & 135
0.033
0.745

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.006
0.816

AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF
38 & 139
0.014
0.783

AFAM_HFQNLGK_vs_SPRL1_VLTHSELAPLR
38 & 140
0.020
0.767

AFAM_HFQNLGK_vs_VTDB_ELPEHTVK
38 & 147
0.010
0.797

ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
42 & 135
0.047
0.729

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.012
0.788

APOH_ATVVYQGER_vs_IBP1_VVESLAK
48 & 97
0.036
0.741

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.033
0.745

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.020
0.767

B2MG_VEHSDLSFSK_vs_IBP2_LIQGAPTIR
50 & 98
0.042
0.734

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.026
0.756

B2MG_VEHSDLSFSK_vs_SOM2.CSH_SVEGSCGF
50 & 139
0.040
0.736

B2MG_VEHSDLSFSK_vs_TENX_LSQLSVTDVTTSSLR
50 & 142
0.030
0.749

B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK
51 & 97
0.045
0.731

B2MG_VNHVTLSQPK_vs_IBP2_LIQGAPTIR
51 & 98
0.032
0.747

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.042
0.734

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.019
0.769

B2MG_VNHVTLSQPK_vs_SOM2.CSH_SVEGSCGF
51 & 139
0.039
0.738

B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR
51 & 142
0.019
0.769

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.007
0.812

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.001
0.886

CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR
57 & 66
0.032
0.747

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.019
0.769

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.020
0.767

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.001
0.866

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.001
0.868

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.010
0.796

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.001
0.870

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.001
0.868

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.029
0.750

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.016
0.776

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.030
0.749

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.003
0.837

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.001
0.866

CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK
57 & 121
0.008
0.807

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.001
0.892

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR
57 & 129
0.008
0.805

CATD_VGFAEAAR_vs_PSG1_FQLPGQK
57 & 131
0.013
0.785

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.016
0.778

CATD_VGFAEAAR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
57 & 135
0.003
0.846

CATD_VGFAEAAR_vs_PSG9_LFIPQITR
57 & 136
0.009
0.801

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.003
0.841

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.001
0.868

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.001
0.875

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.002
0.848

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.017
0.774

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.014
0.783

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.002
0.848

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.001
0.866

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.003
0.846

CATD_VSTLPAITLK_vs_CHL1_VIAVNEVGR
58 & 66
0.010
0.796

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.013
0.787

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.011
0.794

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.001
0.886

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.001
0.895

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.003
0.843

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.000
0.906

CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR
58 & 98
0.001
0.882

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.009
0.799

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.010
0.797

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.016
0.778

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.001
0.870

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.001
0.888

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 & 121
0.004
0.826

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.000
0.926

CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR
58 & 129
0.016
0.776

CATD_VSTLPAITLK_vs_PSG1_FQLPGQK
58 & 131
0.013
0.787

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.006
0.814

CATD_VSTLPAITLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
58 & 135
0.004
0.830

CATD_VSTLPAITLK_vs_PSG9_LFIPQITR
58 & 136
0.010
0.797

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.001
0.875

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.001
0.875

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.001
0.886

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.001
0.868

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.005
0.821

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.028
0.752

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.006
0.816

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.002
0.863

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR
59 & 18
0.014
0.783

CBPN_EALIQFLEQVHQGIK_vs_TENX_LSQLSVTDVTTSSLR
59 & 142
0.043
0.732

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR
60 & 18
0.011
0.794

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.048
0.727

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.017
0.774

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.037
0.740

CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK
62 & 97
0.047
0.729

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.024
0.759

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.036
0.741

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.042
0.734

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.037
0.740

CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTSSLR
67 & 142
0.018
0.772

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR
68 & 142
0.008
0.803

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.045
0.731

CO5_TLLPVSKPEIR_vs_TENX_LSQLSVTDVTTSSLR
70 & 142
0.012
0.790

CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR
71 & 142
0.026
0.756

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.029
0.750

CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR
72 & 142
0.007
0.810

CO8B_QALEEFQK_vs_IBP1_VVESLAK
76 & 97
0.043
0.732

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.033
0.745

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP1_VVESLAK
82 & 97
0.048
0.727

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP2_LIQGAPTIR
82 & 98
0.040
0.736

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.043
0.732

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.033
0.745

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.032
0.747

ENPP2_TYLHTYESEI_vs_IBP1_VVESLAK
83 & 97
0.045
0.731

ENPP2_TYLHTYESEI_vs_IBP2_LIQGAPTIR
83 & 98
0.039
0.738

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.043
0.732

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.037
0.740

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.020
0.767

ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF
83 & 139
0.042
0.734

F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK
84 & 97
0.048
0.727

F13B_GDTYPAELYITGSILR_vs_IBP2_LIQGAPTIR
84 & 98
0.020
0.767

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.036
0.741

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.047
0.729

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.011
0.794

F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTDVTTSSLR
84 & 142
0.040
0.736

FBLN3_IPSNPSHR_vs_TENX_LSQLSVTDVTTSSLR
87 & 142
0.016
0.778

FETUA_FSVVYAK_vs_IBP1_VVESLAK
88 & 97
0.034
0.743

FETUA_FSVVYAK_vs_IBP2_LIQGAPTIR
88 & 98
0.017
0.774

FETUA_FSVVYAK_vs_ITIH4_ILDDLSPR
88 & 112
0.012
0.790

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.007
0.808

FETUA_FSVVYAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
88 & 135
0.021
0.765

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.013
0.787

FETUA_FSVVYAK_vs_SOM2.CSH_SVEGSCGF
88 & 139
0.023
0.761

FETUA_FSVVYAK_vs_VTDB_ELPEHTVK
88 & 147
0.010
0.797

FETUA_HTLNQIDEVK_vs_IBP1_VVESLAK
89 & 97
0.036
0.741

FETUA_HTLNQIDEVK_vs_IBP2_LIQGAPTIR
89 & 98
0.009
0.801

FETUA_HTLNQIDEVK_vs_ITIH4_ILDDLSPR
89 & 112
0.003
0.837

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.005
0.823

FETUA_HTLNQIDEVK_vs_PGRP2_AGLLRPDYALLGHR
89 & 126
0.016
0.778

FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
89 & 135
0.026
0.756

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.003
0.844

FETUA_HTLNQIDEVK_vs_SOM2.CSH_SVEGSCGF
89 & 139
0.021
0.765

FETUA_HTLNQIDEVK_vs_SPRL1_VLTHSELAPLR
89 & 140
0.019
0.769

FETUA_HTLNQIDEVK_vs_VTDB_ELPEHTVK
89 & 147
0.004
0.830

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.021
0.765

HEMO_NFPSPVDAAFR_vs_TENX_LSQLSVTDVTTSSLR
93 & 142
0.023
0.761

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.023
0.761

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.018
0.772

IBP6_GAQTLYVPNCDHR_vs_TENX_LSQLSVTDVTTSSLR
101 & 142
0.008
0.805

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR
102 & 18
0.042
0.734

IBP6_HLDSVLQQLQTEVYR_vs_TENX_LSQLSVTDVTTSSLR
102 & 142
0.006
0.816

ITIH3_ALDLSLK_vs_IBP1_VVESLAK
111 & 97
0.032
0.747

ITIH3_ALDLSLK_vs_IBP2_LIQGAPTIR
111 & 98
0.019
0.770

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.006
0.816

ITIH4_NPLVWVHASPEHVVVTR_vs_ALS_IRPHTFTGLSGLR
113 & 40
0.028
0.753

ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_AHQLAIDTYQEFEETYIPK
113 & 80
0.043
0.733

ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR
113 & 86
0.019
0.769

ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_FLNVLSPR
113 & 99
0.009
0.799

ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_YGQPLPGYTTK
113 & 100
0.023
0.762

ITIH4_NPLVWVHASPEHVVVTR_vs_IGF2_GIVEECCFR
113 & 103
0.010
0.795

ITIH4_NPLVWVHASPEHVVVTR_vs_ITIH4_ILDDLSPR
113 & 112
0.048
0.727

ITIH4_NPLVWVHASPEHVVVTR_vs_NCAM1_GLGEISAASEFK
113 & 121
0.033
0.745

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.010
0.797

ITIH4_NPLVWVHASPEHVVVTR_vs_SOM2.CSH_NYGLLYCFR
113 & 138
0.036
0.742

ITIH4_NPLVWVHASPEHVVVTR_vs_SPRL1_VLTHSELAPLR
113 & 140
0.038
0.738

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR
113 & 141
0.021
0.766

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR
113 & 142
0.003
0.842

ITIH4_NPLVWVHASPEHVVVTR_vs_VTDB_ELPEHTVK
113 & 147
0.021
0.766

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TENX_LSQLSVTDVTTSSLR
114 & 142
0.037
0.740

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR
116 & 142
0.020
0.767

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.028
0.752

KNG1_QVVAGLNFR_vs_TENX_LSQLSVTDVTTSSLR
117 & 142
0.021
0.765

LBP_ITGFLKPGK_vs_TENX_LSQLSVTDVTTSSLR
118 & 142
0.018
0.772

PAPP1_DIPHWLNPTR_vs_IBP1_VVESLAK
122 & 97
0.037
0.740

PAPP1_DIPHWLNPTR_vs_IBP2_LIQGAPTIR
122 & 98
0.023
0.761

PAPP1_DIPHWLNPTR_vs_PGRP2_AGLLRPDYALLGHR
122 & 126
0.037
0.740

PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR
122 & 18
0.033
0.745

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF
122 & 139
0.010
0.797

PEDF_LQSLFDSPDFSK_vs_IBP1_VVESLAK
124 & 97
0.036
0.741

PEDF_LQSLFDSPDFSK_vs_IBP2_LIQGAPTIR
124 & 98
0.040
0.736

PEDF_LQSLFDSPDFSK_vs_ITIH4_ILDDLSPR
124 & 112
0.025
0.758

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.028
0.752

PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR
124 & 126
0.048
0.727

PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
124 & 135
0.045
0.731

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.011
0.794

PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK
124 & 147
0.030
0.749

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR
125 & 18
0.024
0.759

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.020
0.767

PSG11_LFIPQITPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
132 & 135
0.026
0.756

PSG11_LFIPQITPK_vs_SOM2.CSH_SVEGSCGF
132 & 139
0.028
0.752

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.030
0.749

PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF
137 & 139
0.042
0.734

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.040
0.736

THBG_AVLHIGEK_vs_TENX_LSQLSVTDVTTSSLR
143 & 142
0.025
0.758

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.026
0.756

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.029
0.750

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.010
0.797

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.018
0.772

TABLE 43

Reversal Classification Performance, weeks 17 through 21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs

control cut-off of <37 0/7 vs >=37 0/7 weeks, without

BMI stratification.

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.002
0.609

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.002
0.610

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.001
0.614

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.003
0.605

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.001
0.620

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.003
0.608

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.001
0.622

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.001
0.623

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.001
0.618

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.001
0.618

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.001
0.623

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.001
0.624

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.002
0.610

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.001
0.618

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.004
0.602

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.000
0.633

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.000
0.632

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.000
0.640

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.001
0.623

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.000
0.633

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.001
0.618

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.000
0.630

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR
47 & 129
0.001
0.622

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 & 131
0.004
0.603

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.000
0.644

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.003
0.607

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.004
0.601

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.000
0.630

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.003
0.605

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.001
0.616

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.002
0.609

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.000
0.631

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.001
0.624

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.000
0.628

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.000
0.627

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.002
0.613

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.002
0.612

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.003
0.606

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.003
0.607

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL
51 & 134
0.004
0.603

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.002
0.609

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.002
0.613

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.005
0.601

C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR
55 & 129
0.005
0.601

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.003
0.605

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.001
0.616

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.003
0.605

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.002
0.612

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.005
0.600

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.003
0.606

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.003
0.606

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.005
0.600

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.005
0.601

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.004
0.604

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.003
0.605

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.003
0.605

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.004
0.602

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.004
0.604

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.002
0.609

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.004
0.602

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.002
0.608

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.001
0.623

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.004
0.603

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.003
0.608

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.000
0.632

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.001
0.621

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.002
0.611

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.001
0.613

CFAB_YGLVTYATYPK_vs_VTDB_ELPEHTVK
64 & 147
0.004
0.601

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.004
0.603

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.001
0.618

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.002
0.610

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.004
0.602

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.001
0.614

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.002
0.612

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.004
0.602

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.004
0.603

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.001
0.617

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.002
0.613

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.002
0.608

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.002
0.612

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.001
0.620

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.001
0.619

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.003
0.606

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.001
0.616

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.003
0.606

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_VSAPSGTGHLPGLNPL
82 & 134
0.003
0.604

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.001
0.617

ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR
83 & 103
0.004
0.602

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.004
0.602

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL
83 & 134
0.004
0.602

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.002
0.611

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.003
0.605

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.000
0.629

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.001
0.617

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.004
0.604

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR
88 & 141
0.003
0.607

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.002
0.610

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.002
0.612

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.004
0.603

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.002
0.612

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.003
0.607

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.000
0.628

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.001
0.623

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.003
0.607

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.001
0.617

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.004
0.601

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.005
0.600

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.001
0.614

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.004
0.601

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.002
0.610

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.004
0.601

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.000
0.626

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.003
0.606

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.000
0.625

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.000
0.644

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.000
0.635

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.001
0.619

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.002
0.613

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.001
0.614

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.001
0.617

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.000
0.637

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.005
0.600

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.004
0.601

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.001
0.621

INHBC_LDFHFSSDR_vs_PRG2_WNFAYWAAHQPWSR
107 & 129
0.003
0.605

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.000
0.636

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.001
0.617

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.000
0.627

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.002
0.610

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.003
0.606

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.001
0.613

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.000
0.625

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.002
0.609

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.004
0.601

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.005
0.601

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.004
0.602

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.003
0.606

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.002
0.612

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.003
0.607

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 & 126
0.003
0.605

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.000
0.638

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.001
0.621

LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR
118 & 141
0.005
0.600

LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK
118 & 147
0.004
0.601

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.002
0.608

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.001
0.619

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.001
0.615

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.001
0.620

LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
119 & 80
0.004
0.603

LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR
119 & 99
0.003
0.604

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.002
0.610

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.000
0.629

LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR
119 & 112
0.002
0.608

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.000
0.625

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 & 121
0.003
0.606

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.001
0.622

LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR
119 & 129
0.002
0.611

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.000
0.651

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.000
0.636

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.003
0.608

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.001
0.619

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.003
0.606

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.002
0.610

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.000
0.626

PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR
124 & 103
0.004
0.602

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.005
0.601

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.001
0.617

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.004
0.603

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.001
0.614

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.004
0.602

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.003
0.608

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.002
0.613

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.002
0.610

VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR
149 & 40
0.005
0.600

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.002
0.613

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.002
0.609

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.001
0.618

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.000
0.636

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.004
0.603

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.001
0.617

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.001
0.621

VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQPWSR
149 & 129
0.003
0.608

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.000
0.646

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.000
0.640

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.001
0.619

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.004
0.604

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.002
0.609

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.000
0.630

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.001
0.615

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.003
0.606

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.000
0.631

VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR
150 & 112
0.004
0.604

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.001
0.622

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.005
0.601

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.001
0.617

VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQPWSR
150 & 129
0.004
0.603

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.000
0.642

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.000
0.632

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.001
0.616

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.000
0.642

TABLE 44

Reversal Classification Performance, weeks 17 through 21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs

control cut-off of <37 0/7 vs >=37 0/7 weeks, with

BMI stratification (>22 <= 37).

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR
34 & 78
0.016
0.604

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.008
0.613

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.006
0.617

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.003
0.629

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.011
0.609

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.009
0.612

AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR
37 & 99
0.014
0.605

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 & 100
0.004
0.623

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.002
0.636

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.020
0.600

AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR
38 & 66
0.018
0.602

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.005
0.619

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.002
0.635

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.001
0.637

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.011
0.609

ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR
42 & 66
0.015
0.605

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.007
0.615

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.006
0.618

ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK
42 & 100
0.019
0.601

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.008
0.614

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.009
0.612

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.016
0.604

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.012
0.608

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.003
0.626

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.013
0.607

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.012
0.607

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.010
0.610

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.003
0.628

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.003
0.627

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.002
0.632

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.004
0.625

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.005
0.621

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.003
0.628

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.016
0.603

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.002
0.630

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.006
0.617

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.005
0.621

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.008
0.613

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.019
0.601

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.008
0.613

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.016
0.604

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.009
0.613

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.009
0.611

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.011
0.609

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.009
0.613

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.008
0.613

B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR
50 & 103
0.016
0.603

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.008
0.614

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.016
0.603

BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR
52 & 66
0.017
0.602

BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR
52 & 78
0.017
0.603

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.007
0.616

BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR
52 & 103
0.013
0.607

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.008
0.614

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR
52 & 18
0.019
0.601

BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR
52 & 141
0.013
0.606

C1QB_VPGLYYFTYHASSR_vs_CRIS3_YEDLYSNCK
55 & 79
0.018
0.602

C1QB_VPGLYYFTYHASSR_vs_IBP3_FLNVLSPR
55 & 99
0.012
0.608

C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK
55 & 100
0.010
0.610

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.002
0.630

C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR
55 & 120
0.010
0.611

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.006
0.618

C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
55 & 135
0.015
0.605

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.006
0.617

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.013
0.607

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.018
0.601

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.007
0.615

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR
59 & 18
0.013
0.606

CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR
60 & 103
0.015
0.604

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.014
0.606

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.017
0.603

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.012
0.607

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.015
0.605

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.013
0.606

CFAB_YGLVTYATYPK_vs_CRIS3_AVSPPAR
64 & 78
0.018
0.601

CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK
64 & 79
0.010
0.611

CFAB_YGLVTYATYPK_vs_IBP3_FLNVLSPR
64 & 99
0.016
0.603

CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK
64 & 100
0.010
0.610

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.003
0.628

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.004
0.623

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.012
0.608

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.006
0.619

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.009
0.613

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.019
0.600

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.005
0.620

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.019
0.601

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.014
0.605

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.016
0.603

CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR
70 & 78
0.015
0.604

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.009
0.612

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.008
0.614

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.004
0.625

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.009
0.611

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.007
0.616

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.008
0.613

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.019
0.601

CO5_VFQFLEK_vs_CRIS3_AVSPPAR
71 & 78
0.019
0.601

CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK
71 & 79
0.013
0.607

CO5_VFQFLEK_vs_IGF2_GIVEECCFR
71 & 103
0.014
0.606

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.005
0.619

CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR
71 & 126
0.013
0.607

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.016
0.604

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.010
0.610

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.019
0.601

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.017
0.602

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.009
0.612

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.011
0.609

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.017
0.602

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.008
0.613

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.018
0.602

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.016
0.603

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.006
0.617

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.010
0.610

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR
82 & 103
0.018
0.601

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR
82 & 120
0.005
0.620

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.005
0.622

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.013
0.607

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.015
0.605

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.009
0.613

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.004
0.624

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.012
0.608

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.014
0.605

HABP2_FLNWIK_vs_IBP3_FLNVLSPR
92 & 99
0.010
0.610

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.006
0.618

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.001
0.636

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.012
0.608

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.018
0.602

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.012
0.608

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.013
0.607

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.005
0.621

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.002
0.635

IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR
2 & 99
0.009
0.611

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.003
0.626

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.001
0.646

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.001
0.640

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.001
0.637

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.005
0.622

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.002
0.634

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.008
0.614

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.007
0.615

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.017
0.603

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.008
0.614

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.007
0.616

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.015
0.604

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.008
0.614

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.002
0.634

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.001
0.639

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.001
0.649

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.016
0.603

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.008
0.613

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.005
0.620

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.002
0.635

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.006
0.619

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.006
0.617

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.001
0.637

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.008
0.614

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.010
0.610

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.003
0.627

ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR
111 & 78
0.013
0.607

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.009
0.611

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.008
0.615

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.004
0.623

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.013
0.606

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.014
0.605

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.013
0.607

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.019
0.600

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.012
0.608

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.011
0.609

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.019
0.600

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.015
0.604

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.011
0.609

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.004
0.624

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.002
0.630

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.013
0.606

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.005
0.621

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.002
0.635

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.004
0.622

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.006
0.617

LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
119 & 135
0.017
0.603

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.004
0.624

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.015
0.605

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.017
0.603

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.012
0.608

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.007
0.616

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.004
0.623

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.005
0.621

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.011
0.610

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.010
0.610

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.018
0.602

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.009
0.612

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.016
0.603

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.018
0.602

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.015
0.604

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.014
0.605

VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR
149 & 40
0.013
0.607

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.005
0.621

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.005
0.621

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.003
0.627

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.002
0.630

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.001
0.647

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.000
0.653

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.011
0.609

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.000
0.650

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.015
0.604

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.002
0.635

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.001
0.640

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.011
0.609

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.001
0.640

VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF
149 & 139
0.020
0.600

VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR
149 & 140
0.013
0.607

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.005
0.620

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.004
0.624

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.001
0.646

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.007
0.616

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.004
0.624

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.003
0.629

VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR
150 & 99
0.006
0.618

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.002
0.630

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.001
0.641

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.000
0.653

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.013
0.607

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.004
0.624

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.002
0.630

VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
150 & 135
0.012
0.608

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.002
0.633

VTNC_VDTVDPPYPR_vs_SPRL1_VLTHSELAPLR
150 & 140
0.018
0.601

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.009
0.612

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.012
0.608

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.001
0.648

TABLE 45

Reversal Classification Performance, weeks 17 through 21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7

using a case vs control cut-off of <35 0/7 vs >=35 0/7

weeks, without BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK
34 & 97
0.046
0.615

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.023
0.631

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.013
0.642

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.012
0.644

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.041
0.618

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.050
0.613

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.035
0.621

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.036
0.621

AFAM_HFQNLGK_vs_IBP1_VVESLAK
38 & 97
0.044
0.618

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.048
0.614

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.013
0.642

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.005
0.661

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.010
0.648

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.041
0.617

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.010
0.648

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.027
0.627

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.042
0.617

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.015
0.639

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.027
0.627

APOH_ATVVYQGER_vs_IBP1_VVESLAK
48 & 97
0.046
0.615

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.011
0.647

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.045
0.615

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.009
0.651

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.040
0.618

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.024
0.630

B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK
51 & 97
0.047
0.614

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.040
0.618

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.002
0.676

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.032
0.624

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.022
0.632

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.001
0.697

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.013
0.643

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.008
0.653

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.005
0.661

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.009
0.651

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.018
0.636

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.010
0.648

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.050
0.613

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.026
0.628

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.019
0.635

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.003
0.669

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.020
0.634

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.001
0.688

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.009
0.650

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.008
0.652

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.012
0.644

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.010
0.649

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.007
0.655

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.009
0.650

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.004
0.666

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.013
0.643

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.014
0.642

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.023
0.631

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.020
0.634

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.004
0.664

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.012
0.645

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.006
0.657

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.013
0.644

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.023
0.631

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.017
0.638

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.012
0.645

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.017
0.637

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.013
0.643

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.003
0.670

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.045
0.615

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.001
0.684

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.010
0.649

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.006
0.658

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.012
0.644

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.023
0.631

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.020
0.634

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.015
0.640

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.004
0.666

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.015
0.640

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.026
0.628

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.037
0.620

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.020
0.634

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.007
0.656

CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR
60 & 140
0.026
0.628

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.028
0.627

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.044
0.616

CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK
61 & 97
0.019
0.635

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.015
0.640

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.002
0.681

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.009
0.650

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.045
0.615

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.011
0.647

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.033
0.623

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.034
0.622

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.020
0.633

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.011
0.647

CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK
62 & 79
0.033
0.623

CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK
62 & 97
0.021
0.633

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.025
0.629

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.003
0.669

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.015
0.640

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.017
0.638

CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF
62 & 139
0.041
0.618

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR
62 & 140
0.049
0.613

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.024
0.630

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.014
0.641

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.044
0.616

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.028
0.627

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.016
0.638

CLUS_ASSIIDELFQDR_vs_IBP1_VVESLAK
67 & 97
0.039
0.619

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.047
0.614

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.011
0.645

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.001
0.683

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.026
0.628

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.037
0.620

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.017
0.638

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.013
0.643

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.028
0.627

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.014
0.642

CLUS_LFDSDPITVTVPVEVSR_vs_IBP1_VVESLAK
68 & 97
0.039
0.619

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK
68 & 100
0.046
0.615

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.015
0.640

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.004
0.668

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR
68 & 126
0.049
0.613

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR
68 & 18
0.023
0.631

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.014
0.642

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.036
0.620

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.005
0.663

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.043
0.616

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.015
0.641

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.006
0.657

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.039
0.619

CO8A_SLLQPNK_vs_IBP1_VVESLAK
74 & 97
0.046
0.615

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.047
0.614

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.007
0.654

CO8B_QALEEFQK_vs_IBP1_VVESLAK
76 & 97
0.036
0.621

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.046
0.615

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.018
0.636

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.046
0.615

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.021
0.633

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.013
0.643

F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK
84 & 97
0.033
0.623

F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK
84 & 100
0.039
0.619

F13B_GDTYPAELYITGSILR_VS_IGF2_GIVEECCFR
84 & 103
0.011
0.646

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.001
0.695

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.031
0.624

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.020
0.634

F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR
84 & 140
0.031
0.624

FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK
88 & 79
0.045
0.615

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.007
0.654

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.016
0.638

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.033
0.623

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.019
0.635

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.021
0.632

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.011
0.647

IBP4_QCHPALDGQR_vs_IBP1_VVESLAK
2 & 97
0.042
0.617

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.047
0.614

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.003
0.669

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.033
0.623

IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK
102 & 79
0.044
0.616

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.022
0.631

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.039
0.619

KNG1_DIPTNSPELEETLTHTITK_vs_IBP1_VVESLAK
116 & 97
0.048
0.614

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.012
0.645

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.041
0.618

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.020
0.634

KNG1_QVVAGLNFR_vs_IBP1_VVESLAK
117 & 97
0.024
0.630

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.020
0.634

KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR
117 & 112
0.038
0.619

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.002
0.682

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.027
0.627

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.016
0.639

KNG1_QVVAGLNFR_vs_VTDB_ELPEHTVK
117 & 147
0.041
0.618

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.031
0.624

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.034
0.622

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.026
0.628

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.004
0.664

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.027
0.627

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.017
0.638

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.029
0.626

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.002
0.677

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.015
0.640

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.011
0.646

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.020
0.634

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.027
0.627

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.028
0.626

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.042
0.617

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.006
0.658

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.025
0.629

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.014
0.642

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.036
0.621

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.036
0.621

PTGDS_GPGEDFR_vs_IBP1_VVESLAK
137 & 97
0.050
0.613

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.018
0.636

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.015
0.640

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.033
0.622

VTNC_GQYCYELDEK_vs_IBP1_VVESLAK
149 & 97
0.048
0.614

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.029
0.625

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.002
0.675

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.044
0.616

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.032
0.623

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.030
0.625

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.040
0.618

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.049
0.613

VTNC_VDTVDPPYPR_VS_LYAM1_SYYWIGIR
150 & 120
0.004
0.665

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.038
0.619

TABLE 46

Reversal Classification Performance, weeks 17 through 21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7

using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks,

with BMI stratification (>22 <= 37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.047
0.637

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.006
0.689

AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK
37 & 79
0.027
0.652

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.018
0.663

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.007
0.687

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.016
0.666

AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF
37 & 139
0.049
0.636

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.035
0.645

AFAM_HFQNLGK_vs_CRIS3_AVSPPAR
38 & 78
0.043
0.640

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.020
0.660

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.039
0.642

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.031
0.648

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.009
0.680

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.005
0.693

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.013
0.672

AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF
38 & 139
0.026
0.653

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.035
0.645

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.031
0.648

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.004
0.697

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.029
0.650

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.028
0.651

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.049
0.636

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.029
0.650

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.016
0.667

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.016
0.665

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.015
0.668

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.044
0.639

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.031
0.649

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.002
0.709

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.031
0.649

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.001
0.722

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.018
0.664

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.010
0.677

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.008
0.682

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.011
0.676

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.027
0.652

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.036
0.644

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.009
0.679

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.034
0.646

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.001
0.720

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.009
0.680

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.029
0.651

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.016
0.666

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.011
0.675

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.045
0.638

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.028
0.652

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.017
0.664

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.004
0.698

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.009
0.681

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.004
0.698

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.011
0.676

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.020
0.661

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.039
0.642

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.012
0.673

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.019
0.661

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.005
0.693

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.033
0.647

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.001
0.727

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.004
0.700

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.030
0.649

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.019
0.662

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.025
0.654

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.018
0.663

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.014
0.669

CBPN_EALIQFLEQVHQGIK_VS_LYAM1_SYYWIGIR
59 & 120
0.019
0.662

CBPN_NNANGVDLNR_vs_CRIS3_YEDLYSNCK
60 & 79
0.047
0.637

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.006
0.689

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR
61 & 78
0.046
0.637

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.030
0.650

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.003
0.708

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.009
0.679

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.033
0.647

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.044
0.639

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.009
0.679

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.022
0.657

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.038
0.643

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.029
0.651

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.018
0.663

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.003
0.703

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.035
0.645

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.027
0.652

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.021
0.659

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.047
0.637

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.006
0.688

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.024
0.655

CO6_ALNHLPLEYNSALYSR_VS_LYAM1_SYYWIGIR
72 & 120
0.006
0.689

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.026
0.653

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.012
0.674

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.036
0.644

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.016
0.665

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.012
0.672

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.035
0.646

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.001
0.729

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.015
0.668

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.031
0.649

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.013
0.671

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.011
0.674

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.026
0.653

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.035
0.645

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.017
0.664

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.003
0.706

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.046
0.638

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.017
0.664

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.028
0.652

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.049
0.636

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.011
0.675

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.034
0.646

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.020
0.661

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.035
0.645

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.002
0.714

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.025
0.654

PAPP1_DIPHWLNPTR_vs_C163A_INPASLDK
122 & 54
0.050
0.635

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.014
0.669

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.011
0.675

PAPP1_DIPHWLNPTR_vs_CSH_AHQLAIDTYQEFEETYIPK
122 & 80
0.044
0.639

PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPVR
122 & 81
0.040
0.642

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.006
0.689

PAPP1_DIPHWLNPTR_vs_PGRP2_AGLLRPDYALLGHR
122 & 126
0.039
0.642

PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR
122 & 129
0.008
0.681

PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR
122 & 18
0.039
0.643

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYCFR
122 & 138
0.039
0.642

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF
122 & 139
0.005
0.693

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.047
0.637

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.005
0.693

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.042
0.640

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.027
0.653

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.003
0.705

PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR
125 & 126
0.030
0.649

PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR
133 & 40
0.030
0.649

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.004
0.700

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.004
0.700

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.032
0.648

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.047
0.637

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.040
0.641

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.040
0.641

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.009
0.681

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.028
0.652

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.029
0.650

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.017
0.664

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 & 112
0.016
0.666

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.001
0.729

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.007
0.686

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.014
0.669

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.004
0.700

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.013
0.671

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.028
0.652

PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
133 & 144
0.049
0.635

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 & 147
0.021
0.659

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.042
0.640

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.030
0.650

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.011
0.676

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.024
0.655

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.041
0.641

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.023
0.657

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.001
0.719

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.021
0.659

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.047
0.637

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.047
0.637

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.007
0.685

TABLE 47

Reversal Classification Performance, weeks 17, 18 and 19.

Reversal AUROC for gestational weeks 17 0/7 through 19 6/7

using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks,

without BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.003
0.628

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.021
0.600

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.007
0.617

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.016
0.606

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.012
0.609

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.017
0.605

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.011
0.610

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.017
0.605

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.006
0.621

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.009
0.614

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.013
0.608

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.017
0.604

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.013
0.608

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.015
0.606

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.020
0.602

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.002
0.633

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.022
0.600

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.009
0.614

APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR
48 & 66
0.021
0.600

APOH_ATVVYQGER_vs_CSH_AHQLAIDTYQEFEETYIPK
48 & 80
0.009
0.614

APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR
48 & 86
0.011
0.610

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.014
0.607

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.008
0.616

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.000
0.654

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.010
0.612

APOH_ATVVYQGER_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
48 & 144
0.010
0.613

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 & 147
0.021
0.601

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL
51 & 134
0.010
0.613

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.009
0.613

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.010
0.613

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.013
0.608

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 138
0.021
0.600

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.021
0.600

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.004
0.624

CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK
62 & 80
0.020
0.601

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.004
0.625

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.020
0.602

CFAB_YGLVTYATYPK_vs_C163A_INPASLDK
64 & 54
0.007
0.617

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.011
0.611

CFAB_YGLVTYATYPK_vs_CSH_AHQLAIDTYQEFEETYIPK
64 & 80
0.010
0.612

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.014
0.607

CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK
64 & 121
0.009
0.614

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.001
0.645

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.008
0.615

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.001
0.639

CFAB_YGLVTYATYPK_vs_VTDB_ELPEHTVK
64 & 147
0.016
0.605

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.006
0.619

CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL
68 & 134
0.013
0.608

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.001
0.641

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.020
0.602

CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
70 & 144
0.011
0.610

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.003
0.629

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.018
0.604

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.009
0.614

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.020
0.601

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.014
0.607

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.002
0.634

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.004
0.626

COSA_SLLQPNK_vs_CSH_AHQLAIDTYQEFEETYIPK
74 & 80
0.017
0.605

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.002
0.632

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.004
0.625

CO8B_QALEEFQK_vs_CSH_AHQLAIDTYQEFEETYIPK
76 & 80
0.012
0.609

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.003
0.631

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.003
0.628

F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR
84 & 66
0.020
0.601

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.004
0.625

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.010
0.612

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.016
0.605

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.019
0.602

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.021
0.601

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.012
0.609

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.001
0.640

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.017
0.604

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.005
0.622

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.021
0.601

IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFE
2 & 80
0.017
0.604

IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR
2 & 86
0.017
0.604

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.014
0.607

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.000
0.660

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.011
0.612

IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL
101 & 134
0.008
0.616

IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL
102 & 134
0.006
0.621

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.015
0.606

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.003
0.631

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.019
0.602

ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL
111 & 134
0.018
0.603

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.020
0.602

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.004
0.627

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.017
0.604

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.003
0.631

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.012
0.609

LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
119 & 80
0.019
0.602

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.001
0.640

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.013
0.608

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.021
0.602

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.002
0.633

PEDF_TVQAVLTVPK_vs_CSH_AHQLAIDTYQEFEETYIPK
125 & 80
0.020
0.601

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.002
0.636

PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
125 & 144
0.018
0.603

PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL
137 & 134
0.012
0.609

THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL
143 & 134
0.021
0.601

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.013
0.608

VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK
149 & 80
0.012
0.609

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.010
0.612

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.016
0.605

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.011
0.611

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.009
0.613

VTNC_GQYCYELDEK_VS_NCAM1_GLGEISAASEFK
149 & 121
0.010
0.612

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.008
0.616

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.000
0.658

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.004
0.625

VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF
149 & 139
0.019
0.603

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.002
0.633

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.012
0.610

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.018
0.603

VTNC_VDTVDPPYPR_vs_CSH_AHQLAIDTYQEFEETYIPK
150 & 80
0.015
0.606

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.018
0.604

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.010
0.613

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.011
0.610

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.021
0.601

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.000
0.656

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.010
0.612

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.007
0.618

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.007
0.617

TABLE 48

Reversal Classification Performance, weeks 17, 18 and 19.

Reversal AUROC for gestational weeks 17 0/7 through 19 6/7

using a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks,

with BMI stratification (>22 <=37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.030
0.616

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.046
0.607

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.030
0.616

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.020
0.624

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.024
0.621

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.022
0.622

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.040
0.610

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.016
0.630

ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
42 & 144
0.034
0.613

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.007
0.643

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.044
0.607

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.039
0.610

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.045
0.607

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.047
0.606

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.023
0.621

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.050
0.605

APOH_ATVVYQGER_vs_CHL1_VIAVNEVGR
48 & 66
0.047
0.606

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.043
0.608

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.026
0.619

C1QB_VPGLYYFTYHASSR_vs_C163A_INPASLDK
55 & 54
0.048
0.605

C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR
55 & 66
0.033
0.614

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.026
0.619

C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK
55 & 100
0.049
0.605

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.021
0.623

C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR
55 & 120
0.024
0.621

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.020
0.624

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.022
0.622

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.017
0.627

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 138
0.040
0.610

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF
55 & 139
0.040
0.611

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.046
0.606

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.038
0.611

C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
55 & 144
0.033
0.614

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.044
0.607

CFAB_YGLVTYATYPK_vs_C163A_INPASLDK
64 & 54
0.008
0.642

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.030
0.616

CFAB_YGLVTYATYPK_vs_NCAM1_GLGEISAASEFK
64 & 121
0.022
0.622

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.014
0.631

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.007
0.643

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.048
0.605

CO5_TLLPVSKPEIR_vs_CHL1_VIAVNEVGR
70 & 66
0.019
0.625

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.014
0.632

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.039
0.610

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.006
0.647

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.037
0.611

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.040
0.609

CO5_TLLPVSKPEIR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
70 & 144
0.012
0.635

CO5_TLLPVSKPEIR_vs_VTDB_ELPEHTVK
70 & 147
0.047
0.606

CO5_VFQFLEK_vs_CHL1_VIAVNEVGR
71 & 66
0.036
0.612

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.021
0.623

CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR
71 & 126
0.035
0.612

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.016
0.628

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.034
0.613

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.036
0.612

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.012
0.634

CO6_ALNHLPLEYNSALYSR_vs_C163A_INPASLDK
72 & 54
0.043
0.608

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.014
0.631

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.043
0.608

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.026
0.619

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.012
0.634

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.022
0.622

CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR
72 & 142
0.036
0.612

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.004
0.654

CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR
74 & 66
0.049
0.605

COSA_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.025
0.619

COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.011
0.635

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.032
0.614

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.041
0.609

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.012
0.634

F13B_GDTYPAELYITGSILR_vs_CHL1_VIAVNEVGR
84 & 66
0.021
0.623

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.042
0.609

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.040
0.609

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.027
0.618

HABP2_FLNWIK_vs_C163A_INPASLDK
92 & 54
0.028
0.617

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.017
0.628

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.023
0.622

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.033
0.614

HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK
92 & 121
0.036
0.612

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.008
0.642

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.044
0.608

HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF
92 & 139
0.034
0.615

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.009
0.639

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.021
0.623

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.038
0.611

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.039
0.610

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.012
0.633

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.044
0.607

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.037
0.611

INHBC_LDFHFSSDR_vs_C163A_INPASLDK
107 & 54
0.025
0.620

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.016
0.629

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.030
0.616

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.049
0.605

PEDF_LQSLFDSPDFSK_vs_C163A_INPASLDK
124 & 54
0.047
0.606

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.037
0.611

PEDF_TVQAVLTVPK_vs_C163A_INPASLDK
125 & 54
0.021
0.623

PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR
125 & 66
0.026
0.619

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.038
0.611

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.018
0.627

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.041
0.609

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.042
0.608

PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
125 & 144
0.028
0.617

PRDX2_GLFIIDGK_vs_C163A_INPASLDK
128 & 54
0.039
0.610

PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL
128 & 134
0.047
0.606

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.034
0.613

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.048
0.606

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.045
0.607

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.049
0.605

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.031
0.615

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.024
0.620

PSG2_IHPSYTNYR_vs_PSG1_FQLPGQK
133 & 131
0.047
0.606

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.028
0.617

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.026
0.619

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.043
0.609

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.037
0.611

VTNC_GQYCYELDEK_vs_C163A_INPASLDK
149 & 54
0.007
0.643

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.011
0.635

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.035
0.612

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.042
0.609

VTNC_GQYCYELDEK_vs_CSH_AHQLAIDTYQEFEETYIPK
149 & 80
0.040
0.609

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.046
0.606

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.039
0.610

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.035
0.612

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.009
0.640

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.039
0.610

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.017
0.627

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.004
0.652

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.021
0.623

VTNC_GQYCYELDEK_vs_SOM2.CSH_SVEGSCGF
149 & 139
0.028
0.618

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.042
0.609

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.003
0.658

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.013
0.632

VTNC_VDTVDPPYPR_vs_C163A_INPASLDK
150 & 54
0.019
0.625

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.022
0.622

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.047
0.606

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.008
0.640

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.037
0.611

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.044
0.607

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.005
0.648

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.036
0.612

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.010
0.637

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.013
0.633

TABLE 49

Reversal Classification Performance, weeks 17, 18 and 19.

Reversal AUROC for gestational weeks 17 0/7 through 19 6/7

using a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks,

without BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.036
0.648

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.046
0.641

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.025
0.658

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.038
0.646

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.049
0.639

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.043
0.643

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.039
0.646

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.034
0.650

BGH3_LTLLAPLNSVFK_vs_PSG9_LFIPQITR
52 & 136
0.049
0.639

CBPN_EALIQFLEQVHQGIK_vs_PSG9_LFIPQITR
59 & 136
0.047
0.640

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.039
0.646

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.015
0.672

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.014
0.674

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.021
0.663

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.031
0.653

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.038
0.647

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.036
0.648

CLUS_ASSIIDELFQDR_vs_ALS_IRPHTFTGLSGLR
67 & 40
0.043
0.643

CLUS_ASSIIDELFQDR_vs_C163A_INPASLDK
67 & 54
0.041
0.644

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.034
0.650

CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR
67 & 99
0.014
0.674

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.010
0.681

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.001
0.732

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.004
0.702

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.034
0.650

CLUS_LFDSDPITVTVPVEVSR_vs_ALS_IRPHTFTGLSGLR
68 & 40
0.039
0.645

CLUS_LFDSDPITVTVPVEVSR_vs_C163A_INPASLDK
68 & 54
0.037
0.647

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.027
0.656

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.012
0.678

CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK
68 & 80
0.050
0.638

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR
68 & 99
0.005
0.700

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK
68 & 100
0.003
0.707

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.000
0.749

CLUS_LFDSDPITVTVPVEVSR_vs_ITIH4_ILDDLSPR
68 & 112
0.030
0.653

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.004
0.705

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR
68 & 141
0.028
0.655

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR
68 & 142
0.045
0.641

CLUS_LFDSDPITVTVPVEVSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
68 & 144
0.035
0.648

CLUS_LFDSDPITVTVPVEVSR_VS_VTDB_ELPEHTVK
68 & 147
0.015
0.672

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.047
0.640

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.036
0.648

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.021
0.663

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.039
0.645

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.012
0.677

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.007
0.690

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.038
0.647

CO6_ALNHLPLEYNSALYSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
72 & 144
0.017
0.669

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.036
0.648

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.021
0.663

COSA_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.046
0.641

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.027
0.656

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR
82 & 136
0.016
0.670

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.034
0.650

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.023
0.661

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.032
0.651

F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK
84 & 100
0.049
0.639

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.008
0.686

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.009
0.686

FETUA_FSVVYAK_vs_PSG9_LFIPQITR
88 & 136
0.034
0.650

FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
89 & 135
0.037
0.647

FETUA_HTLNQIDEVK_vs_PSG9_LFIPQITR
89 & 136
0.024
0.659

HABP2_FLNWIK_vs_C163A_INPASLDK
92 & 54
0.032
0.651

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.014
0.674

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.020
0.664

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.021
0.663

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.029
0.654

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.034
0.649

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.017
0.668

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.015
0.672

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.012
0.676

IBP6_GAQTLYVPNCDHR_vs_C163A_INPASLDK
101 & 54
0.031
0.652

IBP6_GAQTLYVPNCDHR_vs_CRIS3_YEDLYSNCK
101 & 79
0.045
0.642

IBP6_GAQTLYVPNCDHR_vs_IGF2_GIVEECCFR
101 & 103
0.020
0.664

IBP6_GAQTLYVPNCDHR_vs_LYAM1_SYYWIGIR
101 & 120
0.041
0.644

IBP6_HLDSVLQQLQTEVYR_vs_C163A_INPASLDK
102 & 54
0.027
0.656

IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK
102 & 79
0.036
0.648

IBP6_HLDSVLQQLQTEVYR_vs_IGF2_GIVEECCFR
102 & 103
0.026
0.658

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.045
0.641

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.037
0.647

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.036
0.648

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.031
0.653

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.030
0.653

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.006
0.695

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.013
0.676

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.047
0.640

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.037
0.647

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.042
0.643

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.019
0.665

PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR
133 & 40
0.029
0.654

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.016
0.670

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.049
0.639

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.008
0.687

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.005
0.697

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.011
0.680

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.026
0.658

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.007
0.689

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.027
0.656

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.031
0.652

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.021
0.663

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.016
0.669

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.010
0.681

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 & 112
0.027
0.656

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.004
0.702

PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK
133 & 121
0.021
0.663

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.013
0.676

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.025
0.658

PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR
133 & 138
0.019
0.665

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.034
0.650

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.024
0.660

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR
133 & 141
0.017
0.668

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.014
0.674

PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
133 & 144
0.019
0.666

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 & 147
0.036
0.648

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.043
0.643

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 & 103
0.046
0.641

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.025
0.658

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.014
0.674

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.043
0.643

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.020
0.664

TABLE 50

Reversal Classification Performance, weeks 17, 18 and 19.

Reversal AUROC for gestational weeks 17 0/7 through 19 6/7 using a

case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with

BMI stratification (>22 <=37).

Reversal
SEQ ID NO:
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.012
0.718

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.023
0.696

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.019
0.702

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.035
0.682

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.040
0.678

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.033
0.684

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.037
0.680

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.048
0.671

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.020
0.702

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.020
0.702

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.038
0.679

CLUS_ASSIIDELFQDR_vs_IBP3_FLNVLSPR
67 & 99
0.034
0.684

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.004
0.751

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.010
0.722

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.031
0.687

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR
68 & 99
0.033
0.685

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.008
0.731

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.028
0.690

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.029
0.689

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.015
0.710

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.045
0.673

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.008
0.731

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.011
0.720

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.049
0.671

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR
82 & 40
0.033
0.684

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_FBLN1_TGYYFDGISR
82 & 86
0.020
0.701

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR
82 & 112
0.036
0.681

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_NCAM1_GLGEISAASEFK
82 & 121
0.026
0.693

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2_WNFAYWAAHQPWSR
82 & 129
0.042
0.676

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.019
0.702

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_LFIPQITR
82 & 136
0.006
0.739

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_VTDB_ELPEHTVK
82 & 147
0.016
0.709

ENPP2_TYLHTYESEI_vs_ALS_IRPHTFTGLSGLR
83 & 40
0.042
0.676

ENPP2_TYLHTYESEI_vs_FBLN1_TGYYFDGISR
83 & 86
0.025
0.693

ENPP2_TYLHTYESEI_vs_ITIH4_ILDDLSPR
83 & 112
0.043
0.675

ENPP2_TYLHTYESEI_vs_NCAM1_GLGEISAASEFK
83 & 121
0.030
0.688

ENPP2_TYLHTYESEI_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
83 & 135
0.027
0.692

ENPP2_TYLHTYESEI_vs_PSG9_LFIPQITR
83 & 136
0.009
0.727

ENPP2_TYLHTYESEI_vs_VTDB_ELPEHTVK
83 & 147
0.015
0.712

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.043
0.675

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.030
0.688

F13B_GDTYPAELYITGSILR_vs_IBP3_FLNVLSPR
84 & 99
0.040
0.678

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.004
0.750

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.012
0.718

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.045
0.673

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.035
0.682

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.006
0.737

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.013
0.715

IBP6_HLDSVLQQLQTEVYR_vs_IGF2_GIVEECCFR
102 & 103
0.049
0.670

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.019
0.704

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.030
0.688

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.037
0.681

KNG1_QVVAGLNFR_vs_IBP3_FLNVLSPR
117 & 99
0.019
0.703

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.024
0.696

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.002
0.763

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.014
0.713

PAPP1_DIPHWLNPTR_vs_C163A_INPASLDK
122 & 54
0.049
0.670

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.034
0.683

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.025
0.693

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.036
0.681

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.031
0.687

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.022
0.699

PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR
133 & 40
0.018
0.705

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.010
0.723

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.042
0.676

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.003
0.758

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.003
0.759

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.014
0.713

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.029
0.690

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.014
0.712

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.038
0.679

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.007
0.732

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.010
0.722

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.003
0.754

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 & 112
0.015
0.710

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.002
0.773

PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK
133 & 121
0.035
0.683

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.021
0.700

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.007
0.733

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.028
0.691

PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR
133 & 138
0.021
0.699

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.023
0.697

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.042
0.676

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR
133 & 141
0.016
0.708

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.011
0.720

PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
133 & 144
0.031
0.687

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 & 147
0.017
0.707

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.042
0.676

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 & 103
0.021
0.700

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.018
0.704

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.017
0.707

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.048
0.671

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.040
0.677

TABLE 51

Reversal Classification Performance, weeks 18, 19 and 20.

Reversal AUROC for gestational weeks 18 0/7 through 20 6/7 using

a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks,

without BMI stratification.

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.001
0.633

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.008
0.608

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.001
0.630

AFAM_HFQNLGK_vs_PRG2_WNFAYWAAHQPWSR
38 & 129
0.010
0.605

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.001
0.636

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.013
0.602

AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR
38 & 141
0.007
0.610

ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR
42 & 86
0.008
0.608

ANGT_DPTFIPAPIQAK_vs_PRG2_WNFAYWAAHQPWSR
42 & 129
0.010
0.605

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.001
0.635

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.005
0.614

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.004
0.618

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.001
0.638

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.003
0.620

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.001
0.631

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.001
0.635

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.002
0.627

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.006
0.613

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.001
0.634

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.011
0.603

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.001
0.630

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.002
0.623

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.001
0.633

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.003
0.623

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.001
0.637

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.004
0.617

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.003
0.620

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR
47 & 129
0.001
0.637

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 & 131
0.009
0.606

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.000
0.662

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.005
0.615

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.006
0.612

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.001
0.632

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.006
0.611

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.008
0.609

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.004
0.618

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.001
0.634

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.001
0.630

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.001
0.638

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.001
0.630

APOH_ATVVYQGER_vs_FBLN1_TGYYFDGISR
48 & 86
0.005
0.614

APOH_ATVVYQGER_vs_PRG2_WNFAYWAAHQPWSR
48 & 129
0.013
0.601

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.000
0.649

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.006
0.613

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.008
0.607

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 & 142
0.013
0.602

B2MG_VEHSDLSFSK_vs_PSG3_VSAPSGTGHLPGLNPL
50 & 134
0.011
0.604

B2MG_VNHVTLSQPK_vs_PSG3_VSAPSGTGHLPGLNPL
51 & 134
0.002
0.623

BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL
52 & 134
0.007
0.610

C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR
55 & 66
0.005
0.613

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.005
0.614

C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR
55 & 86
0.001
0.630

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.010
0.605

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.010
0.605

C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR
55 & 129
0.001
0.632

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.000
0.649

C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
55 & 135
0.013
0.602

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.001
0.641

C1QB_VPGLYYFTYHASSR_vs_SPRL1_VLTHSELAPLR
55 & 140
0.011
0.603

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.002
0.624

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.003
0.619

C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
55 & 144
0.007
0.610

CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR
61 & 86
0.011
0.604

CD14_LTVGAAQVPAQLLVGALR_vs_PRG2_WNFAYWAAHQPWSR
61 & 129
0.013
0.602

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.000
0.646

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.006
0.611

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.004
0.616

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.007
0.609

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.011
0.604

CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR
62 & 86
0.013
0.602

CD14_SWLAELQQWLKPGLK_vs_PRG2_WNFAYWAAHQPWSR
62 & 129
0.013
0.602

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.001
0.637

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.007
0.610

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.006
0.611

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.012
0.603

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.014
0.601

CFAB_YGLVTYATYPK_vs_PRG2_WNFAYWAAHQPWSR
64 & 129
0.013
0.601

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.000
0.646

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.008
0.607

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.010
0.605

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.004
0.618

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.002
0.628

CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR
67 & 141
0.014
0.600

CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL
68 & 134
0.004
0.617

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.001
0.631

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.014
0.600

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.014
0.600

CO5_VFQFLEK_vs_FBLN1_TGYYFDGISR
71 & 86
0.012
0.603

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.002
0.629

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.009
0.606

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.011
0.604

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.002
0.624

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.013
0.602

CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR
74 & 66
0.011
0.604

CO8A_SLLQPNK_vs_FBLN1_TGYYFDGISR
74 & 86
0.013
0.601

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.000
0.643

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.006
0.612

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.002
0.624

CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.007
0.610

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.003
0.622

CO8B_QALEEFQK_vs_FBLN1_TGYYFDGISR
76 & 86
0.014
0.600

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.000
0.645

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.006
0.612

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.002
0.628

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.004
0.619

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.002
0.627

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG3_VSAPSGTGHLPGLNPL
82 & 134
0.012
0.602

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL
83 & 134
0.013
0.601

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.005
0.615

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.007
0.611

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.001
0.633

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR
88 & 141
0.013
0.601

FETUA_HTLNQIDEVK_vs_PRG2_WNFAYWAAHQPWSR
89 & 129
0.010
0.604

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.001
0.640

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.013
0.601

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.005
0.614

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.006
0.613

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.005
0.615

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.005
0.613

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.014
0.601

HABP2_FLNWIK_vs_PRG2_WNFAYWAAHQPWSR
92 & 129
0.005
0.615

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.000
0.658

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.004
0.618

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.001
0.631

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.003
0.621

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.005
0.613

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.008
0.609

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.002
0.625

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.007
0.610

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.006
0.612

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.003
0.619

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.009
0.607

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.004
0.618

IBP4_QCHPALDGQR_vs_FBLN1_TGYYFDGISR
2 & 86
0.002
0.629

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.012
0.602

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.008
0.608

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.009
0.606

IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQPWSR
2 & 129
0.004
0.619

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.000
0.688

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.001
0.639

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.010
0.605

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.001
0.634

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.006
0.612

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.003
0.619

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.007
0.610

IBP6_GAQTLYVPNCDHR_vs_PSG3_VSAPSGTGHLPGLNPL
101 & 134
0.008
0.608

IBP6_HLDSVLQQLQTEVYR_vs_PSG3_VSAPSGTGHLPGLNPL
102 & 134
0.006
0.612

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.005
0.614

INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR
107 & 86
0.004
0.616

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.003
0.622

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.008
0.609

INHBC_LDFHFSSDR_v_PRG2_WNFAYWAAHQPWSR
107 & 129
0.002
0.624

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.000
0.659

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.003
0.620

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.008
0.608

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.001
0.637

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.002
0.624

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.003
0.620

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.008
0.608

ITIH3_ALDLSLK_vs_PSG3_VSAPSGTGHLPGLNPL
111 & 134
0.006
0.612

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.006
0.612

ITIH4_NPLVWVHASPEHVVVTR_vs_PRG2_WNFAYWAAHQPWSR
113 & 129
0.007
0.611

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.003
0.623

ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR
113 & 18
0.014
0.601

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR
113 & 141
0.014
0.601

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG3_VSAPSGTGHLPGLNPL
114 & 134
0.014
0.601

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.000
0.643

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.008
0.608

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR
116 & 141
0.010
0.606

KNG1_QVVAGLNFR_vs_FBLN1_TGYYFDGISR
117 & 86
0.013
0.601

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.001
0.636

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.008
0.608

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.009
0.607

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.011
0.603

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.006
0.612

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.011
0.604

LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPWSR
118 & 129
0.007
0.611

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.000
0.659

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.004
0.617

LBP_ITGFLKPGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
118 & 144
0.013
0.601

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.006
0.611

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.003
0.621

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.004
0.619

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.002
0.624

LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
119 & 80
0.013
0.601

LBP_ITLPDFTGDLR_vs_FBLN1_TGYYFDGISR
119 & 86
0.007
0.610

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.004
0.618

LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR
119 & 129
0.003
0.623

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.000
0.670

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.001
0.633

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.007
0.610

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.009
0.607

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.006
0.613

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.004
0.618

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.012
0.602

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.008
0.608

PEDF_LQSLFDSPDFSK_vs_FBLN1_TGYYFDGISR
124 & 86
0.013
0.601

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.000
0.646

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.012
0.602

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.004
0.619

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.004
0.616

PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR
125 & 66
0.014
0.600

PEDF_TVQAVLTVPK_vs_FBLN1_TGYYFDGISR
125 & 86
0.008
0.608

PEDF_TVQAVLTVPK_vs_PRG2_WNFAYWAAHQPWSR
125 & 129
0.010
0.605

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.000
0.649

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR
125 & 18
0.014
0.600

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.004
0.618

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.007
0.609

PTGDS_GPGEDFR_vs_PSG3_VSAPSGTGHLPGLNPL
137 & 134
0.005
0.614

THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL
143 & 134
0.008
0.609

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.008
0.609

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.003
0.620

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.010
0.605

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.005
0.614

VTNC_GQYCYELDEK_vs_PRG2_WNFAYWAAHQPWSR
149 & 129
0.003
0.623

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.000
0.669

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.000
0.642

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.004
0.618

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.006
0.612

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.002
0.624

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.003
0.623

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.010
0.605

VTNC_VDTVDPPYPR_vs_FBLN1_TGYYFDGISR
150 & 86
0.007
0.610

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.004
0.618

VTNC_VDTVDPPYPR_vs_PRG2_WNFAYWAAHQPWSR
150 & 129
0.005
0.615

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.000
0.669

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.001
0.634

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.005
0.614

VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR
150 & 142
0.010
0.605

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.004
0.617

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.001
0.635

TABLE 52

Reversal Classification Performance, weeks 18, 19 and 20.

Reversal AUROC for gestational weeks 18 0/7 through 20 6/7 using

a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with

BMI stratification (>22 <=37).

SEQ

Reversal
ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR
34 & 78
0.015
0.621

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.009
0.631

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.006
0.638

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.032
0.608

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.003
0.648

A2GL_DLLLPQPDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
34 & 135
0.014
0.623

A2GL_DLLLPQPDLR_vs_PSG9_LFIPQITR
34 & 136
0.034
0.606

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.010
0.628

A2GL_DLLLPQPDLR_vs_SPRL1_VLTHSELAPLR
34 & 140
0.017
0.620

A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR
34 & 141
0.031
0.608

A2GL_DLLLPQPDLR_vs_TENX_LSQLSVTDVTTSSLR
34 & 142
0.042
0.602

A2GL_DLLLPQPDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
34 & 144
0.020
0.616

AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK
37 & 79
0.018
0.619

AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR
37 & 99
0.041
0.602

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 & 100
0.036
0.605

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.013
0.624

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.029
0.609

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.003
0.650

AFAM_DADPDTFFAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
37 & 135
0.019
0.618

AFAM_DADPDTFFAK_vs_PSG9_LFIPQITR
37 & 136
0.042
0.602

AFAM_DADPDTFFAK_vs_SPRL1_VLTHSELAPLR
37 & 140
0.042
0.602

AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSFLLR
37 & 141
0.011
0.627

AFAM_DADPDTFFAK_vs_TENX_LSQLSVTDVTTSSLR
37 & 142
0.022
0.614

AFAM_DADPDTFFAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
37 & 144
0.018
0.619

AFAM_HFQNLGK_vs_CHL1_VIAVNEVGR
38 & 66
0.018
0.618

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.021
0.615

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.033
0.607

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.026
0.611

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.024
0.613

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.023
0.614

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.003
0.648

AFAM_HFQNLGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
38 & 135
0.012
0.626

AFAM_HFQNLGK_vs_PSG9_LFIPQITR
38 & 136
0.029
0.610

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.046
0.600

AFAM_HFQNLGK_vs_SPRL1_VLTHSELAPLR
38 & 140
0.017
0.619

AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR
38 & 141
0.009
0.632

AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR
38 & 142
0.015
0.622

AFAM_HFQNLGK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
38 & 144
0.029
0.610

AFAM_HFQNLGK_vs_VTDB_ELPEHTVK
38 & 147
0.037
0.605

ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR
42 & 66
0.010
0.630

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.010
0.628

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.006
0.637

ANGT_DPTFIPAPIQAK_vs_CSH_AHQLAIDTYQEFEETYIPK
42 & 80
0.042
0.602

ANGT_DPTFIPAPIQAK_vs_FBLN1_TGYYFDGISR
42 & 86
0.036
0.605

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.011
0.627

ANGT_DPTFIPAPIQAK_vs_NCAM1_GLGEISAASEFK
42 & 121
0.025
0.613

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.028
0.610

ANGT_DPTFIPAPIQAK_vs_PSG3_VSAPSGTGHLPGLNPL
42 & 134
0.001
0.669

ANGT_DPTFIPAPIQAK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
42 & 135
0.013
0.625

ANGT_DPTFIPAPIQAK_vs_PSG9_LFIPQITR
42 & 136
0.031
0.608

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.002
0.655

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.019
0.619

ANGT_DPTFIPAPIQAK_vs_SPRL1_VLTHSELAPLR
42 & 140
0.019
0.618

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.010
0.628

ANGT_DPTFIPAPIQAK_vs_TENX_LSQLSVTDVTTSSLR
42 & 142
0.011
0.627

ANGT_DPTFIPAPIQAK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
42 & 144
0.019
0.617

ANGT_DPTFIPAPIQAK_vs_VTDB_ELPEHTVK
42 & 147
0.032
0.607

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.013
0.624

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.001
0.662

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.013
0.624

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.001
0.663

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.001
0.669

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.016
0.621

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.024
0.613

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.015
0.622

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.035
0.606

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.004
0.643

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.008
0.633

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.005
0.641

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.016
0.620

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.001
0.660

APOC3_GWVTDGFSSLK_VS_NCAM1_GLGEISAASEFK
47 & 121
0.014
0.623

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.008
0.633

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR
47 & 129
0.041
0.603

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 & 131
0.022
0.615

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.001
0.664

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.005
0.642

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.007
0.636

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.008
0.633

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.035
0.606

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.015
0.624

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.010
0.629

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.005
0.641

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.007
0.636

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.004
0.644

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.007
0.634

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.025
0.612

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.031
0.608

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.013
0.625

APOH_ATVVYQGER_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
48 & 135
0.008
0.633

APOH_ATVVYQGER_vs_PSG9_LFIPQITR
48 & 136
0.020
0.617

APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR
48 & 140
0.036
0.605

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.028
0.610

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 & 142
0.027
0.611

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.030
0.609

B2MG_VNHVTLSQPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
51 & 135
0.024
0.613

BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR
52 & 66
0.036
0.605

BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR
52 & 78
0.039
0.604

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.022
0.615

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.027
0.611

BGH3_LTLLAPLNSVFK_vs_PSG3_VSAPSGTGHLPGLNPL
52 & 134
0.028
0.610

BGH3_LTLLAPLNSVFK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
52 & 135
0.030
0.609

BGH3_LTLLAPLNSVFK_vs_PSG9_LFIPQITR
52 & 136
0.046
0.600

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR
52 & 18
0.043
0.602

BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR
52 & 141
0.024
0.613

C1QB_VPGLYYFTYHASSR_vs_ALS_IRPHTFTGLSGLR
55 & 40
0.033
0.607

C1QB_VPGLYYFTYHASSR_vs_C163A_INPASLDK
55 & 54
0.014
0.623

C1QB_VPGLYYFTYHASSR_vs_CHL1_VIAVNEVGR
55 & 66
0.005
0.641

C1QB_VPGLYYFTYHASSR_vs_CRIS3_AVSPPAR
55 & 78
0.004
0.644

C1QB_VPGLYYFTYHASSR_vs_CRIS3_YEDLYSNCK
55 & 79
0.004
0.646

C1QB_VPGLYYFTYHASSR_vs_CSH_AHQLAIDTYQEFEETYIPK
55 & 80
0.007
0.636

C1QB_VPGLYYFTYHASSR_vs_CSH_ISLLLIESWLEPVR
55 & 81
0.012
0.627

C1QB_VPGLYYFTYHASSR_vs_FBLN1_TGYYFDGISR
55 & 86
0.008
0.634

C1QB_VPGLYYFTYHASSR_vs_IBP2_LIQGAPTIR
55 & 98
0.031
0.608

C1QB_VPGLYYFTYHASSR_vs_IBP3_FLNVLSPR
55 & 99
0.010
0.629

C1QB_VPGLYYFTYHASSR_vs_IBP3_YGQPLPGYTTK
55 & 100
0.012
0.626

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.004
0.645

C1QB_VPGLYYFTYHASSR_vs_ITIH4_ILDDLSPR
55 & 112
0.013
0.625

C1QB_VPGLYYFTYHASSR_vs_LYAM1_SYYWIGIR
55 & 120
0.003
0.651

C1QB_VPGLYYFTYHASSR_vs_NCAM1_GLGEISAASEFK
55 & 121
0.008
0.633

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.002
0.652

C1QB_VPGLYYFTYHASSR_vs_PRG2_WNFAYWAAHQPWSR
55 & 129
0.020
0.617

C1QB_VPGLYYFTYHASSR_vs_PSG1_FQLPGQK
55 & 131
0.024
0.613

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.001
0.671

C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
55 & 135
0.002
0.658

C1QB_VPGLYYFTYHASSR_vs_PSG9_LFIPQITR
55 & 136
0.004
0.643

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.001
0.668

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_NYGLLYCFR
55 & 18
0.014
0.624

C1QB_VPGLYYFTYHASSR_vs_SOM2.CSH_SVEGSCGF
55 & 139
0.009
0.631

C1QB_VPGLYYFTYHASSR_vs_SPRL1_VLTHSELAPLR
55 & 140
0.003
0.648

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.002
0.654

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.002
0.657

C1QB_VPGLYYFTYHASSR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
55 & 144
0.006
0.638

C1QB_VPGLYYFTYHASSR_vs_VTDB_ELPEHTVK
55 & 147
0.013
0.625

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.025
0.613

CBPN_EALIQFLEQVHQGIK_vs_PSG3_VSAPSGTGHLPGLNPL
59 & 134
0.038
0.604

CBPN_EALIQFLEQVHQGIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
59 & 135
0.025
0.612

CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPGAFDSFLLR
59 & 141
0.037
0.605

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.039
0.603

CBPN_NNANGVDLNR_vs_PSG3_VSAPSGTGHLPGLNPL
60 & 134
0.026
0.611

CBPN_NNANGVDLNR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
60 & 135
0.025
0.613

CBPN_NNANGVDLNR_vs_TENX_LNWEAPPGAFDSFLLR
60 & 141
0.043
0.601

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR
61 & 78
0.043
0.601

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.020
0.617

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.012
0.627

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.008
0.632

CD14_LTVGAAQVPAQLLVGALR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
61 & 135
0.025
0.612

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.028
0.610

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.008
0.634

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.009
0.632

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.024
0.613

CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK
62 & 79
0.041
0.603

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.022
0.614

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.015
0.622

CD14_SWLAELQQWLKPGLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
62 & 135
0.027
0.611

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR
62 & 140
0.038
0.604

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.013
0.625

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.016
0.621

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.033
0.607

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.033
0.607

CFAB_YGLVTYATYPK_vs_CRIS3_AVSPPAR
64 & 78
0.039
0.603

CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK
64 & 79
0.023
0.614

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.031
0.608

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.003
0.648

CFAB_YGLVTYATYPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
64 & 135
0.020
0.616

CFAB_YGLVTYATYPK_vs_PSG9_LFIPQITR
64 & 136
0.039
0.603

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.045
0.601

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.019
0.617

CFAB_YGLVTYATYPK_vs_TENX_LSQLSVTDVTTSSLR
64 & 142
0.036
0.605

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.008
0.632

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.026
0.612

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.028
0.610

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.023
0.614

CLUS_ASSIIDELFQDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
67 & 135
0.012
0.626

CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR
67 & 141
0.028
0.610

CLUS_ASSIIDELFQDR_vs_TENX_LSQLSVTDVTTSSLR
67 & 142
0.036
0.605

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.035
0.606

CLUS_LFDSDPITVTVPVEVSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
68 & 135
0.019
0.617

CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR
70 & 78
0.023
0.614

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.015
0.622

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.014
0.623

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.003
0.650

CO5_TLLPVSKPEIR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
70 & 135
0.022
0.615

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.025
0.613

CO5_TLLPVSKPEIR_vs_SPRL1_VLTHSELAPLR
70 & 140
0.041
0.602

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.014
0.623

CO5_TLLPVSKPEIR_vs_TENX_LSQLSVTDVTTSSLR
70 & 142
0.020
0.617

CO5_VFQFLEK_vs_CRIS3_AVSPPAR
71 & 78
0.029
0.610

CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK
71 & 79
0.019
0.618

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.017
0.620

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.009
0.630

CO5_VFQFLEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
71 & 135
0.021
0.615

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.030
0.609

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.013
0.624

CO5_VFQFLEK_vs_TENX_LSQLSVTDVTTSSLR
71 & 142
0.028
0.610

CO5_VFQFLEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
71 & 144
0.035
0.606

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.045
0.601

CO6_ALNHLPLEYNSALYSR_vs_PSG3_VSAPSGTGHLPGLNPL
72 & 134
0.026
0.611

CO6_ALNHLPLEYNSALYSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
72 & 135
0.028
0.611

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.024
0.613

CO6_ALNHLPLEYNSALYSR_vs_TENX_LSQLSVTDVTTSSLR
72 & 142
0.034
0.606

CO8A_SLLQPNK_vs_CHL1_VIAVNEVGR
74 & 66
0.016
0.621

CO8A_SLLQPNK_vs_CRIS3_AVSPPAR
74 & 78
0.035
0.606

CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK
74 & 79
0.014
0.623

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.019
0.618

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.003
0.649

CO8A_SLLQPNK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
74 & 135
0.017
0.620

CO8A_SLLQPNK_vs_PSG9_LFIPQITR
74 & 136
0.038
0.604

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.032
0.607

CO8A_SLLQPNK_vs_SPRL1_VLTHSELAPLR
74 & 140
0.013
0.624

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.004
0.646

CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.007
0.635

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.012
0.626

CO8B_QALEEFQK_vs_CHL1_VIAVNEVGR
76 & 66
0.016
0.621

CO8B_QALEEFQK_vs_CRIS3_AVSPPAR
76 & 78
0.040
0.603

CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK
76 & 79
0.015
0.622

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.034
0.606

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.035
0.606

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.003
0.648

CO8B_QALEEFQK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
76 & 135
0.016
0.620

CO8B_QALEEFQK_vs_PSG9_LFIPQITR
76 & 136
0.032
0.607

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.030
0.609

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 & 140
0.009
0.631

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.002
0.659

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.003
0.651

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.006
0.639

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_VS_LYAM1_SYYWIGIR
82 & 120
0.041
0.602

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.038
0.604

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.021
0.615

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.019
0.617

F13B_GDTYPAELYITGSILR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
84 & 135
0.037
0.604

F13B_GDTYPAELYITGSILR_vs_TENX_LNWEAPPGAFDSFLLR
84 & 141
0.041
0.602

F13B_GDTYPAELYITGSILR_vs_TENX_LSQLSVTDVTTSSLR
84 & 142
0.039
0.603

FBLN3_IPSNPSHR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
87 & 135
0.022
0.615

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.038
0.604

FETUA_FSVVYAK_vs_PSG3_VSAPSGTGHLPGLNPL
88 & 134
0.029
0.609

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.023
0.614

FETUA_HTLNQIDEVK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
89 & 135
0.038
0.604

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.024
0.613

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.015
0.622

HABP2_FLNWIK_vs_CRIS3_AVSPPAR
92 & 78
0.028
0.610

HABP2_FLNWIK_vs_CRIS3_YEDLYSNCK
92 & 79
0.019
0.618

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.014
0.623

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.010
0.629

HABP2_FLNWIK_vs_NCAM1_GLGEISAASEFK
92 & 121
0.026
0.612

HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR
92 & 126
0.044
0.601

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.003
0.648

HABP2_FLNWIK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
92 & 135
0.015
0.622

HABP2_FLNWIK_vs_PSG9_LFIPQITR
92 & 136
0.033
0.607

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.022
0.615

HABP2_FLNWIK_vs_SPRL1_VLTHSELAPLR
92 & 140
0.015
0.622

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.007
0.636

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.008
0.632

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.016
0.620

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.019
0.618

HEMO_NFPSPVDAAFR_vs_CRIS3_YEDLYSNCK
93 & 79
0.036
0.605

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.041
0.603

HEMO_NFPSPVDAAFR_vs_PSG3_VSAPSGTGHLPGLNPL
93 & 134
0.036
0.605

HEMO_NFPSPVDAAFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
93 & 135
0.030
0.609

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.013
0.624

HEMO_NFPSPVDAAFR_vs_TENX_LSQLSVTDVTTSSLR
93 & 142
0.037
0.604

HLACI_WAAVVVPSGEEQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
95 & 135
0.043
0.602

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.014
0.624

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.006
0.639

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.002
0.652

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.018
0.619

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.003
0.648

IBP4_QCHPALDGQR_vs_NCAM1_GLGEISAASEFK
2 & 121
0.041
0.602

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.010
0.630

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.000
0.675

IBP4_QCHPALDGQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
2 & 135
0.010
0.630

IBP4_QCHPALDGQR_vs_PSG9_LFIPQITR
2 & 136
0.023
0.614

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.004
0.643

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.007
0.635

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.003
0.648

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.008
0.633

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.006
0.638

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.026
0.611

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.023
0.614

INHBC_LDFHFSSDR_vs_C163A_INPASLDK
107 & 54
0.030
0.609

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.008
0.633

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.019
0.618

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.010
0.629

INHBC_LDFHFSSDR_vs_FBLN1_TGYYFDGISR
107 & 86
0.029
0.610

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.007
0.636

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.007
0.635

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.003
0.648

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.024
0.613

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.016
0.621

INHBC_LDFHFSSDR_vs_NCAM1_GLGEISAASEFK
107 & 121
0.018
0.618

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.011
0.628

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.000
0.681

INHBC_LDFHFSSDR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
107 & 135
0.012
0.626

INHBC_LDFHFSSDR_vs_PSG9_LFIPQITR
107 & 136
0.015
0.622

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.007
0.634

INHBC_LDFHFSSDR_VS_SPRL1_VLTHSELAPLR
107 & 140
0.003
0.647

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.000
0.675

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.001
0.664

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.006
0.639

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.005
0.639

ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR
111 & 78
0.040
0.603

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.023
0.614

ITIH3_ALDLSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
111 & 135
0.037
0.605

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.036
0.605

ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_AVSPPAR
113 & 78
0.016
0.621

ITIH4_NPLVWVHASPEHVVVTR_vs_CRIS3_YEDLYSNCK
113 & 79
0.011
0.628

ITIH4_NPLVWVHASPEHVVVTR_vs_LYAM1_SYYWIGIR
113 & 120
0.009
0.631

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.020
0.617

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
113 & 135
0.010
0.630

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG9_LFIPQITR
113 & 136
0.031
0.608

ITIH4_NPLVWVHASPEHVVVTR_vs_SHBG_IALGGLLFPASNLR
113 & 18
0.033
0.607

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LNWEAPPGAFDSFLLR
113 & 141
0.018
0.619

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR
113 & 142
0.021
0.615

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CRIS3_YEDLYSNCK
114 & 79
0.042
0.602

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG3_VSAPSGTGHLPGLNPL
114 & 134
0.035
0.606

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
114 & 135
0.035
0.606

KNG1_DIPTNSPELEETLTHTITK_vs_CHL1_VIAVNEVGR
116 & 66
0.045
0.601

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_AVSPPAR
116 & 78
0.036
0.605

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK
116 & 79
0.019
0.617

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.014
0.623

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.012
0.626

KNG1_DIPTNSPELEETLTHTITK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
116 & 135
0.035
0.606

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR
116 & 141
0.028
0.610

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR
116 & 142
0.034
0.606

KNG1_QVVAGLNFR_vs_CHL1_VIAVNEVGR
117 & 66
0.040
0.603

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.027
0.611

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.015
0.622

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.016
0.621

KNG1_QVVAGLNFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
117 & 135
0.028
0.610

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.046
0.600

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.025
0.613

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.013
0.624

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.019
0.618

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.004
0.646

LBP_ITGFLKPGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
118 & 135
0.033
0.607

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.029
0.610

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.021
0.616

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.014
0.623

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.006
0.638

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.004
0.644

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.005
0.642

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 & 121
0.025
0.613

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.028
0.610

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.001
0.665

LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
119 & 135
0.012
0.626

LBP_ITLPDFTGDLR_vs_PSG9_LFIPQITR
119 & 136
0.033
0.607

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.007
0.636

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.022
0.616

LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR
119 & 140
0.034
0.606

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.027
0.611

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.024
0.613

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.027
0.611

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.023
0.614

PEDF_LQSLFDSPDFSK_vs_CHL1_VIAVNEVGR
124 & 66
0.038
0.604

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.012
0.626

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.008
0.633

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.015
0.622

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.006
0.637

PEDF_LQSLFDSPDFSK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
124 & 135
0.024
0.613

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.043
0.601

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.009
0.631

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.010
0.630

PEDF_TVQAVLTVPK_vs_CHL1_VIAVNEVGR
125 & 66
0.018
0.619

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.017
0.619

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.011
0.628

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.010
0.629

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.002
0.654

PEDF_TVQAVLTVPK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
125 & 135
0.021
0.616

PEDF_TVQAVLTVPK_vs_PSG9_LFIPQITR
125 & 136
0.040
0.603

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR
125 & 18
0.043
0.602

PEDF_TVQAVLTVPK_vs_SPRL1_VLTHSELAPLR
125 & 140
0.031
0.608

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.006
0.637

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.009
0.632

PEDF_TVQAVLTVPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
125 & 144
0.038
0.604

PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR
128 & 78
0.029
0.609

PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK
128 & 79
0.016
0.621

PRDX2_GLFIIDGK_vs_PSG3_VSAPSGTGHLPGLNPL
128 & 134
0.014
0.623

PRDX2_GLFIIDGK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
128 & 135
0.029
0.609

PRDX2_GLFIIDGK_vs_PSG9_LFIPQITR
128 & 136
0.041
0.602

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.044
0.601

PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR
128 & 141
0.044
0.601

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.037
0.605

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.028
0.610

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.021
0.616

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.024
0.613

PSG2_IHPSYTNYR_VS_LYAM1_SYYWIGIR
133 & 120
0.026
0.612

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.011
0.628

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.003
0.647

PSG2_IHPSYTNYR_vs_PSG9_LFIPQITR
133 & 136
0.012
0.626

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.044
0.601

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR
133 & 141
0.028
0.610

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.020
0.617

PTGDS_GPGEDFR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
137 & 135
0.026
0.611

PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR
137 & 141
0.034
0.607

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.034
0.606

THBG_AVLHIGEK_vs_PSG3_VSAPSGTGHLPGLNPL
143 & 134
0.045
0.601

THBG_AVLHIGEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
143 & 135
0.020
0.617

VTNC_GQYCYELDEK_vs_C163A_INPASLDK
149 & 54
0.024
0.613

VTNC_GQYCYELDEK_vs_CHL1_VIAVNEVGR
149 & 66
0.007
0.635

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.006
0.638

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.004
0.645

VTNC_GQYCYELDEK_vs_FBLN1_TGYYFDGISR
149 & 86
0.040
0.603

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.032
0.608

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.013
0.624

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.011
0.627

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.034
0.606

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.001
0.664

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.014
0.623

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.007
0.635

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.000
0.681

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.005
0.639

VTNC_GQYCYELDEK_vs_PSG9_LFIPQITR
149 & 136
0.016
0.621

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.002
0.654

VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR
149 & 140
0.006
0.637

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.004
0.644

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.005
0.639

VTNC_GQYCYELDEK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
149 & 144
0.003
0.650

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.003
0.647

VTNC_VDTVDPPYPR_vs_C163A_INPASLDK
150 & 54
0.037
0.604

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.013
0.625

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.006
0.637

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.004
0.645

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.032
0.608

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.001
0.663

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.015
0.622

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.018
0.619

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.000
0.676

VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
150 & 135
0.006
0.637

VTNC_VDTVDPPYPR_vs_PSG9_LFIPQITR
150 & 136
0.020
0.617

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.004
0.643

VTNC_VDTVDPPYPR_vs_SPRL1_VLTHSELAPLR
150 & 140
0.009
0.630

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.009
0.631

VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR
150 & 142
0.010
0.629

VTNC_VDTVDPPYPR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
150 & 144
0.008
0.634

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.002
0.652

TABLE 53

Reversal Classification Performance, weeks 18, 19 and 20.

Reversal AUROC for gestational weeks 18 0/7 through 20 6/7 using

a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without

BMI stratification.

SEQ

Reversal
ID NO:
pval
ROC_AUC

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.037
0.636

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.021
0.651

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.034
0.639

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.026
0.645

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.018
0.654

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.030
0.642

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.016
0.658

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.013
0.662

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.010
0.669

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.020
0.652

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.037
0.636

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.034
0.639

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.023
0.649

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.024
0.648

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.025
0.646

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.037
0.636

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.003
0.692

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.034
0.639

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.042
0.633

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.025
0.647

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.034
0.638

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.025
0.647

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.033
0.640

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.043
0.632

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.038
0.636

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.023
0.648

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.024
0.648

APOH_ATVVYQGER_vs_CRIS3_AVSPPAR
48 & 78
0.025
0.646

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.014
0.660

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.040
0.634

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.003
0.691

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.030
0.642

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.045
0.631

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 & 147
0.011
0.666

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.025
0.646

B2MG_VNHVTLSQPK_vs_C163A_INPASLDK
51 & 54
0.033
0.639

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.039
0.635

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.024
0.647

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.003
0.692

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.018
0.655

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.008
0.674

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.046
0.631

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.030
0.642

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.042
0.633

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.009
0.670

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.047
0.630

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.028
0.643

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.046
0.630

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.035
0.638

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.047
0.630

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.032
0.640

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.013
0.663

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.046
0.630

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.035
0.638

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.047
0.630

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.013
0.662

CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR
60 & 140
0.043
0.632

CD14_LTVGAAQVPAQLLVGALR_vs_C163A_INPASLDK
61 & 54
0.041
0.633

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR
61 & 78
0.044
0.632

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.021
0.651

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.013
0.662

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_ISLLLIESWLEPVR
61 & 81
0.038
0.636

CD14_LTVGAAQVPAQLLVGALR_vs_FBLN1_TGYYFDGISR
61 & 86
0.024
0.647

CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK
61 & 97
0.043
0.633

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.022
0.650

CD14_LTVGAAQVPAQLLVGALR_vs_ITIH4_ILDDLSPR
61 & 112
0.037
0.637

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.001
0.717

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.017
0.655

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.008
0.673

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.015
0.659

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.020
0.652

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.026
0.646

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.024
0.647

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.020
0.652

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.008
0.673

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.002
0.700

CD14_SWLAELQQWLKPGLK_vs_C163A_INPASLDK
62 & 54
0.041
0.634

CD14_SWLAELQQWLKPGLK_vs_CRIS3_AVSPPAR
62 & 78
0.047
0.630

CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK
62 & 79
0.028
0.643

CD14_SWLAELQQWLKPGLK_vs_CSH_AHQLAIDTYQEFEETYIPK
62 & 80
0.027
0.645

CD14_SWLAELQQWLKPGLK_vs_FBLN1_TGYYFDGISR
62 & 86
0.035
0.638

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.039
0.635

CD14_SWLAELQQWLKPGLK_vs_ITIH4_ILDDLSPR
62 & 112
0.036
0.637

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.002
0.701

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.027
0.644

CD14_SWLAELQQWLKPGLK_vs_PSG3_VSAPSGTGHLPGLNPL
62 & 134
0.014
0.660

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.021
0.650

CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF
62 & 139
0.024
0.647

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR
62 & 140
0.036
0.637

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.041
0.634

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.033
0.639

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.013
0.662

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.004
0.686

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.049
0.629

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.026
0.646

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.018
0.654

CLUS_ASSIIDELFQDR_vs_CSH_AHQLAIDTYQEFEETYIPK
67 & 80
0.042
0.633

CLUS_ASSIIDELFQDR_vs_FBLN1_TGYYFDGISR
67 & 86
0.029
0.643

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.013
0.663

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.001
0.712

CLUS_ASSIIDELFQDR_vs_PSG3_VSAPSGTGHLPGLNPL
67 & 134
0.015
0.660

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.022
0.650

CLUS_ASSIIDELFQDR_vs_TENX_LNWEAPPGAFDSFLLR
67 & 141
0.048
0.629

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.005
0.682

CLUS_LFDSDPITVTVPVEVSR_vs_C163A_INPASLDK
68 & 54
0.046
0.631

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.013
0.662

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.008
0.674

CLUS_LFDSDPITVTVPVEVSR_vs_CSH_AHQLAIDTYQEFEETYIPK
68 & 80
0.029
0.643

CLUS_LFDSDPITVTVPVEVSR_vs_FBLN1_TGYYFDGISR
68 & 86
0.041
0.634

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_FLNVLSPR
68 & 99
0.043
0.632

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK
68 & 100
0.028
0.644

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.007
0.675

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.001
0.717

CLUS_LFDSDPITVTVPVEVSR_vs_PSG3_VSAPSGTGHLPGLNPL
68 & 134
0.019
0.653

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR
68 & 18
0.015
0.658

CLUS_LFDSDPITVTVPVEVSR_vs_SPRL1_VLTHSELAPLR
68 & 140
0.048
0.629

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LNWEAPPGAFDSFLLR
68 & 141
0.026
0.646

CLUS_LFDSDPITVTVPVEVSR_vs_TENX_LSQLSVTDVTTSSLR
68 & 142
0.044
0.632

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.002
0.705

CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR
70 & 78
0.038
0.635

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.027
0.644

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.005
0.683

CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK
71 & 79
0.047
0.630

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.008
0.674

CO6_ALNHLPLEYNSALYSR_vs_CRIS3_YEDLYSNCK
72 & 79
0.042
0.633

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.005
0.684

CO6_ALNHLPLEYNSALYSR_vs_TENX_LNWEAPPGAFDSFLLR
72 & 141
0.048
0.629

CO6_ALNHLPLEYNSALYSR_vs_VTDB_ELPEHTVK
72 & 147
0.042
0.633

CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK
74 & 79
0.032
0.640

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.046
0.630

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.003
0.693

CO8A_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.019
0.653

CO8A_SLLQPNK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
74 & 144
0.028
0.644

CO8A_SLLQPNK_vs_VTDB_ELPEHTVK
74 & 147
0.047
0.630

CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK
76 & 79
0.031
0.641

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.044
0.631

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.012
0.664

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.023
0.649

CO8B_QALEEFQK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
76 & 144
0.033
0.640

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.022
0.649

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.014
0.661

F13B_GDTYPAELYITGSILR_vs_FBLN1_TGYYFDGISR
84 & 86
0.048
0.629

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.040
0.634

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.001
0.711

F13B_GDTYPAELYITGSILR_vs_PSG3_VSAPSGTGHLPGLNPL
84 & 134
0.034
0.638

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.045
0.631

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.041
0.633

HABP2_FLNWIK_vs_C163A_INPASLDK
92 & 54
0.025
0.647

HABP2_FLNWIK_vs_CRIS3_AVSPPAR
92 & 78
0.036
0.637

HABP2_FLNWIK_vs_CRIS3_YEDLYSNCK
92 & 79
0.023
0.649

HABP2_FLNWIK_vs_CSH_AHQLAIDTYQEFEETYIPK
92 & 80
0.033
0.639

HABP2_FLNWIK_vs_FBLN1_TGYYFDGISR
92 & 86
0.021
0.651

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.018
0.655

HABP2_FLNWIK_vs_ITIH4_ILDDLSPR
92 & 112
0.028
0.644

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.002
0.699

HABP2_FLNWIK_vs_PGRP2_AGLLRPDYALLGHR
92 & 126
0.023
0.649

HABP2_FLNWIK_vs_PSG3_VSAPSGTGHLPGLNPL
92 & 134
0.009
0.670

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.015
0.659

HABP2_FLNWIK_vs_SOM2.CSH_NYGLLYCFR
92 & 138
0.037
0.637

HABP2_FLNWIK_vs_SOM2.CSH_SVEGSCGF
92 & 139
0.025
0.647

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.017
0.656

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.021
0.651

HABP2_FLNWIK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
92 & 144
0.011
0.665

HABP2_FLNWIK_vs_VTDB_ELPEHTVK
92 & 147
0.002
0.704

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.019
0.653

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.012
0.665

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.008
0.674

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.002
0.705

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.020
0.652

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.039
0.635

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.048
0.629

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.031
0.641

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK
116 & 79
0.042
0.633

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.007
0.678

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.040
0.634

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.020
0.652

KNG1_QVVAGLNFR_vs_CSH_AHQLAIDTYQEFEETYIPK
117 & 80
0.025
0.647

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.040
0.634

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.002
0.703

KNG1_QVVAGLNFR_vs_PSG3_VSAPSGTGHLPGLNPL
117 & 134
0.039
0.635

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.029
0.642

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.050
0.628

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.048
0.629

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.031
0.641

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.024
0.647

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.007
0.677

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.023
0.648

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.017
0.656

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.003
0.692

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.015
0.659

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.011
0.666

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.036
0.637

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.006
0.680

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.050
0.628

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.047
0.630

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.008
0.674

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.011
0.665

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.021
0.651

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.037
0.637

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.039
0.635

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.029
0.642

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.013
0.662

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.011
0.665

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.039
0.635

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.003
0.697

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.021
0.651

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.047
0.630

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.045
0.631

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.042
0.633

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.035
0.638

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.004
0.687

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.036
0.637

TABLE 54

Reversal Classification Performance, weeks 18, 19 and 20.

Reversal AUROC for gestational weeks 18 0/7 through 20 6/7 using

a case vs control cut-off of <35 0/7 vs > 35 0/7 weeks, with

BMI stratification (>22 <=37).

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.017
0.699

AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK
37 & 79
0.031
0.679

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.036
0.674

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.012
0.708

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.039
0.672

AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF
37 & 139
0.044
0.668

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.018
0.697

AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF
38 & 139
0.046
0.666

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.044
0.667

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.007
0.722

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.044
0.667

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.043
0.668

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.019
0.694

APOH_ATVVYQGER_vs_CRIS3_AVSPPAR
48 & 78
0.022
0.690

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.013
0.706

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.005
0.735

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.014
0.704

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 & 147
0.011
0.712

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.040
0.671

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.035
0.675

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.027
0.684

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.004
0.741

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.033
0.677

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.020
0.693

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.015
0.701

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.039
0.672

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.048
0.664

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.030
0.681

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.011
0.711

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.017
0.698

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR
61 & 78
0.028
0.683

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.016
0.699

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.001
0.777

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.013
0.707

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.043
0.668

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.019
0.695

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.009
0.718

CD14_SWLAELQQWLKPGLK_vs_CRIS3_AVSPPAR
62 & 78
0.049
0.663

CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK
62 & 79
0.041
0.669

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.005
0.732

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.027
0.683

CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF
62 & 139
0.040
0.671

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.040
0.671

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.024
0.688

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.020
0.693

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.004
0.736

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.026
0.684

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.019
0.694

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.010
0.714

CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR
70 & 78
0.048
0.664

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.039
0.671

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.008
0.720

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.015
0.701

CO6_ALNHLPLEYNSALYSR_vs_CRIS3_YEDLYSNCK
72 & 79
0.043
0.668

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.005
0.731

CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK
74 & 79
0.033
0.677

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.005
0.735

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.025
0.686

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.014
0.705

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.010
0.713

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.001
0.768

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.012
0.710

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.027
0.683

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.015
0.702

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.011
0.710

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.001
0.774

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.045
0.666

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.017
0.698

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_AVSPPAR
116 & 78
0.047
0.665

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK
116 & 79
0.045
0.667

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.005
0.735

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.026
0.685

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.018
0.696

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.048
0.665

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.002
0.761

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.031
0.679

PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR
122 & 129
0.033
0.677

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.010
0.714

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.033
0.677

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.029
0.681

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.004
0.739

PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR
133 & 40
0.016
0.700

PSG2_IHPSYTNYR_vs_C163A_INPASLDK
133 & 54
0.020
0.693

PSG2_IHPSYTNYR_vs_CHL1_VIAVNEVGR
133 & 66
0.014
0.704

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.001
0.764

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.002
0.759

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.008
0.721

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.015
0.703

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.007
0.725

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.013
0.705

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.013
0.707

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.017
0.699

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.010
0.713

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 & 112
0.008
0.719

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.000
0.790

PSG2_IHPSYTNYR_vs_NCAM1_GLGEISAASEFK
133 & 121
0.043
0.668

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.011
0.712

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.002
0.753

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.003
0.743

PSG2_IHPSYTNYR_vs_SOM2.CSH_NYGLLYCFR
133 & 138
0.013
0.706

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.007
0.726

PSG2_IHPSYTNYR_vs_SPRL1_VLTHSELAPLR
133 & 140
0.018
0.697

PSG2_IHPSYTNYR_vs_TENX_LNWEAPPGAFDSFLLR
133 & 141
0.022
0.690

PSG2_IHPSYTNYR_vs_TENX_LSQLSVTDVTTSSLR
133 & 142
0.019
0.694

PSG2_IHPSYTNYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
133 & 144
0.026
0.685

PSG2_IHPSYTNYR_vs_VTDB_ELPEHTVK
133 & 147
0.005
0.732

PTGDS_GPGEDFR_vs_C163A_INPASLDK
137 & 54
0.035
0.675

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.027
0.683

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.022
0.691

PTGDS_GPGEDFR_VS_LYAM1_SYYWIGIR
137 & 120
0.006
0.729

PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF
137 & 139
0.034
0.677

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.019
0.695

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.031
0.679

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.027
0.684

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.002
0.760

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.049
0.663

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.041
0.669

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.034
0.676

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.006
0.728

TABLE 55

Reversal Classification Performance, weeks 19, 20 and 21

Reversal AUROC for gestational weeks 19 0/7 through 21 6/7 using a

case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, without

BMI stratification.

SEQ ID

Reversal
NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_IBP3_FLNVLSPR
34 & 99
0.021
0.602

A2GL_DLLLPQPDLR_vs_IBP3_YGQPLPGYTTK
34 & 100
0.013
0.610

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.002
0.639

A2GL_DLLLPQPDLR_vs_PRG2_WNFAYWAAHQPWSR
34 & 129
0.019
0.604

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.022
0.602

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.003
0.630

A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR
34 & 141
0.011
0.612

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 & 100
0.022
0.602

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.009
0.616

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.018
0.605

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.003
0.631

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.001
0.642

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.001
0.648

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.002
0.634

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.009
0.617

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.003
0.631

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.002
0.635

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.003
0.634

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.005
0.624

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.003
0.631

APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK
47 & 97
0.023
0.601

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.012
0.611

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.000
0.666

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.000
0.662

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.000
0.675

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.001
0.646

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.000
0.658

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.003
0.630

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.001
0.652

APOC3_GWVTDGFSSLK_vs_PRG2_WNFAYWAAHQPWSR
47 & 129
0.003
0.632

APOC3_GWVTDGFSSLK_vs_PSG1_FQLPGQK
47 & 131
0.016
0.607

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.001
0.646

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.016
0.607

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.020
0.603

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.001
0.652

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_NYGLLYCFR
47 & 138
0.009
0.617

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.003
0.631

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.002
0.637

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.001
0.653

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.001
0.651

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.001
0.642

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.001
0.646

APOH_ATVVYQGER_vs_IBP3_FLNVLSPR
48 & 99
0.010
0.614

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.003
0.631

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.000
0.657

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.019
0.604

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.018
0.605

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.024
0.600

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.007
0.620

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.004
0.627

APOH_ATVVYQGER_vs_TENX_LSQLSVTDVTTSSLR
48 & 142
0.006
0.623

B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR
50 & 103
0.003
0.630

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.012
0.611

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.008
0.617

B2MG_VEHSDLSFSK_vs_TENX_LNWEAPPGAFDSFLLR
50 & 141
0.013
0.610

B2MG_VEHSDLSFSK_vs_TENX_LSQLSVTDVTTSSLR
50 & 142
0.014
0.609

B2MG_VNHVTLSQPK_vs_IBP3_FLNVLSPR
51 & 99
0.013
0.610

B2MG_VNHVTLSQPK_vs_IBP3_YGQPLPGYTTK
51 & 100
0.010
0.614

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.000
0.658

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.006
0.622

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR
51 & 126
0.009
0.615

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.003
0.634

B2MG_VNHVTLSQPK_vs_TENX_LNWEAPPGAFDSFLLR
51 & 141
0.006
0.621

B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR
51 & 142
0.008
0.618

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.004
0.627

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.011
0.613

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.012
0.612

C1QB_VPGLYYFTYHASSR_vs_TENX_LSQLSVTDVTTSSLR
55 & 142
0.020
0.603

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.018
0.605

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.011
0.613

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.012
0.611

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.001
0.645

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.011
0.613

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.011
0.613

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR
57 & 129
0.007
0.619

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.010
0.614

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.006
0.621

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.002
0.636

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.003
0.631

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.014
0.609

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.015
0.608

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.002
0.640

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.016
0.607

CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR
58 & 129
0.023
0.601

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.022
0.602

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.008
0.618

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.004
0.628

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.007
0.620

CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_FLNVLSPR
61 & 99
0.009
0.615

CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_YGQPLPGYTTK
61 & 100
0.011
0.612

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.001
0.649

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.015
0.608

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.024
0.600

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.007
0.619

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.005
0.623

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LSQLSVTDVTTSSLR
61 & 142
0.012
0.611

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.003
0.630

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.022
0.602

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.011
0.613

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.009
0.615

CD14_SWLAELQQWLKPGLK_vs_TENX_LSQLSVTDVTTSSLR
62 & 142
0.024
0.600

CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK
64 & 100
0.017
0.606

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.003
0.634

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.015
0.608

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.006
0.622

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.016
0.607

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.016
0.607

CO5_VFQFLEK_vs_IGF2_GIVEECCFR
71 & 103
0.010
0.614

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.017
0.606

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.015
0.608

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.020
0.603

CO8A_SLLQPNK_vs_ALS_IRPHTFTGLSGLR
74 & 40
0.023
0.601

CO8A_SLLQPNK_vs_IBP3_FLNVLSPR
74 & 99
0.012
0.611

CO8A_SLLQPNK_vs_IBP3_YGQPLPGYTTK
74 & 100
0.006
0.623

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.000
0.656

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.021
0.602

CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.018
0.605

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.010
0.615

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.005
0.624

CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.005
0.624

CO8B_QALEEFQK_vs_ALS_IRPHTFTGLSGLR
76 & 40
0.012
0.612

CO8B_QALEEFQK_vs_IBP3_FLNVLSPR
76 & 99
0.009
0.617

CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK
76 & 100
0.005
0.624

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.000
0.663

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.015
0.608

CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR
76 & 126
0.019
0.604

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.020
0.603

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.011
0.613

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.003
0.632

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.002
0.637

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR
82 & 99
0.016
0.607

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK
82 & 100
0.013
0.610

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR
82 & 103
0.004
0.629

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_VS_LYAM1_SYYWIGIR
82 & 120
0.011
0.613

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.017
0.606

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PRG2_WNFAYWAAHQPWSR
82 & 129
0.024
0.600

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.003
0.633

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR
82 & 141
0.014
0.609

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR
82 & 142
0.019
0.604

ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR
83 & 99
0.012
0.611

ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK
83 & 100
0.012
0.611

ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR
83 & 103
0.003
0.631

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.008
0.618

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.013
0.610

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.004
0.627

ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDSFLLR
83 & 141
0.008
0.617

ENPP2_TYLHTYESEI_vs_TENX_LSQLSVTDVTTSSLR
83 & 142
0.014
0.610

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.022
0.602

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.017
0.606

FETUA_FSVVYAK_vs_IBP3_FLNVLSPR
88 & 99
0.012
0.611

FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK
88 & 100
0.006
0.622

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.001
0.654

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.011
0.613

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR
88 & 141
0.007
0.620

FETUA_FSVVYAK_vs_TENX_LSQLSVTDVTTSSLR
88 & 142
0.013
0.610

FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK
89 & 100
0.017
0.606

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.002
0.636

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.007
0.619

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.005
0.625

FETUA_HTLNQIDEVK_vs_TENX_LSQLSVTDVTTSSLR
89 & 142
0.010
0.615

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.010
0.614

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.022
0.602

HEMO_NFPSPVDAAFR_vs_IBP3_YGQPLPGYTTK
93 & 100
0.018
0.605

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.003
0.632

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.005
0.625

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.012
0.611

IBP4_QCHPALDGQR_vs_ALS_IRPHTFTGLSGLR
2 & 40
0.007
0.619

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.023
0.601

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.004
0.628

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.002
0.637

IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR
2 & 99
0.002
0.635

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.001
0.648

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.000
0.684

IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR
2 & 112
0.001
0.641

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.001
0.650

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.000
0.655

IBP4_QCHPALDGQR_vs_PRG2_WNFAYWAAHQPWSR
2 & 129
0.006
0.622

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.001
0.651

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.000
0.670

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.006
0.622

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.000
0.661

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.001
0.642

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.003
0.634

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.003
0.632

IBP6_GAQTLYVPNCDHR_vs_IGF2_GIVEECCFR
101 & 103
0.008
0.617

IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR
101 & 18
0.020
0.604

IBP6_HLDSVLQQLQTEVYR_vs_IGF2_GIVEECCFR
102 & 103
0.010
0.615

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR
102 & 18
0.013
0.610

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.015
0.608

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.023
0.601

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.003
0.631

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.002
0.638

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.000
0.664

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.013
0.610

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.007
0.620

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.004
0.628

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.007
0.619

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.002
0.635

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.019
0.604

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.001
0.643

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.002
0.636

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.013
0.611

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.010
0.614

ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR
111 & 103
0.015
0.608

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.022
0.602

ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR
111 & 126
0.012
0.611

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.002
0.636

ITIH3_ALDLSLK_vs_TENX_LNWEAPPGAFDSFLLR
111 & 141
0.014
0.609

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.002
0.637

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.010
0.615

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.015
0.608

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LNWEAPPGAFDSFLLR
116 & 141
0.007
0.619

KNG1_DIPTNSPELEETLTHTITK_vs_TENX_LSQLSVTDVTTSSLR
116 & 142
0.013
0.611

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.020
0.603

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.003
0.630

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.010
0.615

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.020
0.603

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.007
0.619

KNG1_QVVAGLNFR_vs_TENX_LNWEAPPGAFDSFLLR
117 & 141
0.012
0.612

KNG1_QVVAGLNFR_vs_TENX_LSQLSVTDVTTSSLR
117 & 142
0.023
0.601

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.016
0.606

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.010
0.615

LBP_ITGFLKPGK_vs_IBP3_FLNVLSPR
118 & 99
0.015
0.608

LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK
118 & 100
0.010
0.614

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.002
0.638

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.012
0.612

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 & 126
0.012
0.611

LBP_ITGFLKPGK_vs_PRG2_WNFAYWAAHQPWSR
118 & 129
0.022
0.601

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.004
0.627

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.004
0.628

LBP_ITGFLKPGK_vs_SPRL1_VLTHSELAPLR
118 & 140
0.024
0.600

LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR
118 & 141
0.010
0.614

LBP_ITGFLKPGK_vs_TENX_LSQLSVTDVTTSSLR
118 & 142
0.018
0.605

LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR
119 & 40
0.013
0.611

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.017
0.606

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.024
0.600

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.005
0.624

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.003
0.633

LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR
119 & 98
0.024
0.600

LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR
119 & 99
0.003
0.630

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.002
0.638

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.000
0.655

LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR
119 & 112
0.006
0.621

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.003
0.632

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.003
0.630

LBP_ITLPDFTGDLR_vs_PRG2_WNFAYWAAHQPWSR
119 & 129
0.009
0.615

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.002
0.640

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.001
0.645

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.023
0.601

LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR
119 & 140
0.009
0.616

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.002
0.634

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.005
0.625

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.011
0.613

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.007
0.621

PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR
124 & 103
0.008
0.617

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.012
0.612

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.013
0.610

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.003
0.630

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.014
0.609

PEDF_TVQAVLTVPK_vs_TENX_LSQLSVTDVTTSSLR
125 & 142
0.018
0.604

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 & 103
0.008
0.618

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.016
0.607

PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR
137 & 141
0.013
0.610

PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR
137 & 142
0.016
0.607

THBG_AVLHIGEK_vs_IGF2_GIVEECCFR
143 & 103
0.011
0.612

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.013
0.610

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.016
0.607

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.006
0.621

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.001
0.641

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.015
0.608

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.002
0.639

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.012
0.612

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.018
0.605

VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR
150 & 99
0.007
0.619

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.004
0.628

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.001
0.649

VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR
150 & 112
0.016
0.606

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.005
0.625

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.009
0.616

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.021
0.602

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.001
0.644

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.005
0.624

VTNC_VDTVDPPYPR_vs_TENX_LSQLSVTDVTTSSLR
150 & 142
0.009
0.615

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.008
0.618

TABLE 56

Reversal Classification Performance, weeks 19, 20 and 21

Reversal AUROC for gestational weeks 19 0/7 through 21 6/7

using a case vs control cut-off of <37 0/7 vs

>=37 0/7 weeks, with BMI stratification (>22 <=37).

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR
34 & 78
0.023
0.622

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.011
0.636

A2GL_DLLLPQPDLR_vs_IBP3_FLNVLSPR
34 & 99
0.023
0.622

A2GL_DLLLPQPDLR_vs_IBP3_YGQPLPGYTTK
34 & 100
0.015
0.631

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.003
0.660

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.003
0.658

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.021
0.624

A2GL_DLLLPQPDLR_vs_PSG3_VSAPSGTGHLPGLNPL
34 & 134
0.044
0.608

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.012
0.636

A2GL_DLLLPQPDLR_vs_TENX_LNWEAPPGAFDSFLLR
34 & 141
0.024
0.622

AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR
37 & 99
0.033
0.614

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 & 100
0.004
0.653

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.004
0.656

AFAM_DADPDTFFAK_vs_TENX_LNWEAPPGAFDSFLLR
37 & 141
0.046
0.607

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.035
0.614

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.035
0.613

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.004
0.653

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.001
0.683

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.001
0.685

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.034
0.614

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.036
0.613

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.045
0.608

AFAM_HFQNLGK_vs_TENX_LNWEAPPGAFDSFLLR
38 & 141
0.028
0.618

AFAM_HFQNLGK_vs_TENX_LSQLSVTDVTTSSLR
38 & 142
0.043
0.609

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.026
0.620

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.017
0.629

ANGT_DPTFIPAPIQAK_vs_IBP3_YGQPLPGYTTK
42 & 100
0.040
0.611

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.017
0.628

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.022
0.623

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.037
0.612

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.026
0.620

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.018
0.627

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.009
0.641

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.006
0.649

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.010
0.639

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.009
0.641

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.005
0.653

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.020
0.625

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.006
0.649

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.045
0.608

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.011
0.637

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.020
0.625

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.027
0.619

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.011
0.636

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.018
0.627

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.035
0.613

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.016
0.630

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.030
0.617

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.030
0.616

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.026
0.619

APOH_ATVVYQGER_vs_CRIS3_AVSPPAR
48 & 78
0.031
0.616

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.015
0.631

APOH_ATVVYQGER_vs_IBP3_FLNVLSPR
48 & 99
0.035
0.613

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.007
0.645

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.005
0.652

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.022
0.623

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.030
0.616

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.033
0.615

APOH_ATVVYQGER_vs_TENX_LNWEAPPGAFDSFLLR
48 & 141
0.033
0.615

B2MG_VEHSDLSFSK_vs_CRIS3_AVSPPAR
50 & 78
0.036
0.613

B2MG_VEHSDLSFSK_vs_CRIS3_YEDLYSNCK
50 & 79
0.015
0.631

B2MG_VEHSDLSFSK_vs_IBP3_YGQPLPGYTTK
50 & 100
0.022
0.623

B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR
50 & 103
0.007
0.644

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.007
0.645

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.036
0.613

B2MG_VEHSDLSFSK_vs_TENX_LNWEAPPGAFDSFLLR
50 & 141
0.035
0.613

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.019
0.627

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.009
0.641

B2MG_VNHVTLSQPK_vs_IBP3_FLNVLSPR
51 & 99
0.019
0.626

B2MG_VNHVTLSQPK_vs_IBP3_YGQPLPGYTTK
51 & 100
0.011
0.637

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.002
0.669

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.005
0.651

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR
51 & 126
0.015
0.630

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.013
0.634

B2MG_VNHVTLSQPK_vs_TENX_LNWEAPPGAFDSFLLR
51 & 141
0.031
0.616

B2MG_VNHVTLSQPK_vs_TENX_LSQLSVTDVTTSSLR
51 & 142
0.042
0.609

BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR
52 & 78
0.038
0.611

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.012
0.635

BGH3_LTLLAPLNSVFK_vs_IBP3_YGQPLPGYTTK
52 & 100
0.042
0.609

BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR
52 & 103
0.025
0.620

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.023
0.622

BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR
52 & 141
0.030
0.617

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.017
0.628

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.049
0.606

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.024
0.622

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.013
0.634

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.032
0.616

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.022
0.623

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.010
0.639

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.022
0.623

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.042
0.609

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.041
0.610

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.011
0.637

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.022
0.623

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.020
0.625

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.009
0.639

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.015
0.631

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.010
0.638

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.005
0.652

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.026
0.620

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.021
0.624

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.023
0.622

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.007
0.646

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.017
0.628

CBPN_EALIQFLEQVHQGIK_vs_CRIS3_YEDLYSNCK
59 & 79
0.035
0.614

CBPN_EALIQFLEQVHQGIK_vs_IBP3_YGQPLPGYTTK
59 & 100
0.035
0.613

CBPN_EALIQFLEQVHQGIK_vs_IGF2_GIVEECCFR
59 & 103
0.029
0.617

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.021
0.624

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR
59 & 18
0.032
0.615

CBPN_EALIQFLEQVHQGIK_vs_TENX_LNWEAPPGAFDSFLLR
59 & 141
0.049
0.606

CBPN_NNANGVDLNR_vs_CRIS3_YEDLYSNCK
60 & 79
0.027
0.619

CBPN_NNANGVDLNR_vs_IBP3_YGQPLPGYTTK
60 & 100
0.021
0.624

CBPN_NNANGVDLNR_vs_IGF2_GIVEECCFR
60 & 103
0.008
0.642

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.019
0.626

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR
60 & 18
0.033
0.615

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.028
0.618

CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_FLNVLSPR
61 & 99
0.037
0.612

CD14_LTVGAAQVPAQLLVGALR_vs_IBP3_YGQPLPGYTTK
61 & 100
0.028
0.618

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.007
0.644

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.018
0.627

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.050
0.606

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.047
0.607

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.032
0.615

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.027
0.619

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.030
0.617

CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK
64 & 79
0.033
0.615

CFAB_YGLVTYATYPK_vs_IBP3_FLNVLSPR
64 & 99
0.043
0.609

CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK
64 & 100
0.013
0.633

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.005
0.650

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.020
0.625

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.041
0.610

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.030
0.617

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.039
0.611

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.017
0.629

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.044
0.608

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.046
0.607

CO5_TLLPVSKPEIR_vs_CRIS3_AVSPPAR
70 & 78
0.047
0.607

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.023
0.622

CO5_TLLPVSKPEIR_vs_IBP3_YGQPLPGYTTK
70 & 100
0.043
0.609

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.014
0.632

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.019
0.626

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.042
0.609

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.032
0.615

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.046
0.607

CO5_VFQFLEK_vs_CRIS3_YEDLYSNCK
71 & 79
0.036
0.613

CO5_VFQFLEK_vs_IGF2_GIVEECCFR
71 & 103
0.030
0.617

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.022
0.623

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.047
0.607

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.037
0.612

CO8A_SLLQPNK_vs_ALS_IRPHTFTGLSGLR
74 & 40
0.043
0.609

CO8A_SLLQPNK_vs_CRIS3_YEDLYSNCK
74 & 79
0.015
0.631

CO8A_SLLQPNK_vs_IBP3_FLNVLSPR
74 & 99
0.024
0.622

CO8A_SLLQPNK_vs_IBP3_YGQPLPGYTTK
74 & 100
0.009
0.640

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.002
0.663

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.021
0.624

CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.036
0.613

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.028
0.618

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.015
0.630

CO8A_SLLQPNK_vs_TENX_LSQLSVTDVTTSSLR
74 & 142
0.020
0.625

CO8B_QALEEFQK_vs_ALS_IRPHTFTGLSGLR
76 & 40
0.014
0.633

CO8B_QALEEFQK_vs_CRIS3_AVSPPAR
76 & 78
0.028
0.618

CO8B_QALEEFQK_vs_CRIS3_YEDLYSNCK
76 & 79
0.013
0.634

CO8B_QALEEFQK_vs_IBP3_FLNVLSPR
76 & 99
0.012
0.635

CO8B_QALEEFQK_vs_IBP3_YGQPLPGYTTK
76 & 100
0.007
0.645

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.001
0.676

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.012
0.635

CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR
76 & 126
0.025
0.620

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.027
0.619

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.027
0.619

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 & 140
0.041
0.610

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.008
0.643

CO8B_QALEEFQK_vs_TENX_LSQLSVTDVTTSSLR
76 & 142
0.007
0.645

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ALS_IRPHTFTGLSGLR
82 & 40
0.037
0.612

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_C163A_INPASLDK
82 & 54
0.043
0.609

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_AVSPPAR
82 & 78
0.031
0.616

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_CRIS3_YEDLYSNCK
82 & 79
0.021
0.624

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_FLNVLSPR
82 & 99
0.021
0.624

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IBP3_YGQPLPGYTTK
82 & 100
0.013
0.634

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR
82 & 103
0.007
0.644

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_ITIH4_ILDDLSPR
82 & 112
0.028
0.618

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR
82 & 120
0.006
0.648

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.017
0.628

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
82 & 135
0.030
0.617

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.005
0.652

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SOM2.CSH_SVEGSCGF
82 & 139
0.029
0.617

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LNWEAPPGAFDSFLLR
82 & 141
0.030
0.617

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_TENX_LSQLSVTDVTTSSLR
82 & 142
0.048
0.606

ENPP2_TYLHTYESEI_vs_C163A_INPASLDK
83 & 54
0.047
0.607

ENPP2_TYLHTYESEI_vs_CRIS3_AVSPPAR
83 & 78
0.050
0.606

ENPP2_TYLHTYESEI_vs_CRIS3_YEDLYSNCK
83 & 79
0.029
0.618

ENPP2_TYLHTYESEI_vs_IBP3_FLNVLSPR
83 & 99
0.032
0.615

ENPP2_TYLHTYESEI_vs_IBP3_YGQPLPGYTTK
83 & 100
0.022
0.623

ENPP2_TYLHTYESEI_vs_IGF2_GIVEECCFR
83 & 103
0.014
0.632

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.011
0.637

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.036
0.613

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.010
0.638

ENPP2_TYLHTYESEI_vs_SOM2.CSH_SVEGSCGF
83 & 139
0.042
0.610

ENPP2_TYLHTYESEI_vs_TENX_LNWEAPPGAFDSFLLR
83 & 141
0.038
0.612

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.029
0.617

F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK
84 & 100
0.040
0.610

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.018
0.628

FETUA_FSVVYAK_vs_CRIS3_AVSPPAR
88 & 78
0.039
0.611

FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK
88 & 79
0.015
0.631

FETUA_FSVVYAK_vs_IBP3_FLNVLSPR
88 & 99
0.033
0.615

FETUA_FSVVYAK_vs_IBP3_YGQPLPGYTTK
88 & 100
0.013
0.633

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.002
0.664

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.038
0.612

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR
88 & 141
0.049
0.606

FETUA_HTLNQIDEVK_vs_CRIS3_YEDLYSNCK
89 & 79
0.027
0.619

FETUA_HTLNQIDEVK_vs_IBP3_YGQPLPGYTTK
89 & 100
0.024
0.621

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.005
0.652

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.048
0.606

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.042
0.610

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.035
0.613

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.041
0.610

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.022
0.623

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.046
0.607

HEMO_NFPSPVDAAFR_vs_CRIS3_AVSPPAR
93 & 78
0.044
0.608

HEMO_NFPSPVDAAFR_vs_CRIS3_YEDLYSNCK
93 & 79
0.024
0.621

HEMO_NFPSPVDAAFR_vs_IBP3_YGQPLPGYTTK
93 & 100
0.041
0.610

HEMO_NFPSPVDAAFR_vs_IGF2_GIVEECCFR
93 & 103
0.013
0.633

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.032
0.615

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.028
0.618

HLACI_WAAVVVPSGEEQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
95 & 135
0.037
0.612

IBP4_QCHPALDGQR_vs_ALS_IRPHTFTGLSGLR
2 & 40
0.009
0.641

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.001
0.682

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.000
0.695

IBP4_QCHPALDGQR_vs_CSH_AHQLAIDTYQEFEETYIPK
2 & 80
0.031
0.616

IBP4_QCHPALDGQR_vs_IBP2_LIQGAPTIR
2 & 98
0.046
0.607

IBP4_QCHPALDGQR_vs_IBP3_FLNVLSPR
2 & 99
0.002
0.663

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.001
0.684

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.000
0.708

IBP4_QCHPALDGQR_vs_ITIH4_ILDDLSPR
2 & 112
0.004
0.657

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.000
0.707

IBP4_QCHPALDGQR_vs_NCAM1_GLGEISAASEFK
2 & 121
0.025
0.620

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.001
0.687

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.002
0.663

IBP4_QCHPALDGQR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
2 & 135
0.040
0.610

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.001
0.680

IBP4_QCHPALDGQR_vs_SOM2.CSH_SVEGSCGF
2 & 139
0.014
0.632

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.007
0.644

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.001
0.675

IBP4_QCHPALDGQR_vs_TENX_LSQLSVTDVTTSSLR
2 & 142
0.009
0.641

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.002
0.663

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.003
0.660

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.004
0.654

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.012
0.635

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.006
0.649

INHBC_LDFHFSSDR_vs_CSH_AHQLAIDTYQEFEETYIPK
107 & 80
0.048
0.606

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.001
0.673

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.001
0.685

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.000
0.704

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.014
0.633

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.005
0.649

INHBC_LDFHFSSDR_vs_NCAM1_GLGEISAASEFK
107 & 121
0.033
0.614

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.005
0.650

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.005
0.651

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.003
0.657

INHBC_LDFHFSSDR_vs_SOM2.CSH_SVEGSCGF
107 & 139
0.020
0.625

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.013
0.633

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.001
0.681

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.002
0.665

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.018
0.627

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.004
0.653

ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR
111 & 78
0.019
0.626

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.012
0.634

ITIH3_ALDLSLK_vs_IGF2_GIVEECCFR
111 & 103
0.041
0.610

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.013
0.633

ITIH3_ALDLSLK_vs_PGRP2_AGLLRPDYALLGHR
111 & 126
0.027
0.619

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.015
0.631

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_AVSPPAR
116 & 78
0.043
0.609

KNG1_DIPTNSPELEETLTHTITK_vs_CRIS3_YEDLYSNCK
116 & 79
0.017
0.628

KNG1_DIPTNSPELEETLTHTITK_vs_IGF2_GIVEECCFR
116 & 103
0.013
0.634

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.015
0.631

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.032
0.615

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.016
0.630

KNG1_QVVAGLNFR_vs_IBP3_YGQPLPGYTTK
117 & 100
0.019
0.626

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.007
0.645

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.008
0.642

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.045
0.608

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.022
0.623

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.011
0.637

LBP_ITGFLKPGK_vs_IBP3_YGQPLPGYTTK
118 & 100
0.032
0.615

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.010
0.639

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.016
0.630

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 & 126
0.025
0.620

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.036
0.613

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.012
0.635

LBP_ITGFLKPGK_vs_SOM2.CSH_SVEGSCGF
118 & 139
0.026
0.619

LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR
118 & 141
0.047
0.607

LBP_ITLPDFTGDLR_vs_ALS_IRPHTFTGLSGLR
119 & 40
0.047
0.607

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.031
0.616

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.006
0.648

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.003
0.660

LBP_ITLPDFTGDLR_vs_IBP2_LIQGAPTIR
119 & 98
0.048
0.606

LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR
119 & 99
0.018
0.628

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.007
0.645

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.003
0.658

LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR
119 & 112
0.022
0.623

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.003
0.657

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 & 121
0.049
0.606

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.005
0.651

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.015
0.631

LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
119 & 135
0.039
0.611

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.004
0.654

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.010
0.639

LBP_ITLPDFTGDLR_vs_SPRL1_VLTHSELAPLR
119 & 140
0.030
0.617

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.011
0.637

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.021
0.624

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.049
0.606

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.022
0.623

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.037
0.612

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.019
0.626

PEDF_LQSLFDSPDFSK_vs_IGF2_GIVEECCFR
124 & 103
0.037
0.612

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.025
0.620

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.033
0.615

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.048
0.606

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.021
0.624

PEDF_TVQAVLTVPK_vs_IBP3_YGQPLPGYTTK
125 & 100
0.049
0.606

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.025
0.620

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.038
0.611

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.049
0.606

PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK
128 & 79
0.049
0.606

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.015
0.631

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.007
0.646

PTGDS_GPGEDFR_vs_IBP3_FLNVLSPR
137 & 99
0.042
0.609

PTGDS_GPGEDFR_vs_IBP3_YGQPLPGYTTK
137 & 100
0.015
0.631

PTGDS_GPGEDFR_vs_IGF2_GIVEECCFR
137 & 103
0.004
0.655

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.019
0.626

PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGHR
137 & 126
0.033
0.615

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.021
0.624

PTGDS_GPGEDFR_vs_TENX_LNWEAPPGAFDSFLLR
137 & 141
0.012
0.636

PTGDS_GPGEDFR_vs_TENX_LSQLSVTDVTTSSLR
137 & 142
0.021
0.624

THBG_AVLHIGEK_vs_CRIS3_YEDLYSNCK
143 & 79
0.028
0.618

THBG_AVLHIGEK_vs_IGF2_GIVEECCFR
143 & 103
0.026
0.620

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.025
0.620

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.047
0.607

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.032
0.616

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.016
0.630

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.032
0.616

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.006
0.647

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.004
0.656

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.030
0.616

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.008
0.643

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.033
0.614

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.036
0.613

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.007
0.645

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.032
0.615

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.043
0.609

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.015
0.630

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.009
0.640

VTNC_VDTVDPPYPR_vs_IBP3_FLNVLSPR
150 & 99
0.019
0.626

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.005
0.652

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.004
0.655

VTNC_VDTVDPPYPR_vs_ITIH4_ILDDLSPR
150 & 112
0.037
0.612

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.005
0.651

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.022
0.623

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.039
0.611

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.005
0.650

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.026
0.620

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.030
0.616

TABLE 57

Reversal Classification Performance, weeks 19, 20 and 21

Reversal AUROC for gestational weeks 19 0/7 through 21 6/7 using a case vs

control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification.

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.043
0.639

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.021
0.659

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.018
0.662

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.018
0.663

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.018
0.663

AFAM_HFQNLGK_vs_IBP1_VVESLAK
38 & 97
0.036
0.648

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.010
0.677

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.017
0.664

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.014
0.670

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.030
0.649

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.013
0.671

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.040
0.641

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.038
0.643

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.038
0.643

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.040
0.641

APOC3_GWVTDGFSSLK_vs_IBP1_VVESLAK
47 & 97
0.023
0.656

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.037
0.644

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.048
0.636

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.032
0.647

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.005
0.693

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.011
0.675

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.011
0.674

APOC3_GWVTDGFSSLK_vs_SOM2.CSH_SVEGSCGF
47 & 139
0.038
0.643

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.027
0.653

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.027
0.652

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.026
0.653

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.035
0.645

APOH_ATVVYQGER_vs_IBP1_VVESLAK
48 & 97
0.021
0.659

APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR
48 & 112
0.025
0.655

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.002
0.712

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.002
0.717

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.020
0.661

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.003
0.704

APOH_ATVVYQGER_vs_SPRL1_VLTHSELAPLR
48 & 140
0.011
0.674

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 & 147
0.007
0.684

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.007
0.687

B2MG_VEHSDLSFSK_vs_PGRP2_AGLLRPDYALLGHR
50 & 126
0.044
0.639

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.012
0.673

B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK
51 & 97
0.046
0.638

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.002
0.717

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR
51 & 126
0.009
0.681

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.005
0.692

B2MG_VNHVTLSQPK_vs_SPRL1_VLTHSELAPLR
51 & 140
0.023
0.656

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.039
0.642

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR
52 & 18
0.049
0.635

CAH1_GGPFSDSYR_vs_IBP1_VVESLAK
56 & 97
0.033
0.647

CAH1_GGPFSDSYR_vs_LYAM1_SYYWIGIR
56 & 120
0.015
0.668

CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR
56 & 126
0.020
0.661

CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR
56 & 18
0.008
0.682

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.001
0.720

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.000
0.772

CATD_VGFAEAAR_vs_CHL1_VIAVNEVGR
57 & 66
0.045
0.638

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.004
0.700

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.004
0.700

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.001
0.739

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.001
0.733

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.001
0.728

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.003
0.702

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.010
0.678

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.005
0.694

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.002
0.708

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.001
0.721

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.001
0.739

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.000
0.778

CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK
57 & 121
0.004
0.701

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.000
0.773

CATD_VGFAEAAR_vs_PRG2_WNFAYWAAHQPWSR
57 & 129
0.010
0.677

CATD_VGFAEAAR_vs_PSG1_FQLPGQK
57 & 131
0.001
0.719

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.001
0.729

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.000
0.749

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.001
0.723

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.001
0.722

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.000
0.762

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.000
0.757

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.000
0.744

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.000
0.743

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.001
0.739

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.001
0.728

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.001
0.725

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.004
0.698

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.004
0.700

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.001
0.724

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.002
0.716

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.001
0.728

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.004
0.700

CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR
58 & 98
0.009
0.680

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.003
0.707

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.001
0.719

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.001
0.732

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.001
0.724

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.000
0.771

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 & 121
0.003
0.704

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.000
0.775

CATD_VSTLPAITLK_vs_PRG2_WNFAYWAAHQPWSR
58 & 129
0.028
0.652

CATD_VSTLPAITLK_vs_PSG1_FQLPGQK
58 & 131
0.005
0.693

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.001
0.737

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.000
0.755

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.003
0.707

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.004
0.696

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.000
0.753

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.000
0.765

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.000
0.742

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.001
0.729

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.000
0.745

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.042
0.640

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR
59 & 18
0.011
0.674

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.020
0.660

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR
60 & 18
0.019
0.661

CBPN_NNANGVDLNR_vs_SPRL1_VLTHSELAPLR
60 & 140
0.016
0.665

CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK
61 & 97
0.028
0.651

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.002
0.717

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.004
0.699

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.003
0.703

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.049
0.635

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.020
0.660

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.031
0.648

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.009
0.680

CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK
62 & 97
0.029
0.650

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.002
0.709

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.005
0.692

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.005
0.695

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR
62 & 140
0.025
0.654

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.028
0.652

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.007
0.684

CLUS_ASSIIDELFQDR_vs_IBP1_VVESLAK
67 & 97
0.048
0.636

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.007
0.686

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.016
0.665

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.006
0.691

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.036
0.644

CLUS_LFDSDPITVTVPVEVSR_vs_IBP1_VVESLAK
68 & 97
0.047
0.637

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.006
0.688

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR
68 & 126
0.023
0.656

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR
68 & 18
0.007
0.687

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.020
0.660

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.012
0.674

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.043
0.639

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.016
0.666

CO5_TLLPVSKPEIR_vs_SPRL1_VLTHSELAPLR
70 & 140
0.042
0.640

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.025
0.654

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.023
0.656

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.043
0.639

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.027
0.653

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.013
0.670

CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.026
0.653

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.022
0.658

CO8B_QALEEFQK_vs_IBP1_VVESLAK
76 & 97
0.044
0.639

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.012
0.673

CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR
76 & 126
0.030
0.649

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.024
0.655

CO8B_QALEEFQK_vs_SPRL1_VLTHSELAPLR
76 & 140
0.040
0.641

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR
82 & 120
0.036
0.644

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_PGRP2_AGLLRPDYALLGHR
82 & 126
0.037
0.643

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.029
0.650

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.021
0.659

ENPP2_TYLHTYESEI_vs_PGRP2_AGLLRPDYALLGHR
83 & 126
0.025
0.655

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.026
0.653

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.044
0.639

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.039
0.643

F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK
84 & 97
0.033
0.647

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.001
0.732

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.005
0.694

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.003
0.708

F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR
84 & 140
0.007
0.685

F13B_GDTYPAELYITGSILR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
84 & 144
0.046
0.638

F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK
84 & 147
0.037
0.644

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.012
0.674

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.017
0.664

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.023
0.657

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.019
0.662

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.014
0.668

HEMO_NFPSPVDAAFR_vs_PGRP2_AGLLRPDYALLGHR
93 & 126
0.046
0.637

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.008
0.683

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.024
0.655

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.024
0.656

IBP4_QCHPALDGQR_vs_IBP1_VVESLAK
2 & 97
0.026
0.653

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.002
0.713

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.008
0.683

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.002
0.709

IBP4_QCHPALDGQR_vs_SPRL1_VLTHSELAPLR
2 & 140
0.015
0.667

IBP6_GAQTLYVPNCDHR_vs_PGRP2_AGLLRPDYALLGHR
101 & 126
0.030
0.650

IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR
101 & 18
0.013
0.671

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.020
0.660

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR
102 & 18
0.010
0.677

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.046
0.637

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.028
0.652

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.033
0.647

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.026
0.653

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.017
0.665

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.027
0.653

KNG1_QVVAGLNFR_vs_IBP1_VVESLAK
117 & 97
0.032
0.648

KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR
117 & 112
0.028
0.651

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.002
0.711

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.010
0.677

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.003
0.703

KNG1_QVVAGLNFR_vs_SPRL1_VLTHSELAPLR
117 & 140
0.019
0.662

PEDF_LQSLFDSPDFSK_vs_IBP1_VVESLAK
124 & 97
0.044
0.639

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.004
0.697

PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR
124 & 126
0.043
0.640

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.017
0.665

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.003
0.702

PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR
125 & 126
0.025
0.654

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR
125 & 18
0.012
0.673

PEDF_TVQAVLTVPK_vs_SPRL1_VLTHSELAPLR
125 & 140
0.036
0.645

PRDX2_GLFIIDGK_vs_CRIS3_AVSPPAR
128 & 78
0.028
0.651

PRDX2_GLFIIDGK_vs_CRIS3_YEDLYSNCK
128 & 79
0.026
0.653

PRDX2_GLFIIDGK_vs_IBP1_VVESLAK
128 & 97
0.024
0.655

PRDX2_GLFIIDGK_vs_IBP2_LIQGAPTIR
128 & 98
0.040
0.641

PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR
128 & 120
0.009
0.681

PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGHR
128 & 126
0.009
0.679

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.004
0.697

PRDX2_GLFIIDGK_vs_SPRL1_VLTHSELAPLR
128 & 140
0.042
0.640

PRDX2_GLFIIDGK_vs_TENX_LNWEAPPGAFDSFLLR
128 & 141
0.038
0.643

PRDX2_GLFIIDGK_vs_VTDB_ELPEHTVK
128 & 147
0.041
0.641

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.049
0.635

PTGDS_GPGEDFR_vs_IBP1_VVESLAK
137 & 97
0.039
0.642

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.009
0.681

PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGHR
137 & 126
0.017
0.665

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.010
0.677

PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF
137 & 139
0.048
0.636

PTGDS_GPGEDFR_vs_SPRL1_VLTHSELAPLR
137 & 140
0.035
0.645

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.018
0.663

THBG_AVLHIGEK_vs_PGRP2_AGLLRPDYALLGHR
143 & 126
0.025
0.655

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.023
0.657

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.008
0.684

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.020
0.660

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.012
0.674

VTNC_GQYCYELDEK_vs_SPRL1_VLTHSELAPLR
149 & 140
0.047
0.637

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.008
0.684

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.019
0.661

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.007
0.686

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.030
0.649

TABLE 58

Reversal Classification Performance, weeks 19, 20 and 21

Reversal AUROC for gestational weeks 19 0/7 through 21 6/7 using

a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, with

BMI stratification (>22 <=37).

Reversal
SEQ ID NO:
pval
ROC_AUC

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.025
0.688

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.029
0.683

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.026
0.687

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.011
0.714

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.002
0.755

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.006
0.730

AFAM_DADPDTFFAK_vs_VTDB_ELPEHTVK
37 & 147
0.024
0.689

AFAM_HFQNLGK_vs_IBP1_VVESLAK
38 & 97
0.034
0.684

AFAM_HFQNLGK_vs_ITIH4_ILDDLSPR
38 & 112
0.025
0.688

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.004
0.744

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.001
0.770

AFAM_HFQNLGK_vs_SHBG_IALGGLLFPASNLR
38 & 18
0.004
0.738

AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF
38 & 139
0.023
0.690

AFAM_HFQNLGK_vs_VTDB_ELPEHTVK
38 & 147
0.009
0.719

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.023
0.690

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.037
0.675

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.006
0.730

APOH_ATVVYQGER_vs_IBP1_VVESLAK
48 & 97
0.049
0.665

APOH_ATVVYQGER_vs_ITIH4_ILDDLSPR
48 & 112
0.049
0.665

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.006
0.729

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.001
0.788

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.003
0.750

APOH_ATVVYQGER_vs_VTDB_ELPEHTVK
48 & 147
0.012
0.711

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.027
0.686

B2MG_VEHSDLSFSK_vs_SHBG_IALGGLLFPASNLR
50 & 18
0.027
0.685

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.004
0.740

B2MG_VNHVTLSQPK_vs_PGRP2_AGLLRPDYALLGHR
51 & 126
0.009
0.718

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.006
0.731

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.043
0.670

BGH3_LTLLAPLNSVFK_vs_PGRP2_AGLLRPDYALLGHR
52 & 126
0.027
0.685

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR
52 & 18
0.027
0.685

CAH1_GGPFSDSYR_vs_LYAM1_SYYWIGIR
56 & 120
0.041
0.671

CAH1_GGPFSDSYR_vs_PGRP2_AGLLRPDYALLGHR
56 & 126
0.041
0.671

CAH1_GGPFSDSYR_vs_SHBG_IALGGLLFPASNLR
56 & 18
0.013
0.708

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.008
0.723

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.000
0.791

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.010
0.716

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.009
0.717

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.001
0.773

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.001
0.771

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.034
0.677

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.012
0.711

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.016
0.701

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.018
0.698

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.014
0.705

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.012
0.711

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.002
0.765

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.000
0.807

CATD_VGFAEAAR_vs_NCAM1_GLGEISAASEFK
57 & 121
0.014
0.706

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.000
0.811

CATD_VGFAEAAR_vs_PSG1_FQLPGQK
57 & 131
0.008
0.723

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.014
0.706

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.001
0.787

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.003
0.751

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.002
0.753

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.003
0.746

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.003
0.745

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.013
0.708

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.005
0.735

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.004
0.743

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.002
0.761

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.002
0.758

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.006
0.731

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.004
0.741

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.001
0.775

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.001
0.769

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.022
0.692

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.006
0.730

CATD_VSTLPAITLK_vs_IBP2_LIQGAPTIR
58 & 98
0.011
0.714

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.005
0.733

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.006
0.729

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.004
0.744

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.001
0.784

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.000
0.825

CATD_VSTLPAITLK_vs_NCAM1_GLGEISAASEFK
58 & 121
0.006
0.728

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.000
0.841

CATD_VSTLPAITLK_vs_PSG1_FQLPGQK
58 & 131
0.016
0.701

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.005
0.734

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.000
0.810

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.003
0.745

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.004
0.741

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.002
0.759

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.001
0.780

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.005
0.736

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.002
0.753

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.001
0.778

CBPN_EALIQFLEQVHQGIK_vs_SHBG_IALGGLLFPASNLR
59 & 18
0.023
0.690

CBPN_NNANGVDLNR_vs_LYAM1_SYYWIGIR
60 & 120
0.038
0.674

CBPN_NNANGVDLNR_vs_SHBG_IALGGLLFPASNLR
60 & 18
0.016
0.702

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.008
0.721

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.005
0.735

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.006
0.731

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.041
0.671

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.015
0.704

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.011
0.712

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.010
0.716

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.020
0.695

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.014
0.705

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.011
0.712

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.044
0.668

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR
68 & 126
0.045
0.668

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR
68 & 18
0.020
0.694

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.039
0.672

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.018
0.698

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.039
0.672

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.022
0.692

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.044
0.669

CO8A_SLLQPNK_vs_PGRP2_AGLLRPDYALLGHR
74 & 126
0.032
0.679

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.032
0.679

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.041
0.671

CO8B_QALEEFQK_vs_PGRP2_AGLLRPDYALLGHR
76 & 126
0.037
0.674

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.039
0.672

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.050
0.664

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.002
0.765

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.002
0.755

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.002
0.764

F13B_GDTYPAELYITGSILR_vs_VTDB_ELPEHTVK
84 & 147
0.041
0.671

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.039
0.673

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.019
0.697

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.034
0.678

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.018
0.699

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.042
0.670

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.015
0.704

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.048
0.666

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.002
0.756

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.004
0.741

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.002
0.760

IBP6_GAQTLYVPNCDHR_vs_PGRP2_AGLLRPDYALLGHR
101 & 126
0.019
0.697

IBP6_GAQTLYVPNCDHR_vs_SHBG_IALGGLLFPASNLR
101 & 18
0.024
0.689

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.014
0.706

IBP6_HLDSVLQQLQTEVYR_vs_PGRP2_AGLLRPDYALLGHR
102 & 126
0.027
0.686

IBP6_HLDSVLQQLQTEVYR_vs_SHBG_IALGGLLFPASNLR
102 & 18
0.009
0.720

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.037
0.675

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.021
0.693

ITIH4_NPLVWVHASPEHVVVTR_vs_ALS_IRPHTFTGLSGLR
113 & 40
0.034
0.678

ITIH4_NPLVWVHASPEHVVVTR_vs_CHL1_VIAVNEVGR
113 & 66
0.045
0.667

ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_AHQLAIDTYQEFEETYIPK
113 & 80
0.044
0.668

ITIH4_NPLVWVHASPEHVVVTR_vs_FBLN1_TGYYFDGISR
113 & 86
0.016
0.701

ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_FLNVLSPR
113 & 99
0.025
0.688

ITIH4_NPLVWVHASPEHVVVTR_vs_IBP3_YGQPLPGYTTK
113 & 100
0.030
0.682

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG3_VSAPSGTGHLPGLNPL
113 & 134
0.033
0.678

ITIH4_NPLVWVHASPEHVVVTR_vs_SOM2.CSH_NYGLLYCFR
113 & 138
0.021
0.693

ITIH4_NPLVWVHASPEHVVVTR_vs_SPRL1_VLTHSELAPLR
113 & 140
0.042
0.670

ITIH4_NPLVWVHASPEHVVVTR_vs_TENX_LSQLSVTDVTTSSLR
113 & 142
0.028
0.684

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TENX_LSQLSVTDVTTSSLR
114 & 142
0.029
0.683

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.040
0.672

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.009
0.717

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.020
0.695

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.012
0.711

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.039
0.672

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.035
0.676

PAPP1_DIPHWLNPTR_vs_CSH_AHQLAIDTYQEFEETYIPK
122 & 80
0.029
0.683

PAPP1_DIPHWLNPTR_vs_CSH_ISLLLIESWLEPVR
122 & 81
0.019
0.696

PAPP1_DIPHWLNPTR_vs_IBP1_VVESLAK
122 & 97
0.047
0.666

PAPP1_DIPHWLNPTR_vs_IBP2_LIQGAPTIR
122 & 98
0.027
0.686

PAPP1_DIPHWLNPTR_vs_ITIH4_ILDDLSPR
122 & 112
0.046
0.667

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.007
0.726

PAPP1_DIPHWLNPTR_vs_PGRP2_AGLLRPDYALLGHR
122 & 126
0.007
0.725

PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR
122 & 129
0.021
0.693

PAPP1_DIPHWLNPTR_vs_PSG1_FQLPGQK
122 & 131
0.043
0.670

PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR
122 & 18
0.005
0.734

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYCFR
122 & 138
0.028
0.684

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF
122 & 139
0.004
0.743

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.008
0.722

PEDF_LQSLFDSPDFSK_vs_PGRP2_AGLLRPDYALLGHR
124 & 126
0.024
0.689

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.008
0.720

PEDF_LQSLFDSPDFSK_vs_VTDB_ELPEHTVK
124 & 147
0.023
0.690

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.008
0.722

PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR
125 & 126
0.019
0.697

PEDF_TVQAVLTVPK_vs_SHBG_IALGGLLFPASNLR
125 & 18
0.007
0.726

PRDX2_GLFIIDGK_vs_LYAM1_SYYWIGIR
128 & 120
0.034
0.677

PRDX2_GLFIIDGK_vs_PGRP2_AGLLRPDYALLGHR
128 & 126
0.026
0.687

PRDX2_GLFIIDGK_vs_SHBG_IALGGLLFPASNLR
128 & 18
0.011
0.713

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.038
0.674

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.023
0.690

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.031
0.680

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.009
0.717

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.006
0.728

PTGDS_GPGEDFR_vs_PGRP2_AGLLRPDYALLGHR
137 & 126
0.006
0.731

PTGDS_GPGEDFR_vs_SHBG_IALGGLLFPASNLR
137 & 18
0.009
0.719

PTGDS_GPGEDFR_vs_SOM2.CSH_SVEGSCGF
137 & 139
0.027
0.685

THBG_AVLHIGEK_vs_PGRP2_AGLLRPDYALLGHR
143 & 126
0.047
0.666

THBG_AVLHIGEK_vs_SHBG_IALGGLLFPASNLR
143 & 18
0.039
0.673

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.009
0.717

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.012
0.711

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.011
0.714

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.023
0.690

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.024
0.688

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.008
0.722

TABLE 59

Additional Reversals

Reversal
SEQ ID NO:

AFAM_DADPDTFFAK_vs_ALS_IRPHTFTGLSGLR
37 & 40

AFAM_DADPDTFFAK_vs_CRIS3_AVSPPAR
37 & 78

AFAM_DADPDTFFAK_vs_CSH_AHQLAIDTYQEFEETYIPK
37 & 80

AFAM_DADPDTFFAK_vs_CSH_ISLLLIESWLEPVR
37 & 81

AFAM_DADPDTFFAK_vs_IBP1_VVESLAK
37 & 97

AFAM_HFQNLGK_vs_C163A_INPASLDK
38 & 54

AFAM_HFQNLGK_vs_CSH_AHQLAIDTYQEFEETYIPK
38 & 80

AFAM_HFQNLGK_vs_CSH_ISLLLIESWLEPVR
38 & 81

AFAM_HFQNLGK_vs_FBLN1_TGYYFDGISR
38 & 86

ANGT_DPTFIPAPIQAK_vs_ALS_IRPHTFTGLSGLR
42 & 40

ANGT_DPTFIPAPIQAK_vs_IBP1_VVESLAK
42 & 97

ANGT_DPTFIPAPIQAK_vs_ITIH4_ILDDLSPR
42 & 112

APOH_ATVVYQGER_vs_CSH_ISLLLIESWLEPVR
48 & 81

APOH_ATVVYQGER_vs_IBP2_LIQGAPTIR
48 & 98

APOH_ATVVYQGER_vs_SOM2.CSH_SVEGSCGF
48 & 139

B2MG_VEHSDLSFSK_vs_C163A_INPASLDK
50 & 54

B2MG_VEHSDLSFSK_vs_IBP1_VVESLAK
50 & 97

B2MG_VEHSDLSFSK_vs_PSG9_LFIPQITR
50 & 136

B2MG_VEHSDLSFSK_vs_SPRL1_VLTHSELAPLR
50 & 140

B2MG_VNHVTLSQPK_vs_CSH_AHQLAIDTYQEFEETYIPK
51 & 80

B2MG_VNHVTLSQPK_vs_FBLN1_TGYYFDGISR
51 & 86

B2MG_VNHVTLSQPK_vs_PSG9_LFIPQITR
51 & 136

B2MG_VNHVTLSQPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
51 & 144

B2MG_VNHVTLSQPK_vs_VTDB_ELPEHTVK
51 & 147

BGH3_LTLLAPLNSVFK_vs_C163A_INPASLDK
52 & 54

BGH3_LTLLAPLNSVFK_vs_IBP1_VVESLAK
52 & 97

BGH3_LTLLAPLNSVFK_vs_SPRL1_VLTHSELAPLR
52 & 140

BGH3_LTLLAPLNSVFK_vs_VTDB_ELPEHTVK
52 & 147

CAH1_GGPFSDSYR_vs_ALS_IRPHTFTGLSGLR
56 & 40

CAH1_GGPFSDSYR_vs_CSH_AHQLAIDTYQEFEETYIPK
56 & 80

CAH1_GGPFSDSYR_vs_CSH_ISLLLIESWLEPVR
56 & 81

CAH1_GGPFSDSYR_vs_FBLN1_TGYYFDGISR
56 & 86

CAH1_GGPFSDSYR_vs_IBP2_LIQGAPTIR
56 & 98

CAH1_GGPFSDSYR_vs_IBP3_YGQPLPGYTTK
56 & 100

CAH1_GGPFSDSYR_vs_IGF2_GIVEECCFR
56 & 103

CAH1_GGPFSDSYR_vs_ITIH4_ILDDLSPR
56 & 112

CAH1_GGPFSDSYR_vs_PRG2_WNFAYWAAHQPWSR
56 & 129

CAH1_GGPFSDSYR_vs_SOM2.CSH_SVEGSCGF
56 & 139

CAH1_GGPFSDSYR_vs_SPRL1_VLTHSELAPLR
56 & 140

CAH1_GGPFSDSYR_vs_VTDB_ELPEHTVK
56 & 147

CBPN_EALIQFLEQVHQGIK_vs_CRIS3_AVSPPAR
59 & 78

CBPN_EALIQFLEQVHQGIK_vs_IBP1_VVESLAK
59 & 97

CBPN_EALIQFLEQVHQGIK_vs_PGRP2_AGLLRPDYALLGHR
59 & 126

CBPN_EALIQFLEQVHQGIK_vs_SPRL1_VLTHSELAPLR
59 & 140

CBPN_NNANGVDLNR_vs_CRIS3_AVSPPAR
60 & 78

CBPN_NNANGVDLNR_vs_IBP1_VVESLAK
60 & 97

CBPN_NNANGVDLNR_vs_PSG9_LFIPQITR
60 & 136

CD14_LTVGAAQVPAQLLVGALR_vs_ALS_IRPHTFTGLSGLR
61 & 40

CD14_LTVGAAQVPAQLLVGALR_vs_IBP2_LIQGAPTIR
61 & 98

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_NYGLLYCFR
61 & 138

CD14_SWLAELQQWLKPGLK_vs_ALS_IRPHTFTGLSGLR
62 & 40

CD14_SWLAELQQWLKPGLK_vs_CSH_ISLLLIESWLEPVR
62 & 81

CD14_SWLAELQQWLKPGLK_vs_IBP3_FLNVLSPR
62 & 99

CD14_SWLAELQQWLKPGLK_vs_IBP3_YGQPLPGYTTK
62 & 100

CD14_SWLAELQQWLKPGLK_vs_NCAM1_GLGEISAASEFK
62 & 121

CD14_SWLAELQQWLKPGLK_vs_PSG9_LFIPQITR
62 & 136

CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_NYGLLYCFR
62 & 138

CFAB_YGLVTYATYPK_vs_IBP1_VVESLAK
64 & 97

CLUS_ASSIIDELFQDR_vs_CSH_ISLLLIESWLEPVR
67 & 81

CLUS_ASSIIDELFQDR_vs_ITIH4_ILDDLSPR
67 & 112

CLUS_ASSIIDELFQDR_vs_PRG2_WNFAYWAAHQPWSR
67 & 129

CLUS_ASSIIDELFQDR_vs_PSG9_LFIPQITR
67 & 136

CLUS_ASSIIDELFQDR_vs_SOM2.CSH_SVEGSCGF
67 & 139

CLUS_ASSIIDELFQDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
67 & 144

CLUS_LFDSDPITVTVPVEVSR_vs_CSH_ISLLLIESWLEPVR
68 & 81

CLUS_LFDSDPITVTVPVEVSR_vs_NCAM1_GLGEISAASEFK
68 & 121

CLUS_LFDSDPITVTVPVEVSR_vs_PSG9_LFIPQITR
68 & 136

CLUS_LFDSDPITVTVPVEVSR_vs_SOM2.CSH_NYGLLYCFR
68 & 138

CLUS_LFDSDPITVTVPVEVSR_vs_SOM2.CSH_SVEGSCGF
68 & 139

CO5_TLLPVSKPEIR_vs_C163A_INPASLDK
70 & 54

CO5_TLLPVSKPEIR_vs_IBP1_VVESLAK
70 & 97

CO5_TLLPVSKPEIR_vs_IBP3_FLNVLSPR
70 & 99

CO5_TLLPVSKPEIR_vs_PSG9_LFIPQITR
70 & 136

CO5_VFQFLEK_vs_IBP1_VVESLAK
71 & 97

CO5_VFQFLEK_vs_PSG9_LFIPQITR
71 & 136

CO5_VFQFLEK_vs_SPRL1_VLTHSELAPLR
71 & 140

CO6_ALNHLPLEYNSALYSR_vs_CRIS3_AVSPPAR
72 & 78

CO6_ALNHLPLEYNSALYSR_vs_IBP1_VVESLAK
72 & 97

CO6_ALNHLPLEYNSALYSR_vs_PSG9_LFIPQITR
72 & 136

CO6_ALNHLPLEYNSALYSR_vs_SPRL1_VLTHSELAPLR
72 & 140

CO8A_SLLQPNK_vs_CSH_ISLLLIESWLEPVR
74 & 81

CO8A_SLLQPNK_vs_ITIH4_ILDDLSPR
74 & 112

CO8A_SLLQPNK_vs_SOM2.CSH_NYGLLYCFR
74 & 138

CO8A_SLLQPNK_vs_SOM2.CSH_SVEGSCGF
74 & 139

CO8B_QALEEFQK_vs_CSH_ISLLLIESWLEPVR
76 & 81

CO8B_QALEEFQK_vs_ITIH4_ILDDLSPR
76 & 112

F13B_GDTYPAELYITGSILR_vs_ALS_IRPHTFTGLSGLR
84 & 40

F13B_GDTYPAELYITGSILR_vs_C163A_INPASLDK
84 & 54

F13B_GDTYPAELYITGSILR_vs_CSH_ISLLLIESWLEPVR
84 & 81

F13B_GDTYPAELYITGSILR_vs_ITIH4_ILDDLSPR
84 & 112

F13B_GDTYPAELYITGSILR_vs_NCAM1_GLGEISAASEFK
84 & 121

F13B_GDTYPAELYITGSILR_vs_PSG9_LFIPQITR
84 & 136

F13B_GDTYPAELYITGSILR_vs_SOM2.CSH_NYGLLYCFR
84 & 138

F13B_GDTYPAELYITGSILR_vs_SOM2.CSH_SVEGSCGF
84 & 139

FBLN3_IPSNPSHR_vs_ALS_IRPHTFTGLSGLR
87 & 40

FBLN3_IPSNPSHR_vs_FBLN1_TGYYFDGISR
87 & 86

FBLN3_IPSNPSHR_vs_IBP3_FLNVLSPR
87 & 99

FBLN3_IPSNPSHR_vs_ITIH4_ILDDLSPR
87 & 112

FBLN3_IPSNPSHR_vs_NCAM1_GLGEISAASEFK
87 & 121

FBLN3_IPSNPSHR_vs_PSG3_VSAPSGTGHLPGLNPL
87 & 134

FBLN3_IPSNPSHR_vs_PSG9_LFIPQITR
87 & 136

FBLN3_IPSNPSHR_vs_VTDB_ELPEHTVK
87 & 147

FETUA_FSVVYAK_vs_NCAM1_GLGEISAASEFK
88 & 121

FETUA_HTLNQIDEVK_vs_NCAM1_GLGEISAASEFK
89 & 121

HABP2_FLNWIK_vs_ALS_IRPHTFTGLSGLR
92 & 40

HABP2_FLNWIK_vs_IBP1_VVESLAK
92 & 97

HEMO_NFPSPVDAAFR_vs_IBP1_VVESLAK
93 & 97

HEMO_NFPSPVDAAFR_vs_PSG9_LFIPQITR
93 & 136

HEMO_NFPSPVDAAFR_vs_SPRL1_VLTHSELAPLR
93 & 140

HLACI_WAAVVVPSGEEQR_vs_IBP1_VVESLAK
95 & 97

HLACI_WAAVVVPSGEEQR_vs_LYAM1_SYYWIGIR
95 & 120

IBP6_GAQTLYVPNCDHR_vs_ALS_IRPHTFTGLSGLR
101 & 40

IBP6_GAQTLYVPNCDHR_vs_CRIS3_AVSPPAR
101 & 78

IBP6_GAQTLYVPNCDHR_vs_IBP1_VVESLAK
101 & 97

IBP6_GAQTLYVPNCDHR_vs_IBP2_LIQGAPTIR
101 & 98

IBP6_GAQTLYVPNCDHR_vs_IBP3_FLNVLSPR
101 & 99

IBP6_GAQTLYVPNCDHR_vs_IBP3_YGQPLPGYTTK
101 & 100

IBP6_GAQTLYVPNCDHR_vs_SPRL1_VLTHSELAPLR
101 & 140

IBP6_GAQTLYVPNCDHR_vs_TENX_LNWEAPPGAFDSFLLR
101 & 141

IBP6_GAQTLYVPNCDHR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
101 & 144

IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_AVSPPAR
102 & 78

IBP6_HLDSVLQQLQTEVYR_vs_IBP1_VVESLAK
102 & 97

IBP6_HLDSVLQQLQTEVYR_vs_IBP2_LIQGAPTIR
102 & 98

IBP6_HLDSVLQQLQTEVYR_vs_IBP3_FLNVLSPR
102 & 99

IBP6_HLDSVLQQLQTEVYR_vs_IBP3_YGQPLPGYTTK
102 & 100

IBP6_HLDSVLQQLQTEVYR_vs_PSG9_LFIPQITR
102 & 136

IBP6_HLDSVLQQLQTEVYR_vs_SOM2.CSH_SVEGSCGF
102 & 139

IBP6_HLDSVLQQLQTEVYR_vs_SPRL1_VLTHSELAPLR
102 & 140

IBP6_HLDSVLQQLQTEVYR_vs_TENX_LNWEAPPGAFDSFLLR
102 & 141

IBP6_HLDSVLQQLQTEVYR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
102 & 144

INHBC_LDFHFSSDR_vs_IBP1_VVESLAK
107 & 97

ITIH3_ALDLSLK_vs_PSG9_LFIPQITR
111 & 136

ITIH4_NPLVWVHASPEHVVVTR_vs_C163A_INPASLDK
113 & 54

ITIH4_NPLVWVHASPEHVVVTR_vs_CSH_ISLLLIESWLEPVR
113 & 81

ITIH4_NPLVWVHASPEHVVVTR_vs_PSG1_FQLPGQK
113 & 131

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_ALS_IRPHTFTGLSGLR
114 & 40

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_C163A_INPASLDK
114 & 54

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CHL1_VIAVNEVGR
114 & 66

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_CSH_AHQLAIDTYQEFEETYIPK
114 & 80

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_FBLN1_TGYYFDGISR
114 & 86

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_IBP3_FLNVLSPR
114 & 99

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_IBP3_YGQPLPGYTTK
114 & 100

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_IGF2_GIVEECCFR
114 & 103

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_ITIH4_ILDDLSPR
114 & 112

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_NCAM1_GLGEISAASEFK
114 & 121

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PRG2_WNFAYWAAHQPWSR
114 & 129

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_PSG1_FQLPGQK
114 & 131

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_SOM2.CSH_NYGLLYCFR
114 & 138

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_SPRL1_VLTHSELAPLR
114 & 140

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TENX_LNWEAPPGAFDSFLLR
114 & 141

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
114 & 144

ITIH4_QLGLPGPPDVPDHAAYHPF_vs_VTDB_ELPEHTVK
114 & 147

KNG1_DIPTNSPELEETLTHTITK_vs_C163A_INPASLDK
116 & 54

KNG1_DIPTNSPELEETLTHTITK_vs_IBP3_FLNVLSPR
116 & 99

KNG1_DIPTNSPELEETLTHTITK_vs_IBP3_YGQPLPGYTTK
116 & 100

KNG1_DIPTNSPELEETLTHTITK_vs_PGRP2_AGLLRPDYALLGHR
116 & 126

KNG1_DIPTNSPELEETLTHTITK_vs_PSG9_LFIPQITR
116 & 136

KNG1_DIPTNSPELEETLTHTITK_vs_SOM2.CSH_SVEGSCGF
116 & 139

KNG1_DIPTNSPELEETLTHTITK_vs_VTDB_ELPEHTVK
116 & 147

KNG1_QVVAGLNFR_vs_ALS_IRPHTFTGLSGLR
117 & 40

KNG1_QVVAGLNFR_vs_CSH_ISLLLIESWLEPVR
117 & 81

KNG1_QVVAGLNFR_vs_PSG9_LFIPQITR
117 & 136

KNG1_QVVAGLNFR_vs_SOM2.CSH_NYGLLYCFR
117 & 138

KNG1_QVVAGLNFR_vs_SOM2.CSH_SVEGSCGF
117 & 139

LBP_ITGFLKPGK_vs_FBLN1_TGYYFDGISR
118 & 86

LBP_ITGFLKPGK_vs_NCAM1_GLGEISAASEFK
118 & 121

PAPP1_DIPHWLNPTR_vs_ALS_IRPHTFTGLSGLR
122 & 40

PAPP1_DIPHWLNPTR_vs_CHL1_VIAVNEVGR
122 & 66

PAPP1_DIPHWLNPTR_vs_FBLN1_TGYYFDGISR
122 & 86

PAPP1_DIPHWLNPTR_vs_IBP3_FLNVLSPR
122 & 99

PAPP1_DIPHWLNPTR_vs_IBP3_YGQPLPGYTTK
122 & 100

PAPP1_DIPHWLNPTR_vs_IGF2_GIVEECCFR
122 & 103

PAPP1_DIPHWLNPTR_vs_NCAM1_GLGEISAASEFK
122 & 121

PAPP1_DIPHWLNPTR_vs_PSG3_VSAPSGTGHLPGLNPL
122 & 134

PAPP1_DIPHWLNPTR_vs_SPRL1_VLTHSELAPLR
122 & 140

PAPP1_DIPHWLNPTR_vs_TENX_LNWEAPPGAFDSFLLR
122 & 141

PAPP1_DIPHWLNPTR_vs_TENX_LSQLSVTDVTTSSLR
122 & 142

PAPP1_DIPHWLNPTR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
122 & 144

PAPP1_DIPHWLNPTR_vs_VTDB_ELPEHTVK
122 & 147

PEDF_LQSLFDSPDFSK_vs_PSG9_LFIPQITR
124 & 136

PEDF_LQSLFDSPDFSK_vs_SPRL1_VLTHSELAPLR
124 & 140

PEDF_TVQAVLTVPK_vs_IBP1_VVESLAK
125 & 97

PEDF_TVQAVLTVPK_vs_IBP2_LIQGAPTIR
125 & 98

PEDF_TVQAVLTVPK_vs_IBP3_FLNVLSPR
125 & 99

PEDF_TVQAVLTVPK_vs_ITIH4_ILDDLSPR
125 & 112

PRDX2_GLFIIDGK_vs_ALS_IRPHTFTGLSGLR
128 & 40

PRDX2_GLFIIDGK_vs_CSH_AHQLAIDTYQEFEETYIPK
128 & 80

PRDX2_GLFIIDGK_vs_CSH_ISLLLIESWLEPVR
128 & 81

PRDX2_GLFIIDGK_vs_FBLN1_TGYYFDGISR
128 & 86

PRDX2_GLFIIDGK_vs_IBP3_FLNVLSPR
128 & 99

PRDX2_GLFIIDGK_vs_IBP3_YGQPLPGYTTK
128 & 100

PRDX2_GLFIIDGK_vs_IGF2_GIVEECCFR
128 & 103

PRDX2_GLFIIDGK_vs_ITIH4_ILDDLSPR
128 & 112

PRDX2_GLFIIDGK_vs_NCAM1_GLGEISAASEFK
128 & 121

PRDX2_GLFIIDGK_vs_PSG1_FQLPGQK
128 & 131

PRDX2_GLFIIDGK_vs_SOM2.CSH_NYGLLYCFR
128 & 138

PRDX2_GLFIIDGK_vs_SOM2.CSH_SVEGSCGF
128 & 139

PSG11_LFIPQITPK_vs_LYAM1_SYYWIGIR
132 & 120

PSG11_LFIPQITPK_vs_SHBG_IALGGLLFPASNLR
132 & 18

PSG2_IHPSYTNYR_vs_PRG2_WNFAYWAAHQPWSR
133 & 129

PTGDS_GPGEDFR_vs_CSH_AHQLAIDTYQEFEETYIPK
137 & 80

PTGDS_GPGEDFR_vs_CSH_ISLLLIESWLEPVR
137 & 81

PTGDS_GPGEDFR_vs_IBP2_LIQGAPTIR
137 & 98

PTGDS_GPGEDFR_vs_PSG9_LFIPQITR
137 & 136

THBG_AVLHIGEK_vs_CRIS3_AVSPPAR
143 & 78

THBG_AVLHIGEK_vs_IBP1_VVESLAK
143 & 97

THBG_AVLHIGEK_vs_IBP3_FLNVLSPR
143 & 99

THBG_AVLHIGEK_vs_PSG9_LFIPQITR
143 & 136

THBG_AVLHIGEK_vs_SPRL1_VLTHSELAPLR
143 & 140

VTNC_VDTVDPPYPR_vs_IBP1_VVESLAK
150 & 97

TABLE 60

Clock Proteins

ShortName
ProteinName
Analyte
SEQ ID NO:

ADA12
Adam 12
FGFGGSTDSGPIR
151

ADA12
Adam 12
LIEIANHVDK
152

ANGT
Angiotensinogen
DPTFIPAPIQAK
42

CSH
Chorionic somatomammotropin hormone
AHQLAIDTYQEFEETYIPK
80

1 & 2

CSH
Chorionic somatomammotropin hormone
ISLLLIESWLEPVR
81

1 & 2

FBLN1
Fibulin-1
TGYYFDGISR
86

PAI2
Plasminogen activator inhibitor 2
LNIGYIEDLK
153

PAPP1
Pappalysin-1
DIPHWLNPTR
122

PSG11
Pregnancy-specific beta-1-glycoprotein 11
DLYHYITSYVVDGEIIIYGPAYSGR
130

PSG1
Pregnancy-specific beta-1-glycoprotein 1
FQLPGQK
131

PSG2
Pregnancy-specific beta-1-glycoprotein 2
IHPSYTNYR
133

PSG6
Pregnancy-specific beta-1-glycoprotein 6
SNPVTLNVLYGPDLPR
154

PSG9
Pregnancy-specific beta-1-glycoprotein 9
DVLLLVHNLPQNLPGYFWYK
135

PSG9
Pregnancy-specific beta-1-glycoprotein 9
LFIPQITR
136

SOM2.CSH
Placenta-specific growth hormone &
NYGLLYCFR
138

Chorionic somatomammotropin hormone

1 & 2

SOM2.CSH
Placenta-specific growth hormone &
SVEGSCGF
139

Chorionic somatomammotropin hormone

1 & 2

TENX
Tenascin-X
LSQLSVTDVTTSSLR
142

TIE1
Tyrosine-protein kinase receptor
VSWSLPLVPGPLVGDGFLLR
144

VGFR3
Vascular endothelial growth factor receptor
SGVDLADSNQK
155

3

VGFR3
Vascular endothelial growth factor receptor
HATLSLSIPR
156

3

TABLE 61

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21

6/7 using a case vs control cut-off of <37 0/7 vs >=37

0/7 weeks, without BMI stratification, separately for

PPROM and PTL.

119_
119_
119_
119_

153_
153_
153_
153_

aBMI_37
aBMI_37
aBMI_37
aBMI_37

SEQ ID
PTL
PTL
PPROM
PPROM

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.56
0.18
0.66
0.001

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.58
0.0951
0.65
0.0019

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.56
0.2369
0.66
0.0012

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.57
0.1185
0.67
5.00E-04

APOC3_GWVTDGFSSLK_vs_ALS_IRPHTFTGLSGLR
47 & 40
0.58
0.0739
0.66
8.00E-04

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.58
0.0834
0.67
7.00E-04

APOC3_GWVTDGFSSLK_vs_CHL1_VIAVNEVGR
47 & 66
0.58
0.0919
0.66
0.0011

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.56
0.1948
0.68
2.00E-04

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.57
0.1492
0.68
2.00E-04

APOC3_GWVTDGFSSLK_vs_CSH_AHQLAIDTYQEFEETYIPK
47 & 80
0.59
0.0705
0.66
7.00E-04

APOC3_GWVTDGFSSLK_vs_CSH_ISLLLIESWLEPVR
47 & 81
0.58
0.1112
0.65
0.0026

APOC3_GWVTDGFSSLK_vs_FBLN1_TGYYFDGISR
47 & 86
0.56
0.1845
0.68
3.00E-04

APOC3_GWVTDGFSSLK_vs_IBP2_LIQGAPTIR
47 & 98
0.54
0.3592
0.66
8.00E-04

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.6
0.0431
0.67
3.00E-04

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.59
0.0487
0.67
4.00E-04

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.6
0.0289
0.68
2.00E-04

APOC3_GWVTDGFSSLK_vs_ITIH4_ILDDLSPR
47 & 112
0.59
0.0664
0.66
8.00E-04

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.57
0.1171
0.69
1.00E-04

APOC3_GWVTDGFSSLK_vs_NCAM1_GLGEISAASEFK
47 & 121
0.58
0.081
0.65
0.0014

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.58
0.0931
0.68
2.00E-04

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.63
0.0045
0.65
0.0014

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.56
0.2234
0.66
0.001

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.55
0.2511
0.65
0.0018

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.59
0.0618
0.67
4.00E-04

APOC3_GWVTDGFSSLK_vs_SPRL1_VLTHSELAPLR
47 & 140
0.56
0.2251
0.66
7.00E-04

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.58
0.0834
0.68
2.00E-04

APOC3_GWVTDGFSSLK_vs_TENX_LSQLSVTDVTTSSLR
47 & 142
0.58
0.0829
0.67
5.00E-04

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.59
0.0703
0.67
4.00E-04

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.59
0.0703
0.67
4.00E-04

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.66
0.001
0.57
0.1723

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.55
0.2492
0.67
6.00E-04

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.55
0.2632
0.65
0.0018

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.57
0.1178
0.66
9.00E-04

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.55
0.3208
0.67
6.00E-04

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.55
0.3012
0.66
7.00E-04

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.54
0.403
0.67
5.00E-04

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.55
0.2536
0.67
6.00E-04

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.54
0.3953
0.67
6.00E-04

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.57
0.1412
0.65
0.0023

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.67
3.00E-04
0.59
0.0542

CFAB_YGLVTYATYPK_vs_SHBG_IALGGLLFPASNLR
64 & 18
0.6
0.0426
0.65
0.0024

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.66
0.001
0.58
0.1098

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.57
0.1453
0.65
0.0016

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.55
0.2704
0.65
0.0015

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.65
0.0013
0.57
0.129

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.57
0.1316
0.66
0.0013

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.56
0.2455
0.65
0.0018

COSA_SLLQPNK_vs_PSG3_VSAPSGTGHLPGLNPL
74 & 134
0.65
0.002
0.58
0.1094

CO8A_SLLQPNK_vs_SHBG_IALGGLLFPASNLR
74 & 18
0.57
0.1375
0.65
0.0024

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.58
0.1016
0.65
0.0021

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.65
0.002
0.59
0.0605

CO8B_QALEEFQK_vs_SHBG_IALGGLLFPASNLR
76 & 18
0.56
0.181
0.65
0.0017

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.58
0.1026
0.66
0.0012

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.57
0.1566
0.67
5.00E-04

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.55
0.3336
0.66
8.00E-04

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.55
0.2717
0.67
3.00E-04

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.59
0.0659
0.67
4.00E-04

FETUA_FSVVYAK_vs_SHBG_IALGGLLFPASNLR
88 & 18
0.54
0.4516
0.67
3.00E-04

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR
88 & 141
0.54
0.3979
0.68
2.00E-04

FETUA_HTLNQIDEVK_vs_SHBG_IALGGLLFPASNLR
89 & 18
0.54
0.3878
0.67
5.00E-04

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.55
0.3019
0.68
2.00E-04

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.56
0.2049
0.66
0.0013

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.61
0.0245
0.65
0.0019

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.55
0.26
0.66
8.00E-04

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.56
0.2393
0.68
2.00E-04

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.54
0.3466
0.66
9.00E-04

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.56
0.2286
0.67
3.00E-04

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.54
0.4212
0.67
5.00E-04

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.55
0.2684
0.65
0.0016

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.55
0.2523
0.66
9.00E-04

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.57
0.1643
0.69
1.00E-04

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.67
3.00E-04
0.61
0.0185

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.6
0.0371
0.67
3.00E-04

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.57
0.1255
0.67
6.00E-04

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.56
0.188
0.67
6.00E-04

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.56
0.243
0.68
3.00E-04

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.56
0.188
0.67
3.00E-04

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.59
0.0635
0.69
1.00E-04

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.54
0.3936
0.66
7.00E-04

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.53
0.549
0.68
2.00E-04

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.54
0.3911
0.71
0

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.6
0.0281
0.67
4.00E-04

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.56
0.1922
0.68
3.00E-04

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.56
0.2054
0.7
0

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.55
0.2724
0.67
4.00E-04

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.55
0.29
0.66
7.00E-04

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.55
0.3313
0.68
1.00E-04

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.56
0.1969
0.69
1.00E-04

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.55
0.3283
0.66
0.001

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.53
0.4899
0.67
3.00E-04

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.56
0.2357
0.65
0.0019

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.54
0.3459
0.67
4.00E-04

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.58
0.1007
0.65
0.0024

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.53
0.487
0.68
1.00E-04

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 & 126
0.53
0.4842
0.68
2.00E-04

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.63
0.0062
0.65
0.0024

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.56
0.2049
0.69
1.00E-04

LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR
118 & 141
0.54
0.382
0.66
8.00E-04

LBP_ITGFLKPGK_vs_VTDB_ELPEHTVK
118 & 147
0.54
0.3672
0.66
8.00E-04

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.54
0.3746
0.68
3.00E-04

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.57
0.1308
0.67
5.00E-04

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.55
0.3298
0.69
1.00E-04

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.56
0.2228
0.69
1.00E-04

LBP_ITLPDFTGDLR_vs_CSH_AHQLAIDTYQEFEETYIPK
119 & 80
0.56
0.1911
0.65
0.0025

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.6
0.0373
0.66
9.00E-04

LBP_ITLPDFTGDLR_vs_ITIH4_ILDDLSPR
119 & 112
0.54
0.3482
0.67
3.00E-04

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.55
0.3048
0.71
0

LBP_ITLPDFTGDLR_vs_NCAM1_GLGEISAASEFK
119 & 121
0.57
0.1553
0.65
0.0025

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.55
0.3105
0.7
0

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.64
0.0028
0.66
9.00E-04

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.57
0.115
0.7
0

LBP_ITLPDFTGDLR_vs_SOM2.CSH_SVEGSCGF
119 & 139
0.57
0.1245
0.65
0.0027

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.56
0.2387
0.68
1.00E-04

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.55
0.2921
0.67
6.00E-04

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.56
0.1974
0.66
8.00E-04

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.56
0.1703
0.69
1.00E-04

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.53
0.5622
0.68
2.00E-04

PEDF_LQSLFDSPDFSK_vs_SHBG_IALGGLLFPASNLR
124 & 18
0.55
0.2724
0.66
0.0012

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.55
0.2473
0.68
3.00E-04

PEDF_LQSLFDSPDFSK_vs_TENX_LSQLSVTDVTTSSLR
124 & 142
0.56
0.2393
0.65
0.0019

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.56
0.2022
0.66
0.0012

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.54
0.403
0.68
1.00E-04

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.57
0.1428
0.67
5.00E-04

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.57
0.1518
0.68
3.00E-04

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.68
2.00E-04
0.61
0.0197

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.6
0.0293
0.68
2.00E-04

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.57
0.1513
0.67
3.00E-04

VTNC_GQYCYELDEK_vs_TENX_LSQLSVTDVTTSSLR
149 & 142
0.56
0.1901
0.65
0.0023

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.6
0.029
0.66
0.0011

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.59
0.0722
0.65
0.0025

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.62
0.0142
0.65
0.0023

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.57
0.1416
0.68
2.00E-04

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.55
0.2479
0.68
2.00E-04

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.67
5.00E-04
0.62
0.0164

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.59
0.0644
0.68
2.00E-04

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.56
0.1805
0.67
4.00E-04

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.61
0.0248
0.68
2.00E-04

TABLE 62

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using

a case vs control cut-off of <37 0/7 vs >=37 0/7 weeks, with

BMI stratification (>22 <=37), separately for PPROM and PTL.

119_
119_
119_
119_

153_
153_
153_
153_

rBMI_37
rBMI_37
rBMI_37
rBMI_37

SEQ ID
PTL
PTL
PPROM
PPROM

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.65
0.0065
0.58
0.195

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.61
0.0376
0.65
0.015

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.57
0.1794
0.65
0.0119

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.58
0.153
0.65
0.0106

AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR
37 & 99
0.57
0.2071
0.65
0.0131

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.61
0.0383
0.66
0.0068

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.56
0.2409
0.69
0.0019

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.61
0.0525
0.67
0.0047

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.61
0.0559
0.68
0.0034

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.57
0.1892
0.67
0.0053

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.58
0.1223
0.66
0.0082

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.54
0.4394
0.7
0.0011

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.53
0.6034
0.7
0.0011

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.55
0.371
0.72
3.00E-04

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.55
0.4081
0.68
0.0023

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.59
0.1051
0.68
0.0034

APOC3_GWVTDGFSSLK_vs_CRIS3_AVSPPAR
47 & 78
0.6
0.0815
0.67
0.006

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.61
0.0525
0.66
0.0066

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.61
0.0538
0.65
0.0142

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.6
0.082
0.67
0.004

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.58
0.1338
0.66
0.0079

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.57
0.223
0.67
0.0046

APOC3_GWVTDGFSSLK_vs_PSG9_LFIPQITR
47 & 136
0.55
0.3213
0.66
0.0088

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.59
0.1185
0.65
0.0145

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.65
0.0057
0.57
0.2705

BGH3_LTLLAPLNSVFK_vs_LYAM1_SYYWIGIR
52 & 120
0.57
0.1883
0.67
0.0059

BGH3_LTLLAPLNSVFK_vs_SHBG_IALGGLLFPASNLR
52 & 18
0.54
0.4803
0.68
0.0032

BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR
52 & 141
0.56
0.2834
0.66
0.0062

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.58
0.1331
0.66
0.0068

C1QB_VPGLYYFTYHASSR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
55 & 135
0.54
0.4346
0.68
0.0027

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.59
0.1159
0.65
0.0102

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.65
0.0075
0.56
0.3512

CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK
64 & 100
0.66
0.0032
0.55
0.4332

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.67
0.0019
0.57
0.2156

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.65
0.008
0.6
0.1111

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.7
3.00E-04
0.52
0.7399

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.67
0.0026
0.56
0.2866

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.66
0.0034
0.56
0.345

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.69
4.00E-04
0.52
0.7583

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.59
0.1116
0.65
0.0156

CO5_VFQFLEK_vs_IGF2_GIVEECCFR
71 & 103
0.67
0.0024
0.53
0.6116

CO5_VFQFLEK_vs_PSG3_VSAPSGTGHLPGLNPL
71 & 134
0.69
6.00E-04
0.5
0.994

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.65
0.0073
0.57
0.2475

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.55
0.3239
0.66
0.0075

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.67
0.0017
0.54
0.5019

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.66
0.0044
0.57
0.2487

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_LYAM1_SYYWIGIR
82 & 120
0.58
0.1424
0.67
0.0051

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.58
0.1601
0.68
0.0033

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.57
0.2271
0.66
0.0091

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.55
0.3581
0.67
0.0044

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.65
0.0059
0.62
0.0489

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.56
0.3019
0.67
0.0045

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.56
0.2726
0.67
0.0059

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.59
0.1197
0.66
0.0063

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.61
0.0378
0.66
0.0073

IBP4_QCHPALDGQR_vs_IBP3_YGQPLPGYTTK
2 & 100
0.66
0.0034
0.58
0.1711

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.67
0.0015
0.61
0.0651

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.61
0.0451
0.68
0.0032

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.58
0.1417
0.71
6.00E-04

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.68
0.0014
0.56
0.3528

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.6
0.0834
0.68
0.0024

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.56
0.2846
0.68
0.0026

INHBC_LDFHFSSDR_vs_CHL1_VIAVNEVGR
107 & 66
0.58
0.1366
0.66
0.0088

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.55
0.3173
0.67
0.006

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.57
0.2179
0.67
0.0043

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.59
0.1086
0.69
0.0015

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.61
0.0439
0.67
0.004

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.63
0.0188
0.67
0.0039

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.54
0.441
0.68
0.0031

INHBC_LDFHFSSDR_VS_LYAM1_SYYWIGIR
107 & 120
0.55
0.3239
0.69
0.0021

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.56
0.3109
0.7
9.00E-04

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.57
0.2071
0.68
0.0029

INHBC_LDFHFSSDR_vs_SPRL1_VLTHSELAPLR
107 & 140
0.57
0.21
0.68
0.0034

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.59
0.1074
0.7
0.001

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.58
0.1633
0.66
0.0078

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.56
0.2388
0.67
0.0056

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.56
0.2531
0.71
6.00E-04

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.58
0.1338
0.67
0.0042

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.56
0.3147
0.67
0.005

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.56
0.2882
0.67
0.0055

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.56
0.2822
0.65
0.012

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.57
0.1725
0.65
0.0135

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.56
0.307
0.67
0.004

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.54
0.4442
0.68
0.0027

LBP_ITLPDFTGDLR_vs_C163A_INPASLDK
119 & 54
0.54
0.4604
0.69
0.0013

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.58
0.1395
0.68
0.0035

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.59
0.0853
0.67
0.0039

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.58
0.1601
0.71
6.00E-04

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.56
0.2519
0.69
0.0012

LBP_ITLPDFTGDLR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
119 & 135
0.54
0.4236
0.67
0.0037

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.56
0.2553
0.7
9.00E-04

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.56
0.3057
0.67
0.0044

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.58
0.1461
0.66
0.0074

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.6
0.082
0.66
0.0088

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.57
0.1856
0.68
0.0027

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.57
0.2324
0.66
0.0065

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.57
0.2139
0.66
0.0075

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.55
0.393
0.69
0.0014

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.55
0.3856
0.67
0.0045

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.56
0.2919
0.66
0.0065

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.66
0.0043
0.6
0.1065

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.69
4.00E-04
0.59
0.1378

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.69
4.00E-04
0.6
0.0916

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.65
0.0078
0.65
0.01

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.61
0.0463
0.67
0.0057

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.7
2.00E-04
0.56
0.3077

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.57
0.1975
0.66
0.0093

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.62
0.0297
0.67
0.0059

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.66
0.0031
0.63
0.0374

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.67
0.0021
0.58
0.1711

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.68
0.0011
0.6
0.1139

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.64
0.0101
0.67
0.0056

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.59
0.0914
0.66
0.0072

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.69
4.00E-04
0.55
0.3901

VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
150 & 135
0.57
0.2139
0.66
0.0089

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.6
0.0628
0.67
0.0047

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.65
0.0051
0.64
0.0187

TABLE 63

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using

a case vs control cut-off of <35 0/7 vs >=35 0/7 weeks, without

BMI stratification, separately for PPROM and PTL.

119_
119_
119_

119_
153_
153_
153_

153_
aBMI_35
aBMI_35
aBMI_35

SEQ ID
aBMI_35
PTL
PPROM
PPROM

Reversal
NO:
PTL AUC
P-value
AUC
P-value

A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK
34 & 97
0.52
0.8126
0.67
0.0107

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.52
0.8436
0.68
0.0079

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.59
0.3629
0.67
0.0124

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.56
0.5765
0.68
0.0077

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.54
0.7315
0.66
0.018

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.54
0.6701
0.66
0.0228

AFAM_HFQNLGK_vs_IBP1_VVESLAK
38 & 97
0.53
0.7973
0.65
0.0251

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.51
0.959
0.67
0.0126

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.53
0.8024
0.7
0.0037

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.54
0.6798
0.72
0.0014

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.52
0.8411
0.7
0.0029

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.54
0.7117
0.65
0.025

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.52
0.8101
0.72
0.001

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.53
0.787
0.67
0.0122

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.5
0.9669
0.68
0.0083

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.51
0.9537
0.71
0.0018

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.58
0.4588
0.65
0.0262

APOH_ATVVYQGER_vs_IBP1_VVESLAK
48 & 97
0.5
1
0.66
0.0156

APOH_ATVVYQGER_VS_LYAM1_SYYWIGIR
48 & 120
0.57
0.4771
0.68
0.0079

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.58
0.4409
0.75
2.00E-04

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.53
0.7692
0.68
0.0068

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.5
0.9802
0.69
0.0059

B2MG_VNHVTLSQPK_vs_IBP1_VVESLAK
51 & 97
0.55
0.6485
0.68
0.0074

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.51
0.9379
0.68
0.0076

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.53
0.7516
0.77
1.00E-04

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.51
0.888
0.68
0.01

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.51
0.9537
0.69
0.0048

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.51
0.9379
0.77
1.00E-04

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.52
0.8281
0.71
0.0016

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.51
0.93
0.72
0.0014

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.57
0.5063
0.7
0.0029

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.57
0.5063
0.69
0.0064

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.54
0.6774
0.71
0.0017

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.53
0.8024
0.72
0.0012

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.56
0.5342
0.69
0.0057

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.5
0.9907
0.69
0.0062

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.5
0.9749
0.69
0.0042

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.54
0.6847
0.73
8.00E-04

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.57
0.5063
0.72
0.0012

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.52
0.8644
0.78
1.00E-04

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.51
0.9274
0.71
0.0019

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.55
0.597
0.75
2.00E-04

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.5
1
0.71
0.0024

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.57
0.4895
0.68
0.0074

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.61
0.2945
0.68
0.0101

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.51
0.9247
0.72
0.0013

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.52
0.8462
0.73
7.00E-04

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.53
0.7566
0.72
0.001

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.53
0.7845
0.72
0.0014

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.58
0.4311
0.72
0.0011

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.52
0.8853
0.69
0.006

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.5
0.9775
0.73
7.00E-04

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.5
0.9749
0.71
0.002

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.53
0.7491
0.71
0.0017

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.57
0.4916
0.68
0.0091

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.56
0.5563
0.66
0.0177

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.55
0.639
0.72
0.0013

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.52
0.8333
0.72
0.0015

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.52
0.8436
0.69
0.0049

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.53
0.7794
0.7
0.0041

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.57
0.5277
0.72
0.0012

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.55
0.6438
0.69
0.0063

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.5
0.9907
0.76
1.00E-04

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.52
0.8359
0.7
0.0027

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.53
0.7415
0.75
3.00E-04

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.51
0.8932
0.7
0.003

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.56
0.5342
0.66
0.0194

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.6
0.3182
0.65
0.0282

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.51
0.9116
0.7
0.0038

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.55
0.6605
0.72
0.001

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.51
0.9511
0.71
0.0021

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.53
0.7415
0.7
0.0031

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.55
0.5993
0.7
0.0038

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.57
0.5299
0.66
0.0166

CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR
157 & 120
0.59
0.4063
0.68
0.0067

CBPN_NGVDLNR_vs_SPRL1_VLTHSELAPLR
157 & 140
0.56
0.5787
0.65
0.0235

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.59
0.3989
0.65
0.0332

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.66
0.1165
0.6
0.1512

CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK
61 & 97
0.52
0.8411
0.68
0.0075

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.62
0.2535
0.66
0.0218

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.6
0.3208
0.71
0.0016

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.61
0.2972
0.67
0.0121

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.63
0.2169
0.66
0.0202

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.68
0.084
0.6
0.1355

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.56
0.5585
0.65
0.0309

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.6
0.3508
0.65
0.0271

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.59
0.3734
0.67
0.0112

CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK
62 & 79
0.56
0.5563
0.65
0.0272

CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK
62 & 97
0.51
0.959
0.69
0.0064

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.57
0.4936
0.66
0.0192

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.56
0.5765
0.72
0.0013

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.57
0.4916
0.67
0.0113

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.61
0.3049
0.66
0.0204

CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF
62 & 139
0.65
0.1421
0.61
0.1227

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR
62 & 140
0.53
0.7819
0.65
0.0299

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.56
0.5652
0.66
0.0169

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.52
0.8749
0.7
0.0042

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.56
0.5787
0.65
0.0294

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.6
0.3128
0.65
0.0257

CLUS_ASSIIDELFQDR_vs_IBP1_VVESLAK
67 & 97
0.52
0.8671
0.66
0.0187

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.64
0.1768
0.65
0.0256

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.63
0.1944
0.7
0.0028

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.62
0.236
0.65
0.0322

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.65
0.1389
0.64
0.0437

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.57
0.4709
0.65
0.0308

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.6
0.3208
0.66
0.0213

CLUS_LFDSDPITVTVPVEVSR_vs_IBP1_VVESLAK
68 & 97
0.52
0.8775
0.66
0.0188

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.65
0.147
0.64
0.0395

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.62
0.2386
0.69
0.0064

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.63
0.2145
0.65
0.0299

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.57
0.5234
0.65
0.0313

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.6
0.3473
0.7
0.0041

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.59
0.3989
0.67
0.0137

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.57
0.4853
0.69
0.0042

CO8A_SLLQPNK_vs_IBP1_VVESLAK
74 & 97
0.5
0.9987
0.66
0.0164

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.6
0.3525
0.68
0.0076

CO8B_QALEEFQK_vs_IBP1_VVESLAK
76 & 97
0.5
0.9987
0.67
0.012

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.57
0.5105
0.67
0.0131

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.55
0.6179
0.66
0.0157

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.58
0.4488
0.67
0.0134

F13B_GDTYPAELYITGSILR_vs_IBP1_VVESLAK
84 & 97
0.51
0.9379
0.67
0.0123

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.6
0.3273
0.67
0.0146

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.58
0.437
0.74
4.00E-04

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.58
0.4429
0.66
0.0197

F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR
84 & 140
0.54
0.6677
0.65
0.0254

FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK
88 & 79
0.55
0.6629
0.69
0.0056

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.6
0.3456
0.76
1.00E-04

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.57
0.5212
0.73
7.00E-04

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.6
0.3372
0.72
0.0012

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.5
0.996
0.7
0.0041

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.53
0.7769
0.71
0.0025

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.52
0.8566
0.71
0.0022

IBP4_QCHPALDGQR_vs_IBP1_VVESLAK
2 & 97
0.54
0.6798
0.69
0.0062

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.56
0.5924
0.65
0.0254

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.51
0.9142
0.75
2.00E-04

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.53
0.787
0.67
0.0125

IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK
102 & 79
0.54
0.6994
0.69
0.0063

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.57
0.5277
0.72
0.0016

KNG1_DIPTNSPELEETLTHTITK_vs_IBP1_VVESLAK
116 & 97
0.53
0.7769
0.67
0.0108

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.52
0.8644
0.7
0.003

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.6
0.3144
0.65
0.0294

KNG1_QVVAGLNFR_vs_IBP1_VVESLAK
117 & 97
0.51
0.9168
0.68
0.0087

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.65
0.1517
0.63
0.0487

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.61
0.2896
0.71
0.0017

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.6
0.3128
0.66
0.0214

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.55
0.6319
0.71
0.0026

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.5
0.9775
0.68
0.0093

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.52
0.8359
0.68
0.01

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.53
0.787
0.73
9.00E-04

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.5
0.9749
0.68
0.0084

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.54
0.729
0.68
0.0071

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.54
0.7216
0.67
0.013

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.53
0.7491
0.74
4.00E-04

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.61
0.2762
0.65
0.0254

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.63
0.2244
0.66
0.0228

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.58
0.4429
0.65
0.0299

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.63
0.1978
0.67
0.0132

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.65
0.1498
0.62
0.0668

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.63
0.2194
0.65
0.0315

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.57
0.5105
0.65
0.0303

PTGDS_GPGEDFR_vs_IBP1_VVESLAK
137 & 97
0.51
0.9037
0.67
0.0143

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.52
0.8152
0.68
0.0071

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.56
0.5742
0.68
0.01

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.56
0.5697
0.66
0.0213

VTNC_GQYCYELDEK_vs_IBP1_VVESLAK
149 & 97
0.51
0.9168
0.67
0.0124

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.59
0.3664
0.65
0.0232

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.57
0.5212
0.73
8.00E-04

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.57
0.5256
0.67
0.0152

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.58
0.4508
0.66
0.0227

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.52
0.8307
0.67
0.0145

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.52
0.8307
0.67
0.0143

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.5
0.9669
0.74
4.00E-04

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.53
0.7642
0.66
0.0159

TABLE 64

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7

using a case vs control cut-off of <35 0/7 vs >= 35 0/7 weeks,

with BMI stratification (>22 <=37), separately for PPROM and PTL.

119_
119_
119_
119_

153_
153_
153_
153_

rBMI_35
rBMI_35
rBMI_35
rBMI_35

SEQ ID
PTL
PTL
PPROM
PPROM

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.59
0.4023
0.67
0.0438

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.56
0.6023
0.77
0.0014

AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK
37 & 79
0.63
0.2599
0.67
0.0425

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.64
0.2206
0.69
0.0268

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.59
0.4116
0.75
0.0043

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.6
0.3694
0.71
0.0154

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.56
0.6023
0.7
0.0193

AFAM_HFQNLGK_vs_CRIS3_AVSPPAR
38 & 78
0.56
0.5612
0.69
0.0271

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.6
0.3665
0.7
0.0184

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.52
0.8893
0.73
0.008

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.53
0.7955
0.73
0.0071

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.58
0.4597
0.75
0.0037

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.56
0.5686
0.77
0.0014

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.56
0.5797
0.74
0.0051

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.52
0.8807
0.73
0.0077

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.53
0.7913
0.72
0.0088

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.53
0.7704
0.8
5.00E-04

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.54
0.7455
0.72
0.0091

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.58
0.4664
0.7
0.02

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.61
0.3141
0.71
0.0166

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.61
0.3115
0.7
0.0216

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.53
0.8124
0.79
8.00E-04

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.53
0.7787
0.71
0.0151

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.56
0.5723
0.71
0.0151

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.52
0.8336
0.82
2.00E-04

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.57
0.5466
0.69
0.024

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.53
0.8039
0.83
1.00E-04

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.54
0.6924
0.74
0.0061

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.58
0.4697
0.74
0.0055

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.65
0.1786
0.7
0.0191

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.65
0.17
0.69
0.0306

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.58
0.5004
0.7
0.0188

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.56
0.5835
0.7
0.0209

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.61
0.3115
0.72
0.0095

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.52
0.8336
0.74
0.005

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.55
0.6684
0.82
2.00E-04

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.57
0.5215
0.74
0.0047

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.56
0.6138
0.7
0.0174

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.64
0.2085
0.68
0.0387

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.56
0.6176
0.69
0.0286

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.53
0.7913
0.73
0.0084

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.59
0.4178
0.71
0.0154

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.52
0.855
0.8
4.00E-04

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.56
0.5835
0.75
0.0032

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.61
0.3355
0.76
0.0028

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.65
0.1858
0.7
0.0229

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.64
0.2105
0.67
0.0443

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.52
0.8507
0.74
0.0056

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.6
0.3932
0.73
0.0085

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.59
0.4023
0.71
0.0152

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.64
0.2186
0.73
0.0065

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.5
0.9848
0.73
0.0071

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.56
0.5872
0.83
1.00E-04

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.58
0.463
0.77
0.0017

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.5
0.9674
0.75
0.0042

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.57
0.5393
0.72
0.0103

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.55
0.6487
0.75
0.0043

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.56
0.6099
0.73
0.007

CBPN_NGVDLNR_vs_CRIS3_YEDLYSNCK
157 & 79
0.59
0.4147
0.67
0.0466

CBPN_NGVDLNR_VS_LYAM1_SYYWIGIR
157 & 120
0.59
0.4305
0.75
0.0032

CD14_LTVGAAQVPAQLLVGALR_VS_LYAM1_SYYWIGIR
61 & 120
0.65
0.1858
0.75
0.0038

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.63
0.2289
0.71
0.0156

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.73
0.0354
0.59
0.315

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.6
0.3812
0.73
0.0071

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.6
0.3782
0.7
0.0226

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.67
0.1206
0.73
0.0083

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.64
0.2085
0.67
0.0429

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.65
0.1751
0.72
0.0096

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.64
0.2186
0.68
0.0403

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.63
0.2247
0.73
0.0078

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.64
0.2227
0.67
0.0466

COSA_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.64
0.2027
0.7
0.0204

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.61
0.341
0.68
0.0412

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.62
0.2716
0.69
0.0248

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.64
0.2027
0.69
0.024

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.62
0.2692
0.79
6.00E-04

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.6
0.3812
0.71
0.0166

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.61
0.3194
0.67
0.0456

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.58
0.4935
0.82
2.00E-04

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.54
0.7127
0.81
3.00E-04

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.53
0.8209
0.73
0.0064

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.53
0.7871
0.72
0.0093

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.57
0.5074
0.73
0.007

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.54
0.7372
0.82
2.00E-04

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.58
0.4901
0.68
0.0326

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.53
0.7787
0.78
0.001

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.61
0.3328
0.69
0.0302

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.57
0.525
0.74
0.0045

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.65
0.17
0.75
0.003

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.62
0.2861
0.7
0.0224

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.65
0.1913
0.69
0.0234

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.61
0.3274
0.74
0.006

PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR
122 & 129
0.77
0.0162
0.63
0.1266

PAPP1_DIPHWLNPTR_vs_SHBG_IALGGLLFPASNLR
122 & 18
0.59
0.4369
0.67
0.0434

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_NYGLLYCFR
122 & 138
0.73
0.0405
0.58
0.3298

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF
122 & 139
0.77
0.0155
0.65
0.0869

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.59
0.4336
0.67
0.0466

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.6
0.3522
0.76
0.0029

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.57
0.5109
0.68
0.0319

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.6
0.3636
0.69
0.0265

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.6
0.3551
0.77
0.0016

PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR
125 & 126
0.58
0.4498
0.69
0.0302

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.67
0.1232
0.72
0.0099

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.68
0.1011
0.72
0.012

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.59
0.4241
0.67
0.0416

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.67
0.1232
0.69
0.0268

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.66
0.1429
0.67
0.0429

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.68
0.0966
0.76
0.0024

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.66
0.1414
0.7
0.0204

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.68
0.1081
0.67
0.0456

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.68
0.1057
0.71
0.0134

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.74
0.0336
0.64
0.1069

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.6
0.3812
0.72
0.0088

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.61
0.341
0.69
0.0265

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.6
0.3871
0.68
0.0383

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.62
0.2886
0.69
0.0245

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.62
0.2788
0.79
8.00E-04

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.62
0.2986
0.7
0.0209

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.61
0.3355
0.67
0.0476

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.57
0.5144
0.69
0.0286

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.55
0.6253
0.78
0.0012

TABLE 65

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs

control cut-off of <37 0/7 vs >=37 0/7 weeks, without BMI stratification,

separately for primigravida and multigravida.

119_153_
119_153_
119_153_
119_153_

aBMI_37
aBMI_37
aBMI_37
aBMI_37

SEQ ID
multi
multi
primi
primi

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.59
0.0399
0.67
0.0102

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.65
4.00E−04
0.53
0.6818

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.65
5.00E−04
0.56
0.3992

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.65
3.00E−04
0.62
0.0687

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.63
0.0017
0.65
0.0238

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.62
0.0049
0.67
0.0104

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.65
4.00E−04
0.65
0.0277

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.62
0.0049
0.66
0.0148

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.62
0.0036
0.65
0.0218

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.59
0.0394
0.65
0.0255

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.57
0.0849
0.7
0.0029

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.57
0.1204
0.68
0.0058

C1QB_VPGLYYFTYHASSR_vs_PSG3_VSAPSGTGHLPGLNPL
55 & 134
0.58
0.0476
0.66
0.0171

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.58
0.0754
0.71
0.0017

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.58
0.0678
0.68
0.0077

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.57
0.0986
0.68
0.0055

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.58
0.0743
0.69
0.0038

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.57
0.1127
0.69
0.0049

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.57
0.1066
0.69
0.0035

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.58
0.0737
0.68
0.0068

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.58
0.0622
0.66
0.0135

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.59
0.0371
0.66
0.0148

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.59
0.0404
0.65
0.023

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.66
2.00E−04
0.55
0.493

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.6
0.0247
0.65
0.0255

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.65
6.00E−04
0.61
0.1087

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.58
0.066
0.69
0.0049

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.58
0.0557
0.67
0.0119

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.59
0.0314
0.66
0.013

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.58
0.0515
0.65
0.0234

COSA_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.66
2.00E−04
0.52
0.8158

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.66
2.00E−04
0.53
0.6297

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.61
0.0121
0.66
0.0171

ENPP2_TYLHTYESEI_vs_PSG3_VSAPSGTGHLPGLNPL
83 & 134
0.59
0.0287
0.65
0.023

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.59
0.0253
0.66
0.0135

FBLN3_IPSNPSHR_vs_SHBG_IALGGLLFPASNLR
87 & 18
0.55
0.2452
0.73
4.00E−04

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.68
0
0.51
0.862

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.66
2.00E−04
0.51
0.9138

HABP2_FLNWIK_vs_SHBG_IALGGLLFPASNLR
92 & 18
0.59
0.0407
0.66
0.0162

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.59
0.0277
0.67
0.0108

HEMO_NFPSPVDAAFR_vs_SHBG_IALGGLLFPASNLR
93 & 18
0.59
0.0432
0.67
0.0088

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.58
0.0642
0.66
0.0128

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.57
0.0774
0.73
5.00E−04

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.63
0.0017
0.67
0.0095

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.6
0.0241
0.72
7.00E−04

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.59
0.0444
0.69
0.0048

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.65
6.00E−04
0.54
0.5224

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.67
1.00E−04
0.55
0.4254

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.61
0.009
0.65
0.0242

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.66
2.00E−04
0.59
0.1755

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.61
0.0073
0.65
0.0207

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.59
0.0285
0.66
0.0138

KNG1_DIPTNSPELEETLTHTITK_vs_SHBG_IALGGLLFPASNLR
116 & 18
0.56
0.1468
0.69
0.0045

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.56
0.1453
0.68
0.0062

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.65
3.00E−04
0.61
0.0989

LBP_ITGFLKPGK_vs_SHBG_IALGGLLFPASNLR
118 & 18
0.61
0.0097
0.65
0.0277

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.65
5.00E−04
0.55
0.4254

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.65
3.00E−04
0.57
0.3108

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.65
4.00E−04
0.57
0.3015

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.61
0.0103
0.67
0.0116

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.66
1.00E−04
0.64
0.0397

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.62
0.0039
0.66
0.0128

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.61
0.0132
0.65
0.0218

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.59
0.0331
0.65
0.0222

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.66
1.00E−04
0.57
0.2689

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.59
0.0262
0.68
0.0069

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.65
6.00E−04
0.65
0.0218

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.62
0.0039
0.68
0.0058

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.6
0.0134
0.65
0.0204

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.62
0.0036
0.65
0.0255

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.66
1.00E−04
0.56
0.3883

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.59
0.0402
0.68
0.0078

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.64
7.00E−04
0.65
0.0215

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.61
0.0068
0.67
0.0114

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.65
4.00E−04
0.63
0.0558

TABLE 66

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control cut-off of

<37 0/7 vs >=37 0/7 weeks, with BMI stratification (>22 <=37),

separately for primigravida and multigravida.

119_153_
119_153_
119_153_
119_153_

rBMI_37
rBMI_37
rBMI_37
rBMI_37

SEQ ID
multi
multi
primi
primi

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_CRIS3_AVSPPAR
34 & 78
0.65
0.0038
0.52
0.8315

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.65
0.0037
0.52
0.8126

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.65
0.0026
0.51
0.9467

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.62
0.0209
0.65
0.071

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.57
0.1962
0.72
0.0073

A2GL_DLLLPQPDLR_vs_SHBG_IALGGLLFPASNLR
34 & 18
0.59
0.0826
0.69
0.0219

AFAM_DADPDTFFAK_vs_IBP3_FLNVLSPR
37 & 99
0.67
9.00E−04
0.57
0.4118

AFAM_DADPDTFFAK_vs_IBP3_YGQPLPGYTTK
37 & 100
0.68
3.00E−04
0.55
0.5885

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.71
0
0.57
0.4118

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.67
9.00E−04
0.51
0.8792

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.68
4.00E−04
0.5
0.9854

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.7
1.00E−04
0.53
0.7565

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.66
0.001
0.54
0.6484

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.66
0.0016
0.5
1

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.65
0.003
0.51
0.8696

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.6
0.0486
0.69
0.0212

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.57
0.1908
0.71
0.0121

APOC3_GWVTDGFSSLK_vs_C163A_INPASLDK
47 & 54
0.6
0.0479
0.68
0.0291

APOC3_GWVTDGFSSLK_vs_CRIS3_YEDLYSNCK
47 & 79
0.63
0.0104
0.65
0.0673

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.61
0.0229
0.65
0.0789

APOC3_GWVTDGFSSLK_vs_IBP3_YGQPLPGYTTK
47 & 100
0.61
0.036
0.65
0.0789

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.6
0.0418
0.71
0.0129

APOC3_GWVTDGFSSLK_vs_PGRP2_AGLLRPDYALLGHR
47 & 126
0.57
0.1362
0.72
0.0088

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.6
0.0572
0.69
0.0257

APOC3_GWVTDGFSSLK_vs_SHBG_IALGGLLFPASNLR
47 & 18
0.58
0.1164
0.7
0.0186

APOC3_GWVTDGFSSLK_vs_TENX_LNWEAPPGAFDSFLLR
47 & 141
0.58
0.1194
0.7
0.0163

APOC3_GWVTDGFSSLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
47 & 144
0.58
0.0932
0.67
0.0393

APOC3_GWVTDGFSSLK_vs_VTDB_ELPEHTVK
47 & 147
0.58
0.1312
0.69
0.0249

APOH_ATVVYQGER_vs_IBP3_YGQPLPGYTTK
48 & 100
0.65
0.0021
0.51
0.908

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.67
5.00E−04
0.58
0.3523

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.65
0.0034
0.5
1

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.57
0.1547
0.68
0.0339

BGH3_LTLLAPLNSVFK_vs_CRIS3_AVSPPAR
52 & 78
0.65
0.0022
0.52
0.841

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.66
0.0015
0.5
0.9854

BGH3_LTLLAPLNSVFK_vs_IGF2_GIVEECCFR
52 & 103
0.66
0.0014
0.56
0.4998

BGH3_LTLLAPLNSVFK_vs_TENX_LNWEAPPGAFDSFLLR
52 & 141
0.58
0.112
0.66
0.0496

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.57
0.1483
0.71
0.0109

C1QB_VPGLYYFTYHASSR_vs_SHBG_IALGGLLFPASNLR
55 & 18
0.57
0.1962
0.72
0.0073

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.55
0.3241
0.72
0.0082

CBPN_NGVDLNR_vs_IGF2_GIVEECCFR
157 & 103
0.66
0.0017
0.55
0.5392

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.65
0.0038
0.51
0.8696

CFAB_YGLVTYATYPK_vs_CRIS3_AVSPPAR
64 & 78
0.65
0.0037
0.53
0.6838

CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK
64 & 79
0.65
0.0033
0.5
0.9951

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.67
8.00E−04
0.51
0.9273

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.57
0.1865
0.7
0.0175

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.55
0.3241
0.7
0.018

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.65
0.0021
0.54
0.6311

CO5_TLLPVSKPEIR_vs_IGF2_GIVEECCFR
70 & 103
0.65
0.0028
0.51
0.9177

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.6
0.0461
0.68
0.0291

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.55
0.2997
0.74
0.0035

CO5_TLLPVSKPEIR_vs_PSG3_VSAPSGTGHLPGLNPL
70 & 134
0.59
0.0814
0.68
0.0309

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.57
0.1519
0.73
0.0066

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.54
0.4195
0.75
0.0032

CO5_VFQFLEK_vs_CRIS3_AVSPPAR
71 & 78
0.65
0.0033
0.55
0.5801

CO5_VFQFLEK_vs_IGF2_GIVEECCFR
71 & 103
0.65
0.0035
0.54
0.6397

CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR
71 & 126
0.55
0.2779
0.73
0.0068

CO5_VFQFLEK_vs_SHBG_IALGGLLFPASNLR
71 & 18
0.58
0.1217
0.69
0.0199

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.55
0.3581
0.72
0.0076

CO6_ALNHLPLEYNSALYSR_vs_IGF2_GIVEECCFR
72 & 103
0.66
0.0016
0.54
0.6311

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.56
0.2613
0.7
0.0148

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.66
0.0015
0.52
0.7751

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.55
0.2952
0.72
0.0094

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.66
0.0018
0.51
0.9273

CO8B_QALEEFQK_vs_TENX_LNWEAPPGAFDSFLLR
76 & 141
0.55
0.2894
0.72
0.0076

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_SHBG_IALGGLLFPASNLR
82 & 18
0.6
0.058
0.69
0.0206

ENPP2_TYLHTYESEI_vs_LYAM1_SYYWIGIR
83 & 120
0.57
0.1612
0.67
0.0429

ENPP2_TYLHTYESEI_vs_SHBG_IALGGLLFPASNLR
83 & 18
0.56
0.1973
0.7
0.0175

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.65
0.0029
0.52
0.8315

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.69
1.00E−04
0.57
0.4188

FETUA_HTLNQIDEVK_vs_IGF2_GIVEECCFR
89 & 103
0.68
4.00E−04
0.57
0.3847

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.65
0.0025
0.58
0.3158

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.54
0.4049
0.74
0.0033

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.65
0.0034
0.54
0.6224

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.65
0.0022
0.57
0.3847

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.68
3.00E−04
0.54
0.6139

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.62
0.022
0.7
0.0163

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.58
0.1353
0.77
0.0013

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.59
0.0656
0.69
0.0199

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.59
0.0724
0.75
0.0027

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.54
0.3716
0.75
0.0025

IBP4_QCHPALDGQR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
2 & 144
0.59
0.0826
0.67
0.0455

IBP4_QCHPALDGQR_vs_VTDB_ELPEHTVK
2 & 147
0.57
0.17
0.7
0.0158

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.65
0.0036
0.53
0.7658

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.65
0.0033
0.52
0.8601

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.66
0.0011
0.52
0.8505

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.67
9.00E−04
0.53
0.7381

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.69
2.00E−04
0.51
0.8984

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.59
0.0661
0.67
0.036

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.6
0.0414
0.65
0.0655

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.6
0.0447
0.73
0.0068

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.59
0.075
0.68
0.0319

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.62
0.0177
0.65
0.081

ITIH3_ALDLSLK_vs_CRIS3_AVSPPAR
111 & 78
0.66
0.002
0.54
0.6572

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.65
0.0031
0.51
0.937

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.61
0.031
0.65
0.0673

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.57
0.1519
0.67
0.0417

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.57
0.1632
0.68
0.0349

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.66
0.0016
0.53
0.7381

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.66
0.002
0.57
0.4188

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.66
0.0018
0.5
0.9854

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.59
0.0661
0.69
0.0219

LBP_ITLPDFTGDLR_vs_SHBG_IALGGLLFPASNLR
119 & 18
0.61
0.0352
0.66
0.0525

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.56
0.2302
0.68
0.0291

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.67
6.00E−04
0.54
0.6749

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.67
0.001
0.5
0.9661

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.56
0.2086
0.71
0.0109

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.66
0.0019
0.55
0.5312

PEDF_TVQAVLTVPK_vs_TENX_LNWEAPPGAFDSFLLR
125 & 141
0.54
0.3854
0.73
0.0055

PSG2_IHPSYTNYR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
133 & 135
0.67
5.00E−04
0.58
0.3399

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.66
0.0014
0.51
0.9177

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.66
0.0018
0.55
0.5718

VTNC_GQYCYELDEK_vs_IBP3_FLNVLSPR
149 & 99
0.66
0.002
0.56
0.4845

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.68
4.00E−04
0.56
0.4921

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.7
1.00E−04
0.51
0.9273

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.64
0.0058
0.67
0.0442

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.59
0.061
0.72
0.0076

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.62
0.0184
0.68
0.0273

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.62
0.0198
0.71
0.0125

VTNC_GQYCYELDEK_vs_TENX_LNWEAPPGAFDSFLLR
149 & 141
0.58
0.1345
0.72
0.0085

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.63
0.0085
0.68
0.0291

VTNC_VDTVDPPYPR_vs_CRIS3_AVSPPAR
150 & 78
0.66
0.0014
0.5
0.9661

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.66
0.0018
0.54
0.6484

VTNC_VDTVDPPYPR_vs_IBP3_YGQPLPGYTTK
150 & 100
0.66
0.002
0.56
0.4998

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.68
3.00E−04
0.5
0.9854

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.64
0.0066
0.69
0.0249

VTNC_VDTVDPPYPR_vs_PGRP2_AGLLRPDYALLGHR
150 & 126
0.58
0.1345
0.72
0.0079

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.6
0.0516
0.72
0.0098

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.6
0.0375
0.7
0.0175

VTNC_VDTVDPPYPR_vs_TENX_LNWEAPPGAFDSFLLR
150 & 141
0.57
0.1962
0.71
0.0101

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.64
0.0066
0.68
0.0339

TABLE 67

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs

control cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification,

separately for primigravida and multigravida.

119_153_
119_153_
119_153_
119_153_

aBMI_35
aBMI_35
aBMI_35
aBMI_35

SEQ ID
multi
multi
primi
primi

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_IBP1_VVESLAK
34 & 97
0.65
0.0463
0.58
0.4028

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.68
0.0136
0.61
0.2481

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.7
0.0065
0.56
0.5483

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.55
0.5449
0.73
0.0121

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.54
0.6027
0.71
0.0204

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.69
0.0121
0.5
1

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.69
0.0122
0.54
0.6691

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.69
0.0097
0.51
0.9348

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.74
0.0012
0.52
0.8343

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.73
0.0021
0.55
0.5667

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.55
0.5034
0.73
0.0137

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.72
0.0028
0.59
0.335

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.58
0.2847
0.71
0.0219

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.61
0.1507
0.75
0.0069

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.71
0.0043
0.53
0.778

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.66
0.0299
0.68
0.0561

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.56
0.4083
0.71
0.0241

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.7
0.0068
0.61
0.2128

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.74
0.001
0.51
0.8771

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.75
7.00E−04
0.51
0.942

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.74
0.0014
0.54
0.6624

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.72
0.0034
0.66
0.0808

B2MG_VNHVTLSQPK_vs_SHBG_IALGGLLFPASNLR
51 & 18
0.57
0.3602
0.71
0.0241

CATD_VGFAEAAR_vs_ALS_IRPHTFTGLSGLR
57 & 40
0.68
0.015
0.56
0.5423

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.69
0.0114
0.74
0.0103

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.72
0.0038
0.57
0.4449

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.73
0.0021
0.57
0.4183

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.67
0.0256
0.69
0.0425

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.65
0.0392
0.68
0.0505

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.65
0.0378
0.65
0.1035

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.65
0.0428
0.65
0.096

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.57
0.3353
0.7
0.0318

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.71
0.0057
0.53
0.778

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.71
0.0044
0.54
0.7025

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.75
9.00E−04
0.57
0.4669

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.67
0.0239
0.58
0.3777

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.71
0.0054
0.71
0.0247

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.62
0.0991
0.72
0.0148

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.66
0.0353
0.65
0.1035

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.59
0.2231
0.74
0.0098

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.66
0.0372
0.67
0.0689

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.64
0.0634
0.7
0.0293

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.66
0.0292
0.68
0.0454

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.66
0.0356
0.71
0.0204

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.65
0.0437
0.67
0.0689

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.68
0.0163
0.62
0.1965

CATD_VSTLPAITLK_vs_ALS_IRPHTFTGLSGLR
58 & 40
0.68
0.018
0.57
0.4669

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.66
0.034
0.69
0.039

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.73
0.0024
0.55
0.5667

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.73
0.0016
0.56
0.4894

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.66
0.0353
0.65
0.1115

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.66
0.0292
0.63
0.1431

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.65
0.0463
0.65
0.0925

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.71
0.0049
0.55
0.6233

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.72
0.0032
0.55
0.6105

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.74
0.0012
0.58
0.3876

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.7
0.0071
0.7
0.0277

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.61
0.1448
0.74
0.0093

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.66
0.0295
0.68
0.055

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.59
0.2532
0.75
0.0073

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.65
0.0447
0.62
0.2095

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.64
0.0557
0.68
0.0484

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.65
0.0444
0.73
0.0115

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.66
0.0308
0.62
0.1997

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.71
0.0055
0.56
0.5244

CBPN_NGVDLNR_VS_LYAM1_SYYWIGIR
157 & 120
0.72
0.0034
0.6
0.2791

CBPN_NGVDLNR_vs_SPRL1_VLTHSELAPLR
157 & 140
0.68
0.0137
0.55
0.5544

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.75
9.00E−04
0.52
0.8485

CD14_LTVGAAQVPAQLLVGALR_vs_CSH_AHQLAIDTYQEFEETYIPK
61 & 80
0.68
0.0131
0.54
0.6957

CD14_LTVGAAQVPAQLLVGALR_vs_IBP1_VVESLAK
61 & 97
0.66
0.0301
0.61
0.2371

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.81
0
0.58
0.3876

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.76
4.00E−04
0.62
0.1934

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.66
0.0364
0.68
0.0484

CD14_LTVGAAQVPAQLLVGALR_vs_PSG3_VSAPSGTGHLPGLNPL
61 & 134
0.67
0.0237
0.56
0.5483

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.62
0.1048
0.69
0.0349

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.67
0.0206
0.57
0.4491

CD14_LTVGAAQVPAQLLVGALR_vs_SPRL1_VLTHSELAPLR
61 & 140
0.72
0.0038
0.55
0.5544

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.76
6.00E−04
0.52
0.8272

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.73
0.0023
0.52
0.8272

CD14_SWLAELQQWLKPGLK_vs_CRIS3_YEDLYSNCK
62 & 79
0.74
0.0012
0.51
0.9059

CD14_SWLAELQQWLKPGLK_vs_IBP1_VVESLAK
62 & 97
0.66
0.0301
0.6
0.2791

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.79
1.00E−04
0.57
0.4235

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.75
8.00E−04
0.62
0.2029

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.61
0.1334
0.68
0.0484

CD14_SWLAELQQWLKPGLK_vs_SOM2.CSH_SVEGSCGF
62 & 139
0.66
0.0297
0.57
0.4714

CD14_SWLAELQQWLKPGLK_vs_SPRL1_VLTHSELAPLR
62 & 140
0.7
0.0069
0.55
0.5979

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.74
0.0013
0.51
0.942

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.71
0.0047
0.54
0.6691

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.67
0.0215
0.58
0.3826

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.71
0.0041
0.53
0.771

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.73
0.0024
0.53
0.716

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.72
0.0026
0.54
0.6757

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.74
0.0012
0.52
0.87

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.71
0.0056
0.68
0.0484

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.56
0.4152
0.74
0.0098

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.57
0.3539
0.73
0.0115

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_AVSPPAR
68 & 78
0.7
0.0059
0.53
0.7296

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.72
0.0035
0.55
0.5544

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK
68 & 100
0.72
0.0036
0.53
0.7572

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.73
0.0021
0.52
0.806

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.67
0.0199
0.68
0.0444

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR
68 & 126
0.55
0.5309
0.73
0.0137

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR
68 & 18
0.55
0.4899
0.73
0.0106

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.73
0.0023
0.5
1

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.69
0.0089
0.68
0.0538

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.54
0.5469
0.72
0.0164

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.69
0.0108
0.62
0.1873

CO6_ALNHLPLEYNSALYSR_VS_LYAM1_SYYWIGIR
72 & 120
0.7
0.0069
0.65
0.1074

CO6_ALNHLPLEYNSALYSR_vs_SHBG_IALGGLLFPASNLR
72 & 18
0.55
0.5053
0.72
0.0176

CO8A_SLLQPNK_vs_IGF2_GIVEECCFR
74 & 103
0.73
0.002
0.55
0.6233

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.71
0.0049
0.62
0.1842

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.72
0.0037
0.52
0.792

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.67
0.0194
0.62
0.1965

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.73
0.0018
0.5
0.9927

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.74
0.0012
0.52
0.792

F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK
84 & 100
0.74
0.0015
0.56
0.4952

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.75
7.00E−04
0.51
0.8771

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.72
0.0026
0.68
0.0538

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.59
0.2445
0.69
0.0407

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.57
0.3445
0.7
0.0265

F13B_GDTYPAELYITGSILR_vs_SPRL1_VLTHSELAPLR
84 & 140
0.65
0.0392
0.61
0.2335

FETUA_FSVVYAK_vs_CRIS3_YEDLYSNCK
88 & 79
0.7
0.0069
0.53
0.7572

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.67
0.0258
0.67
0.0689

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.67
0.022
0.61
0.2128

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.66
0.0271
0.64
0.1335

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.75
8.00E−04
0.51
0.9348

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.76
4.00E−04
0.51
0.8987

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.71
0.0039
0.52
0.806

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.7
0.0078
0.67
0.0649

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.56
0.4544
0.71
0.023

IBP6_HLDSVLQQLQTEVYR_vs_CRIS3_YEDLYSNCK
102 & 79
0.75
6.00E−04
0.57
0.4235

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.7
0.0067
0.54
0.6559

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.7
0.008
0.65
0.1135

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.72
0.0035
0.51
0.8987

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.73
0.0023
0.54
0.6691

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.76
4.00E−04
0.53
0.7572

KNG1_QVVAGLNFR_vs_ITIH4_ILDDLSPR
117 & 112
0.69
0.0121
0.54
0.6559

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.73
0.0021
0.65
0.0925

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.61
0.1533
0.7
0.0333

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.59
0.2433
0.7
0.0259

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.71
0.0055
0.55
0.5728

PEDF_LQSLFDSPDFSK_vs_CRIS3_AVSPPAR
124 & 78
0.74
0.0011
0.52
0.799

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.75
8.00E−04
0.52
0.8557

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.7
0.0062
0.63
0.156

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.75
9.00E−04
0.52
0.8343

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.76
6.00E−04
0.5
0.9927

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.77
3.00E−04
0.58
0.3876

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.72
0.0033
0.64
0.1156

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.72
0.0036
0.54
0.6757

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.72
0.0033
0.55
0.5728

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.67
0.0189
0.59
0.3215

PSG2_IHPSYTNYR_vs_IBP1_VVESLAK
133 & 97
0.66
0.0372
0.58
0.3583

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.69
0.0123
0.52
0.8414

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.7
0.008
0.62
0.1965

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.73
0.0023
0.52
0.8343

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.67
0.0224
0.61
0.2299

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.69
0.0106
0.59
0.3215

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.7
0.0066
0.54
0.6298

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.7
0.0064
0.54
0.6823

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.68
0.0136
0.7
0.0297

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.54
0.6305
0.75
0.0065

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.59
0.2185
0.7
0.0311

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.55
0.4842
0.73
0.0137

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.69
0.0095
0.55
0.6169

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.68
0.0139
0.53
0.7434

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.66
0.0361
0.72
0.0168

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.54
0.5818
0.73
0.0121

TABLE 68

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs

control cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <=37),

separately for primigravida and multigravida.

119_153_
119_153_
119_153_
119_153_

rBMI_35
rBMI_35
rBMI_35
rBMI_35

SEQ ID
multi
multi
primi
primi

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.79
0.0013
0.51
0.9432

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.73
0.0091
0.68
0.1013

AFAM_DADPDTFFAK_vs_CRIS3_YEDLYSNCK
37 & 79
0.74
0.0073
0.56
0.5959

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.79
0.0015
0.51
0.9432

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.69
0.0371
0.71
0.0525

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.68
0.0404
0.72
0.0388

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.63
0.1361
0.72
0.047

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.75
0.0048
0.54
0.7456

AFAM_HFQNLGK_vs_CRIS3_AVSPPAR
38 & 78
0.72
0.015
0.56
0.585

AFAM_HFQNLGK_vs_CRIS3_YEDLYSNCK
38 & 79
0.75
0.0062
0.57
0.5215

AFAM_HFQNLGK_vs_IBP3_FLNVLSPR
38 & 99
0.75
0.0057
0.51
0.9558

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.78
0.0022
0.54
0.7099

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.81
7.00E−04
0.5
0.9811

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.64
0.115
0.72
0.0436

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.79
0.0012
0.51
0.9684

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.8
9.00E−04
0.52
0.893

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.76
0.0037
0.67
0.1152

ANGT_DPTFIPAPIQAK_vs_SOM2.CSH_SVEGSCGF
42 & 139
0.7
0.0293
0.57
0.5528

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.73
0.0107
0.59
0.4241

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.65
0.0888
0.73
0.032

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.6
0.283
0.77
0.0116

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.76
0.0038
0.54
0.7099

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.77
0.0028
0.56
0.585

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.71
0.0201
0.75
0.0213

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.69
0.0387
0.8
0.0057

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.7
0.0256
0.66
0.1431

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.72
0.0126
0.66
0.152

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.7
0.0292
0.7
0.0629

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.68
0.0409
0.7
0.0629

CATD_VGFAEAAR_vs_IBP3_FLNVLSPR
57 & 99
0.69
0.0346
0.63
0.2259

CATD_VGFAEAAR_vs_IBP3_YGQPLPGYTTK
57 & 100
0.68
0.0404
0.62
0.2782

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.74
0.0077
0.62
0.2853

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.69
0.0341
0.82
0.0037

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.61
0.2372
0.83
0.0027

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.58
0.3917
0.78
0.0092

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.68
0.0409
0.66
0.1388

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.62
0.167
0.73
0.0374

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.62
0.1968
0.73
0.0307

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.66
0.0685
0.76
0.0165

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.73
0.01
0.66
0.1475

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.75
0.0057
0.67
0.1189

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.7
0.0275
0.67
0.1152

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.68
0.0426
0.67
0.1266

CATD_VSTLPAITLK_vs_IBP3_FLNVLSPR
58 & 99
0.71
0.0217
0.68
0.0949

CATD_VSTLPAITLK_vs_IBP3_YGQPLPGYTTK
58 & 100
0.7
0.0287
0.65
0.1565

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.73
0.0098
0.66
0.1306

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.69
0.0304
0.83
0.0026

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.61
0.226
0.85
0.0012

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.64
0.1317
0.72
0.0404

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.58
0.3639
0.81
0.0043

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.69
0.0327
0.62
0.2853

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.63
0.1584
0.77
0.0121

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.71
0.0186
0.63
0.2199

CBPN_NGVDLNR_vs_CRIS3_YEDLYSNCK
157 & 79
0.77
0.0023
0.52
0.8805

CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR
157 & 120
0.73
0.0094
0.68
0.1047

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR
61 & 78
0.77
0.0029
0.52
0.893

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.78
0.0022
0.52
0.8308

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.76
0.0043
0.71
0.0585

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.68
0.0444
0.72
0.0452

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.75
0.0057
0.51
0.9055

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.74
0.0082
0.67
0.1116

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.68
0.0463
0.64
0.2026

CLUS_ASSIIDELFQDR_vs_CRIS3_AVSPPAR
67 & 78
0.75
0.0051
0.54
0.6865

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.76
0.0035
0.57
0.5528

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.7
0.0292
0.74
0.0295

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.59
0.3461
0.74
0.0295

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.74
0.0088
0.57
0.5215

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.62
0.1871
0.73
0.0374

CO5_TLLPVSKPEIR_vs_CRIS3_YEDLYSNCK
70 & 79
0.76
0.0042
0.52
0.8805

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.7
0.0252
0.74
0.0283

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.71
0.0207
0.73
0.0307

CO6_ALNHLPLEYNSALYSR_vs_PGRP2_AGLLRPDYALLGHR
72 & 126
0.61
0.226
0.76
0.0172

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.71
0.0173
0.67
0.1116

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.78
0.0021
0.54
0.6981

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.79
0.0015
0.56
0.5741

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.78
0.0017
0.55
0.6405

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.74
0.0081
0.74
0.0295

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.63
0.1346
0.72
0.0404

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.65
0.0989
0.74
0.0283

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.66
0.0703
0.72
0.0436

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.62
0.1705
0.74
0.0241

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.74
0.0075
0.57
0.5011

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.77
0.0027
0.59
0.4241

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.7
0.0283
0.78
0.0111

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.56
0.5187
0.73
0.036

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.73
0.0098
0.6
0.3711

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.76
0.0045
0.56
0.585

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.68
0.0475
0.58
0.4911

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.67
0.0557
0.74
0.0251

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.73
0.011
0.59
0.4241

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.74
0.0079
0.61
0.3148

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.78
0.0016
0.52
0.8431

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.71
0.022
0.76
0.0158

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.6
0.2655
0.75
0.0204

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.72
0.0148
0.58
0.4812

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.72
0.0134
0.59
0.3883

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF
122 & 139
0.68
0.043
0.68
0.1047

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.78
0.0021
0.51
0.9684

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.75
0.0062
0.66
0.152

PEDF_TVQAVLTVPK_vs_CRIS3_AVSPPAR
125 & 78
0.78
0.0022
0.5
0.9811

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.79
0.0015
0.52
0.8555

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.75
0.0065
0.68
0.0949

PSG2_IHPSYTNYR_vs_ALS_IRPHTFTGLSGLR
133 & 40
0.68
0.0482
0.62
0.2853

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.78
0.0022
0.6
0.3463

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.78
0.0022
0.61
0.2998

PSG2_IHPSYTNYR_vs_CSH_AHQLAIDTYQEFEETYIPK
133 & 80
0.69
0.0393
0.6
0.3382

PSG2_IHPSYTNYR_vs_CSH_ISLLLIESWLEPVR
133 & 81
0.68
0.0438
0.58
0.4714

PSG2_IHPSYTNYR_vs_IBP3_FLNVLSPR
133 & 99
0.7
0.023
0.58
0.4426

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.7
0.0237
0.58
0.4812

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.73
0.0105
0.57
0.5422

PSG2_IHPSYTNYR_vs_ITIH4_ILDDLSPR
133 & 112
0.69
0.0361
0.64
0.197

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.75
0.0054
0.72
0.0452

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.69
0.0356
0.69
0.0776

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.69
0.0361
0.72
0.0452

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.71
0.0202
0.62
0.2853

PTGDS_GPGEDFR_vs_CRIS3_AVSPPAR
137 & 78
0.75
0.0057
0.53
0.8062

PTGDS_GPGEDFR_vs_CRIS3_YEDLYSNCK
137 & 79
0.76
0.0038
0.55
0.6519

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.68
0.0409
0.7
0.0724

VTNC_GQYCYELDEK_vs_CRIS3_AVSPPAR
149 & 78
0.72
0.0157
0.59
0.3971

VTNC_GQYCYELDEK_vs_CRIS3_YEDLYSNCK
149 & 79
0.74
0.0078
0.6
0.3544

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.7
0.0292
0.8
0.0052

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.56
0.486
0.79
0.0066

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.56
0.4824
0.74
0.0272

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.7
0.0241
0.61
0.3225

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.63
0.1518
0.82
0.0032

TABLE 69

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs

control cut-off of <37 0/7 vs >=37 0/7 weeks,

without BMI stratification, separately by fetal gender.

119_153_
119_153_
119_153_
119_153_

aBMI_37
aBMI_37
aBMI_37
aBMI_37

SEQ ID
Female
Female
Male
Male

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.56
0.2281
0.66
0.001

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.58
0.1136
0.65
0.0019

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.54
0.5033
0.67
3.00E−04

APOC3_GWVTDGFSSLK_vs_IBP3_FLNVLSPR
47 & 99
0.61
0.0344
0.65
0.0024

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.61
0.0397
0.66
9.00E−04

APOC3_GWVTDGFSSLK_vs_PSG3_VSAPSGTGHLPGLNPL
47 & 134
0.62
0.0235
0.66
7.00E−04

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.57
0.1935
0.65
0.0025

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.54
0.4302
0.67
4.00E−04

APOH_ATVVYQGER_vs_PSG3_VSAPSGTGHLPGLNPL
48 & 134
0.53
0.6338
0.69
1.00E−04

APOH_ATVVYQGER_vs_SHBG_IALGGLLFPASNLR
48 & 18
0.53
0.5575
0.67
5.00E−04

C1QB_VPGLYYFTYHASSR_vs_TENX_LNWEAPPGAFDSFLLR
55 & 141
0.66
0.003
0.56
0.1846

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.56
0.2984
0.66
0.0012

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.54
0.4632
0.65
0.0022

CD14_LTVGAAQVPAQLLVGALR_vs_TENX_LNWEAPPGAFDSFLLR
61 & 141
0.66
0.0035
0.56
0.199

CD14_SWLAELQQWLKPGLK_vs_TENX_LNWEAPPGAFDSFLLR
62 & 141
0.66
0.0025
0.56
0.2459

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.65
0.0043
0.57
0.1591

CFAB_YGLVTYATYPK_vs_PSG3_VSAPSGTGHLPGLNPL
64 & 134
0.61
0.0329
0.66
9.00E−04

CFAB_YGLVTYATYPK_vs_TENX_LNWEAPPGAFDSFLLR
64 & 141
0.67
0.0015
0.57
0.1549

CO5_TLLPVSKPEIR_vs_TENX_LNWEAPPGAFDSFLLR
70 & 141
0.67
0.0016
0.55
0.334

CO5_VFQFLEK_vs_TENX_LNWEAPPGAFDSFLLR
71 & 141
0.66
0.0037
0.55
0.2611

CO8A_SLLQPNK_vs_TENX_LNWEAPPGAFDSFLLR
74 & 141
0.66
0.0025
0.58
0.0994

CO8B_QALEEFQK_vs_IGF2_GIVEECCFR
76 & 103
0.57
0.1956
0.66
8.00E−04

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.59
0.0972
0.65
0.002

FETUA_FSVVYAK_vs_TENX_LNWEAPPGAFDSFLLR
88 & 141
0.67
0.0019
0.56
0.1782

FETUA_HTLNQIDEVK_vs_PSG3_VSAPSGTGHLPGLNPL
89 & 134
0.57
0.1999
0.65
0.0014

FETUA_HTLNQIDEVK_vs_TENX_LNWEAPPGAFDSFLLR
89 & 141
0.65
0.0044
0.58
0.096

HABP2_FLNWIK_vs_TENX_LNWEAPPGAFDSFLLR
92 & 141
0.67
0.0016
0.58
0.1096

HABP2_FLNWIK_vs_TENX_LSQLSVTDVTTSSLR
92 & 142
0.66
0.0033
0.55
0.254

HEMO_NFPSPVDAAFR_vs_TENX_LNWEAPPGAFDSFLLR
93 & 141
0.66
0.0034
0.56
0.2346

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.59
0.0866
0.65
0.0018

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.58
0.1291
0.7
0

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.58
0.1611
0.68
1.00E−04

IBP4_QCHPALDGQR_vs_TENX_LNWEAPPGAFDSFLLR
2 & 141
0.65
0.0064
0.59
0.049

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.55
0.307
0.67
4.00E−04

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.57
0.2257
0.67
5.00E−04

INHBC_LDFHFSSDR_vs_IGF2_GIVEECCFR
107 & 103
0.57
0.1988
0.7
0

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.53
0.5951
0.66
9.00E−04

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.56
0.2695
0.7
0

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.54
0.4196
0.68
2.00E−04

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.56
0.2577
0.65
0.0018

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.54
0.4632
0.68
2.00E−04

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.59
0.0821
0.65
0.0017

KNG1_DIPTNSPELEETLTHTITK_vs_PSG3_VSAPSGTGHLPGLNPL
116 & 134
0.56
0.2885
0.66
0.001

LBP_ITGFLKPGK_vs_CHL1_VIAVNEVGR
118 & 66
0.65
0.0056
0.56
0.1773

LBP_ITGFLKPGK_vs_IGF2_GIVEECCFR
118 & 103
0.66
0.0037
0.58
0.0905

LBP_ITGFLKPGK_vs_PGRP2_AGLLRPDYALLGHR
118 & 126
0.65
0.004
0.56
0.2517

LBP_ITGFLKPGK_vs_PSG3_VSAPSGTGHLPGLNPL
118 & 134
0.65
0.0046
0.63
0.0063

LBP_ITGFLKPGK_vs_TENX_LNWEAPPGAFDSFLLR
118 & 141
0.66
0.0032
0.55
0.2563

LBP_ITLPDFTGDLR_vs_CHL1_VIAVNEVGR
119 & 66
0.67
0.0019
0.58
0.0905

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.65
0.0049
0.6
0.0403

LBP_ITLPDFTGDLR_vs_IBP3_FLNVLSPR
119 & 99
0.66
0.0037
0.57
0.1693

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.67
0.0017
0.57
0.1667

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.68
0.0011
0.59
0.0503

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.66
0.0024
0.6
0.0414

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.68
6.00E−04
0.57
0.1746

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.66
0.0025
0.65
0.0021

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.68
0.001
0.57
0.1241

LBP_ITLPDFTGDLR_vs_TENX_LSQLSVTDVTTSSLR
119 & 142
0.67
0.0013
0.55
0.2757

LBP_ITLPDFTGDLR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
119 & 144
0.66
0.0032
0.57
0.1276

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.67
0.0015
0.59
0.0516

PEDF_LQSLFDSPDFSK_vs_PSG3_VSAPSGTGHLPGLNPL
124 & 134
0.57
0.1704
0.67
3.00E−04

PEDF_LQSLFDSPDFSK_vs_TENX_LNWEAPPGAFDSFLLR
124 & 141
0.65
0.0056
0.59
0.058

PEDF_TVQAVLTVPK_vs_PSG3_VSAPSGTGHLPGLNPL
125 & 134
0.57
0.2234
0.66
7.00E−04

VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR
149 & 40
0.55
0.3415
0.65
0.0022

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.6
0.0581
0.67
5.00E−04

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.59
0.0871
0.69
1.00E−04

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.59
0.0774
0.68
2.00E−04

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.59
0.0805
0.66
0.001

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.59
0.0871
0.66
7.00E−04

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.54
0.4502
0.65
0.0017

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.58
0.137
0.7
0

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.59
0.1055
0.67
3.00E−04

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.6
0.0523
0.68
2.00E−04

TABLE 70

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control

cut-off of <37 0/7 vs >= 37 0/7 weeks, with BMI stratification (>22 <=37),

separately by fetal gender.

119_153_
119_153_
119_153_
119_153_

rBMI_37
rBMI_37
rBMI_3
rBMI

SEQ ID
Female
Female
7 Male
37 Male

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_IGF2_GIVEECCFR
34 & 103
0.65
0.0229
0.6
0.0902

A2GL_DLLLPQPDLR_vs_PGRP2_AGLLRPDYALLGHR
34 & 126
0.66
0.0133
0.56
0.3335

AFAM_DADPDTFFAK_vs_IGF2_GIVEECCFR
37 & 103
0.62
0.069
0.65
0.0081

AFAM_DADPDTFFAK_vs_PSG3_VSAPSGTGHLPGLNPL
37 & 134
0.52
0.7127
0.66
0.0057

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.66
0.0169
0.63
0.026

AFAM_HFQNLGK_vs_PSG3_VSAPSGTGHLPGLNPL
38 & 134
0.55
0.4359
0.66
0.0069

ANGT_DPTFIPAPIQAK_vs_CHL1_VIAVNEVGR
42 & 66
0.67
0.0087
0.55
0.382

ANGT_DPTFIPAPIQAK_vs_CRIS3_AVSPPAR
42 & 78
0.68
0.0059
0.57
0.1945

ANGT_DPTFIPAPIQAK_vs_CRIS3_YEDLYSNCK
42 & 79
0.68
0.0048
0.58
0.1677

ANGT_DPTFIPAPIQAK_vs_IGF2_GIVEECCFR
42 & 103
0.65
0.0197
0.59
0.1059

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.66
0.0164
0.58
0.1661

ANGT_DPTFIPAPIQAK_VS_PGRP2_AGLLRPDYALLGHR
42 & 126
0.67
0.0074
0.54
0.5241

ANGT_DPTFIPAPIQAK_vs_TENX_LNWEAPPGAFDSFLLR
42 & 141
0.65
0.018
0.57
0.2186

APOC3_GWVTDGFSSLK_vs_IGF2_GIVEECCFR
47 & 103
0.59
0.1479
0.65
0.0087

APOC3_GWVTDGFSSLK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
47 & 135
0.57
0.2718
0.65
0.0081

APOH_ATVVYQGER_vs_IGF2_GIVEECCFR
48 & 103
0.56
0.3934
0.66
0.0056

B2MG_VEHSDLSFSK_vs_IGF2_GIVEECCFR
50 & 103
0.65
0.0222
0.57
0.2386

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.66
0.0169
0.58
0.1465

BGH3_LTLLAPLNSVFK_vs_CHL1_VIAVNEVGR
52 & 66
0.65
0.0206
0.57
0.2597

BGH3_LTLLAPLNSVFK_vs_CRIS3_YEDLYSNCK
52 & 79
0.65
0.0262
0.6
0.0892

C1QB_VPGLYYFTYHASSR_vs_IGF2_GIVEECCFR
55 & 103
0.65
0.0226
0.62
0.0321

C1QB_VPGLYYFTYHASSR_vs_PGRP2_AGLLRPDYALLGHR
55 & 126
0.66
0.0164
0.58
0.1629

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.65
0.0247
0.57
0.2206

CFAB_YGLVTYATYPK_vs_CHL1_VIAVNEVGR
64 & 66
0.66
0.014
0.57
0.2284

CFAB_YGLVTYATYPK_vs_CRIS3_YEDLYSNCK
64 & 79
0.65
0.0226
0.59
0.1395

CFAB_YGLVTYATYPK_vs_IBP3_YGQPLPGYTTK
64 & 100
0.65
0.0236
0.59
0.1381

CFAB_YGLVTYATYPK_vs_IGF2_GIVEECCFR
64 & 103
0.65
0.0209
0.62
0.0435

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.65
0.0222
0.61
0.0601

CFAB_YGLVTYATYPK_vs_PGRP2_AGLLRPDYALLGHR
64 & 126
0.67
0.0108
0.56
0.3133

CFAB_YGLVTYATYPK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
64 & 144
0.66
0.0166
0.6
0.0902

CO5_TLLPVSKPEIR_vs_PGRP2_AGLLRPDYALLGHR
70 & 126
0.66
0.0123
0.57
0.2206

CO5_TLLPVSKPEIR_vs_SHBG_IALGGLLFPASNLR
70 & 18
0.56
0.3419
0.65
0.0106

CO5_VFQFLEK_vs_PGRP2_AGLLRPDYALLGHR
71 & 126
0.66
0.0159
0.56
0.3387

CO6_ALNHLPLEYNSALYSR_vs_CHL1_VIAVNEVGR
72 & 66
0.65
0.0209
0.56
0.2753

ENPP2_TEFLSNYLTNVDDITLVPGTLGR_vs_IGF2_GIVEECCFR
82 & 103
0.65
0.0216
0.56
0.3083

FETUA_FSVVYAK_vs_IGF2_GIVEECCFR
88 & 103
0.65
0.0229
0.62
0.0429

HABP2_FLNWIK_vs_CHL1_VIAVNEVGR
92 & 66
0.65
0.02
0.56
0.3011

HABP2_FLNWIK_vs_IBP3_YGQPLPGYTTK
92 & 100
0.65
0.0229
0.59
0.1104

HABP2_FLNWIK_vs_IGF2_GIVEECCFR
92 & 103
0.65
0.0254
0.62
0.0321

IBP4_QCHPALDGQR_vs_CHL1_VIAVNEVGR
2 & 66
0.66
0.014
0.57
0.2597

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.66
0.0159
0.64
0.018

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.61
0.0895
0.65
0.0073

IBP4_QCHPALDGQR_vs_PGRP2_AGLLRPDYALLGHR
2 & 126
0.66
0.0149
0.6
0.0942

IBP4_QCHPALDGQR_vs_PSG3_VSAPSGTGHLPGLNPL
2 & 134
0.57
0.2572
0.66
0.0058

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.58
0.2385
0.67
0.0024

INHBC_LDFHFSSDR_vs_ALS_IRPHTFTGLSGLR
107 & 40
0.51
0.8798
0.72
2.00E−04

INHBC_LDFHFSSDR_vs_CRIS3_AVSPPAR
107 & 78
0.55
0.4808
0.66
0.0068

INHBC_LDFHFSSDR_vs_CRIS3_YEDLYSNCK
107 & 79
0.57
0.2644
0.65
0.0082

INHBC_LDFHFSSDR_vs_IBP3_FLNVLSPR
107 & 99
0.56
0.3903
0.7
6.00E−04

INHBC_LDFHFSSDR_vs_IBP3_YGQPLPGYTTK
107 & 100
0.57
0.2718
0.7
5.00E−04

INHBC_LDFHFSSDR_VS_IGF2_GIVEECCFR
107 & 103
0.57
0.2768
0.71
2.00E−04

INHBC_LDFHFSSDR_vs_ITIH4_ILDDLSPR
107 & 112
0.51
0.9204
0.67
0.0028

INHBC_LDFHFSSDR_vs_LYAM1_SYYWIGIR
107 & 120
0.54
0.5585
0.67
0.004

INHBC_LDFHFSSDR_vs_PGRP2_AGLLRPDYALLGHR
107 & 126
0.57
0.3082
0.65
0.0073

INHBC_LDFHFSSDR_vs_PSG3_VSAPSGTGHLPGLNPL
107 & 134
0.53
0.6459
0.72
1.00E−04

INHBC_LDFHFSSDR_vs_SHBG_IALGGLLFPASNLR
107 & 18
0.51
0.8439
0.7
6.00E−04

INHBC_LDFHFSSDR_VS_SPRL1_VLTHSELAPLR
107 & 140
0.56
0.3419
0.66
0.0062

INHBC_LDFHFSSDR_vs_TENX_LNWEAPPGAFDSFLLR
107 & 141
0.59
0.1479
0.67
0.0027

INHBC_LDFHFSSDR_vs_TENX_LSQLSVTDVTTSSLR
107 & 142
0.56
0.3477
0.66
0.0061

INHBC_LDFHFSSDR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
107 & 144
0.55
0.4632
0.67
0.004

INHBC_LDFHFSSDR_vs_VTDB_ELPEHTVK
107 & 147
0.52
0.7688
0.71
2.00E−04

ITIH3_ALDLSLK_vs_CRIS3_YEDLYSNCK
111 & 79
0.65
0.024
0.59
0.1116

ITIH3_ALDLSLK_vs_SHBG_IALGGLLFPASNLR
111 & 18
0.57
0.3082
0.66
0.0044

LBP_ITGFLKPGK_vs_CRIS3_AVSPPAR
118 & 78
0.65
0.0209
0.56
0.2708

LBP_ITGFLKPGK_vs_CRIS3_YEDLYSNCK
118 & 79
0.67
0.0089
0.57
0.2469

LBP_ITGFLKPGK_vs_LYAM1_SYYWIGIR
118 & 120
0.65
0.0216
0.57
0.1963

LBP_ITLPDFTGDLR_vs_CRIS3_AVSPPAR
119 & 78
0.68
0.005
0.58
0.1523

LBP_ITLPDFTGDLR_vs_CRIS3_YEDLYSNCK
119 & 79
0.7
0.0026
0.59
0.1327

LBP_ITLPDFTGDLR_vs_IBP3_YGQPLPGYTTK
119 & 100
0.69
0.0044
0.56
0.3387

LBP_ITLPDFTGDLR_vs_IGF2_GIVEECCFR
119 & 103
0.7
0.0024
0.57
0.2148

LBP_ITLPDFTGDLR_vs_LYAM1_SYYWIGIR
119 & 120
0.69
0.0038
0.6
0.0882

LBP_ITLPDFTGDLR_vs_PGRP2_AGLLRPDYALLGHR
119 & 126
0.69
0.0029
0.56
0.3133

LBP_ITLPDFTGDLR_vs_PSG3_VSAPSGTGHLPGLNPL
119 & 134
0.65
0.0197
0.6
0.0932

LBP_ITLPDFTGDLR_vs_TENX_LNWEAPPGAFDSFLLR
119 & 141
0.66
0.0121
0.56
0.2986

LBP_ITLPDFTGDLR_vs_VTDB_ELPEHTVK
119 & 147
0.68
0.0059
0.56
0.3059

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.65
0.0229
0.61
0.0497

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.65
0.0229
0.56
0.2708

VTNC_GQYCYELDEK_vs_ALS_IRPHTFTGLSGLR
149 & 40
0.55
0.4844
0.67
0.0035

VTNC_GQYCYELDEK_vs_IBP3_YGQPLPGYTTK
149 & 100
0.65
0.0251
0.66
0.0071

VTNC_GQYCYELDEK_vs_IGF2_GIVEECCFR
149 & 103
0.63
0.0519
0.68
0.0023

VTNC_GQYCYELDEK_vs_ITIH4_ILDDLSPR
149 & 112
0.55
0.4325
0.65
0.0086

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.63
0.0407
0.66
0.0052

VTNC_GQYCYELDEK_vs_NCAM1_GLGEISAASEFK
149 & 121
0.53
0.6174
0.65
0.0082

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.65
0.0247
0.62
0.0369

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.57
0.2596
0.69
0.0012

VTNC_GQYCYELDEK_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
149 & 135
0.55
0.4359
0.66
0.0051

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.58
0.2273
0.69
0.0013

VTNC_GQYCYELDEK_vs_VTDB_ELPEHTVK
149 & 147
0.6
0.1311
0.68
0.0017

VTNC_VDTVDPPYPR_vs_CHL1_VIAVNEVGR
150 & 66
0.65
0.0226
0.59
0.1211

VTNC_VDTVDPPYPR_vs_IGF2_GIVEECCFR
150 & 103
0.62
0.0555
0.66
0.0065

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.63
0.0396
0.66
0.0063

VTNC_VDTVDPPYPR_vs_NCAM1_GLGEISAASEFK
150 & 121
0.54
0.5662
0.66
0.0068

VTNC_VDTVDPPYPR_vs_PSG3_VSAPSGTGHLPGLNPL
150 & 134
0.57
0.3028
0.67
0.0027

VTNC_VDTVDPPYPR_vs_PSG9_DVLLLVHNLPQNLPGYFWYK
150 & 135
0.54
0.5282
0.67
0.0034

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.58
0.204
0.68
0.0023

VTNC_VDTVDPPYPR_vs_VTDB_ELPEHTVK
150 & 147
0.61
0.0832
0.68
0.0015

TABLE 71

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control

cut-off of <35 0/7 vs >=35 0/7 weeks, without BMI stratification, separately by

fetal gender.

119_153_
119_153_
119_153_
119_153_

aBMI_35
aBMI 35
aBMI_3
aBMI

SEQ ID
Female
Female
5 Male
35 Male

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.57
0.4262
0.67
0.0243

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.51
0.9381
0.73
0.0018

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.51
0.9466
0.69
0.0116

AFAM_DADPDTFFAK_vs_SHBG_IALGGLLFPASNLR
37 & 18
0.53
0.7662
0.66
0.0248

AFAM_HFQNLGK_vs_IBP3_YGQPLPGYTTK
38 & 100
0.7
0.0336
0.62
0.1104

AFAM_HFQNLGK_vs_IGF2_GIVEECCFR
38 & 103
0.71
0.0263
0.63
0.0778

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.51
0.921
0.73
0.0018

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.51
0.9594
0.69
0.0098

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.54
0.643
0.71
0.0035

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.55
0.6315
0.67
0.0217

APOC3_GWVTDGFSSLK_vs_LYAM1_SYYWIGIR
47 & 120
0.57
0.4262
0.68
0.0146

APOH_ATVVYQGER_vs_CRIS3_YEDLYSNCK
48 & 79
0.6
0.2924
0.65
0.0451

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.53
0.7377
0.71
0.0037

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.52
0.8198
0.69
0.0097

B2MG_VEHSDLSFSK_vs_LYAM1_SYYWIGIR
50 & 120
0.6
0.285
0.68
0.0166

B2MG_VNHVTLSQPK_vs_IGF2_GIVEECCFR
51 & 103
0.72
0.0217
0.56
0.4027

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.62
0.1848
0.71
0.0044

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.63
0.176
0.73
0.0014

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.57
0.4387
0.68
0.0125

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.59
0.3124
0.68
0.0119

CATD_VGFAEAAR_vs_CSH_AHQLAIDTYQEFEETYIPK
57 & 80
0.63
0.183
0.68
0.0138

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.59
0.3443
0.69
0.0095

CATD_VGFAEAAR_vs_FBLN1_TGYYFDGISR
57 & 86
0.57
0.4547
0.68
0.0157

CATD_VGFAEAAR_vs_IBP1_VVESLAK
57 & 97
0.61
0.2593
0.67
0.02

CATD_VGFAEAAR_vs_IBP2_LIQGAPTIR
57 & 98
0.52
0.8198
0.67
0.0205

CATD_VGFAEAAR_vs_IGF2_GIVEECCFR
57 & 103
0.66
0.0821
0.67
0.0224

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.54
0.6623
0.69
0.0111

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.57
0.4324
0.76
4.00E−04

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.53
0.7621
0.72
0.0029

CATD_VGFAEAAR_vs_PSG3_VSAPSGTGHLPGLNPL
57 & 134
0.57
0.4678
0.7
0.0055

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.56
0.5538
0.69
0.0087

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.61
0.2593
0.68
0.0139

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.58
0.381
0.71
0.0051

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.6
0.2826
0.68
0.0125

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.59
0.3202
0.71
0.0051

CATD_VGFAEAAR_vs_TENX_LSQLSVTDVTTSSLR
57 & 142
0.59
0.347
0.67
0.0181

CATD_VGFAEAAR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
57 & 144
0.59
0.3124
0.67
0.0207

CATD_VGFAEAAR_vs_VTDB_ELPEHTVK
57 & 147
0.56
0.5395
0.67
0.0187

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.58
0.3987
0.71
0.004

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.56
0.4911
0.7
0.0071

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.59
0.3497
0.7
0.0064

CATD_VSTLPAITLK_vs_CSH_AHQLAIDTYQEFEETYIPK
58 & 80
0.59
0.3308
0.66
0.0274

CATD_VSTLPAITLK_vs_CSH_ISLLLIESWLEPVR
58 & 81
0.57
0.458
0.66
0.0259

CATD_VSTLPAITLK_vs_FBLN1_TGYYFDGISR
58 & 86
0.57
0.4645
0.68
0.0131

CATD_VSTLPAITLK_vs_IBP1_VVESLAK
58 & 97
0.58
0.3957
0.67
0.0181

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.66
0.0802
0.67
0.0203

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.52
0.8575
0.68
0.0152

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.55
0.6088
0.77
2.00E−04

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.5
0.9679
0.74
0.0013

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.58
0.4138
0.71
0.0043

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.53
0.7296
0.7
0.0052

CATD_VSTLPAITLK_vs_SOM2.CSH_NYGLLYCFR
58 & 138
0.58
0.4077
0.66
0.0299

CATD_VSTLPAITLK_vs_SOM2.CSH_SVEGSCGF
58 & 139
0.55
0.5755
0.69
0.0116

CATD_VSTLPAITLK_vs_SPRL1_VLTHSELAPLR
58 & 140
0.57
0.4645
0.68
0.0136

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.58
0.3927
0.72
0.0032

CATD_VSTLPAITLK_vs_TENX_LSQLSVTDVTTSSLR
58 & 142
0.57
0.458
0.68
0.0141

CATD_VSTLPAITLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
58 & 144
0.56
0.536
0.67
0.0235

CATD_VSTLPAITLK_vs_VTDB_ELPEHTVK
58 & 147
0.54
0.6976
0.67
0.0187

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.61
0.2395
0.66
0.0302

CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR
157 & 120
0.63
0.1693
0.68
0.0159

CD14_LTVGAAQVPAQLLVGALR_vs_IGF2_GIVEECCFR
61 & 103
0.72
0.0193
0.6
0.1921

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.61
0.2526
0.73
0.0014

CD14_LTVGAAQVPAQLLVGALR_vs_PGRP2_AGLLRPDYALLGHR
61 & 126
0.57
0.4711
0.68
0.0139

CD14_LTVGAAQVPAQLLVGALR_vs_SHBG_IALGGLLFPASNLR
61 & 18
0.58
0.3898
0.68
0.0153

CD14_LTVGAAQVPAQLLVGALR_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
61 & 144
0.69
0.0425
0.6
0.1631

CD14_LTVGAAQVPAQLLVGALR_vs_VTDB_ELPEHTVK
61 & 147
0.64
0.1428
0.67
0.0179

CD14_SWLAELQQWLKPGLK_vs_IGF2_GIVEECCFR
62 & 103
0.72
0.0175
0.57
0.3174

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.62
0.1901
0.7
0.0059

CD14_SWLAELQQWLKPGLK_vs_PGRP2_AGLLRPDYALLGHR
62 & 126
0.57
0.4387
0.66
0.0306

CD14_SWLAELQQWLKPGLK_vs_SHBG_IALGGLLFPASNLR
62 & 18
0.58
0.3898
0.65
0.0351

CD14_SWLAELQQWLKPGLK_vs_TIE1_VSWSLPLVPGPLVGDGFLLR
62 & 144
0.71
0.029
0.59
0.204

CD14_SWLAELQQWLKPGLK_vs_VTDB_ELPEHTVK
62 & 147
0.66
0.0961
0.65
0.0442

CFAB_YGLVTYATYPK_vs_LYAM1_SYYWIGIR
64 & 120
0.52
0.866
0.67
0.0187

CLUS_ASSIIDELFQDR_vs_CRIS3_YEDLYSNCK
67 & 79
0.63
0.176
0.65
0.0465

CLUS_ASSIIDELFQDR_vs_IBP3_YGQPLPGYTTK
67 & 100
0.71
0.0267
0.56
0.4076

CLUS_ASSIIDELFQDR_vs_IGF2_GIVEECCFR
67 & 103
0.7
0.031
0.61
0.1288

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.59
0.3334
0.73
0.0014

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.54
0.6937
0.67
0.0189

CLUS_ASSIIDELFQDR_vs_SHBG_IALGGLLFPASNLR
67 & 18
0.58
0.4017
0.67
0.0172

CLUS_ASSIIDELFQDR_vs_VTDB_ELPEHTVK
67 & 147
0.6
0.2779
0.68
0.0148

CLUS_LFDSDPITVTVPVEVSR_vs_CRIS3_YEDLYSNCK
68 & 79
0.63
0.1627
0.65
0.0446

CLUS_LFDSDPITVTVPVEVSR_vs_IBP3_YGQPLPGYTTK
68 & 100
0.7
0.0359
0.56
0.3861

CLUS_LFDSDPITVTVPVEVSR_vs_IGF2_GIVEECCFR
68 & 103
0.71
0.0267
0.6
0.1593

CLUS_LFDSDPITVTVPVEVSR_vs_LYAM1_SYYWIGIR
68 & 120
0.58
0.3898
0.72
0.0027

CLUS_LFDSDPITVTVPVEVSR_vs_PGRP2_AGLLRPDYALLGHR
68 & 126
0.53
0.7867
0.66
0.0326

CLUS_LFDSDPITVTVPVEVSR_vs_SHBG_IALGGLLFPASNLR
68 & 18
0.57
0.4324
0.66
0.0254

CLUS_LFDSDPITVTVPVEVSR_vs_VTDB_ELPEHTVK
68 & 147
0.58
0.3839
0.68
0.0146

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.61
0.2593
0.7
0.0056

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.53
0.7498
0.71
0.0043

CO6_ALNHLPLEYNSALYSR_vs_LYAM1_SYYWIGIR
72 & 120
0.58
0.4077
0.71
0.0049

CO8A_SLLQPNK_vs_IBP1_VVESLAK
74 & 97
0.57
0.4844
0.65
0.0398

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.51
0.9551
0.74
0.001

CO8B_QALEEFQK_vs_IBP1_VVESLAK
76 & 97
0.55
0.5939
0.67
0.024

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.55
0.5939
0.75
7.00E−04

CO8B_QALEEFQK_vs_PSG3_VSAPSGTGHLPGLNPL
76 & 134
0.51
0.8828
0.68
0.0161

F13B_GDTYPAELYITGSILR_vs_IBP3_YGQPLPGYTTK
84 & 100
0.74
0.0113
0.54
0.5451

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.74
0.011
0.59
0.2071

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.63
0.1812
0.74
0.0011

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.54
0.7016
0.67
0.021

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.59
0.3281
0.66
0.0262

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.56
0.5324
0.71
0.0037

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.51
0.9295
0.72
0.0032

HABP2_FLNWIK_vs_LYAM1_SYYWIGIR
92 & 120
0.54
0.6858
0.68
0.0161

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.5
1
0.71
0.0037

IBP4_QCHPALDGQR_vs_CRIS3_AVSPPAR
2 & 78
0.58
0.3898
0.66
0.0248

IBP4_QCHPALDGQR_vs_CRIS3_YEDLYSNCK
2 & 79
0.61
0.229
0.67
0.0219

IBP4_QCHPALDGQR_vs_IGF2_GIVEECCFR
2 & 103
0.68
0.0541
0.57
0.33

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.54
0.6353
0.74
0.0013

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.53
0.7498
0.67
0.0229

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.55
0.5755
0.68
0.0122

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.51
0.9423
0.73
0.002

KNG1_QVVAGLNFR_vs_CRIS3_AVSPPAR
117 & 78
0.57
0.4515
0.65
0.042

KNG1_QVVAGLNFR_vs_CRIS3_YEDLYSNCK
117 & 79
0.61
0.229
0.65
0.0428

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.58
0.4169
0.75
7.00E−04

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.54
0.6468
0.67
0.0212

KNG1_QVVAGLNFR_vs_SHBG_IALGGLLFPASNLR
117 & 18
0.6
0.285
0.66
0.0248

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.6
0.2899
0.71
0.0044

PEDF_TVQAVLTVPK_vs_IGF2_GIVEECCFR
125 & 103
0.7
0.0294
0.58
0.2682

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.59
0.3361
0.73
0.0015

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.61
0.2395
0.66
0.0326

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.63
0.1611
0.66
0.0316

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.57
0.4645
0.67
0.0189

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.57
0.4483
0.66
0.0316

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.59
0.3415
0.7
0.0072

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.6
0.3099
0.65
0.0363

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.58
0.3723
0.67
0.0189

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.55
0.6051
0.69
0.0094

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.56
0.5395
0.69
0.0091

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.53
0.7176
0.76
4.00E−04

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.53
0.7826
0.7
0.0069

VTNC_GQYCYELDEK_vs_PSG3_VSAPSGTGHLPGLNPL
149 & 134
0.53
0.7703
0.68
0.0127

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.53
0.7296
0.68
0.0159

VTNC_VDTVDPPYPR_vs_CRIS3_YEDLYSNCK
150 & 79
0.58
0.3752
0.65
0.0451

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.52
0.8407
0.75
6.00E−04

VTNC_VDTVDPPYPR_vs_SHBG_IALGGLLFPASNLR
150 & 18
0.52
0.8744
0.68
0.0134

TABLE 72

Reversal Classification Performance, weeks 17-21.

Reversal AUROC for gestational weeks 17 0/7 through 21 6/7 using a case vs control

cut-off of <35 0/7 vs >=35 0/7 weeks, with BMI stratification (>22 <= 37),

separately by fetal gender.

119_153_
119_153_
119_153_
119_153_

rBMI_35
rBMI_35
rBMI_3
rBMI

SEQ ID
Female
Female
5 Male
35 Male

Reversal
NO:
ROC_AUC
P-value
ROC_AUC
P-value

A2GL_DLLLPQPDLR_vs_CRIS3_YEDLYSNCK
34 & 79
0.76
0.0345
0.59
0.3046

A2GL_DLLLPQPDLR_vs_LYAM1_SYYWIGIR
34 & 120
0.7
0.0972
0.68
0.0323

AFAM_DADPDTFFAK_vs_LYAM1_SYYWIGIR
37 & 120
0.53
0.828
0.76
0.0018

AFAM_DADPDTFFAK_vs_PGRP2_AGLLRPDYALLGHR
37 & 126
0.51
0.962
0.74
0.0044

AFAM_DADPDTFFAK_vs_SOM2.CSH_SVEGSCGF
37 & 139
0.55
0.6755
0.67
0.0422

AFAM_HFQNLGK_vs_ALS_IRPHTFTGLSGLR
38 & 40
0.61
0.3649
0.67
0.0493

AFAM_HFQNLGK_vs_LYAM1_SYYWIGIR
38 & 120
0.54
0.7626
0.76
0.0019

AFAM_HFQNLGK_vs_PGRP2_AGLLRPDYALLGHR
38 & 126
0.5
0.9789
0.74
0.004

AFAM_HFQNLGK_vs_SOM2.CSH_SVEGSCGF
38 & 139
0.57
0.5494
0.69
0.0278

ANGT_DPTFIPAPIQAK_vs_LYAM1_SYYWIGIR
42 & 120
0.59
0.4361
0.75
0.0034

ANGT_DPTFIPAPIQAK_vs_PGRP2_AGLLRPDYALLGHR
42 & 126
0.54
0.7626
0.69
0.0224

ANGT_DPTFIPAPIQAK_vs_SHBG_IALGGLLFPASNLR
42 & 18
0.55
0.6755
0.69
0.0257

APOH_ATVVYQGER_vs_LYAM1_SYYWIGIR
48 & 120
0.54
0.7226
0.73
0.0071

APOH_ATVVYQGER_vs_PGRP2_AGLLRPDYALLGHR
48 & 126
0.51
0.9535
0.73
0.0072

B2MG_VNHVTLSQPK_vs_CRIS3_AVSPPAR
51 & 78
0.74
0.0446
0.59
0.3046

B2MG_VNHVTLSQPK_vs_CRIS3_YEDLYSNCK
51 & 79
0.78
0.02
0.6
0.251

B2MG_VNHVTLSQPK_vs_LYAM1_SYYWIGIR
51 & 120
0.71
0.091
0.71
0.0134

CATD_VGFAEAAR_vs_C163A_INPASLDK
57 & 54
0.68
0.1393
0.73
0.006

CATD_VGFAEAAR_vs_CRIS3_AVSPPAR
57 & 78
0.64
0.2374
0.67
0.0476

CATD_VGFAEAAR_vs_CRIS3_YEDLYSNCK
57 & 79
0.67
0.1572
0.67
0.0412

CATD_VGFAEAAR_vs_CSH_ISLLLIESWLEPVR
57 & 81
0.64
0.2416
0.68
0.0294

CATD_VGFAEAAR_vs_ITIH4_ILDDLSPR
57 & 112
0.55
0.6833
0.68
0.0362

CATD_VGFAEAAR_vs_LYAM1_SYYWIGIR
57 & 120
0.61
0.3705
0.77
0.0013

CATD_VGFAEAAR_vs_PGRP2_AGLLRPDYALLGHR
57 & 126
0.58
0.5353
0.72
0.011

CATD_VGFAEAAR_vs_SHBG_IALGGLLFPASNLR
57 & 18
0.56
0.6147
0.68
0.0342

CATD_VGFAEAAR_vs_SOM2.CSH_NYGLLYCFR
57 & 138
0.66
0.1835
0.67
0.0493

CATD_VGFAEAAR_vs_SOM2.CSH_SVEGSCGF
57 & 139
0.67
0.1572
0.68
0.0371

CATD_VGFAEAAR_vs_SPRL1_VLTHSELAPLR
57 & 140
0.58
0.4876
0.67
0.0397

CATD_VGFAEAAR_vs_TENX_LNWEAPPGAFDSFLLR
57 & 141
0.53
0.8363
0.72
0.011

CATD_VSTLPAITLK_vs_C163A_INPASLDK
58 & 54
0.64
0.2416
0.72
0.0087

CATD_VSTLPAITLK_vs_CRIS3_AVSPPAR
58 & 78
0.65
0.2092
0.69
0.0233

CATD_VSTLPAITLK_vs_CRIS3_YEDLYSNCK
58 & 79
0.69
0.118
0.7
0.0179

CATD_VSTLPAITLK_vs_IGF2_GIVEECCFR
58 & 103
0.74
0.0469
0.67
0.0484

CATD_VSTLPAITLK_vs_ITIH4_ILDDLSPR
58 & 112
0.53
0.828
0.68
0.0362

CATD_VSTLPAITLK_vs_LYAM1_SYYWIGIR
58 & 120
0.59
0.481
0.79
5.00E−04

CATD_VSTLPAITLK_vs_PGRP2_AGLLRPDYALLGHR
58 & 126
0.57
0.578
0.74
0.0042

CATD_VSTLPAITLK_vs_PSG3_VSAPSGTGHLPGLNPL
58 & 134
0.55
0.7068
0.7
0.0175

CATD_VSTLPAITLK_vs_SHBG_IALGGLLFPASNLR
58 & 18
0.54
0.7226
0.71
0.0149

CATD_VSTLPAITLK_vs_TENX_LNWEAPPGAFDSFLLR
58 & 141
0.52
0.8529
0.74
0.0048

CBPN_EALIQFLEQVHQGIK_vs_LYAM1_SYYWIGIR
59 & 120
0.6
0.4115
0.7
0.0206

CBPN_NGVDLNR_vs_LYAM1_SYYWIGIR
157 & 120
0.63
0.2821
0.72
0.0087

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_AVSPPAR
61 & 78
0.76
0.0319
0.57
0.3774

CD14_LTVGAAQVPAQLLVGALR_vs_CRIS3_YEDLYSNCK
61 & 79
0.77
0.0237
0.6
0.2605

CD14_LTVGAAQVPAQLLVGALR_vs_LYAM1_SYYWIGIR
61 & 120
0.71
0.091
0.73
0.0077

CD14_LTVGAAQVPAQLLVGALR_vs_SOM2.CSH_SVEGSCGF
61 & 139
0.75
0.0393
0.59
0.2954

CD14_SWLAELQQWLKPGLK_vs_LYAM1_SYYWIGIR
62 & 120
0.69
0.1156
0.68
0.0311

CLUS_ASSIIDELFQDR_vs_LYAM1_SYYWIGIR
67 & 120
0.6
0.4115
0.74
0.0038

CLUS_ASSIIDELFQDR_vs_PGRP2_AGLLRPDYALLGHR
67 & 126
0.54
0.7305
0.67
0.0435

CLUS_LFDSDPITVTVPVEVSR_VS_YAM1_SYYWIGIR
68 & 120
0.57
0.5708
0.7
0.0168

CO5_TLLPVSKPEIR_vs_LYAM1_SYYWIGIR
70 & 120
0.63
0.2681
0.72
0.0101

CO5_VFQFLEK_vs_LYAM1_SYYWIGIR
71 & 120
0.54
0.7147
0.71
0.0128

CO6_ALNHLPLEYNSALYSR_Vs_LYAM1_SYYWIGIR
72 & 120
0.68
0.1451
0.7
0.0211

CO8A_SLLQPNK_vs_LYAM1_SYYWIGIR
74 & 120
0.53
0.8363
0.74
0.0042

CO8B_QALEEFQK_vs_LYAM1_SYYWIGIR
76 & 120
0.54
0.7385
0.73
0.0068

F13B_GDTYPAELYITGSILR_vs_CRIS3_AVSPPAR
84 & 78
0.75
0.0364
0.63
0.125

F13B_GDTYPAELYITGSILR_vs_CRIS3_YEDLYSNCK
84 & 79
0.77
0.0264
0.63
0.1307

F13B_GDTYPAELYITGSILR_vs_IGF2_GIVEECCFR
84 & 103
0.77
0.0271
0.59
0.2905

F13B_GDTYPAELYITGSILR_vs_LYAM1_SYYWIGIR
84 & 120
0.68
0.1422
0.76
0.0022

F13B_GDTYPAELYITGSILR_vs_PGRP2_AGLLRPDYALLGHR
84 & 126
0.58
0.5146
0.68
0.0305

F13B_GDTYPAELYITGSILR_vs_SHBG_IALGGLLFPASNLR
84 & 18
0.6
0.4055
0.67
0.0493

FETUA_FSVVYAK_vs_LYAM1_SYYWIGIR
88 & 120
0.59
0.4614
0.71
0.0145

FETUA_HTLNQIDEVK_vs_LYAM1_SYYWIGIR
89 & 120
0.56
0.6448
0.73
0.0077

HEMO_NFPSPVDAAFR_vs_LYAM1_SYYWIGIR
93 & 120
0.51
0.9451
0.72
0.0099

IBP4_QCHPALDGQR_vs_LYAM1_SYYWIGIR
2 & 120
0.58
0.5146
0.76
0.0021

IBP4_QCHPALDGQR_vs_SHBG_IALGGLLFPASNLR
2 & 18
0.52
0.8612
0.67
0.0443

IBP6_HLDSVLQQLQTEVYR_vs_LYAM1_SYYWIGIR
102 & 120
0.61
0.3593
0.7
0.0158

ITIH3_ALDLSLK_vs_LYAM1_SYYWIGIR
111 & 120
0.63
0.2727
0.68
0.0342

KNG1_DIPTNSPELEETLTHTITK_vs_LYAM1_SYYWIGIR
116 & 120
0.55
0.6678
0.73
0.006

KNG1_QVVAGLNFR_vs_IGF2_GIVEECCFR
117 & 103
0.74
0.0435
0.61
0.2099

KNG1_QVVAGLNFR_vs_LYAM1_SYYWIGIR
117 & 120
0.62
0.3375
0.76
0.0023

KNG1_QVVAGLNFR_vs_PGRP2_AGLLRPDYALLGHR
117 & 126
0.54
0.7385
0.69
0.0237

PAPP1_DIPHWLNPTR_vs_CRIS3_AVSPPAR
122 & 78
0.68
0.1338
0.67
0.0443

PAPP1_DIPHWLNPTR_vs_CRIS3_YEDLYSNCK
122 & 79
0.71
0.0795
0.67
0.0467

PAPP1_DIPHWLNPTR_vs_LYAM1_SYYWIGIR
122 & 120
0.64
0.2459
0.72
0.0106

PAPP1_DIPHWLNPTR_vs_PRG2_WNFAYWAAHQPWSR
122 & 129
0.76
0.0319
0.62
0.1714

PAPP1_DIPHWLNPTR_vs_SOM2.CSH_SVEGSCGF
122 & 139
0.72
0.0708
0.69
0.0268

PEDF_LQSLFDSPDFSK_vs_CRIS3_YEDLYSNCK
124 & 79
0.74
0.0493
0.61
0.1762

PEDF_LQSLFDSPDFSK_vs_LYAM1_SYYWIGIR
124 & 120
0.65
0.217
0.72
0.0079

PEDF_TVQAVLTVPK_vs_CRIS3_YEDLYSNCK
125 & 79
0.75
0.0373
0.62
0.1489

PEDF_TVQAVLTVPK_vs_LYAM1_SYYWIGIR
125 & 120
0.63
0.2774
0.76
0.0023

PEDF_TVQAVLTVPK_vs_PGRP2_AGLLRPDYALLGHR
125 & 126
0.57
0.5494
0.67
0.0451

PSG2_IHPSYTNYR_vs_CRIS3_AVSPPAR
133 & 78
0.76
0.0345
0.68
0.0355

PSG2_IHPSYTNYR_vs_CRIS3_YEDLYSNCK
133 & 79
0.77
0.0286
0.68
0.0369

PSG2_IHPSYTNYR_vs_FBLN1_TGYYFDGISR
133 & 86
0.61
0.3649
0.67
0.0476

PSG2_IHPSYTNYR_vs_IBP2_LIQGAPTIR
133 & 98
0.69
0.118
0.68
0.039

PSG2_IHPSYTNYR_vs_IBP3_YGQPLPGYTTK
133 & 100
0.74
0.0446
0.62
0.1599

PSG2_IHPSYTNYR_vs_IGF2_GIVEECCFR
133 & 103
0.76
0.0336
0.63
0.1287

PSG2_IHPSYTNYR_vs_LYAM1_SYYWIGIR
133 & 120
0.72
0.0759
0.74
0.005

PSG2_IHPSYTNYR_vs_PGRP2_AGLLRPDYALLGHR
133 & 126
0.69
0.1156
0.68
0.03

PSG2_IHPSYTNYR_vs_PSG3_VSAPSGTGHLPGLNPL
133 & 134
0.67
0.1541
0.68
0.0362

PSG2_IHPSYTNYR_vs_SHBG_IALGGLLFPASNLR
133 & 18
0.68
0.1283
0.71
0.0149

PSG2_IHPSYTNYR_vs_SOM2.CSH_SVEGSCGF
133 & 139
0.76
0.0345
0.63
0.1122

PTGDS_GPGEDFR_vs_LYAM1_SYYWIGIR
137 & 120
0.59
0.4614
0.72
0.0099

THBG_AVLHIGEK_vs_LYAM1_SYYWIGIR
143 & 120
0.59
0.4361
0.7
0.0211

VTNC_GQYCYELDEK_vs_LYAM1_SYYWIGIR
149 & 120
0.53
0.8363
0.81
3.00E−04

VTNC_GQYCYELDEK_vs_PGRP2_AGLLRPDYALLGHR
149 & 126
0.54
0.7626
0.75
0.0037

VTNC_GQYCYELDEK_vs_SHBG_IALGGLLFPASNLR
149 & 18
0.51
0.9282
0.69
0.0219

VTNC_VDTVDPPYPR_vs_LYAM1_SYYWIGIR
150 & 120
0.51
0.9451
0.76
0.0023

TABLE 73

SHBG Antibody Pair Screening

Pair

1
2
3
4
5
6
7
8
9
10
11
12

Capture

MAB
MAB
MAB

6001-
6001-
6001-
6002-
6002-
6002-

2656
2656
2656
AF2656
AF2656
AF2656
100050
100050
100050
100051
100051
100051

Detection

6001-
6002-
MAB
6001-
6002-
MAB

6002-
MAB

6001-

AF2656
100050
100051
2656
100050
100051
2656
AF2656
100051
2656
AF2656
100050

Conc.

(pg/mL)
Avg. Signal

200,000
196,199
1,482
40
17,248
77
82
87
493
140
15
357
59

50,000
45,345
230
68
6,424
81
72
77
323
134
74
286
62

12,500
10,250
111
62
1,309
69
85
27
205
74
52
253
3

3,125
2,218
5
31
310
45
66
83
240
137
29
194
60

781
586
58
43
135
57
50
80
253
174
74
212
116

195
285
112
69
85
68
58
73
281
156
95
236
32

48.8
192
78
51
79
80
57
35
241
82
51
239
45

0
134
57
36
65
31
81
70
222
145
61
207
50

Sample
Dil. Factor
Avg. Signal

Sera Ser
100
24,276
759,257
95,554
72,420
540,435
33,723
52,016
1,519,054
124,739
257,126
2,651,568
2,483,374

SHBG

High

Sera Ser
500
11,920
151,855
25,205
53,509
435,835
28,879
39,185
1,310,604
112,980
103,294
1,365,240
1,236,988

SHBG

High

Sera Ser
100
4,968
466,625
60,954
81,666
488,908
30,966
54,664
1,409,717
113,560
211,022
2,093,523
1,854,111

SHBG

Low

Sera Ser
500
2,323
77,558
13,979
51,484
341,422
24,496
39,792
1,092,474
98,450
66,981
741,153
635,079

SHBG

Low

Sera
100
16,046
543,595
67,876
70,299
537,819
32,769
55,762
1,448,544
117,378
211,125
2,290,099
2,161,934

Pregnant

Pool

Sera
200
8,181
265,320
36,282
62,676
484,876
31,089
45,555
1,387,992
117,090
144,146
1,756,643
1,644,496

Pregnant

Pool

Sera
400
3,798
126,947
20,332
50,249
430,699
27,311
35,459
1,240,271
110,478
106,820
1,148,673
1,023,157

Pregnant

Pool

Sera
800
1,854
48,533
8,691
39,042
337,119
14,848
29,455
1,053,286
93,762
61,748
660,872
591,820

Pregnant

Pool

TABLE 74

Top Performing SHBG Antibody Pairs with Additional Calibrators

Pair

2
3
10
12

Capture

MAB
MAB
MAB
MAB
MAB
MAB
6001-
6001-
6001-
6001-
6001-
6001-

2656
2656
2656
2656
2656
2656
100051
100051
100051
100051
100051
100051

Detection

6001-
6001-
6001-
6002-
6002-
6002-
MAB
MAB
MAB
6001-
6001-
6001-

10050
10050
10050
100051
100051
100051
2656
2656
2656
10050
10050
10050

Calibrator

Conc.
R&D
Bios

R&D
Bios

R&D
Bios

R&D
Bios

(pg/mL)
Systems
Pacific
NIBSC
Systems
Pacific
NIBSC
Systems
Pacific
NIBSC
Systems
Pacific
NIBSC

Std-01
200,000
238,290
249,922
412,613
186,867
196,012
426,503
596,225
293,312
554,954
1,898,159
1,779,244
3,175,127

Std-02
50,000
88,340
76,077
107,001
77,374
88,009
134,934
158,181
150,021
237,546
554,319
882,130
1,538,720

Std-03
12,500
22,003
14,194
18,988
20,160
20,899
33,358
35,226
32,464
54,024
129,885
227,721
452,461

Std-04
3,125
5,261
3,137
3,960
5,215
5,151
8,048
8,701
7,791
12,118
32,771
57,949
117,096

Std-05
781
1,650
813
1,126
1,351
1,211
2,121
2,165
1,781
2,842
9,383
14,943
33,614

Std-06
195
534
247
323
474
371
554
751
482
766
2,869
3,630
8,559

Std-07
48.8
193
107
108
173
151
145
260
198
265
832
1,045
2,337

Std-08
0
87
68
42
83
60
58
93
127
100
171
232
210

Hill
0.96
1.09
1.07
0.99
1.04
1.05
1.00
1.13
1.08
0.96
1.04
0.99

Slope

LLCD
34
96
65
42
51
36
25
51
29
15
12
2.4

(pg/mL)

Sig-
Std-02
100%
86%
121%
100%
114%
174%
100%
95%
150%
100%
159%
278%

nals
Std-03
100%
65%
86%
100%
104%
165%
100%
92%
153%
100%
175%
348%

Norm.
Std-04
100%
60%
75%
100%
99%
154%
100%
90%
139%
100%
177%
357%

to
Std-05
100%
49%
68%
100%
90%
157%
100%
82%
131%
100%
159%
358%

R&D

Average
100%
65%
88%
100%
101%
163%
100%
90%
144%
100%
138%
335%

(STD02-05)

TABLE 75

IGFBP-4 Antibody Screen

Pair

1
2

Capture
Ansh AI039
Ansh AI042

Detection
Ansh AI042
Ansh AI039

Cond. (pg/mL)
Avg. Signal
Ratio

STD01
200,000
425,323
1,804,559
4.2

STD02
50,000
119,806
532,966
4.4

STD03
12,500
24,178
117,219
4.8

STD04
3,125
6,232
37,258
6.0

STD05
781
2,816
17,032
6.0

STD06
195
2,176
13,425
6.2

STD07
48.8
2,019
11,901
5.9

STD08
0
1,710
10,995
6.4

Hill Slope
1.20
1.10

LLOD (pg/mL)
317
129

Sample
Dil. Factor
Avg. Signal
Ratio

Sera Serum
5
80,262
923,638
11.5

IGFBP-4 High

Sera Serum
5
57,033
671,088
11.8

IGFBP-4 Low

Pregnant Pooled
2
177,461
1,608,197
9.1

Serum 1

Pregnant Pooled
4
68,359
771,385
11.3

Serum 2

Pregnant Pooled
8
26,032
335,292
12.9

Serum 3

Pregnant Pooled
16
10,001
143,381
14.3

Serum 4

Pregnant Pooled
32
4,813
60,651
12.6

Serum 5

Pregnant Pooled
64
2,796
21,126
7.6

Serum 6

MSD Serum 1
2
103,259
1,249,741
12.1

MSD Serum 1
4
37,414
571,584
15.3

MSD Serum 1
8
17,946
291,750
16.3

MSD Serum 1
16
7,203
126,275
17.5

MSD Serum 2
2
66,061
767,724
11.6

MSD Serum 2
4
29,099
425,207
14.6

* Pregnant Pooled Serum 6 sample exhibited signals within 2X assay background

TABLE 76

Transition Classification Performance, weeks

19-20. Transition AUROC for gestational weeks

19 1/7 through 20 6/7 using a case vs control

cut-off of <37 0/7 vs >=37 0/7 weeks, without

BMI stratification, for PTL.

134_146_aBMI_37

Transition
SEQ ID NO:
PTL ROC_AUC

PSG3_VSAPSGTGHLPGLNPL
134
0.66

IGF2_GIVEECCFR
103
0.66

IBP4_QCHPALDGQR
2
0.64

IBP3_YGQPLPGYTTK
100
0.64

F13B_GDTYPAELYITGSILR
84
0.61

APOH_ATVVYQGER
48
0.6

IBP3_FLNVLSPR
99
0.6

TABLE 77

Transition Classification Performance, weeks

19-20. Transition AUROC for gestational weeks

19 1/7 through 20 6/7 using a case vs control

cut-off of <37 0/7 vs >=37 0/7 weeks, without

BMI stratification, for PPROM.

SEQ ID
134_146_aBMI_

Analytes
NO:
37 ROC_AUC

APOC3_GWVTDGFSSLK
47
0.76

PEDF_TVQAVLTVPK
125
0.76

INHBC_LDFHFSSDR
107
0.76

IBP4_QCHPALDGQR
2
0.73

PEDF_LQSLFDSPDFSK
124
0.73

A1AT_LSITGTYDLK
33
0.73

KNG1_QVVAGLNFR
117
0.72

CD14_LTVGAAQVPAQLLVGALR
61
0.72

VTNC_VDTVDPPYPR
150
0.71

KNG1_DIPTNSPELEETLTHTITK
116
0.71

CD14_SWLAELQQWLKPGLK
62
0.71

CO8A_SLLQPNK
74
0.69

CATD_VGFAEAAR
57
0.69

SHBG_IALGGLLFPASNLR
18
0.69

CO5_VFQFLEK
71
0.69

FETUA_FSVVYAK
88
0.68

HABP2_FLNWIK
92
0.68

VTNC_GQYCYELDEK
149
0.68

B2MG_VNHVTLSQPK
51
0.68

ENPP2_TYLHTYESEI
83
0.67

AFAM_HFQNLGK
38
0.67

APOH_ATVVYQGER
48
0.66

ITIH4_NPLVWVHASPEHVVVTR
113
0.66

CFAB_YGLVTYATYPK
64
0.66

CO8B_QALEEFQK
76
0.65

BGH3_LTLLAPLNSVFK
52
0.65

FETUA_HTLNQIDEVK
89
0.65

CO3_IHWESASLLR
69
0.65

ENPP2_TEFLSNYLTNVDDITLVPGTLGR
82
0.65

HEMO_NFPSPVDAAFR
93
0.65

LBP_ITLPDFTGDLR
119
0.65

CO5_TLLPVSKPEIR
70
0.65

FIBA_ESSSHHPGIAEFPSR
90
0.64

AFAM_DADPDTFFAK
37
0.64

ITIH3_ALDLSLK
111
0.64

LBP_ITGFLKPGK
118
0.64

CATD_VSTLPAITLK
58
0.64

PRDX2_GLFIIDGK
128
0.63

CO6_ALNHLPLEYNSALYSR
72
0.63

ANGT_DPTFIPAPIQAK
42
0.62

PRG2_WNFAYWAAHQPWSR
129
0.62

CBPN_NNANGVDLNR
60
0.62

IBP6_HLDSVLQQLQTEVYR
102
0.62

ITIH4_ILDDLSPR
112
0.62

IBP6_GAQTLYVPNCDHR
101
0.62

F13B_GDTYPAELYITGSILR
84
0.61

CLUS_LFDSDPITVTVPVEVSR
68
0.61

FBLN1_TGYYFDGISR
86
0.61

PAPP1_DIPHWLNPTR
122
0.61

TIE1_VSWSLPLVPGPLVGDGFLLR
144
0.6

CAH1_GGPFSDSYR
56
0.6

A2GL_DLLLPQPDLR
34
0.6

B2MG_VEHSDLSFSK
50
0.6

PSG2_IHPSYTNYR
133
0.6

Number	Name	Date	Kind
4683195	Mullis et al.	Jul 1987	A
4683202	Mullis	Jul 1987	A
4800159	Mullis et al.	Jan 1989	A
4965188	Mullis et al.	Oct 1990	A
5130238	Malek et al.	Jul 1992	A
5270184	Walker et al.	Dec 1993	A
5399491	Kacian et al.	Mar 1995	A
5455166	Walker	Oct 1995	A
5480784	Kacian et al.	Jan 1996	A
7091316	Uchida et al.	Aug 2006	B2
7191068	Rosenfeld et al.	Mar 2007	B2
7323346	Thadhani et al.	Jan 2008	B2
7425419	Poston et al.	Sep 2008	B2
7435419	Karumanchi et al.	Oct 2008	B2
7790463	Mor et al.	Sep 2010	B2
20020137086	Olek et al.	Sep 2002	A1
20030105731	Lapointe et al.	Jun 2003	A1
20040197930	Rosenfeld et al.	Oct 2004	A1
20040203023	Chandrasiri-Herath	Oct 2004	A1
20050043640	Chang	Feb 2005	A1
20050059013	Kokudo	Mar 2005	A1
20050074746	Mor et al.	Apr 2005	A1
20050148023	Thadhani et al.	Jul 2005	A1
20050148040	Thadhani et al.	Jul 2005	A1
20050233400	Weiner et al.	Oct 2005	A1
20060046265	Becker et al.	Mar 2006	A1
20060094039	Rosenfeld et al.	May 2006	A1
20060127962	Buhimschi et al.	Jun 2006	A1
20060166242	Pennell et al.	Jul 2006	A1
20060166280	Strauss et al.	Jul 2006	A1
20070054329	Fung et al.	Mar 2007	A1
20070111326	Sogin et al.	May 2007	A1
20070141055	Kajander et al.	Jun 2007	A1
20070161125	Rosenfeld et al.	Jul 2007	A1
20070178605	Mor et al.	Aug 2007	A1
20080090759	Kokenyesi et al.	Apr 2008	A1
20080187929	Meiri et al.	Aug 2008	A1
20080213794	Thadhani et al.	Sep 2008	A1
20080233583	Fisher et al.	Sep 2008	A1
20080274481	Fung et al.	Nov 2008	A1
20090018778	Nation et al.	Jan 2009	A1
20100016173	Nagalla et al.	Jan 2010	A1
20100017143	Nagalla et al.	Jan 2010	A1
20100035284	Buhimschi et al.	Feb 2010	A1
20100062471	Kantor	Mar 2010	A1
20100113286	Lajoie et al.	May 2010	A1
20100143949	Petricoin	Jun 2010	A1
20100163721	Graves et al.	Jul 2010	A1
20100167267	Schulzknappe et al.	Jul 2010	A1
20100173317	Nakamura et al.	Jul 2010	A1
20100173786	Brun et al.	Jul 2010	A1
20100216250	Lopez et al.	Aug 2010	A1
20100291612	Luider et al.	Nov 2010	A1
20100297679	Graves et al.	Nov 2010	A1
20110008805	Urdea	Jan 2011	A1
20110165554	Levin et al.	Jul 2011	A1
20110171645	McManus et al.	Jul 2011	A1
20110195478	Chen et al.	Aug 2011	A1
20110247404	Graves et al.	Oct 2011	A1
20110256560	Diamandis	Oct 2011	A1
20120046261	Manuck et al.	Feb 2012	A1
20120149041	Graves et al.	Jun 2012	A1
20120190561	Wildt et al.	Jul 2012	A1
20120315630	Gong et al.	Dec 2012	A1
20130040844	Wyss-Coray	Feb 2013	A1
20130130278	Gruslin et al.	May 2013	A1
20130137595	Zangar et al.	May 2013	A1
20130296198	Gordon et al.	Nov 2013	A1
20140287947	Boniface et al.	Sep 2014	A1
20140287948	Boniface et al.	Sep 2014	A1
20140287950	Hickok et al.	Sep 2014	A1
20140296108	Hickok et al.	Oct 2014	A1
20160003837	Murtha et al.	Jan 2016	A1
20160154003	Boniface et al.	Jun 2016	A1
20170022565	Boniface et al.	Jan 2017	A1
20170146548	Hickok et al.	May 2017	A1
20180143202	Boniface et al.	May 2018	A1
20180172696	Boniface et al.	Jun 2018	A1
20180172698	Boniface et al.	Jun 2018	A1
20190219588	Boniface et al.	Jul 2019	A1
20190317107	Boniface et al.	Oct 2019	A1

Number	Date	Country
2629451	May 2007	CA
002520	Jun 2002	EA
0684315	Jun 2002	EP
1914548	Apr 2008	EP
1914552	Apr 2008	EP
1914553	Apr 2008	EP
2014-505264	Feb 2014	JP
2014-526032	Oct 2014	JP
2486519	Jun 2013	RU
WO 1991016633	Oct 1991	WO
WO 1993009438	May 1993	WO
WO 2002070742	Sep 2002	WO
WO 2004088324	Oct 2004	WO
WO 2005014635	Feb 2005	WO
WO 2005031364	Apr 2005	WO
WO 2006029838	Mar 2006	WO
WO 2006034427	Mar 2006	WO
WO 2006074360	Jul 2006	WO
WO 2007022248	Feb 2007	WO
WO 2007051069	May 2007	WO
WO 2007053161	May 2007	WO
WO 2007092353	Aug 2007	WO
WO 2007110625	Oct 2007	WO
WO 2008046160	Apr 2008	WO
WO 2008054764	May 2008	WO
WO 2008063369	May 2008	WO
WO 2009014987	Jan 2009	WO
WO 2009158423	Dec 2009	WO
WO 2011022526	Feb 2011	WO
WO 2011077129	Jun 2011	WO
WO 2011100792	Aug 2011	WO
WO 2012017071	Feb 2012	WO
WO 2012170711	Dec 2012	WO
WO 2014066568	May 2014	WO
WO 2014089124	Jun 2014	WO
WO 2014143977	Sep 2014	WO
WO 2014144129	Sep 2014	WO
WO 2016205723	Dec 2016	WO
WO 2018027160	Feb 2018	WO
WO 2018027171	Feb 2018	WO
WO 2019036032	Feb 2019	WO

Number	Date	Country
62290796	Feb 2016	US
62387420	Dec 2015	US
62182349	Jun 2015	US

	Number	Date	Country
Parent	16380938	Apr 2019	US
Child	17189048		US
Parent	15186322	Jun 2016	US
Child	16380938		US

Biomarker pairs for predicting preterm birth

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Term Extension

Abstract

Description

Claims

Parent Case Info

US Referenced Citations (81)

Foreign Referenced Citations (41)

Non-Patent Literature Citations (164)

Related Publications (1)

Provisional Applications (3)

Continuations (2)